data_1uju_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1uju _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.51 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -97.77 33.06 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.929 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 -104.12 177.82 4.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.0 112.22 14.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.2 mt -119.85 163.38 17.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 96' ' ' LEU . 18.9 p -144.3 159.47 42.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.87 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.6 mt -122.34 112.96 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -84.47 115.39 22.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -127.41 166.77 17.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.889 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.459 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.06 168.27 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.543 0.687 . . . . 0.0 111.118 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.8 -2.01 9.48 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.653 2.235 . . . . 0.0 112.333 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.49 37.89 0.27 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 40.8 tp10 -102.68 143.58 32.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.864 0.364 . . . . 0.0 110.893 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.6 ptt180 -84.13 121.5 27.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.849 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.464 ' CD1' ' HB3' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -33.63 -53.16 0.42 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 41.12 9.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.46 HG12 ' CD1' ' A' ' 23' ' ' LEU . 3.3 pt -121.35 162.57 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.409 ' C ' HG23 ' A' ' 27' ' ' ILE . 1.5 m -130.57 145.13 51.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.819 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.409 HG23 ' C ' ' A' ' 26' ' ' SER . 21.1 pt -136.2 156.2 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.107 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -132.48 132.9 43.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.873 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.07 -142.32 9.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.507 -179.927 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.8 mt -126.88 119.2 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.385 . . . . 0.0 111.106 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.72 149.12 52.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.833 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.468 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 94.7 mt -54.59 132.76 17.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.428 ' C ' HG12 ' A' ' 65' ' ' VAL . 4.4 p -108.59 -13.41 14.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -175.5 156.47 1.96 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.853 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 93.4 t -143.63 123.24 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.109 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 t -69.22 143.15 93.49 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.684 0.754 . . . . 0.0 110.858 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -35.6 12.15 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.33 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.3 p -88.27 0.95 55.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.449 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -80.57 153.05 34.54 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -45.18 -38.9 5.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.769 0.319 . . . . 0.0 111.11 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.464 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -73.32 -64.0 1.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -35.44 -44.56 0.62 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.8 ptt180 -79.3 -37.24 38.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 57' ' ' ALA . 22.1 t0 -40.66 -64.57 0.51 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.38 -9.75 22.23 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.24 -24.35 11.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.456 ' CD1' HD12 ' A' ' 48' ' ' ILE . 0.8 OUTLIER -92.29 126.25 37.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -142.6 174.46 10.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.468 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 6.4 t -82.62 92.33 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.68 -13.66 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.47 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 52.7 mt -77.05 118.71 19.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.568 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 46.5 ttt180 -69.12 122.69 19.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.455 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.4 mm? -72.95 108.96 6.15 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.419 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 4.4 mm? -84.31 -52.37 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.951 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.419 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 11.3 mt-10 -157.85 134.99 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.434 ' CG1' HD12 ' A' ' 96' ' ' LEU . 88.8 t -106.58 110.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.075 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 18.6 m-20 64.73 41.66 5.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 64.17 31.89 12.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -128.86 91.05 3.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.887 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 36.2 t -50.45 130.89 24.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.3 mt -80.29 5.14 15.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.04 114.95 11.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.932 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -37.39 3.17 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.494 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -86.42 167.89 14.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.904 0.383 . . . . 0.0 110.917 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 61.8 p -104.37 160.59 14.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.1 -55.19 0.39 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.821 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.24 -46.11 51.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 81' ' ' THR . 29.4 mm-40 -70.03 -47.87 60.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.863 0.364 . . . . 0.0 110.857 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.18 -48.76 70.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 75.2 t -55.57 -55.22 18.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.476 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.9 mm-40 -54.27 -27.3 34.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -70.43 -29.59 66.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.41 -30.5 47.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.921 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.476 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.8 ptp180 -93.36 -1.14 56.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.83 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -90.64 30.0 1.23 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.444 HG22 ' N ' ' A' ' 93' ' ' GLY . 2.6 p -112.1 144.66 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.154 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.444 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -61.73 -94.51 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.481 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -119.52 -8.78 9.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 m -152.92 134.68 14.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.434 HD12 ' CG1' ' A' ' 72' ' ' VAL . 1.2 pt? -122.8 171.87 8.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.4 m -120.8 98.64 6.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.158 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.46 131.91 40.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.1 tp -101.15 31.47 3.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.935 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.455 HG13 ' CD2' ' A' ' 69' ' ' LEU . 4.5 m -65.96 175.47 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.133 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.4 p -165.17 154.23 12.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -46.26 101.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.478 -179.925 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.468 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -83.31 20.19 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.892 -179.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.3 mmt180 -90.24 168.01 12.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 31.9 tt0 -74.25 114.84 13.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.893 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.8 mt -118.58 160.06 22.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.6 p -139.5 155.77 47.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 31.0 mt -122.97 109.78 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.19 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -80.31 115.93 20.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.426 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -131.98 178.26 6.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.83 163.62 2.71 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.554 0.692 . . . . 0.0 111.093 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 1.23 4.65 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.688 2.259 . . . . 0.0 112.328 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -162.59 26.14 0.23 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.488 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.1 tp10 -94.43 142.22 27.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.909 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.9 mpt_? -86.32 123.72 31.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.466 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -46.53 0.24 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.58 41.18 30.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.527 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.466 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.5 pt -121.41 162.97 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 0.0 111.143 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.405 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -120.12 159.1 25.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.835 -179.894 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.4 pt -151.69 145.65 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -129.26 132.14 47.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.929 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.67 -146.19 15.17 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.478 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.464 -179.907 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 60.3 mt -139.18 115.86 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 111.135 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.4 OUTLIER -132.54 163.5 28.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.959 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.451 HD13 ' CD1' ' A' ' 63' ' ' LEU . 27.4 mt -67.72 125.49 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.434 ' C ' HG13 ' A' ' 65' ' ' VAL . 82.7 p -96.85 -11.02 25.36 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.823 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.405 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 16.8 ttmm -175.86 167.25 3.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.5 t -150.06 114.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.139 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.5 t -67.27 140.01 95.17 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.61 0.719 . . . . 0.0 110.85 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.74 21.68 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.646 2.231 . . . . 0.0 112.361 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.5 p -86.57 -8.57 57.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.137 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -75.56 158.2 50.07 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -50.17 -39.39 43.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.766 0.317 . . . . 0.0 111.087 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.42 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -70.34 -60.26 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.079 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.63 -42.88 2.84 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 23.3 ptt180 -80.29 -31.53 38.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.83 0.348 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -50.17 -72.29 0.05 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 119.72 -9.58 11.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.492 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -104.32 -10.93 17.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.876 0.37 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.451 ' CD1' HD13 ' A' ' 48' ' ' ILE . 2.4 tm? -105.83 134.0 49.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.431 ' N ' HD13 ' A' ' 63' ' ' LEU . 19.7 mtp180 -144.28 178.97 7.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.434 HG13 ' C ' ' A' ' 49' ' ' SER . 9.1 t -88.02 92.86 3.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.138 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 151.91 -13.16 0.74 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.465 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 32.6 mt -73.0 110.41 7.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.803 0.335 . . . . 0.0 110.879 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.569 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 16.6 ttm180 -62.34 122.8 16.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.858 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.48 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.4 mm? -71.24 107.03 4.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.495 ' O ' ' CG ' ' A' ' 71' ' ' GLU . 1.7 mm? -86.37 -42.14 13.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 40.3 mt-10 -161.82 139.55 8.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.885 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 66.7 t -117.6 108.0 23.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.089 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 65.44 41.35 4.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 63.65 36.66 10.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -131.92 91.16 2.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.3 t -47.55 127.04 10.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.01 1.06 22.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.12 111.39 7.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.964 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.92 -37.28 2.73 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.524 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.42 HD13 ' N ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -87.16 167.03 14.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.953 0.406 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 81.0 p -102.66 -179.97 4.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -50.32 -51.48 44.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.85 -45.57 79.54 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.418 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.1 mt-10 -67.1 -58.36 5.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.819 0.342 . . . . 0.0 110.889 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.42 ' N ' HD13 ' A' ' 80' ' ' LEU . . . -44.27 -46.79 9.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.123 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 74.5 t -57.05 -60.45 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.11 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.47 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.3 mm-40 -50.39 -26.27 4.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.902 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.6 tt -74.73 -32.12 62.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -31.66 44.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.47 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.4 ptm180 -90.81 3.54 54.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.897 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 5.5 m -96.59 29.23 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.47 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 17.4 t -94.25 149.94 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.463 ' N ' HG11 ' A' ' 92' ' ' VAL . . . -88.59 -76.7 1.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.53 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -123.28 -17.76 6.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.84 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 56.2 m -163.16 137.04 5.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.093 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.47 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.2 pt? -119.0 169.08 10.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.439 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.1 m -119.71 100.15 7.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.0 m -96.72 130.66 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.7 tp -99.19 24.83 7.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.48 HG13 ' CD2' ' A' ' 69' ' ' LEU . 2.7 m -61.84 172.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.122 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.3 p -163.35 163.02 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -54.31 95.15 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.485 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.502 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.31 28.81 0.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.813 0.339 . . . . 0.0 110.934 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -98.5 161.93 13.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.42 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 35.2 tt0 -68.21 107.37 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.869 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 98' ' ' VAL . 18.9 mt -113.48 157.49 21.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 20.6 p -139.36 165.33 27.5 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.4 mt -128.99 105.62 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -80.68 117.55 21.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.4 ptpp? -126.91 168.6 14.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.463 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -46.51 168.34 0.12 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 0.0 111.103 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.463 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 1.61 4.27 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.727 2.285 . . . . 0.0 112.339 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.32 43.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 tp10 -111.59 142.7 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.814 0.34 . . . . 0.0 110.86 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -86.6 124.5 32.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 -179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.459 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -33.46 -52.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 41.04 13.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.505 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 3.1 pt -119.39 157.33 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.813 0.339 . . . . 0.0 111.141 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.6 m -123.5 140.06 53.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 pt -132.79 157.09 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.429 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 3.3 ptm85 -132.58 138.87 47.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.23 -144.75 13.2 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 -179.957 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.6 mt -125.21 117.63 50.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.829 0.347 . . . . 0.0 111.136 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.06 156.53 43.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.452 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 65.3 mt -64.19 130.46 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.158 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 43.5 t -110.23 -14.57 14.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.837 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.465 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 11.2 tttm -167.02 161.21 14.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.455 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 86.7 t -152.78 129.28 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.144 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.1 t -72.52 137.65 80.72 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.611 0.719 . . . . 0.0 110.867 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -25.29 28.84 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.676 2.251 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -101.71 12.88 36.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.187 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -91.92 161.94 27.21 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.506 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -50.04 -35.51 25.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 111.115 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.425 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -77.17 -57.11 4.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.123 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.27 -43.85 4.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.497 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -80.83 -26.25 37.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.821 0.343 . . . . 0.0 110.889 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -48.58 -58.23 5.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.79 -25.12 11.19 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.468 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -94.73 -53.48 3.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.855 0.36 . . . . 0.0 110.883 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.432 HD11 ' N ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER -58.6 132.49 53.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.432 ' N ' HD11 ' A' ' 63' ' ' LEU . 3.6 ptp180 -165.33 147.57 7.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.465 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 62.0 t -49.79 106.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.153 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.13 -26.3 2.03 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.486 ' CD2' ' C ' ' A' ' 101' ' ' CYS . 20.3 mt -75.25 118.55 18.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.765 0.316 . . . . 0.0 110.942 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -69.61 131.66 45.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.475 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.1 mm? -80.29 111.75 16.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 4.0 mm? -88.84 -49.78 6.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.957 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.416 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -158.39 140.41 13.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.923 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 88.4 t -111.84 109.77 29.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.159 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 65.07 41.9 4.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 64.21 32.99 12.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.21 90.54 3.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.912 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.8 t -47.3 130.08 13.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.433 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 5.8 mt -83.31 8.34 13.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.965 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -76.97 115.45 16.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.886 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.11 -32.52 5.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.468 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.449 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -88.04 167.12 13.96 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.918 0.389 . . . . 0.0 110.9 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 84' ' ' GLU . 44.5 p -105.94 162.92 13.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.102 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.426 ' C ' ' O ' ' A' ' 81' ' ' THR . 1.7 t-80 -34.82 -55.96 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.62 -41.12 49.23 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.442 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' A' ' 81' ' ' THR . 5.7 mm-40 -73.16 -48.6 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.856 0.36 . . . . 0.0 110.868 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.3 -51.64 64.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.152 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 61.0 t -53.17 -62.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.125 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.472 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 15.9 mm-40 -49.51 -23.44 1.6 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.07 -33.47 61.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.2 -32.76 56.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.472 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 8.2 ptm180 -89.24 -3.36 58.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.1 m -91.41 33.52 0.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.84 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG23 ' CA ' ' A' ' 96' ' ' LEU . 2.3 p -112.88 145.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.115 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.446 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -61.25 -98.15 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -116.15 -6.96 11.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.923 0.392 . . . . 0.0 110.918 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.4 m -156.17 130.64 8.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.172 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.461 ' CA ' HG23 ' A' ' 92' ' ' VAL . 1.1 pt? -116.99 168.2 10.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.42 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.6 m -116.85 97.77 6.14 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.113 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 13' ' ' LEU . 3.3 m -95.43 129.32 45.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.152 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.3 tp -99.51 34.17 2.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.475 HG11 ' CD2' ' A' ' 69' ' ' LEU . 3.0 m -69.91 173.0 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.486 ' C ' ' CD2' ' A' ' 67' ' ' LEU . 7.9 p -165.15 168.34 17.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -52.51 114.32 1.34 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.494 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.465 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.79 38.99 0.73 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.924 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 53.8 mtp180 -109.68 144.95 37.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 52.9 tt0 -55.52 110.09 0.65 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.5 mt -105.1 168.67 8.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.944 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.444 ' SG ' ' CG2' ' A' ' 95' ' ' THR . 7.2 t -150.35 144.22 25.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.931 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 95' ' ' THR . 15.6 mt -120.71 127.2 75.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -97.72 113.54 25.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -124.83 170.5 10.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.453 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -47.89 168.05 0.17 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.582 0.706 . . . . 0.0 111.1 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.453 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.81 2.37 3.62 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.344 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.05 39.43 0.17 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 26.1 tp10 -101.73 144.19 30.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.812 0.339 . . . . 0.0 110.926 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 25.5 mtt-85 -83.75 120.23 25.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.462 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -49.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.35 42.6 18.12 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.471 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.462 HG12 ' CD1' ' A' ' 23' ' ' LEU . 2.2 pt -122.74 161.5 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.803 0.335 . . . . 0.0 111.133 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.465 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -119.17 160.37 22.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.891 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 17.7 pt -151.55 147.27 15.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.169 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.473 ' NH1' ' CB ' ' A' ' 49' ' ' SER . 6.1 ptt-85 -125.09 139.42 53.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 137.87 -149.93 20.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.514 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.542 -179.893 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 48.6 mt -123.62 118.69 55.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.844 0.354 . . . . 0.0 111.117 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.75 147.51 50.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.452 HD13 ' CD1' ' A' ' 63' ' ' LEU . 95.3 mt -55.88 135.66 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.149 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.473 ' CB ' ' NH1' ' A' ' 28' ' ' ARG . 70.0 p -113.87 -13.39 12.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.853 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.465 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 17.9 ttmm -170.38 161.23 7.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 85.8 t -150.08 121.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -68.01 139.27 92.89 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 110.871 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -29.91 23.26 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.716 2.277 . . . . 0.0 112.367 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.3 p -92.7 4.49 53.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -85.45 161.45 35.46 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.447 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -51.39 -39.55 57.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.795 0.331 . . . . 0.0 111.116 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -70.55 -59.36 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -38.69 -42.43 1.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 24.9 ptt180 -82.95 -30.09 28.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.8 0.333 . . . . 0.0 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 57' ' ' ALA . 48.2 t0 -45.9 -56.97 4.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.876 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.4 -20.23 40.43 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.36 -20.52 18.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.845 0.355 . . . . 0.0 110.865 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.452 ' CD1' HD13 ' A' ' 48' ' ' ILE . 1.1 tm? -89.55 134.35 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.425 ' HG2' ' C ' ' A' ' 63' ' ' LEU . 14.2 mmm-85 -143.15 154.12 43.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.887 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.3 t -70.49 87.21 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.99 -17.35 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.499 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.0 mt -67.82 124.64 23.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.907 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 36.2 ttt180 -71.84 119.74 16.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.469 ' CD2' HG13 ' A' ' 100' ' ' VAL . 1.6 mm? -67.04 111.43 3.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.887 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -86.79 -54.24 4.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.92 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -156.58 133.6 10.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.467 ' CG2' HD12 ' A' ' 69' ' ' LEU . 93.1 t -106.76 110.92 33.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.453 ' ND2' HG23 ' A' ' 92' ' ' VAL . 15.0 m-20 64.91 41.06 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 37.4 mt-30 63.86 31.55 13.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -129.38 91.24 3.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -46.4 138.97 5.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 18.2 mt -91.52 5.17 50.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.4 117.97 17.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 117.28 -39.62 2.6 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.544 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -82.8 167.36 18.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.888 0.375 . . . . 0.0 110.894 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 72.5 p -103.84 162.06 13.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 81' ' ' THR . 1.8 t-80 -33.83 -56.02 0.47 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.04 55.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.525 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.419 ' N ' ' O ' ' A' ' 81' ' ' THR . 14.7 mm-40 -69.04 -49.02 61.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.829 0.347 . . . . 0.0 110.875 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.87 -45.34 74.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 88.7 t -57.2 -58.18 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.474 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 66.6 mm-40 -52.09 -22.48 4.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 tt -79.37 -28.24 41.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.906 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.76 -25.86 30.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.896 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.474 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.8 ptm180 -96.04 0.91 52.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.834 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 32.6 t -93.68 28.04 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.481 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 17.1 t -92.81 148.91 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.463 ' N ' HG12 ' A' ' 92' ' ' VAL . . . -88.76 -77.76 1.3 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.499 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -125.16 -17.72 5.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.916 0.388 . . . . 0.0 110.869 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.444 ' CG2' ' SG ' ' A' ' 14' ' ' CYS . 5.0 m -158.38 137.28 11.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.481 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 0.9 OUTLIER -122.69 160.65 25.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.912 179.986 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -113.24 96.62 6.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.96 130.01 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.1 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.7 tp -97.08 17.77 16.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.872 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.469 HG13 ' CD2' ' A' ' 69' ' ' LEU . 35.9 m -49.38 178.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.416 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 1.9 p -167.62 161.58 13.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -60.77 102.28 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.509 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.489 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.97 19.78 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -88.71 162.26 16.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.848 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.45 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -73.18 110.78 7.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.3 161.57 15.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.0 p -143.01 153.2 42.74 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.3 mt -121.85 120.94 62.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.111 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -93.12 110.59 22.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.416 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -124.1 179.75 4.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.418 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -59.18 166.4 2.84 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.566 0.698 . . . . 0.0 111.088 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.418 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.9 Cg_endo -69.71 -0.28 6.65 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.65 2.233 . . . . 0.0 112.369 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.59 29.34 0.22 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -94.25 140.42 29.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.924 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 5.9 ptt-85 -82.95 120.57 25.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.457 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.99 -49.15 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.94 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.24 42.07 24.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.5 pt -121.19 164.41 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.143 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.423 ' C ' HG21 ' A' ' 27' ' ' ILE . 0.6 OUTLIER -128.97 150.9 50.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.809 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.423 HG21 ' C ' ' A' ' 26' ' ' SER . 30.2 pt -140.36 149.39 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.097 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 35.0 ptt180 -125.14 123.16 39.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.04 -141.87 8.49 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.475 -179.914 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.459 -0.257 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.7 mt -128.76 119.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.911 0.386 . . . . 0.0 111.152 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.5 OUTLIER -132.14 -179.94 5.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.905 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.454 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 69.9 mt -88.01 121.4 38.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.5 t -97.32 -17.36 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.444 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 12.3 ttmt -166.23 160.09 15.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 63' ' ' LEU . 84.0 t -149.31 115.08 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.136 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.6 t -60.3 134.37 90.95 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.694 0.759 . . . . 0.0 110.859 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -19.52 35.75 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.702 2.268 . . . . 0.0 112.351 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 19.4 p -102.24 3.47 38.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.16 172.89 49.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.73 -39.7 85.57 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.808 0.337 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.472 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -69.3 -61.5 1.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.83 -39.94 2.07 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 14.5 ptt180 -82.24 -25.06 34.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 0.0 110.852 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.472 ' N ' ' O ' ' A' ' 57' ' ' ALA . 30.3 t0 -53.27 -62.01 1.93 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 111.57 -16.24 26.56 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.1 -29.05 11.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.872 0.367 . . . . 0.0 110.866 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.467 HD11 ' N ' ' A' ' 64' ' ' ARG . 1.1 tm? -87.4 134.16 33.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.966 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.467 ' N ' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.72 150.2 24.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.454 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 44.2 t -56.63 104.48 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.33 -13.25 1.62 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.432 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 87.7 mt -83.49 123.75 30.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.56 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 36.7 ttt180 -72.55 125.39 27.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.483 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.1 mm? -74.35 107.56 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.427 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 70.3 mt -86.58 -48.91 7.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.958 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.427 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 20.0 mt-10 -158.92 138.47 11.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.0 t -112.99 110.37 31.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 17.8 m-20 65.49 40.55 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 64.4 32.13 12.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.929 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -127.23 89.58 2.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.0 t -44.26 132.23 5.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 19.8 mt -79.4 0.07 30.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.99 119.94 17.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.31 -34.73 4.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.499 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.461 ' CD1' ' HA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -92.42 158.8 15.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.902 -179.91 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.5 p -92.04 178.94 5.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.421 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 4.0 t-80 -50.06 -53.85 24.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.49 -48.69 63.89 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.484 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.445 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 22.4 mt-10 -61.04 -51.96 66.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.867 0.365 . . . . 0.0 110.887 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.461 ' HA ' ' CD1' ' A' ' 80' ' ' LEU . . . -50.19 -50.85 48.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.089 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.7 t -52.3 -58.84 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.468 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 59.9 mm-40 -53.11 -21.22 4.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tt -78.03 -26.75 48.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.443 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -84.02 -28.47 27.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.468 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.3 ptm180 -93.72 1.19 56.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 46.3 t -96.24 33.1 1.81 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.465 HG21 ' N ' ' A' ' 93' ' ' GLY . 2.4 p -111.28 136.53 47.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.163 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.465 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -57.46 -101.57 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.518 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -112.55 -3.71 14.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.868 0.366 . . . . 0.0 110.841 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 m -158.47 135.31 9.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.451 ' HB3' ' CG2' ' A' ' 92' ' ' VAL . 0.9 OUTLIER -123.82 168.16 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.918 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.45 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -118.14 96.24 5.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.118 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.93 129.84 43.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.7 tp -99.18 25.19 7.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.934 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.483 HG13 ' CD2' ' A' ' 69' ' ' LEU . 3.7 m -62.43 166.84 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.119 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.9 p -158.37 152.84 24.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.432 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 3.8 m-20 -43.83 104.61 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.53 -179.959 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.508 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -94.98 28.07 2.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.416 ' C ' HD11 ' A' ' 99' ' ' LEU . 1.0 OUTLIER -98.02 171.43 8.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.39 108.45 7.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.23 158.02 21.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.923 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.9 p -137.83 148.68 45.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.7 mt -114.18 96.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -69.2 112.95 6.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.437 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -124.71 172.6 9.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.62 164.35 7.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.547 0.689 . . . . 0.0 111.091 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 2.41 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.329 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 24.74 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -95.4 132.13 40.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.91 0.386 . . . . 0.0 110.892 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.441 ' O ' ' C ' ' A' ' 23' ' ' LEU . 67.2 mtt180 -82.35 118.49 23.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.872 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.443 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.19 -51.63 0.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.952 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.82 28.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.5 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.443 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.4 pt -119.42 170.36 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 111.143 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.508 ' N ' ' O ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -132.61 166.86 21.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.44 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 19.7 pt -155.41 145.05 12.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ptt180 -124.02 124.76 43.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.76 -148.5 19.03 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.457 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.524 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.457 HG12 ' N ' ' A' ' 30' ' ' GLY . 39.5 mt -115.34 119.49 61.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.867 0.365 . . . . 0.0 111.131 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.608 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -133.09 -174.7 3.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.918 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.48 ' CD1' HD21 ' A' ' 63' ' ' LEU . 54.8 mt -90.48 128.4 42.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.418 ' C ' HG11 ' A' ' 65' ' ' VAL . 2.6 t -105.21 -12.95 15.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.508 ' O ' ' N ' ' A' ' 26' ' ' SER . 39.4 ttmt -175.79 139.7 0.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.4 ' CG2' HG21 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -146.14 118.38 2.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.868 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 18.2 t -48.01 134.08 11.75 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.675 0.75 . . . . 0.0 110.881 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -16.12 37.39 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.728 2.286 . . . . 0.0 112.319 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.67 -6.98 13.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.173 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -63.79 174.24 11.84 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.468 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.463 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -52.88 -37.13 60.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.476 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -80.8 -60.38 2.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.115 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -36.56 -47.25 1.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.478 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.463 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 21.1 ptt180 -69.72 -36.4 75.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.36 . . . . 0.0 110.897 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ALA . 28.7 t70 -39.91 -56.12 1.87 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.81 -22.78 15.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -95.29 -44.66 7.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.841 0.353 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.48 HD21 ' CD1' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -58.11 145.12 37.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 -179.956 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.416 ' N ' HD13 ' A' ' 67' ' ' LEU . 12.2 ptt-85 -175.23 146.61 0.85 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 57.4 t -57.89 105.49 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.106 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.72 -25.56 2.42 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.451 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.429 HD21 ' C ' ' A' ' 101' ' ' CYS . 11.4 mt -69.74 118.41 12.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.796 0.332 . . . . 0.0 110.933 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.562 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 25.4 ttt180 -68.85 123.25 20.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.476 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.6 mm? -74.24 110.03 8.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.933 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -85.61 -50.47 7.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -152.47 139.73 19.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.446 ' CG2' HD13 ' A' ' 69' ' ' LEU . 97.0 t -114.42 109.53 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.092 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.432 ' ND2' ' HB2' ' A' ' 96' ' ' LEU . 9.7 m-20 65.64 40.88 4.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 63.62 34.07 12.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 33.2 mt-30 -130.69 92.19 3.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 t -43.97 129.72 5.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 16.8 mt -89.65 10.14 24.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -80.88 122.57 27.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.15 -33.51 5.68 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.44 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -85.82 164.2 17.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.93 -179.934 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 82' ' ' HIS . 75.2 p -98.66 160.59 14.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.44 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.7 t-80 -33.67 -55.76 0.45 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -55.1 -46.99 76.17 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.466 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -62.86 -44.34 96.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 110.89 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.404 ' HA ' ' CD1' ' A' ' 80' ' ' LEU . . . -62.26 -51.77 66.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 38.2 t -49.45 -61.5 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.479 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 86.6 mm-40 -47.41 -24.08 0.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 tt -78.39 -33.03 49.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.9 -30.27 44.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.479 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.5 ptm180 -90.14 4.48 50.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.84 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.0 t -97.2 19.35 13.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.478 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 26.1 t -82.14 150.54 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.46 ' N ' HG13 ' A' ' 92' ' ' VAL . . . -94.64 -78.9 1.43 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -120.31 -22.35 6.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -160.23 131.94 6.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.134 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.478 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.1 pt? -113.09 171.5 7.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -121.19 97.65 5.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.149 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.54 130.13 44.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.416 HD11 ' C ' ' A' ' 11' ' ' ARG . 23.7 tp -104.11 33.9 3.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.476 HG13 ' CD2' ' A' ' 69' ' ' LEU . 2.4 m -66.51 -179.27 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.429 ' C ' HD21 ' A' ' 67' ' ' LEU . 1.2 p -173.09 158.15 3.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.46 104.42 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.897 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 -179.921 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.51 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.53 16.12 1.83 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.812 0.339 . . . . 0.0 110.933 -179.935 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.5 mmt180 -85.63 160.92 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.918 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -70.44 113.82 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 19.6 mt -114.54 172.32 7.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.9 p -151.59 159.32 44.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.466 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 72.5 mt -129.12 112.43 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -80.33 127.44 32.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -139.92 173.62 11.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.472 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -61.4 169.18 2.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.593 0.711 . . . . 0.0 111.091 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.77 -3.07 11.29 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.333 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 34.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.8 tp10 -101.17 137.89 38.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.865 0.364 . . . . 0.0 110.9 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.482 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.3 mtp180 -81.86 118.68 23.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.859 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.482 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -31.55 -43.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.937 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.92 40.89 42.8 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.411 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.2 pt -119.92 161.62 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -130.6 135.68 48.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 18.2 pt -129.56 156.41 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -132.73 132.93 42.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.36 -137.72 5.84 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.469 -179.931 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 mt -132.34 117.02 30.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 111.142 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.09 155.77 45.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.818 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.471 HD13 ' CD2' ' A' ' 63' ' ' LEU . 77.7 mt -64.57 126.32 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.156 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -105.37 -18.25 14.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.462 ' CA ' HG23 ' A' ' 65' ' ' VAL . 8.9 tttp -165.76 154.35 11.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.422 HG22 ' C ' ' A' ' 50' ' ' LYS . 98.1 t -145.27 124.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -68.05 133.15 91.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.67 0.748 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -8.35 23.37 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.645 2.23 . . . . 0.0 112.332 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 54.9 p -111.13 -9.58 14.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.68 168.53 51.32 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.55 -35.01 67.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.78 0.324 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.479 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -74.33 -65.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.103 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.79 -40.08 2.08 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -77.01 -28.45 55.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.796 0.331 . . . . 0.0 110.892 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 57' ' ' ALA . 9.9 t0 -54.28 -64.03 0.96 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.06 -24.23 6.36 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -92.46 -66.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.813 0.339 . . . . 0.0 110.833 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.471 ' CD2' HD13 ' A' ' 48' ' ' ILE . 1.4 tm? -48.34 118.02 2.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.475 ' CG ' ' CD1' ' A' ' 67' ' ' LEU . 2.2 ptp180 -142.69 154.85 44.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.462 HG23 ' CA ' ' A' ' 50' ' ' LYS . 63.1 t -61.31 106.06 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 147.68 -27.18 1.48 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.459 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.475 ' CD1' ' CG ' ' A' ' 64' ' ' ARG . 7.6 mp -74.79 140.62 44.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.773 0.32 . . . . 0.0 110.892 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 57.2 ttt180 -87.61 121.01 29.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.826 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.457 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.0 mm? -67.87 105.97 2.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.949 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.422 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 1.7 mm? -80.15 -50.43 10.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.422 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 24.2 mt-10 -159.17 142.92 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.6 t -114.75 109.6 29.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.131 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.411 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.1 m-20 65.38 41.77 4.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.411 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 28.4 mt-30 64.6 34.04 10.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.26 90.59 3.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.941 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.5 t -46.1 129.19 9.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.879 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.0 mt -78.82 -0.49 30.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.06 116.7 17.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.59 -34.7 4.28 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.457 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.41 HD12 ' N ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -88.48 170.9 10.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.888 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 82' ' ' HIS . 42.0 p -107.8 160.92 15.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.095 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.446 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -32.97 -53.5 0.36 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.87 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.28 -49.96 57.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -64.38 -45.41 87.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.844 0.354 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.41 ' N ' HD12 ' A' ' 80' ' ' LEU . . . -57.67 -47.51 82.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 78.6 t -59.25 -58.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.476 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 74.7 mm-40 -51.24 -26.06 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 tt -72.3 -29.24 63.67 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.962 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.5 -29.59 46.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.895 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.476 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 2.4 ptm85 -92.51 0.77 57.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 21.6 t -98.99 36.24 1.73 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.88 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.501 HG23 ' CA ' ' A' ' 96' ' ' LEU . 2.1 p -111.6 144.94 18.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.09 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.481 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -64.8 -105.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 19' ' ' PRO . 1.3 t70 -103.39 -3.33 25.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.912 0.386 . . . . 0.0 110.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.426 ' O ' ' CG2' ' A' ' 92' ' ' VAL . 49.8 m -166.14 143.08 5.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.501 ' CA ' HG23 ' A' ' 92' ' ' VAL . 1.0 OUTLIER -120.8 168.41 11.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -120.33 98.18 5.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.16 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.2 m -98.65 130.37 47.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.104 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.4 tp -96.4 21.49 9.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.457 HG11 ' CD2' ' A' ' 69' ' ' LEU . 3.0 m -52.26 -175.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.106 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.5 p -175.96 157.58 1.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -52.65 100.82 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.465 -179.905 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.496 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.3 29.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.796 0.332 . . . . 0.0 110.914 -179.924 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.48 ' CZ ' ' HB2' ' A' ' 11' ' ' ARG . 23.1 mtm105 -96.32 142.36 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.422 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.5 tt0 -53.35 114.9 1.65 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.69 163.49 16.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.943 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.7 p -146.09 153.72 41.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.431 ' CG2' ' HB2' ' A' ' 56' ' ' ALA . 82.7 mt -120.95 110.34 27.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.083 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -85.11 102.45 13.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.443 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 3.4 ptpp? -112.33 171.56 7.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.854 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.47 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.72 168.79 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.619 0.723 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.47 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.85 0.95 4.97 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.321 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.61 41.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.507 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -105.66 140.53 38.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 110.889 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.467 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.3 ptm180 -86.36 122.78 30.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.824 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.47 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.16 -46.9 0.17 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.32 44.76 51.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.47 HG12 ' CD1' ' A' ' 23' ' ' LEU . 0.9 OUTLIER -118.68 168.04 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.854 0.359 . . . . 0.0 111.111 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.414 ' C ' HG23 ' A' ' 27' ' ' ILE . 1.8 m -133.75 147.16 51.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.433 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.7 pt -138.32 155.63 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.152 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.5 ptt180 -126.83 124.54 39.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.857 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.55 -147.15 15.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 mt -126.85 116.99 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.111 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.57 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -129.13 153.85 47.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.477 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 23.5 mt -62.78 138.26 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.1 t -118.18 -16.91 9.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.848 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.464 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 64.9 tttt -165.22 146.96 7.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.889 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.4 t -142.11 133.62 26.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.168 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 7.8 t -74.7 141.79 76.31 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.681 0.753 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -31.21 20.96 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.663 2.242 . . . . 0.0 112.324 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 47.8 p -93.56 -6.66 46.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.151 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.9 150.63 46.37 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.443 ' CB ' ' HB3' ' A' ' 17' ' ' LYS . . . -40.88 -31.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.809 0.338 . . . . 0.0 111.098 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.478 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -77.8 -65.55 0.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.088 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -41.11 -34.44 0.88 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -90.82 -23.22 20.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.478 ' N ' ' O ' ' A' ' 57' ' ' ALA . 10.7 t0 -52.58 -52.24 56.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.34 -7.94 40.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.518 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -115.39 -48.61 2.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.43 ' HB3' ' CB ' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -67.39 130.84 44.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.413 ' HD3' ' C ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER -161.52 157.41 24.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.849 179.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 80.5 t -59.67 105.89 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.31 -15.58 1.67 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.422 HD22 ' C ' ' A' ' 101' ' ' CYS . 58.1 mt -85.45 134.27 34.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.57 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 72.3 ttt180 -84.1 121.79 27.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.42 ' CD2' HG11 ' A' ' 100' ' ' VAL . 1.6 mm? -70.28 116.14 10.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 71.6 mt -96.87 -49.42 5.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.94 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -155.13 141.75 18.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.4 t -118.73 108.27 23.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.075 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 65.7 40.91 4.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 64.01 35.21 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -131.07 91.1 2.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.4 t -42.4 128.79 3.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.68 9.01 6.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.933 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.09 137.6 34.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.76 -33.22 6.05 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.489 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.434 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -88.08 166.96 14.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.887 0.375 . . . . 0.0 110.91 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.0 p -106.92 165.43 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 81' ' ' THR . 1.8 t-80 -33.82 -60.54 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.53 -47.68 22.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.434 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.3 mt-10 -66.01 -53.01 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.853 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -49.4 -49.35 45.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 61.2 t -59.1 -57.06 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -53.04 -17.51 1.54 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 tt -83.98 -28.08 28.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.424 HD11 ' CD1' ' A' ' 25' ' ' ILE . 0.6 OUTLIER -84.12 -27.4 28.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.9 ptm180 -97.03 5.74 49.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 m -102.27 32.43 3.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.885 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.459 HG21 ' N ' ' A' ' 93' ' ' GLY . 2.5 p -111.11 140.04 32.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.117 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.459 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -56.56 -100.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.487 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.408 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -113.17 -10.56 13.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.906 0.384 . . . . 0.0 110.868 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.1 m -151.64 135.39 16.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.131 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.451 ' CB ' HG22 ' A' ' 92' ' ' VAL . 1.1 pt? -124.17 171.26 9.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.422 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.4 m -120.69 96.6 5.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.2 m -94.25 128.64 45.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.162 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.6 tp -97.11 29.07 3.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.42 HG11 ' CD2' ' A' ' 69' ' ' LEU . 14.0 m -58.48 172.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.115 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.422 ' C ' HD22 ' A' ' 67' ' ' LEU . 2.8 p -162.27 148.47 13.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.16 110.62 0.45 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.921 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.481 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.21 33.94 0.51 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 110.939 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.432 ' O ' ' CD1' ' A' ' 13' ' ' LEU . 20.5 mtt-85 -99.28 165.03 11.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.421 ' CG ' HG23 ' A' ' 97' ' ' THR . 42.1 tt0 -77.84 110.18 12.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.432 ' CD1' ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -115.27 166.12 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.93 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.4 p -146.89 160.9 41.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.8 mt -124.1 115.17 44.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mp0 -85.21 113.11 21.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.6 ptpp? -126.89 165.41 19.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.472 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -47.65 169.12 0.13 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.78 -2.84 10.87 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.36 38.28 0.33 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.556 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -103.53 140.64 37.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.815 0.34 . . . . 0.0 110.909 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.453 ' O ' ' C ' ' A' ' 23' ' ' LEU . 6.2 ptt85 -83.27 121.22 26.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -33.9 -54.12 0.47 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.37 40.51 9.98 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.439 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.431 ' CD1' HD13 ' A' ' 89' ' ' LEU . 4.1 pt -120.22 169.72 11.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.146 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.4 m -141.17 145.07 35.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.7 pt -134.85 158.96 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.118 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -131.4 133.29 45.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.73 -142.61 10.08 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.499 -179.929 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.2 mt -129.51 118.34 45.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.864 0.364 . . . . 0.0 111.151 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -132.17 -177.74 4.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.476 ' CD1' ' CD1' ' A' ' 63' ' ' LEU . 54.8 mt -87.57 133.82 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.142 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -113.59 -14.55 12.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.47 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 24.6 tttm -172.51 145.21 1.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.944 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 65' ' ' VAL . 0.6 OUTLIER -152.92 110.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.15 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.4 t -53.83 129.6 56.12 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.678 0.751 . . . . 0.0 110.85 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.36 18.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.712 2.274 . . . . 0.0 112.29 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 32.2 p -105.07 -18.43 14.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.173 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.24 179.81 14.15 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.49 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.428 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -57.69 -39.1 76.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.762 0.315 . . . . 0.0 111.08 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -74.99 -63.65 1.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.14 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.46 -48.56 1.69 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.441 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.428 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.5 ptt180 -70.63 -31.17 68.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 57' ' ' ALA . 31.2 t0 -44.55 -61.62 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.838 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.38 -20.34 10.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.477 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.6 mmp_? -99.61 -47.47 5.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.896 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.479 HD13 ' N ' ' A' ' 64' ' ' ARG . 0.5 OUTLIER -61.11 130.36 45.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.936 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.479 ' N ' HD13 ' A' ' 63' ' ' LEU . 16.8 ptt85 -162.01 146.0 12.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 82.7 t -53.87 106.58 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.156 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 143.09 -11.42 2.31 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.48 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 34.6 mt -86.52 124.02 32.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.854 0.359 . . . . 0.0 110.922 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.546 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 57.5 ttt180 -75.23 117.49 17.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.463 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.6 mm? -71.45 114.24 9.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 75.5 mt -90.43 -54.76 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.975 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -150.1 143.34 25.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.2 t -115.94 110.13 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.127 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 14.2 m-20 65.62 41.12 4.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 64.43 30.46 13.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 22.8 mt-30 -124.64 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 t -44.04 133.87 4.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.811 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.413 ' C ' HD23 ' A' ' 80' ' ' LEU . 13.3 mt -88.94 7.63 33.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.31 116.16 17.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.76 -33.25 5.3 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.463 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -86.4 164.54 16.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.91 0.386 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 82' ' ' HIS . 81.9 p -104.1 165.51 11.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.167 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -34.7 -59.92 0.46 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.834 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.09 -49.85 23.3 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.436 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.9 mt-10 -63.02 -51.7 65.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.89 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.01 -51.75 55.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.117 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.15 -60.45 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.471 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 78.1 mm-40 -50.36 -26.17 4.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.04 -29.95 62.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.923 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.431 HD13 ' CD1' ' A' ' 25' ' ' ILE . 0.6 OUTLIER -79.84 -27.11 40.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.471 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 0.6 OUTLIER -96.96 -3.17 42.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.86 179.94 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.4 m -89.76 29.94 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.872 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.472 HG21 ' N ' ' A' ' 93' ' ' GLY . 3.0 p -110.45 144.04 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.17 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.472 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -61.94 -101.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -111.39 -6.67 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.897 0.379 . . . . 0.0 110.854 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.7 m -155.24 136.47 13.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.468 ' CB ' HG22 ' A' ' 92' ' ' VAL . 1.0 OUTLIER -126.49 167.2 15.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.983 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.421 HG23 ' CG ' ' A' ' 12' ' ' GLU . 1.3 m -116.54 94.52 4.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.175 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.5 m -91.05 127.15 43.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.162 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 19.1 tp -95.97 33.03 1.77 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.878 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' A' ' 69' ' ' LEU . 5.9 m -60.98 174.62 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.146 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -167.78 155.12 8.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.83 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -51.5 107.6 0.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.852 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.467 -179.948 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.263 0 N-CA-C 112.489 -0.245 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.498 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.43 30.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.328 . . . . 0.0 110.907 -179.916 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.4 mtp180 -94.95 161.37 14.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -70.92 112.17 6.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.873 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.6 mt -116.88 159.52 22.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 3.0 m -142.45 159.66 41.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mt -125.58 114.57 40.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.173 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -88.6 107.66 19.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.416 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 1.0 OUTLIER -116.18 166.14 12.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.469 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.25 168.72 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.578 0.704 . . . . 0.0 111.097 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.79 3.35 2.83 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.703 2.268 . . . . 0.0 112.334 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -169.79 36.24 0.18 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.462 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.411 ' O ' ' CD ' ' A' ' 17' ' ' LYS . 17.7 tp10 -105.47 142.52 35.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.889 0.376 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' O ' ' C ' ' A' ' 23' ' ' LEU . 58.8 mtt180 -88.94 123.37 33.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.829 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.48 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -31.49 -49.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 77.41 32.48 47.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.487 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.466 HG12 ' CG ' ' A' ' 23' ' ' LEU . 1.5 pt -108.87 160.0 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.817 0.342 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.429 ' C ' HG21 ' A' ' 27' ' ' ILE . 0.5 OUTLIER -123.6 150.61 43.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.464 ' CD1' HG21 ' A' ' 86' ' ' VAL . 27.5 pt -140.36 150.92 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -128.47 131.85 48.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.9 -144.85 13.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.443 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.443 HG12 ' N ' ' A' ' 30' ' ' GLY . 26.8 mt -128.83 116.43 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.871 0.367 . . . . 0.0 111.133 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.6 m-85 -131.13 153.26 49.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.401 HD11 ' CD1' ' A' ' 63' ' ' LEU . 70.3 mt -62.67 128.22 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.419 ' C ' HG11 ' A' ' 65' ' ' VAL . 1.4 t -107.13 -18.89 13.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.483 ' CA ' HG21 ' A' ' 65' ' ' VAL . 8.4 tttp -159.89 153.41 22.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.46 HG23 ' CD1' ' A' ' 63' ' ' LEU . 78.7 t -143.28 127.52 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 29.1 t -66.24 140.29 96.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.726 0.774 . . . . 0.0 110.813 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -35.66 12.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.721 2.281 . . . . 0.0 112.328 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.02 -1.43 45.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.092 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -73.11 148.83 41.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.501 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.468 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -39.86 -35.18 0.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.82 0.343 . . . . 0.0 111.119 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.409 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -74.11 -59.66 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.082 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -47.89 -33.18 9.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.468 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.6 ptt-85 -84.97 -32.26 23.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.457 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 11.1 t0 -50.1 -61.57 2.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.839 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.22 -18.74 13.76 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.501 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -96.71 -42.81 7.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.828 0.347 . . . . 0.0 110.89 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.472 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.2 tm? -69.83 136.54 50.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.472 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -166.67 155.26 10.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.483 HG21 ' CA ' ' A' ' 50' ' ' LYS . 85.2 t -61.25 105.55 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.45 -24.74 1.22 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.533 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.426 HD23 ' C ' ' A' ' 101' ' ' CYS . 12.7 mt -74.85 135.88 41.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 45.8 ttt180 -85.69 117.59 24.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.873 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.473 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.3 mm? -68.11 116.07 8.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 75.8 mt -94.09 -52.29 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -152.13 145.71 24.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.873 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.9 t -119.5 108.38 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.118 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 65.12 41.54 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.9 mt-30 64.07 32.11 13.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -125.35 91.11 3.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 t -47.82 126.41 10.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.422 ' C ' HD21 ' A' ' 80' ' ' LEU . 11.4 mt -78.04 -0.37 27.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.863 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.37 115.38 11.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.922 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.93 -34.4 4.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.479 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.463 HD11 ' N ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -90.99 164.01 14.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.841 0.353 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 82' ' ' HIS . 38.1 p -102.18 163.39 12.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -34.32 -58.33 0.47 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.837 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.33 -45.68 21.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.46 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.435 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 10.3 mm-40 -70.93 -53.46 14.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.853 0.359 . . . . 0.0 110.838 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.463 ' N ' HD11 ' A' ' 80' ' ' LEU . . . -47.03 -49.01 21.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.049 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.464 HG21 ' CD1' ' A' ' 27' ' ' ILE . 70.0 t -57.34 -59.12 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.477 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 83.3 mm-40 -51.08 -22.79 2.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.917 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -75.62 -31.83 60.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.966 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.87 -27.93 49.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.962 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.477 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.9 ptm180 -94.41 1.5 55.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.866 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.9 t -94.62 30.92 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.407 HG22 ' N ' ' A' ' 93' ' ' GLY . 2.4 p -113.17 146.48 17.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.13 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.407 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -63.62 -95.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.492 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -119.55 -2.08 10.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.912 0.387 . . . . 0.0 110.9 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 m -157.14 132.01 8.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -122.95 164.37 18.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.944 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -113.07 94.14 4.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.74 129.04 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.0 tp -98.51 29.81 3.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.956 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.473 HG11 ' CD2' ' A' ' 69' ' ' LEU . 15.7 m -54.42 179.19 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.426 ' C ' HD23 ' A' ' 67' ' ' LEU . 3.3 p -171.52 148.75 2.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -41.19 113.61 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.849 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.467 -179.949 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.418 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.477 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.37 41.39 0.61 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.794 0.331 . . . . 0.0 110.889 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.7 mmm180 -111.34 152.37 27.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.465 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 19.0 tt0 -68.38 109.18 3.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.909 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.6 mt -106.52 168.72 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -151.4 147.85 27.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.423 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 71.1 mt -118.66 120.23 63.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -88.46 125.61 34.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.8 ptpp? -138.68 168.56 19.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.471 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -48.69 168.9 0.17 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.585 0.707 . . . . 0.0 111.122 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.471 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.7 2.02 3.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.672 2.248 . . . . 0.0 112.379 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.58 35.53 0.17 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.5 tp10 -99.02 149.74 22.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' C ' ' A' ' 23' ' ' LEU . 86.4 mtt180 -89.46 121.6 31.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.461 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -32.91 -46.55 0.15 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.5 42.55 17.7 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.43 HG12 ' CD1' ' A' ' 23' ' ' LEU . 2.6 pt -126.01 168.66 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.842 0.353 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -138.91 142.73 38.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 pt -128.82 163.08 34.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.471 ' CG ' ' HB3' ' A' ' 49' ' ' SER . 22.6 ptt180 -134.56 124.71 25.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 158.81 -143.17 8.99 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 -179.913 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.8 mt -133.86 117.75 27.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.821 0.343 . . . . 0.0 111.132 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.1 m-85 -131.25 154.07 48.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.463 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 37.6 mt -58.99 138.14 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.471 ' HB3' ' CG ' ' A' ' 28' ' ' ARG . 60.7 p -117.48 -18.68 9.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.845 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.416 ' CA ' HG23 ' A' ' 65' ' ' VAL . 5.0 ttpm? -165.56 155.01 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.919 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.4 t -148.68 128.66 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 33.9 t -81.74 139.15 46.94 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.668 0.747 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.57 23.83 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.713 2.275 . . . . 0.0 112.356 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 59.7 p -80.83 -19.25 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.06 170.62 40.76 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.08 -33.65 72.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.326 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.488 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -71.2 -70.45 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.59 -40.95 0.76 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.471 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 10.7 ptt180 -75.68 -34.67 60.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.783 0.325 . . . . 0.0 110.829 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 57' ' ' ALA . 15.3 t0 -47.72 -64.7 0.72 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.36 -19.4 8.63 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.476 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 42.9 mtm180 -96.72 -61.55 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.888 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.476 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.8 tm? -46.4 133.4 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.476 ' N ' HD13 ' A' ' 63' ' ' LEU . 6.2 ptt180 -156.24 149.95 24.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.847 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.463 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 45.1 t -61.26 100.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.106 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 153.59 -19.89 0.7 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.445 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.429 HD22 ' C ' ' A' ' 101' ' ' CYS . 9.8 mt -77.81 140.74 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.783 0.325 . . . . 0.0 110.921 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 70.8 ttt180 -88.72 119.13 28.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.467 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.1 mm? -71.4 107.0 4.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.425 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 11.1 mp -83.45 -53.29 5.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.425 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -151.68 146.65 25.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.5 t -117.84 109.49 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 66.18 41.81 3.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.918 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.9 mt-30 64.64 29.96 12.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -122.9 89.04 3.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.1 t -40.49 129.03 2.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 83.9 mt -83.08 12.27 5.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.939 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -86.13 112.83 21.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.05 -38.97 2.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.442 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -84.15 168.53 15.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 23.0 p -108.62 166.1 11.04 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.168 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -33.13 -61.77 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.4 -48.55 21.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.481 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.442 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.6 mt-10 -65.05 -55.98 15.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.87 0.366 . . . . 0.0 110.863 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -45.76 -50.36 14.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 71.2 t -55.64 -59.61 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.469 ' NE2' ' HD3' ' A' ' 90' ' ' ARG . 51.8 mm-40 -50.12 -25.41 3.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.886 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.1 tt -74.85 -32.16 61.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.881 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.96 -30.09 50.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.469 ' HD3' ' NE2' ' A' ' 87' ' ' GLN . 12.6 ptm180 -92.72 -7.13 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.874 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.5 m -87.84 30.01 0.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.471 HG21 ' CB ' ' A' ' 96' ' ' LEU . 2.9 p -106.69 143.73 16.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.466 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -62.51 -102.68 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.481 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -105.98 -13.41 15.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.886 0.374 . . . . 0.0 110.843 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.4 ' O ' ' CG2' ' A' ' 92' ' ' VAL . 3.3 m -153.89 141.29 19.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.177 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.471 ' CB ' HG21 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -124.01 169.52 11.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.465 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -122.02 99.35 6.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.9 m -96.14 130.99 44.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp -97.12 31.31 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.467 HG13 ' CD2' ' A' ' 69' ' ' LEU . 11.3 m -59.8 177.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.137 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.429 ' C ' HD22 ' A' ' 67' ' ' LEU . 13.2 p -175.23 143.06 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -38.69 104.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.871 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.455 -179.954 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.47 ' N ' HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.17 39.87 0.6 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.915 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.8 mtp180 -111.76 148.13 34.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.434 ' CG ' ' CG2' ' A' ' 97' ' ' THR . 33.7 tt0 -61.89 111.29 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.5 mt -113.08 161.83 16.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -140.66 155.25 46.55 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 88.7 mt -123.01 108.71 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -84.53 114.98 22.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.411 ' NZ ' ' C ' ' A' ' 94' ' ' ASP . 0.5 OUTLIER -125.65 171.02 10.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.459 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.85 168.2 0.11 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.583 0.706 . . . . 0.0 111.07 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 2.81 3.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.704 2.27 . . . . 0.0 112.379 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -173.61 41.04 0.14 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.481 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -107.36 147.16 30.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.876 0.37 . . . . 0.0 110.899 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.7 mmt-85 -83.95 122.95 29.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.478 ' CD1' ' HB3' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.53 -47.58 0.23 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.16 41.48 13.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 3.0 pt -121.54 166.89 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.845 0.355 . . . . 0.0 111.154 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.444 ' C ' HG22 ' A' ' 27' ' ' ILE . 0.5 OUTLIER -130.3 149.76 51.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.85 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.444 HG22 ' C ' ' A' ' 26' ' ' SER . 30.1 pt -140.57 149.25 21.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.102 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.419 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 4.3 ptm85 -130.81 144.37 51.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 125.51 -155.48 18.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.454 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.454 HG12 ' N ' ' A' ' 30' ' ' GLY . 52.5 mt -139.95 116.65 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.874 0.368 . . . . 0.0 111.114 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 0.7 OUTLIER -133.46 156.17 48.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.861 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.46 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 82.9 mt -58.98 129.95 21.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.145 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.429 ' C ' HG12 ' A' ' 65' ' ' VAL . 11.2 p -103.89 -13.3 16.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.473 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 40.2 tttt -173.9 162.89 4.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.473 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 99.3 t -150.14 133.1 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.407 ' N ' HG12 ' A' ' 51' ' ' VAL . 8.2 t -75.35 142.3 74.72 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.678 0.751 . . . . 0.0 110.878 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -23.47 30.44 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.713 2.275 . . . . 0.0 112.343 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 80.0 p -103.52 -14.59 16.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.42 154.95 19.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.41 ' CB ' ' HB3' ' A' ' 17' ' ' LYS . . . -46.46 -33.75 4.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.821 0.343 . . . . 0.0 111.123 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.478 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -75.19 -60.52 2.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.35 -43.49 6.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -79.82 -21.88 43.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.77 0.319 . . . . 0.0 110.84 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 57' ' ' ALA . 12.9 t70 -55.02 -59.45 4.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.865 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.8 -4.19 14.56 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -118.48 -70.5 0.79 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 110.927 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.473 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -37.22 140.34 0.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.473 ' N ' HD13 ' A' ' 63' ' ' LEU . 9.0 ptm180 -167.04 161.4 14.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.46 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 18.7 t -70.27 102.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.125 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.68 -9.03 1.37 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.5 mt -89.25 128.22 35.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.331 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -78.59 121.54 24.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.47 ' HB3' ' CD1' ' A' ' 77' ' ' LEU . 2.1 mm? -70.24 111.79 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.3 mt -89.24 -49.44 6.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.928 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -155.17 141.87 18.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.937 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.456 ' HB ' ' CD2' ' A' ' 88' ' ' LEU . 72.7 t -118.67 109.31 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 65.43 40.65 4.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.7 mt-30 63.75 34.62 11.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.881 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -129.2 90.31 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.7 t -42.89 131.47 4.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.47 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 23.5 mt -89.81 9.04 28.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.953 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.32 131.5 38.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.943 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.03 -43.98 1.57 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.438 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -79.18 155.89 28.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.884 0.373 . . . . 0.0 110.948 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 68.7 p -93.71 -174.54 3.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -49.52 -61.91 1.84 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -46.35 -57.48 6.42 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 27.2 mt-10 -56.08 -42.05 76.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.902 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -60.91 -48.54 81.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.11 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 67.8 t -52.52 -57.78 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.122 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.469 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 57.3 mm-40 -52.67 -20.35 3.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.899 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.456 ' CD2' ' HB ' ' A' ' 72' ' ' VAL . 1.7 tt -79.71 -26.85 40.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.944 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.409 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -82.27 -22.43 35.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.844 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.469 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.0 ptm180 -96.74 -0.15 48.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 p -83.21 16.69 2.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.487 HG22 ' N ' ' A' ' 93' ' ' GLY . 4.5 p -106.8 141.05 22.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.487 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -70.99 -86.51 0.15 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.48 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.411 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 2.0 p30 -119.89 -12.54 9.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.2 m -149.3 132.65 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.175 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.461 ' CA ' HG23 ' A' ' 92' ' ' VAL . 0.8 OUTLIER -123.47 170.98 9.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.434 ' CG2' ' CG ' ' A' ' 12' ' ' GLU . 3.3 m -121.5 99.31 6.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.1 m -96.41 131.42 43.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 18.4 tp -98.32 31.3 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.953 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.467 HG13 ' CD2' ' A' ' 69' ' ' LEU . 5.8 m -62.59 176.88 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.112 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.1 p -171.67 145.23 1.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -42.27 100.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.912 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.53 -179.956 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.339 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.482 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.67 16.06 1.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.888 -179.909 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -89.44 149.29 23.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.416 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 30.3 tt0 -59.7 115.31 3.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.1 mt -116.69 160.66 20.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 2.7 m -139.93 157.39 45.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.403 ' C ' HG21 ' A' ' 95' ' ' THR . 34.8 mt -125.42 107.04 17.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -80.53 107.76 13.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -117.29 168.24 10.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.428 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -47.92 166.78 0.2 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.58 0.705 . . . . 0.0 111.103 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.428 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.4 Cg_endo -69.75 2.87 3.14 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.659 2.24 . . . . 0.0 112.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.24 38.18 0.19 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.482 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.5 tp10 -101.98 133.98 45.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.837 0.351 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 23' ' ' LEU . 91.3 mtt180 -78.95 116.87 19.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.475 HD13 ' CB ' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -34.02 -51.84 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.939 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.27 42.62 34.57 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.474 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.431 HG22 ' CD1' ' A' ' 23' ' ' LEU . 1.3 pt -116.26 177.59 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.881 0.372 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.493 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -141.91 157.53 44.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.409 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.3 pt -149.33 151.01 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -127.11 122.99 35.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.63 -156.91 28.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.879 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.486 -0.245 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 62.9 mt -124.66 118.32 53.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.113 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CZ ' ' HD2' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.41 -175.6 3.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.468 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 96.4 mt -85.47 138.65 18.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.088 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 53.4 p -116.04 -16.44 11.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.493 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -171.83 150.94 2.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.467 ' CG1' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -160.95 110.24 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.092 179.836 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 40.1 t -58.12 137.75 84.23 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.742 . . . . 0.0 110.853 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -23.15 31.13 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.665 2.244 . . . . 0.0 112.353 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.5 p -89.24 -16.91 30.13 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.15 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.51 172.28 35.57 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.17 -38.84 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.78 0.324 . . . . 0.0 111.086 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.475 ' CB ' HD13 ' A' ' 23' ' ' LEU . . . -73.32 -59.33 2.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.072 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.17 -39.38 6.84 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.51 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 23.5 ptt180 -80.73 -20.76 42.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.844 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.402 ' N ' ' O ' ' A' ' 57' ' ' ALA . 13.9 t70 -60.53 -58.99 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.28 -15.71 32.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.476 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? -108.37 8.92 27.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.858 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.462 HD12 ' N ' ' A' ' 64' ' ' ARG . 0.9 OUTLIER -123.3 119.38 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.462 ' N ' HD12 ' A' ' 63' ' ' LEU . 28.2 mtp180 -145.3 165.64 27.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 77.9 t -77.11 97.17 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.49 -23.21 0.5 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.478 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.5 mp -71.75 159.93 33.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HD2' ' CZ ' ' A' ' 47' ' ' PHE . 29.8 ttt-85 -105.71 118.06 35.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.453 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.3 mm? -66.3 103.18 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.907 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.502 ' CD1' ' NH1' ' A' ' 68' ' ' ARG . 9.7 mp -82.42 -42.23 18.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 68.8 mt-10 -162.05 142.73 10.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.6 108.23 21.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.153 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.437 ' ND2' HG21 ' A' ' 92' ' ' VAL . 12.5 m-20 65.33 41.2 4.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 63.37 31.84 14.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -126.16 92.61 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.8 t -46.4 124.09 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.435 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 9.6 mt -81.29 3.46 23.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.66 122.67 26.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.87 -31.78 6.81 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.442 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -89.87 160.82 16.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.932 0.396 . . . . 0.0 110.901 -179.903 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 13.9 p -97.61 161.14 13.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.1 t-80 -33.91 -57.83 0.45 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.11 -44.05 56.71 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.495 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.442 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 23.5 mt-10 -67.17 -47.7 70.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.86 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -58.95 -55.71 31.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 91.9 t -43.54 -64.46 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.08 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.481 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 70.4 mm-40 -46.86 -25.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -75.85 -34.35 60.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.453 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -76.67 -29.03 56.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.962 179.85 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.481 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.2 ptm180 -93.82 4.49 53.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.897 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.6 t -96.3 29.71 2.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.475 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 12.4 t -94.5 150.58 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.472 ' N ' HG11 ' A' ' 92' ' ' VAL . . . -93.55 -75.15 1.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -121.27 -26.03 5.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 0.0 110.855 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.403 HG21 ' C ' ' A' ' 15' ' ' ILE . 32.1 m -155.81 138.74 15.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.138 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.475 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.0 OUTLIER -120.01 165.25 14.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.416 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.8 m -116.41 96.47 5.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.136 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.45 ' CG1' HD12 ' A' ' 96' ' ' LEU . 3.4 m -98.38 129.42 48.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . 0.412 ' CD1' ' HA ' ' A' ' 12' ' ' GLU . 22.6 tp -96.16 20.23 10.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.453 HG11 ' CD2' ' A' ' 69' ' ' LEU . 26.2 m -48.88 177.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.057 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -175.46 162.93 2.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.69 118.9 6.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.472 -179.933 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.452 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.88 36.86 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.791 0.329 . . . . 0.0 110.918 -179.919 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -108.31 173.86 6.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.447 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.4 tt0 -81.92 112.71 19.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.906 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.2 mp -117.26 168.92 9.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.5 p -148.29 157.02 43.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.416 ' CG2' ' HB3' ' A' ' 56' ' ' ALA . 86.8 mt -120.97 111.33 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -80.0 117.73 21.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.7 ptpt -132.18 166.47 21.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.86 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.466 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.0 168.63 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.551 0.691 . . . . 0.0 111.115 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.1 Cg_endo -69.83 -2.26 9.93 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 0.0 112.3 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.82 35.69 0.25 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.7 tp10 -99.84 147.14 25.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.915 0.388 . . . . 0.0 110.85 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 11.2 mtt-85 -86.93 123.67 32.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.847 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.458 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -34.23 -52.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.68 41.3 9.01 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.458 HG12 ' CD1' ' A' ' 23' ' ' LEU . 3.5 pt -122.76 170.91 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.785 0.326 . . . . 0.0 111.16 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.423 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -130.36 160.79 32.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.829 -179.901 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.433 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 14.8 pt -151.2 145.62 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.169 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.457 ' CG ' ' HB2' ' A' ' 49' ' ' SER . 18.8 ptt85 -128.88 122.01 29.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 163.6 -149.41 16.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.26 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.884 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.3 mt -132.84 117.9 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 111.097 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -131.63 154.86 48.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.93 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.462 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 38.7 mt -58.2 134.44 22.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.156 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.457 ' HB2' ' CG ' ' A' ' 28' ' ' ARG . 36.8 t -112.47 -10.49 13.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.884 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.454 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 19.8 ttmt -173.79 148.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.454 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 86.7 t -138.3 114.36 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.126 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.4 t -64.59 140.69 98.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.711 0.767 . . . . 0.0 110.846 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -30.15 22.75 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 30.1 p -89.99 -4.16 57.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.442 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -76.87 155.88 45.22 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.514 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -47.0 -39.11 11.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.764 0.316 . . . . 0.0 111.098 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.464 ' CB ' ' HB3' ' A' ' 63' ' ' LEU . . . -72.78 -58.76 3.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -39.3 -43.88 2.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 27.8 ptt180 -82.43 -26.15 32.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 110.855 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.444 ' N ' ' O ' ' A' ' 57' ' ' ALA . 24.5 t70 -53.58 -69.28 0.12 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.862 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.01 -13.73 12.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -101.5 -17.96 16.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.464 ' HB3' ' CB ' ' A' ' 57' ' ' ALA . 2.0 tm? -103.33 125.5 49.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.456 ' N ' HD11 ' A' ' 63' ' ' LEU . 15.1 mtm-85 -139.5 174.81 10.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.462 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 8.0 t -82.64 90.01 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.69 -15.37 0.3 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 56.0 mt -74.35 132.7 42.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.572 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 55.4 ttt180 -81.7 119.58 24.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.467 ' HB3' ' CD1' ' A' ' 77' ' ' LEU . 2.3 mm? -72.19 108.27 5.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.945 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 11.1 mp -86.39 -52.46 5.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -151.41 141.81 22.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.867 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 66.9 t -115.77 110.0 30.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.13 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 65.65 40.56 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 64.03 30.08 14.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.7 mt-30 -125.26 90.86 3.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.938 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 35.9 t -40.2 130.29 2.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.854 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.467 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 24.9 mt -88.11 17.44 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.939 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.452 ' O ' ' CD2' ' A' ' 80' ' ' LEU . 1.1 tp -85.75 152.69 22.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.907 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.07 -31.77 2.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.498 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.452 ' CD2' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -88.19 163.24 16.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.862 0.363 . . . . 0.0 110.923 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 56.7 p -99.06 -174.68 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.126 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.433 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.0 t-80 -52.66 -55.07 25.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.14 -50.19 63.3 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.415 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -58.75 -45.47 89.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.905 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -63.01 -48.76 77.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.0 t -53.96 -60.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.181 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.48 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 50.0 mm-40 -50.04 -23.42 2.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.957 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -76.8 -30.76 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.96 -30.55 44.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.925 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.48 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.2 ptp180 -89.96 1.74 55.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.4 t -93.26 29.51 1.9 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.465 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 17.6 t -97.39 149.12 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.109 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.454 ' N ' HG13 ' A' ' 92' ' ' VAL . . . -88.57 -77.79 1.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -118.85 -23.88 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.889 0.376 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 8.2 m -158.12 143.09 16.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.145 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.465 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.2 pt? -124.05 168.97 12.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.447 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.7 m -120.57 98.84 6.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.144 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 6.5 m -95.62 131.19 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.107 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 17.6 tp -98.1 35.74 1.69 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.458 HG11 ' CD2' ' A' ' 69' ' ' LEU . 4.6 m -68.48 173.07 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.6 p -162.55 150.37 14.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -49.99 101.78 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.476 -179.898 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.476 HD22 ' N ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.07 39.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 -179.894 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.429 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 5.3 mmm180 -113.76 158.27 21.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.404 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -67.43 109.66 3.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.7 mt -114.98 155.5 26.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 28.2 p -138.24 151.95 48.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.472 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 39.4 mt -115.06 116.44 52.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -87.95 120.52 29.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.91 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.448 ' CB ' ' HB2' ' A' ' 56' ' ' ALA . 0.5 OUTLIER -129.89 164.27 24.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.958 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.479 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -46.31 169.13 0.1 OUTLIER Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.596 0.712 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.479 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.81 3.15 2.97 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.687 2.258 . . . . 0.0 112.308 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.35 34.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -103.62 140.27 37.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.843 0.354 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.0 mmp_? -85.83 123.93 31.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -34.05 -43.77 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.882 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 71.53 44.79 49.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.524 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.429 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.1 pt -125.76 177.58 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.809 0.338 . . . . 0.0 111.126 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.43 ' C ' HG23 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -141.02 154.29 45.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.433 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.2 pt -138.72 149.37 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -125.53 125.94 44.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.07 -150.79 22.6 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.492 -179.861 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 mt -123.38 118.13 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.896 0.379 . . . . 0.0 111.117 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.577 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -128.61 150.91 50.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.5 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 56.0 mt -56.37 146.36 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.104 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.474 ' N ' HG23 ' A' ' 48' ' ' ILE . 82.1 p -120.85 -24.53 5.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.856 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.466 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 24.5 ttmt -154.97 156.05 35.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.491 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 76.8 t -147.95 113.83 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 42.5 t -57.6 137.14 82.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.688 0.756 . . . . 0.0 110.844 -179.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -22.23 32.49 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.29 -9.22 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.77 155.86 53.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -44.15 -35.08 2.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 111.109 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 -56.47 5.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -51.5 -38.65 43.28 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.7 ptt-85 -76.73 -28.85 55.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.799 0.333 . . . . 0.0 110.86 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -55.27 -64.36 0.87 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.55 -6.02 16.6 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.468 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -109.44 -50.36 3.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.836 0.35 . . . . 0.0 110.91 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.5 ' CD2' ' CD1' ' A' ' 48' ' ' ILE . 1.6 tm? -64.59 122.54 17.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.432 ' N ' HD13 ' A' ' 63' ' ' LEU . 30.9 mtt180 -152.81 141.53 20.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.448 ' O ' ' CG2' ' A' ' 65' ' ' VAL . 0.1 OUTLIER -51.54 95.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 179.968 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.47 -12.82 0.5 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.492 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.449 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 50.5 mt -83.24 151.22 25.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.745 0.307 . . . . 0.0 110.95 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.577 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 74.6 ttt180 -95.68 114.79 26.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.463 ' CD2' HG11 ' A' ' 100' ' ' VAL . 3.3 mm? -72.71 108.11 5.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.411 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 10.1 mp -84.4 -45.73 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.411 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 39.2 mt-10 -158.64 146.64 18.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 72.3 t -119.37 108.17 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.165 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 13.3 m-20 65.68 41.38 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.0 mt-30 64.16 34.4 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -128.49 91.24 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.6 t -47.76 123.88 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.425 ' C ' HD21 ' A' ' 80' ' ' LEU . 10.9 mt -79.73 9.96 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.1 123.37 27.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.932 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.69 -35.97 4.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.478 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -81.66 166.29 20.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.895 0.378 . . . . 0.0 110.914 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.462 ' O ' ' C ' ' A' ' 82' ' ' HIS . 70.8 p -101.24 158.74 15.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.1 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.462 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.57 -52.82 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.8 -45.7 90.92 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.472 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.436 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.8 mm-40 -63.97 -46.55 84.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.931 0.396 . . . . 0.0 110.907 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.417 ' N ' HD11 ' A' ' 80' ' ' LEU . . . -58.74 -47.87 83.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 70.7 t -54.74 -63.16 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.128 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 7.1 mm-40 -47.5 -26.57 1.43 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.6 tt -72.65 -33.82 66.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.964 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.78 -33.61 62.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.939 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.0 ptt85 -91.62 9.62 31.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 33.4 t -99.26 28.44 4.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.852 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.444 HG23 ' CB ' ' A' ' 96' ' ' LEU . 19.0 t -96.16 166.52 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.416 ' N ' HG13 ' A' ' 92' ' ' VAL . . . -103.04 -66.21 0.74 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.515 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.61 -24.92 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.899 0.381 . . . . 0.0 110.89 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.426 HG22 ' C ' ' A' ' 15' ' ' ILE . 24.9 m -159.8 140.48 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.182 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.444 ' CB ' HG23 ' A' ' 92' ' ' VAL . 1.1 pt? -116.48 167.64 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.929 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.404 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.0 m -118.91 96.36 5.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.17 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.8 m -95.9 128.45 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.1 tp -93.14 36.55 1.04 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.463 HG11 ' CD2' ' A' ' 69' ' ' LEU . 5.8 m -66.45 168.2 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.1 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.445 ' O ' ' C ' ' A' ' 102' ' ' ASP . 28.7 p -166.01 133.29 2.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.449 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 2.4 p30 -34.52 108.27 0.06 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 -179.91 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.55 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -86.4 26.54 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -92.89 169.68 10.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.876 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.455 ' CG ' HG21 ' A' ' 97' ' ' THR . 34.5 tt0 -80.06 110.44 15.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.3 mp -116.34 166.8 11.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.7 p -144.47 156.92 44.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.864 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.65 108.82 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.121 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -79.53 118.47 21.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.913 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.472 ' HZ2' ' N ' ' A' ' 95' ' ' THR . 0.4 OUTLIER -128.87 171.05 12.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.456 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -49.58 168.07 0.21 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.632 0.729 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.456 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.74 2.9 3.11 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.313 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.62 34.82 0.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.5 tp10 -104.11 130.59 51.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.877 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 9.3 ptt-85 -80.3 117.46 21.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.484 ' CD2' HG12 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -33.36 -50.67 0.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.933 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.73 47.52 8.64 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.477 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.484 HG12 ' CD2' ' A' ' 23' ' ' LEU . 2.9 pt -112.39 158.1 12.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 111.168 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -125.08 134.9 52.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.2 pt -126.86 163.51 29.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.4 ptt180 -136.23 125.75 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.61 -144.64 11.37 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.505 -179.915 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.454 -0.259 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 33.1 mt -125.74 117.6 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.851 0.358 . . . . 0.0 111.087 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.86 154.26 46.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.893 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.464 ' CD1' HD22 ' A' ' 63' ' ' LEU . 85.2 mt -64.23 126.58 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.101 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.9 t -103.97 -18.13 14.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.461 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 17.4 ttmt -165.56 160.75 17.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.927 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.444 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 95.6 t -157.07 127.98 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.105 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -67.94 141.99 94.99 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.658 0.742 . . . . 0.0 110.902 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -35.3 12.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.628 2.219 . . . . 0.0 112.403 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.2 p -91.25 3.65 54.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -78.49 161.5 48.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.437 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.4 ' HB2' ' CD1' ' A' ' 23' ' ' LEU . . . -51.12 -32.76 23.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.751 0.31 . . . . 0.0 111.104 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.54 -64.06 1.27 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.097 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.28 -33.4 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.475 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 60' ' ' ASP . 12.1 ptt180 -81.24 -47.09 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.868 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 17.2 t0 -40.95 -66.37 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.871 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 -13.52 13.85 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.466 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -97.76 -12.64 22.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.464 HD22 ' CD1' ' A' ' 48' ' ' ILE . 1.5 tm? -111.16 134.63 52.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.417 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -154.84 159.04 40.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.895 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 42.7 t -64.5 97.65 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.202 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.03 -20.91 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.46 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 66.3 mt -77.1 136.35 38.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.82 0.343 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.579 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 63.0 ttt180 -84.02 123.65 30.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.46 ' CD2' HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -72.77 111.62 8.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.42 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 49.1 mt -89.4 -49.36 6.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.42 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 13.5 mt-10 -158.28 140.86 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.419 ' CG1' HD11 ' A' ' 96' ' ' LEU . 84.0 t -112.09 111.2 35.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.0 m-20 65.23 40.96 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 40.4 mt-30 64.36 32.12 12.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -127.56 90.03 3.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 t -42.94 130.31 4.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.858 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 14.7 mt -81.31 6.93 12.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.95 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.62 123.96 27.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.943 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.13 -37.19 3.78 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.413 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -84.99 168.88 14.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.933 -179.925 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' C ' ' A' ' 82' ' ' HIS . 77.8 p -106.69 161.27 14.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.471 ' C ' ' O ' ' A' ' 81' ' ' THR . 4.3 t-80 -32.81 -55.8 0.37 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.31 -47.32 56.3 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.464 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.42 ' N ' ' O ' ' A' ' 81' ' ' THR . 11.1 mm-40 -66.51 -49.88 65.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.838 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -50.17 -50.15 49.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 68.9 t -56.16 -57.3 9.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.122 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.468 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 9.9 mm-40 -52.17 -23.33 5.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.912 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 tt -76.41 -27.15 56.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.408 HD12 ' CG1' ' A' ' 25' ' ' ILE . 0.5 OUTLIER -82.84 -25.12 32.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.861 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.468 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.4 ptm180 -97.63 -3.57 39.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 31.2 t -89.6 28.82 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.902 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.461 HG21 ' CA ' ' A' ' 96' ' ' LEU . 3.3 p -109.26 147.66 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.23 -98.49 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.495 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.464 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 0.8 OUTLIER -112.4 -11.31 13.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.89 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.472 ' N ' ' HZ2' ' A' ' 17' ' ' LYS . 6.4 m -153.03 137.22 16.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.104 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.461 ' CA ' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -121.65 169.42 10.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.455 HG21 ' CG ' ' A' ' 12' ' ' GLU . 1.3 m -117.28 95.58 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.4 m -91.98 128.87 43.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.148 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.9 21.13 10.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.923 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 69' ' ' LEU . 22.6 m -49.8 177.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.405 ' C ' HD23 ' A' ' 67' ' ' LEU . 1.8 p -169.26 147.62 3.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.46 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 0.7 OUTLIER -43.07 113.4 0.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.508 -179.921 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.475 ' N ' HD21 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.16 31.21 0.5 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.742 0.306 . . . . 0.0 110.854 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 -104.91 162.48 13.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.865 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.46 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 50.2 tt0 -73.31 113.17 10.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.46 ' O ' ' CG2' ' A' ' 97' ' ' THR . 26.2 mt -105.46 -174.87 2.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.909 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' O ' ' A' ' 96' ' ' LEU . 1.7 t -164.47 153.28 13.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.5 mt -125.82 118.72 52.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -94.04 115.68 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -128.65 164.53 22.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.469 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.12 168.75 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.578 0.704 . . . . 0.0 111.092 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.83 1.19 4.71 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.679 2.253 . . . . 0.0 112.325 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.48 42.88 0.23 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -107.77 141.24 39.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.903 0.383 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.9 mtt180 -83.59 120.72 26.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.468 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -32.55 -56.97 0.35 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.56 41.1 7.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.545 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.468 ' CD1' HD13 ' A' ' 89' ' ' LEU . 2.7 pt -121.68 171.17 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.414 ' C ' HG21 ' A' ' 27' ' ' ILE . 1.5 m -142.92 146.47 34.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.414 HG21 ' C ' ' A' ' 26' ' ' SER . 28.8 pt -136.41 161.32 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.153 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.417 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 4.4 ptm85 -132.14 140.42 48.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.11 -155.35 24.45 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.911 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 86.6 mt -127.81 117.95 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.837 0.351 . . . . 0.0 111.178 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.2 m-85 -131.49 -176.67 4.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.494 ' CD1' ' CD1' ' A' ' 63' ' ' LEU . 78.6 mt -84.74 139.92 16.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.136 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 24.4 p -119.07 -12.07 9.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.468 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 22.0 tttp -175.78 149.84 0.98 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.898 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.47 ' CG1' HG21 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -156.1 117.57 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.099 179.887 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.7 t -66.25 137.79 95.72 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.67 0.748 . . . . 0.0 110.846 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -26.45 27.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.354 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 67.5 p -82.33 -26.37 33.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.153 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.96 174.31 2.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.483 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.3 -32.3 73.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.845 0.355 . . . . 0.0 111.134 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -77.45 -69.33 0.54 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.19 -45.63 1.23 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.447 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.9 ptt180 -68.04 -35.27 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ALA . 32.0 t70 -45.29 -64.77 0.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.49 -19.35 6.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -98.34 -51.47 3.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.494 ' CD1' ' CD1' ' A' ' 48' ' ' ILE . 0.2 OUTLIER -55.31 130.43 42.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.896 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -162.69 151.23 14.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.481 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 64.7 t -59.92 104.89 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.67 -8.43 1.8 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.47 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.425 HD23 ' C ' ' A' ' 101' ' ' CYS . 23.5 mt -89.95 129.29 36.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.579 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 62.2 ttt180 -79.31 124.24 28.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.886 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.469 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.4 mm? -75.31 114.14 13.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.427 HD11 ' N ' ' A' ' 70' ' ' LEU . 7.4 mp -91.16 -50.69 5.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.917 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -155.4 141.98 18.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.459 ' CG1' HD11 ' A' ' 96' ' ' LEU . 88.0 t -114.58 108.38 25.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 65.93 42.06 3.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.925 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 64.43 29.86 13.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 -123.47 89.88 3.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.6 t -42.99 130.92 4.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.466 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 36.7 mt -85.25 7.68 21.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.41 126.66 31.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.41 -36.11 4.62 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.492 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.457 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -85.73 162.51 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.846 0.355 . . . . 0.0 110.928 -179.889 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 82' ' ' HIS . 43.0 p -105.68 167.38 9.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.54 -65.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -41.77 -48.1 5.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.6 mt-10 -66.86 -50.91 61.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.852 0.358 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.25 -55.27 22.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 88.4 t -51.37 -61.7 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.17 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.474 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.1 mm-40 -50.07 -24.78 2.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.6 -30.9 61.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.468 HD13 ' CD1' ' A' ' 25' ' ' ILE . 0.7 OUTLIER -78.42 -28.9 46.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.474 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.9 ptp180 -93.61 1.16 56.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.1 t -95.05 31.3 1.92 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.477 HG23 ' N ' ' A' ' 93' ' ' GLY . 2.8 p -112.89 142.93 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.477 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -60.08 -101.48 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.0 p-10 -114.81 0.24 13.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 0.0 110.876 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.441 ' O ' ' CG2' ' A' ' 92' ' ' VAL . 19.3 m -159.02 135.72 9.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.128 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.464 ' CB ' HG21 ' A' ' 92' ' ' VAL . 0.6 OUTLIER -132.13 157.21 44.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.894 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' THR . . . . . 0.46 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 9.6 m -107.99 103.53 12.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.128 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.413 ' O ' ' CG2' ' A' ' 98' ' ' VAL . 2.9 m -97.1 126.31 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.0 tp -91.89 29.41 1.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.469 HG11 ' CD2' ' A' ' 69' ' ' LEU . 11.7 m -61.07 166.43 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.169 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.425 ' C ' HD23 ' A' ' 67' ' ' LEU . 25.0 p -164.34 146.01 8.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.832 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -42.63 119.96 1.58 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.517 -179.951 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.518 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.94 23.53 1.46 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.791 0.329 . . . . 0.0 110.93 -179.935 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.429 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 4.7 mmm180 -93.1 157.65 16.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -65.71 106.84 1.59 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mt -109.25 170.73 7.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.936 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.9 p -150.59 155.35 39.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 34.4 mt -120.73 120.51 62.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.153 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -92.26 115.34 27.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.931 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.422 ' CB ' ' HB1' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -128.17 164.62 22.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.895 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.468 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.33 168.65 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.562 0.696 . . . . 0.0 111.06 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.468 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.78 3.49 2.75 Favored 'Trans proline' 0 N--CA 1.466 -0.146 0 C-N-CA 122.698 2.265 . . . . 0.0 112.321 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.18 37.84 0.16 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 tp10 -100.29 138.41 37.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.463 ' O ' ' C ' ' A' ' 23' ' ' LEU . 30.1 mmt-85 -81.07 116.71 21.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.463 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.0 OUTLIER -32.56 -46.79 0.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.81 42.82 52.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.43 HG12 ' CG ' ' A' ' 23' ' ' LEU . 1.3 pt -119.56 166.54 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.338 . . . . 0.0 111.135 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.437 ' C ' HG21 ' A' ' 27' ' ' ILE . 0.6 OUTLIER -130.51 150.37 51.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.437 HG21 ' C ' ' A' ' 26' ' ' SER . 30.7 pt -139.53 151.39 22.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.114 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -129.07 124.67 35.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.36 -150.83 22.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.485 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.443 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.443 HG12 ' N ' ' A' ' 30' ' ' GLY . 36.6 mt -135.72 115.95 17.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.592 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.59 149.97 51.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.461 HD12 ' CD1' ' A' ' 63' ' ' LEU . 18.1 mt -55.59 140.95 12.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.129 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 49.8 p -114.15 -26.55 8.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.429 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 37.5 tttm -158.61 157.05 31.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.429 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 85.8 t -150.79 116.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.114 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.5 t -62.91 140.48 97.48 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.679 0.752 . . . . 0.0 110.853 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -16.46 37.82 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.707 2.271 . . . . 0.0 112.353 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.9 p -105.62 -6.28 19.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.117 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' ALA . . . -76.72 145.9 31.94 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.503 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -37.51 -33.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 111.094 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.425 ' CB ' HD11 ' A' ' 23' ' ' LEU . . . -74.98 -62.71 1.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.02 -40.22 6.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.502 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 1.6 ptt-85 -73.91 -29.94 62.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.866 0.365 . . . . 0.0 110.893 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . 0.422 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 6.5 t70 -55.16 -69.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.71 -22.01 4.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -96.28 -52.64 3.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.82 0.343 . . . . 0.0 110.905 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.461 ' CD1' HD12 ' A' ' 48' ' ' ILE . 0.6 OUTLIER -61.9 110.85 1.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.944 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -152.8 136.3 15.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.836 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.438 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 0.2 OUTLIER -39.59 99.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.123 179.944 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.66 -32.41 0.52 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.54 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.448 HD23 ' CG2' ' A' ' 100' ' ' VAL . 7.8 mp -73.73 151.82 40.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.845 0.355 . . . . 0.0 110.882 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 61.5 ttt180 -97.66 116.54 30.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.449 ' CD2' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -66.09 105.64 1.42 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 9.5 mp -80.5 -49.64 11.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.941 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -158.94 145.12 16.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.3 t -115.31 110.21 31.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.11 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.404 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.7 m-20 64.88 40.56 5.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.404 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 35.4 mt-30 64.61 29.85 12.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.955 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.8 mm100 -123.64 90.76 3.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.885 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.1 t -44.96 130.86 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.82 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.6 mt -79.85 0.26 31.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -74.7 118.4 17.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.6 -34.02 4.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.5 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -92.98 171.38 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.945 0.402 . . . . 0.0 110.903 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.7 p -109.85 162.5 14.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.162 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.33 -55.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -49.83 -49.53 34.73 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.494 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -68.01 -51.75 43.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.878 0.37 . . . . 0.0 110.862 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.47 ' N ' HD12 ' A' ' 80' ' ' LEU . . . -47.81 -48.62 30.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 98.3 t -57.96 -54.24 34.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.135 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.476 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 61.6 mm-40 -56.79 -22.0 32.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 tt -76.42 -27.07 56.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.412 HD11 ' CD1' ' A' ' 25' ' ' ILE . 0.7 OUTLIER -82.71 -29.1 30.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.964 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.476 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.7 ptm180 -92.49 0.81 57.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.871 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 44.4 t -94.25 28.06 2.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.834 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 93' ' ' GLY . 3.0 p -108.77 140.28 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.164 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.475 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -59.59 -98.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.518 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -114.16 -11.87 12.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.883 0.373 . . . . 0.0 110.858 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 2.0 m -150.29 137.11 19.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.116 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.434 ' CB ' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -125.95 167.94 14.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.936 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 m -115.98 97.54 6.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.1 m -97.04 130.6 45.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.136 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.78 24.07 6.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.449 HG12 ' CD2' ' A' ' 69' ' ' LEU . 21.7 m -51.59 -176.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.111 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 5.3 p -175.45 153.93 1.58 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -55.68 105.38 0.18 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.46 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.46 18.47 1.47 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.928 -179.894 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.0 mmm180 -87.35 165.33 15.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.853 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -72.18 115.12 11.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -123.62 160.14 27.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 14.3 p -143.33 156.35 44.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.856 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 59.0 mt -117.74 102.66 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -77.31 117.85 19.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.403 ' NZ ' HD11 ' A' ' 23' ' ' LEU . 0.5 OUTLIER -134.03 165.4 25.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.837 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.455 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.38 168.43 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.633 0.73 . . . . 0.0 111.091 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.455 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.82 -0.15 6.54 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.626 2.217 . . . . 0.0 112.338 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -171.04 33.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -92.1 126.05 37.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.866 0.365 . . . . 0.0 110.85 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.488 ' O ' ' C ' ' A' ' 23' ' ' LEU . 62.5 mtt180 -70.82 97.01 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.887 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.488 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -30.95 -48.85 0.12 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.6 47.64 7.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.47 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 4.8 pt -117.61 153.67 19.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.83 0.348 . . . . 0.0 111.161 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.422 ' C ' HG23 ' A' ' 27' ' ' ILE . 0.9 OUTLIER -122.04 151.77 40.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.888 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.0 pt -137.28 145.96 28.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.099 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.415 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 1.5 ptm85 -122.76 137.21 54.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.845 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.96 -145.57 17.54 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.491 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.367 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 -179.89 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 mt -126.22 119.53 54.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.886 0.374 . . . . 0.0 111.1 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.6 OUTLIER -132.04 150.68 52.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.858 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.475 HD13 ' CD1' ' A' ' 63' ' ' LEU . 44.1 mt -60.25 139.43 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' SER . . . . . 0.407 ' N ' HG22 ' A' ' 48' ' ' ILE . 1.3 t -112.01 -24.53 9.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.418 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 23.9 tttp -155.1 154.87 33.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.418 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 80.4 t -148.71 120.59 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 42.9 t -58.79 138.02 86.86 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.652 0.739 . . . . 0.0 110.877 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -38.42 7.66 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.645 2.23 . . . . 0.0 112.36 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.9 p -92.95 -2.95 55.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.55 172.86 38.12 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.14 -34.04 74.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.75 0.31 . . . . 0.0 111.063 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.478 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -76.83 -60.97 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.41 -42.75 4.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -77.74 -27.96 50.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -53.55 -66.98 0.3 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.85 -5.7 22.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.509 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.414 ' HA ' ' NH1' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -115.22 -7.76 12.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.38 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.475 ' CD1' HD13 ' A' ' 48' ' ' ILE . 1.3 tm? -114.55 124.63 52.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.467 ' N ' HD12 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.91 151.73 25.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 179.956 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -55.8 107.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.57 -25.54 1.67 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.424 HD21 ' C ' ' A' ' 101' ' ' CYS . 12.5 mt -70.89 142.36 51.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.927 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.525 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 75.5 ttt180 -88.91 112.89 23.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.466 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.9 mm? -64.94 103.06 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.924 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -79.61 -52.37 8.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -155.72 136.98 13.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.44 110.35 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.15 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.403 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.5 m-20 64.79 41.72 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . 0.403 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 29.6 mt-30 64.17 30.36 13.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -126.42 90.55 3.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.7 t -42.67 133.26 3.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.824 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.1 mt -87.62 13.19 10.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.941 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.74 133.18 35.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 101.18 -36.15 4.39 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.438 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -87.12 156.92 19.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.865 0.364 . . . . 0.0 110.925 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 30.7 p -92.06 -177.26 4.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . 0.435 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 3.2 t-80 -51.33 -56.12 14.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.868 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -53.29 -51.47 46.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.494 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 6.8 mm-40 -58.54 -45.92 87.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.881 0.372 . . . . 0.0 110.871 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . 0.424 ' HA ' ' CD1' ' A' ' 80' ' ' LEU . . . -57.87 -49.62 76.07 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 55.4 t -53.08 -56.92 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.473 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.7 mm-40 -52.1 -22.84 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 tt -78.92 -28.04 43.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.929 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . 0.402 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -83.09 -26.36 31.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.864 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.473 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.5 ptp180 -95.05 0.89 54.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 24.9 t -96.36 33.28 1.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.455 HG21 ' N ' ' A' ' 93' ' ' GLY . 2.0 p -112.0 145.57 17.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.455 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -64.63 -100.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.452 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -112.47 -1.69 14.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.884 0.373 . . . . 0.0 110.893 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 26.8 m -162.96 136.6 5.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.143 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.438 ' CA ' HG22 ' A' ' 92' ' ' VAL . 1.2 pt? -119.39 166.83 12.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.6 m -115.68 96.08 5.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.131 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.6 m -93.49 133.0 36.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.119 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -103.09 26.53 8.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.466 HG11 ' CD2' ' A' ' 69' ' ' LEU . 2.5 m -60.28 178.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.095 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.424 ' C ' HD21 ' A' ' 67' ' ' LEU . 2.4 p -171.65 146.02 2.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -37.89 109.98 0.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.462 -179.918 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.458 ' N ' HD21 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.33 32.43 0.5 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.799 0.333 . . . . 0.0 110.913 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -99.39 150.65 21.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.77 113.77 2.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.4 mt -117.37 167.35 11.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 23.0 p -146.42 158.9 43.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.418 ' C ' HG22 ' A' ' 95' ' ' THR . 22.6 mt -125.85 106.25 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.116 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -81.31 107.33 14.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.412 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -118.81 172.74 7.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.48 165.09 0.3 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.609 0.718 . . . . 0.0 111.099 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.424 ' HA ' ' CG ' ' A' ' 94' ' ' ASP . 53.6 Cg_endo -69.83 1.87 4.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.337 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.55 32.1 0.18 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.466 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 33.5 tp10 -97.92 153.34 18.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.876 0.369 . . . . 0.0 110.886 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.81 125.65 35.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . 0.47 ' CD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -37.58 -52.46 1.2 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.911 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.44 40.9 14.35 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 7.5 pt -121.26 157.43 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 111.096 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.413 ' C ' HG23 ' A' ' 27' ' ' ILE . 1.6 m -122.16 144.1 49.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.413 HG23 ' C ' ' A' ' 26' ' ' SER . 21.1 pt -135.85 149.27 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.114 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.0 ptt180 -128.67 135.1 48.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 139.95 -140.93 11.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.26 117.76 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.857 0.36 . . . . 0.0 111.132 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -131.04 149.61 52.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.471 HD11 ' CD1' ' A' ' 63' ' ' LEU . 65.1 mt -58.14 123.71 10.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.155 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.9 t -99.3 -10.8 21.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.855 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.452 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 13.1 ttmt -175.06 160.35 2.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.915 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.452 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 58.8 t -144.42 114.09 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.6 t -61.54 138.28 94.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.681 0.753 . . . . 0.0 110.821 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -25.1 28.9 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.252 . . . . 0.0 112.329 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.3 p -94.99 1.22 55.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.78 158.94 34.07 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.484 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -50.25 -44.09 53.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.47 ' HB2' ' CD1' ' A' ' 23' ' ' LEU . . . -63.75 -58.76 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.089 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.11 -42.15 5.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.47 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 30.2 ptt180 -85.01 -24.22 28.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 110.914 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -54.42 -69.13 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.37 -13.54 15.9 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -101.38 -7.46 22.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.811 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.471 ' CD1' HD11 ' A' ' 48' ' ' ILE . 2.4 tm? -108.79 135.17 50.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.908 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.42 ' N ' HD11 ' A' ' 63' ' ' LEU . 2.5 mmp_? -140.5 158.09 44.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . 0.413 HG11 ' N ' ' A' ' 50' ' ' LYS . 5.4 t -73.82 88.95 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 155.8 -17.76 0.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 13.0 mt -65.72 130.35 42.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.803 0.335 . . . . 0.0 110.901 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.569 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 60.4 ttt180 -78.6 122.1 25.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.451 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.2 mm? -73.86 111.87 9.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.953 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.448 ' N ' HD13 ' A' ' 70' ' ' LEU . 9.0 mp -87.48 -52.94 5.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.91 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -156.73 135.77 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 53.0 t -108.66 111.72 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.101 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 65.46 40.58 4.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 63.98 36.38 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.928 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -134.77 90.91 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.0 t -41.11 139.13 0.98 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.832 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.43 ' C ' HD22 ' A' ' 80' ' ' LEU . 11.5 mt -86.11 9.78 16.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.958 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.471 ' O ' ' CD2' ' A' ' 80' ' ' LEU . 6.8 tt -83.69 156.64 22.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 79.71 -19.51 6.1 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' LEU . . . . . 0.471 ' CD2' ' O ' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -110.38 155.06 22.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.381 . . . . 0.0 110.907 -179.91 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 65.5 p -91.75 179.03 5.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -48.62 -58.11 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.84 -49.87 27.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.45 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.0 mt-10 -61.72 -46.84 87.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.841 0.353 . . . . 0.0 110.923 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.63 -51.64 64.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.085 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.422 HG13 ' NE2' ' A' ' 87' ' ' GLN . 65.0 t -48.22 -58.01 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.101 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLN . . . . . 0.721 HE21 ' N ' ' A' ' 87' ' ' GLN . 0.9 OUTLIER -51.49 -24.89 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.911 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.421 HD13 ' CD2' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -74.84 -32.19 61.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.914 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.83 -24.75 55.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.473 ' CZ ' ' OE1' ' A' ' 87' ' ' GLN . 4.2 ptt180 -96.55 -0.11 49.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 p -83.36 20.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 93' ' ' GLY . 2.4 p -106.42 145.84 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.162 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.475 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -78.47 -80.66 0.71 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.501 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ASP . . . . . 0.424 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -121.13 -13.74 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.863 0.364 . . . . 0.0 110.852 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.418 HG22 ' C ' ' A' ' 15' ' ' ILE . 14.3 m -157.1 134.61 10.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -118.88 -179.24 3.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.926 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -126.61 95.92 4.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.4 m -96.92 129.31 47.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -94.96 21.6 7.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.451 HG13 ' CD2' ' A' ' 69' ' ' LEU . 20.8 m -49.65 169.29 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 8.6 p -161.6 154.08 20.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -48.8 111.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.853 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.512 -0.235 . . . . 0.0 112.512 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.1 t -82.58 135.23 35.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.829 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -147.44 138.94 23.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.862 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -117.28 -74.91 0.52 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.6 m -69.02 -64.55 0.85 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.88 0.372 . . . . 0.0 110.857 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.2 t 69.78 37.16 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.61 145.28 10.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.499 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 157.79 59.06 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.693 2.262 . . . . 0.0 112.326 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -141.4 -39.68 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.51 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -97.77 33.06 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.929 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 -104.12 177.82 4.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -78.0 112.22 14.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.2 mt -119.85 163.38 17.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 96' ' ' LEU . 18.9 p -144.3 159.47 42.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.87 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.6 mt -122.34 112.96 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -84.47 115.39 22.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -127.41 166.77 17.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.889 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.459 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.06 168.27 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.543 0.687 . . . . 0.0 111.118 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.8 -2.01 9.48 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.653 2.235 . . . . 0.0 112.333 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.49 37.89 0.27 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 40.8 tp10 -102.68 143.58 32.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.864 0.364 . . . . 0.0 110.893 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.6 ptt180 -84.13 121.5 27.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.849 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.464 ' CD1' ' HB3' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -33.63 -53.16 0.42 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 41.12 9.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.46 HG12 ' CD1' ' A' ' 23' ' ' LEU . 3.3 pt -121.35 162.57 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.409 ' C ' HG23 ' A' ' 27' ' ' ILE . 1.5 m -130.57 145.13 51.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.819 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.409 HG23 ' C ' ' A' ' 26' ' ' SER . 21.1 pt -136.2 156.2 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.107 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -132.48 132.9 43.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.873 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.07 -142.32 9.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.95 149.89 9.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.507 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.452 ' O ' ' CD ' ' A' ' 44' ' ' GLU . . . -57.86 -11.09 2.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 111.105 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 33' ' ' GLY . 42.6 mtp180 -130.17 -44.76 1.14 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -35.39 150.5 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' C ' ' O ' ' A' ' 33' ' ' GLY . 7.9 p80 -35.67 129.23 0.6 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -43.27 110.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.097 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.31 -40.11 22.02 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -88.35 118.96 70.07 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.569 0.7 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -11.91 31.86 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.718 2.278 . . . . 0.0 112.342 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 -81.17 -60.66 2.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.91 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -111.49 125.22 30.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.65 0.738 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -14.46 36.21 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.694 2.263 . . . . 0.0 112.342 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 p -87.43 33.64 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.161 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -124.91 115.79 21.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.452 ' CD ' ' O ' ' A' ' 31' ' ' ALA . 24.8 mt-10 -107.67 18.47 21.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -52.55 162.86 2.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.486 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.8 mt -126.88 119.2 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.385 . . . . 0.0 111.106 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.568 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.72 149.12 52.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.833 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.468 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 94.7 mt -54.59 132.76 17.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.428 ' C ' HG12 ' A' ' 65' ' ' VAL . 4.4 p -108.59 -13.41 14.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 28.4 tttm -175.5 156.47 1.96 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.853 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 93.4 t -143.63 123.24 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.109 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 t -69.22 143.15 93.49 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.684 0.754 . . . . 0.0 110.858 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -35.6 12.15 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.33 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.3 p -88.27 0.95 55.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.449 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -80.57 153.05 34.54 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -45.18 -38.9 5.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.769 0.319 . . . . 0.0 111.11 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.464 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -73.32 -64.0 1.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -35.44 -44.56 0.62 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.8 ptt180 -79.3 -37.24 38.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 57' ' ' ALA . 22.1 t0 -40.66 -64.57 0.51 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.38 -9.75 22.23 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.24 -24.35 11.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.456 ' CD1' HD12 ' A' ' 48' ' ' ILE . 0.8 OUTLIER -92.29 126.25 37.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -142.6 174.46 10.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.468 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 6.4 t -82.62 92.33 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.538 ' HA2' ' CE2' ' A' ' 104' ' ' PHE . . . 154.68 -13.66 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.47 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 52.7 mt -77.05 118.71 19.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.568 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 46.5 ttt180 -69.12 122.69 19.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.455 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.4 mm? -72.95 108.96 6.15 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.419 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 4.4 mm? -84.31 -52.37 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.951 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.419 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 11.3 mt-10 -157.85 134.99 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.434 ' CG1' HD12 ' A' ' 96' ' ' LEU . 88.8 t -106.58 110.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.075 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 18.6 m-20 64.73 41.66 5.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 64.17 31.89 12.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -128.86 91.05 3.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.887 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 36.2 t -50.45 130.89 24.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.3 mt -80.29 5.14 15.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.04 114.95 11.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.932 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -37.39 3.17 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.494 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -86.42 167.89 14.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.904 0.383 . . . . 0.0 110.917 -179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 61.8 p -104.37 160.59 14.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.1 -55.19 0.39 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.821 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.24 -46.11 51.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 81' ' ' THR . 29.4 mm-40 -70.03 -47.87 60.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.863 0.364 . . . . 0.0 110.857 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.18 -48.76 70.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 75.2 t -55.57 -55.22 18.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.476 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.9 mm-40 -54.27 -27.3 34.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -70.43 -29.59 66.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.41 -30.5 47.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.921 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.476 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.8 ptp180 -93.36 -1.14 56.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.83 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -90.64 30.0 1.23 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.444 HG22 ' N ' ' A' ' 93' ' ' GLY . 2.6 p -112.1 144.66 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.154 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.444 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -61.73 -94.51 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.481 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -119.52 -8.78 9.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 m -152.92 134.68 14.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.434 HD12 ' CG1' ' A' ' 72' ' ' VAL . 1.2 pt? -122.8 171.87 8.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.4 m -120.8 98.64 6.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.158 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.46 131.91 40.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.1 tp -101.15 31.47 3.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.935 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.455 HG13 ' CD2' ' A' ' 69' ' ' LEU . 4.5 m -65.96 175.47 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.133 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.4 p -165.17 154.23 12.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -46.26 101.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -96.5 -51.73 1.66 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.478 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.538 ' CE2' ' HA2' ' A' ' 66' ' ' GLY . 6.0 p90 -168.34 121.87 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.795 0.331 . . . . 0.0 110.865 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -69.84 133.82 47.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 76.5 p -100.56 40.51 1.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 80.79 -176.53 54.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 155.98 64.6 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.701 2.267 . . . . 0.0 112.362 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 23.4 t -130.37 170.12 14.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 5.1 t -122.04 146.61 47.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.859 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.485 180.0 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 81.1 p -84.99 122.44 29.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.361 . . . . 0.0 110.874 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 31.4 m -112.09 -57.83 2.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.02 -151.52 20.02 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.465 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 97.5 p -85.25 -51.72 6.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.852 0.358 . . . . 0.0 110.859 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 99.0 p -68.49 117.14 9.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -110.18 -78.56 1.0 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.513 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.82 158.54 56.53 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.688 2.259 . . . . 0.0 112.307 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -140.01 -36.5 0.12 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.485 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.468 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -83.31 20.19 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.892 -179.906 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.3 mmt180 -90.24 168.01 12.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 31.9 tt0 -74.25 114.84 13.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.893 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.8 mt -118.58 160.06 22.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.6 p -139.5 155.77 47.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 31.0 mt -122.97 109.78 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.19 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -80.31 115.93 20.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.426 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -131.98 178.26 6.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.83 163.62 2.71 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.554 0.692 . . . . 0.0 111.093 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 1.23 4.65 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.688 2.259 . . . . 0.0 112.328 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -162.59 26.14 0.23 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.488 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.1 tp10 -94.43 142.22 27.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.909 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.9 mpt_? -86.32 123.72 31.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.466 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -46.53 0.24 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.58 41.18 30.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.527 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.466 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.5 pt -121.41 162.97 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 0.0 111.143 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.405 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -120.12 159.1 25.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.835 -179.894 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 14.4 pt -151.69 145.65 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.11 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -129.26 132.14 47.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.929 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.67 -146.19 15.17 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.478 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 125.69 139.27 5.11 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -52.91 -14.74 0.61 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 111.107 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.469 ' NE ' HG21 ' A' ' 81' ' ' THR . 12.1 ptp180 -123.53 -28.51 3.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.86 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -35.51 124.48 0.69 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' GLY . 91.9 m-70 -37.83 -34.56 0.11 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 110.844 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.96 173.87 2.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.09 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 32.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.467 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 24.9 t30 -155.2 117.29 2.39 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 0.0 110.911 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 2.19 3.73 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.73 2.287 . . . . 0.0 112.317 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -103.86 -47.67 4.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -140.41 116.88 7.87 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.605 0.717 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -29.21 24.25 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.69 2.26 . . . . 0.0 112.357 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 p -82.39 44.57 0.89 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.139 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -143.71 115.55 8.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.852 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.485 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 14.2 mp0 -81.31 41.58 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.23 175.7 48.19 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.466 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 60.3 mt -139.18 115.86 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 111.135 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.4 OUTLIER -132.54 163.5 28.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.959 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.451 HD13 ' CD1' ' A' ' 63' ' ' LEU . 27.4 mt -67.72 125.49 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.434 ' C ' HG13 ' A' ' 65' ' ' VAL . 82.7 p -96.85 -11.02 25.36 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.823 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.405 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 16.8 ttmm -175.86 167.25 3.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.5 t -150.06 114.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.139 179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.5 t -67.27 140.01 95.17 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.61 0.719 . . . . 0.0 110.85 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.74 21.68 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.646 2.231 . . . . 0.0 112.361 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.5 p -86.57 -8.57 57.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.137 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -75.56 158.2 50.07 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -50.17 -39.39 43.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.766 0.317 . . . . 0.0 111.087 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.42 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -70.34 -60.26 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.079 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.63 -42.88 2.84 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 23.3 ptt180 -80.29 -31.53 38.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.83 0.348 . . . . 0.0 110.886 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -50.17 -72.29 0.05 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 119.72 -9.58 11.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.492 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -104.32 -10.93 17.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.876 0.37 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.451 ' CD1' HD13 ' A' ' 48' ' ' ILE . 2.4 tm? -105.83 134.0 49.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.431 ' N ' HD13 ' A' ' 63' ' ' LEU . 19.7 mtp180 -144.28 178.97 7.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.434 HG13 ' C ' ' A' ' 49' ' ' SER . 9.1 t -88.02 92.86 3.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.138 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 151.91 -13.16 0.74 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.465 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 32.6 mt -73.0 110.41 7.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.803 0.335 . . . . 0.0 110.879 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.569 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 16.6 ttm180 -62.34 122.8 16.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.858 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.48 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.4 mm? -71.24 107.03 4.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.495 ' O ' ' CG ' ' A' ' 71' ' ' GLU . 1.7 mm? -86.37 -42.14 13.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 40.3 mt-10 -161.82 139.55 8.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.885 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 66.7 t -117.6 108.0 23.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.089 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 11.5 m-20 65.44 41.35 4.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 63.65 36.66 10.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -131.92 91.16 2.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.3 t -47.55 127.04 10.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.01 1.06 22.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.12 111.39 7.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.964 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.92 -37.28 2.73 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.524 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.42 HD13 ' N ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -87.16 167.03 14.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.953 0.406 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.469 HG21 ' NE ' ' A' ' 32' ' ' ARG . 81.0 p -102.66 -179.97 4.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -50.32 -51.48 44.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.85 -45.57 79.54 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.418 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.1 mt-10 -67.1 -58.36 5.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.819 0.342 . . . . 0.0 110.889 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.42 ' N ' HD13 ' A' ' 80' ' ' LEU . . . -44.27 -46.79 9.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.123 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 74.5 t -57.05 -60.45 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.11 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.47 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.3 mm-40 -50.39 -26.27 4.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.902 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.6 tt -74.73 -32.12 62.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -79.08 -31.66 44.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.47 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.4 ptm180 -90.81 3.54 54.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.897 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 5.5 m -96.59 29.23 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.47 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 17.4 t -94.25 149.94 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.463 ' N ' HG11 ' A' ' 92' ' ' VAL . . . -88.59 -76.7 1.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.53 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -123.28 -17.76 6.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.84 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 56.2 m -163.16 137.04 5.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.093 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.47 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.2 pt? -119.0 169.08 10.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.439 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.1 m -119.71 100.15 7.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.0 m -96.72 130.66 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.7 tp -99.19 24.83 7.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.48 HG13 ' CD2' ' A' ' 69' ' ' LEU . 2.7 m -61.84 172.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.122 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.3 p -163.35 163.02 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -54.31 95.15 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -89.11 -47.44 4.13 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.485 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 7.9 p90 -171.51 117.49 0.43 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.817 0.342 . . . . 0.0 110.898 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -80.06 129.4 34.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 88.0 p -60.85 -44.73 96.61 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.835 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.17 142.6 4.34 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 154.69 67.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.707 2.271 . . . . 0.0 112.388 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.1 t -169.44 156.46 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 26.7 p -62.67 127.49 31.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.503 -179.969 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 m -100.28 117.65 34.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.901 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.5 m -53.16 -56.03 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.858 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.38 -121.22 6.25 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.534 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.3 t -121.41 87.94 2.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.827 0.346 . . . . 0.0 110.856 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 65.2 m -65.26 156.38 32.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.22 144.37 3.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.509 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 153.95 68.55 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.703 2.268 . . . . 0.0 112.381 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . 172.65 -43.34 0.17 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.502 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.31 28.81 0.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.813 0.339 . . . . 0.0 110.934 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -98.5 161.93 13.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.42 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 35.2 tt0 -68.21 107.37 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.869 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 98' ' ' VAL . 18.9 mt -113.48 157.49 21.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 20.6 p -139.36 165.33 27.5 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.4 mt -128.99 105.62 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -80.68 117.55 21.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.4 ptpp? -126.91 168.6 14.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.463 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -46.51 168.34 0.12 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 0.0 111.103 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.463 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 1.61 4.27 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.727 2.285 . . . . 0.0 112.339 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.32 43.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.8 tp10 -111.59 142.7 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.814 0.34 . . . . 0.0 110.86 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -86.6 124.5 32.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 -179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.459 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -33.46 -52.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 41.04 13.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.505 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 3.1 pt -119.39 157.33 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.813 0.339 . . . . 0.0 111.141 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.6 m -123.5 140.06 53.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 pt -132.79 157.09 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.121 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.429 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 3.3 ptm85 -132.58 138.87 47.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.23 -144.75 13.2 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.79 162.87 12.97 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.16 -1.99 57.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.772 0.32 . . . . 0.0 111.077 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 28.9 mmt180 -130.72 -31.18 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.43 -156.17 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.47 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.493 ' O ' ' N ' ' A' ' 36' ' ' GLY . 9.8 m170 -81.26 43.24 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.845 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.423 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . 36.37 30.18 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.07 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 38.24 40.3 0.86 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -172.58 114.84 0.38 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.656 0.741 . . . . 0.0 110.926 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.63 24.09 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.26 . . . . 0.0 112.352 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.5 tpt180 -87.99 -57.44 2.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.405 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 5.8 m-20 -121.69 103.63 40.41 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.592 0.71 . . . . 0.0 110.868 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 53.8 Cg_endo -69.69 1.85 4.01 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -89.2 -29.88 18.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -69.11 100.39 1.25 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.889 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 50.2 mp0 -80.62 13.9 2.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -59.95 150.4 39.71 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.6 mt -125.21 117.63 50.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.829 0.347 . . . . 0.0 111.136 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.06 156.53 43.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.452 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 65.3 mt -64.19 130.46 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.158 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 43.5 t -110.23 -14.57 14.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.837 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.465 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 11.2 tttm -167.02 161.21 14.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.455 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 86.7 t -152.78 129.28 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.144 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.1 t -72.52 137.65 80.72 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.611 0.719 . . . . 0.0 110.867 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -25.29 28.84 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.676 2.251 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -101.71 12.88 36.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.187 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -91.92 161.94 27.21 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.506 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -50.04 -35.51 25.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 111.115 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.425 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -77.17 -57.11 4.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.123 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.27 -43.85 4.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.497 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -80.83 -26.25 37.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.821 0.343 . . . . 0.0 110.889 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -48.58 -58.23 5.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.79 -25.12 11.19 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.468 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -94.73 -53.48 3.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.855 0.36 . . . . 0.0 110.883 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.432 HD11 ' N ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER -58.6 132.49 53.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.432 ' N ' HD11 ' A' ' 63' ' ' LEU . 3.6 ptp180 -165.33 147.57 7.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.465 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 62.0 t -49.79 106.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.153 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.13 -26.3 2.03 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.486 ' CD2' ' C ' ' A' ' 101' ' ' CYS . 20.3 mt -75.25 118.55 18.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.765 0.316 . . . . 0.0 110.942 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -69.61 131.66 45.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.475 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.1 mm? -80.29 111.75 16.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 4.0 mm? -88.84 -49.78 6.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.957 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.416 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -158.39 140.41 13.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.923 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 88.4 t -111.84 109.77 29.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.159 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 65.07 41.9 4.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 64.21 32.99 12.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.21 90.54 3.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.912 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.8 t -47.3 130.08 13.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.433 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 5.8 mt -83.31 8.34 13.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.965 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -76.97 115.45 16.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.886 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.11 -32.52 5.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.468 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.449 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -88.04 167.12 13.96 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.918 0.389 . . . . 0.0 110.9 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.453 ' O ' ' N ' ' A' ' 84' ' ' GLU . 44.5 p -105.94 162.92 13.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.102 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.426 ' C ' ' O ' ' A' ' 81' ' ' THR . 1.7 t-80 -34.82 -55.96 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.62 -41.12 49.23 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.442 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.453 ' N ' ' O ' ' A' ' 81' ' ' THR . 5.7 mm-40 -73.16 -48.6 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.856 0.36 . . . . 0.0 110.868 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.3 -51.64 64.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.152 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 61.0 t -53.17 -62.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.125 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.472 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 15.9 mm-40 -49.51 -23.44 1.6 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.07 -33.47 61.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.2 -32.76 56.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.472 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 8.2 ptm180 -89.24 -3.36 58.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.1 m -91.41 33.52 0.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.84 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG23 ' CA ' ' A' ' 96' ' ' LEU . 2.3 p -112.88 145.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.115 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.446 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -61.25 -98.15 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -116.15 -6.96 11.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.923 0.392 . . . . 0.0 110.918 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.4 m -156.17 130.64 8.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.172 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.461 ' CA ' HG23 ' A' ' 92' ' ' VAL . 1.1 pt? -116.99 168.2 10.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.42 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.6 m -116.85 97.77 6.14 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.113 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 13' ' ' LEU . 3.3 m -95.43 129.32 45.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.152 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.3 tp -99.51 34.17 2.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.475 HG11 ' CD2' ' A' ' 69' ' ' LEU . 3.0 m -69.91 173.0 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.486 ' C ' ' CD2' ' A' ' 67' ' ' LEU . 7.9 p -165.15 168.34 17.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -52.51 114.32 1.34 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.435 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -107.53 -36.73 2.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.494 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.435 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.6 OUTLIER -156.23 109.86 2.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.36 . . . . 0.0 110.892 -179.85 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 60.6 mt-10 -44.08 -45.24 7.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 80.3 p 43.73 34.91 0.93 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.819 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.75 -158.02 3.27 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.456 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 112.61 3.12 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.671 2.247 . . . . 0.0 112.366 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.9 t -84.64 113.91 21.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 12.2 t -144.74 111.47 5.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.95 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 76.6 p -42.15 -44.43 3.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.877 0.37 . . . . 0.0 110.852 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 55.2 m -46.9 101.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.872 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.38 -136.85 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.445 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.7 m -110.56 124.87 52.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.896 0.379 . . . . 0.0 110.85 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 78.8 p -134.47 172.82 12.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.884 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.84 166.52 22.84 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.434 ' CB ' ' HD2' ' A' ' 11' ' ' ARG . 53.8 Cg_endo -69.81 158.22 57.62 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.681 2.254 . . . . 0.0 112.331 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . -145.13 -36.94 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.496 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.465 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.79 38.99 0.73 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.924 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.434 ' HD2' ' CB ' ' A' ' 8' ' ' PRO . 53.8 mtp180 -109.68 144.95 37.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 52.9 tt0 -55.52 110.09 0.65 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.5 mt -105.1 168.67 8.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.944 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.444 ' SG ' ' CG2' ' A' ' 95' ' ' THR . 7.2 t -150.35 144.22 25.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.931 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 95' ' ' THR . 15.6 mt -120.71 127.2 75.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -97.72 113.54 25.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -124.83 170.5 10.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.453 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -47.89 168.05 0.17 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.582 0.706 . . . . 0.0 111.1 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.453 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.81 2.37 3.62 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.344 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.05 39.43 0.17 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 26.1 tp10 -101.73 144.19 30.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.812 0.339 . . . . 0.0 110.926 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 25.5 mtt-85 -83.75 120.23 25.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.462 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -49.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.35 42.6 18.12 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.471 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.462 HG12 ' CD1' ' A' ' 23' ' ' LEU . 2.2 pt -122.74 161.5 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.803 0.335 . . . . 0.0 111.133 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.465 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -119.17 160.37 22.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.891 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 17.7 pt -151.55 147.27 15.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.169 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.473 ' NH1' ' CB ' ' A' ' 49' ' ' SER . 6.1 ptt-85 -125.09 139.42 53.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 137.87 -149.93 20.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.514 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.22 141.56 7.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.542 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.462 ' HA ' ' CG ' ' A' ' 44' ' ' GLU . . . -63.05 -7.98 6.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.719 0.295 . . . . 0.0 111.089 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.5 mtt180 -126.73 23.43 6.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.38 172.42 18.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.506 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' A' ' 35' ' ' ALA . 46.0 m170 -76.97 125.03 28.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.774 0.321 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.432 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . -35.71 120.8 0.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.46 ' CA ' ' HD2' ' A' ' 28' ' ' ARG . . . -35.78 -52.11 1.13 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.514 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.421 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 21.1 t30 -88.79 134.23 34.2 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.576 0.703 . . . . 0.0 110.93 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -1.49 8.53 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.691 2.261 . . . . 0.0 112.32 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.421 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 9.5 tpp85 -66.17 -49.65 66.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 35' ' ' ALA . 26.3 m-20 -139.78 112.15 7.58 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.593 0.711 . . . . 0.0 110.827 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -0.01 6.28 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.664 2.243 . . . . 0.0 112.351 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 75.9 p -101.17 49.49 0.88 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.117 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -138.86 111.52 7.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.462 ' CG ' ' HA ' ' A' ' 31' ' ' ALA . 5.3 mp0 -84.75 3.19 38.61 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -53.98 153.43 9.06 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.503 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 48.6 mt -123.62 118.69 55.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.844 0.354 . . . . 0.0 111.117 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.75 147.51 50.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.452 HD13 ' CD1' ' A' ' 63' ' ' LEU . 95.3 mt -55.88 135.66 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.149 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.473 ' CB ' ' NH1' ' A' ' 28' ' ' ARG . 70.0 p -113.87 -13.39 12.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.853 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.465 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 17.9 ttmm -170.38 161.23 7.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 85.8 t -150.08 121.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -68.01 139.27 92.89 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 110.871 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -29.91 23.26 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.716 2.277 . . . . 0.0 112.367 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.3 p -92.7 4.49 53.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -85.45 161.45 35.46 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.447 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -51.39 -39.55 57.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.795 0.331 . . . . 0.0 111.116 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -70.55 -59.36 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -38.69 -42.43 1.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 24.9 ptt180 -82.95 -30.09 28.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.8 0.333 . . . . 0.0 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 57' ' ' ALA . 48.2 t0 -45.9 -56.97 4.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.876 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.4 -20.23 40.43 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.36 -20.52 18.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.845 0.355 . . . . 0.0 110.865 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.452 ' CD1' HD13 ' A' ' 48' ' ' ILE . 1.1 tm? -89.55 134.35 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.425 ' HG2' ' C ' ' A' ' 63' ' ' LEU . 14.2 mmm-85 -143.15 154.12 43.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.887 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 18.3 t -70.49 87.21 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.99 -17.35 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.499 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 18.0 mt -67.82 124.64 23.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.907 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 36.2 ttt180 -71.84 119.74 16.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.469 ' CD2' HG13 ' A' ' 100' ' ' VAL . 1.6 mm? -67.04 111.43 3.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.887 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -86.79 -54.24 4.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.92 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -156.58 133.6 10.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.467 ' CG2' HD12 ' A' ' 69' ' ' LEU . 93.1 t -106.76 110.92 33.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.453 ' ND2' HG23 ' A' ' 92' ' ' VAL . 15.0 m-20 64.91 41.06 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 37.4 mt-30 63.86 31.55 13.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -129.38 91.24 3.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -46.4 138.97 5.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 18.2 mt -91.52 5.17 50.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.4 117.97 17.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 117.28 -39.62 2.6 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.544 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.419 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -82.8 167.36 18.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.888 0.375 . . . . 0.0 110.894 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 72.5 p -103.84 162.06 13.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 81' ' ' THR . 1.8 t-80 -33.83 -56.02 0.47 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.04 55.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.525 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.419 ' N ' ' O ' ' A' ' 81' ' ' THR . 14.7 mm-40 -69.04 -49.02 61.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.829 0.347 . . . . 0.0 110.875 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.87 -45.34 74.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 88.7 t -57.2 -58.18 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.474 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 66.6 mm-40 -52.09 -22.48 4.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 tt -79.37 -28.24 41.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.906 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.76 -25.86 30.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.896 179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.474 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.8 ptm180 -96.04 0.91 52.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.834 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 32.6 t -93.68 28.04 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.481 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 17.1 t -92.81 148.91 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.463 ' N ' HG12 ' A' ' 92' ' ' VAL . . . -88.76 -77.76 1.3 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.499 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -125.16 -17.72 5.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.916 0.388 . . . . 0.0 110.869 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.444 ' CG2' ' SG ' ' A' ' 14' ' ' CYS . 5.0 m -158.38 137.28 11.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.481 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 0.9 OUTLIER -122.69 160.65 25.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.912 179.986 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -113.24 96.62 6.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.103 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.96 130.01 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.1 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.7 tp -97.08 17.77 16.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.872 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.469 HG13 ' CD2' ' A' ' 69' ' ' LEU . 35.9 m -49.38 178.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.416 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 1.9 p -167.62 161.58 13.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -60.77 102.28 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -92.56 -60.29 1.23 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.509 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -164.39 113.39 1.15 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.862 0.363 . . . . 0.0 110.883 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -54.79 -55.61 28.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.4 m 58.59 51.4 7.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -138.65 -126.89 2.44 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.483 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -7.24 20.57 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.343 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 96.0 p -53.0 -28.98 26.61 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 10.7 m -50.03 -52.59 32.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.842 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.481 -179.988 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 t -47.22 -58.68 3.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.868 0.366 . . . . 0.0 110.869 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 68.5 p -75.98 75.09 2.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -103.95 -71.45 0.85 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.514 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.3 m -98.29 142.75 29.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.876 0.37 . . . . 0.0 110.866 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 m -97.18 56.17 1.35 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.86 145.81 17.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.481 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 176.59 6.59 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.669 2.246 . . . . 0.0 112.315 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 169.26 -55.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.48 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.489 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.97 19.78 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -88.71 162.26 16.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.848 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.45 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -73.18 110.78 7.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.3 161.57 15.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.0 p -143.01 153.2 42.74 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.3 mt -121.85 120.94 62.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.111 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -93.12 110.59 22.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.416 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -124.1 179.75 4.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.418 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -59.18 166.4 2.84 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.566 0.698 . . . . 0.0 111.088 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.418 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.9 Cg_endo -69.71 -0.28 6.65 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.65 2.233 . . . . 0.0 112.369 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.59 29.34 0.22 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -94.25 140.42 29.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.924 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 5.9 ptt-85 -82.95 120.57 25.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.457 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.99 -49.15 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.94 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.24 42.07 24.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.457 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.5 pt -121.19 164.41 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.143 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.423 ' C ' HG21 ' A' ' 27' ' ' ILE . 0.6 OUTLIER -128.97 150.9 50.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.809 -179.906 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.423 HG21 ' C ' ' A' ' 26' ' ' SER . 30.2 pt -140.36 149.39 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.097 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 35.0 ptt180 -125.14 123.16 39.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.04 -141.87 8.49 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 119.34 133.62 4.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.475 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -70.82 112.1 6.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.741 0.305 . . . . 0.0 111.124 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 mtp180 70.11 27.83 4.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -99.26 -101.35 2.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 35' ' ' ALA . 9.7 p80 -128.52 116.37 19.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.826 0.346 . . . . 0.0 110.873 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.426 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -35.97 125.68 0.73 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.056 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.37 -52.57 0.87 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.0 m-20 -88.9 127.76 54.68 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.656 0.741 . . . . 0.0 110.877 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.8 Cg_endo -69.75 -43.57 2.58 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.729 2.286 . . . . 0.0 112.323 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.441 ' C ' ' O ' ' A' ' 38' ' ' PRO . 16.0 mmm180 -34.21 -70.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.846 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -119.06 119.89 31.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.632 0.729 . . . . 0.0 110.848 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -24.42 29.7 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.356 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 59.9 p -89.04 41.73 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.153 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -136.85 111.3 8.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.853 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.507 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 7.2 mp0 -101.3 71.36 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.912 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.88 162.5 24.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.459 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.7 mt -128.76 119.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.911 0.386 . . . . 0.0 111.152 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.5 OUTLIER -132.14 -179.94 5.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.905 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.454 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 69.9 mt -88.01 121.4 38.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.5 t -97.32 -17.36 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.444 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 12.3 ttmt -166.23 160.09 15.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 63' ' ' LEU . 84.0 t -149.31 115.08 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.136 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.6 t -60.3 134.37 90.95 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.694 0.759 . . . . 0.0 110.859 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -19.52 35.75 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.702 2.268 . . . . 0.0 112.351 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 19.4 p -102.24 3.47 38.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.16 172.89 49.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.73 -39.7 85.57 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.808 0.337 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.472 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -69.3 -61.5 1.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.83 -39.94 2.07 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 14.5 ptt180 -82.24 -25.06 34.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 0.0 110.852 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.472 ' N ' ' O ' ' A' ' 57' ' ' ALA . 30.3 t0 -53.27 -62.01 1.93 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 111.57 -16.24 26.56 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.1 -29.05 11.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.872 0.367 . . . . 0.0 110.866 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.467 HD11 ' N ' ' A' ' 64' ' ' ARG . 1.1 tm? -87.4 134.16 33.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.966 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.467 ' N ' HD11 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.72 150.2 24.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.454 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 44.2 t -56.63 104.48 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.33 -13.25 1.62 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.432 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 87.7 mt -83.49 123.75 30.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.56 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 36.7 ttt180 -72.55 125.39 27.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.483 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.1 mm? -74.35 107.56 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.427 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 70.3 mt -86.58 -48.91 7.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.958 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.427 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 20.0 mt-10 -158.92 138.47 11.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 93.0 t -112.99 110.37 31.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 17.8 m-20 65.49 40.55 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 64.4 32.13 12.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.929 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -127.23 89.58 2.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.0 t -44.26 132.23 5.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 19.8 mt -79.4 0.07 30.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -72.99 119.94 17.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.31 -34.73 4.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.499 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.461 ' CD1' ' HA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -92.42 158.8 15.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.902 -179.91 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.5 p -92.04 178.94 5.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.421 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 4.0 t-80 -50.06 -53.85 24.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.49 -48.69 63.89 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.484 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.445 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 22.4 mt-10 -61.04 -51.96 66.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.867 0.365 . . . . 0.0 110.887 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.461 ' HA ' ' CD1' ' A' ' 80' ' ' LEU . . . -50.19 -50.85 48.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.089 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.7 t -52.3 -58.84 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.468 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 59.9 mm-40 -53.11 -21.22 4.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tt -78.03 -26.75 48.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.443 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -84.02 -28.47 27.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.468 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.3 ptm180 -93.72 1.19 56.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 46.3 t -96.24 33.1 1.81 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.465 HG21 ' N ' ' A' ' 93' ' ' GLY . 2.4 p -111.28 136.53 47.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.163 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.465 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -57.46 -101.57 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.518 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -112.55 -3.71 14.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.868 0.366 . . . . 0.0 110.841 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 m -158.47 135.31 9.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.451 ' HB3' ' CG2' ' A' ' 92' ' ' VAL . 0.9 OUTLIER -123.82 168.16 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.918 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.45 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -118.14 96.24 5.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.118 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.93 129.84 43.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.7 tp -99.18 25.19 7.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.934 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.483 HG13 ' CD2' ' A' ' 69' ' ' LEU . 3.7 m -62.43 166.84 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.119 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.9 p -158.37 152.84 24.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.432 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 3.8 m-20 -43.83 104.61 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.81 -41.81 5.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.53 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -144.96 106.75 4.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.86 0.362 . . . . 0.0 110.84 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -39.05 -39.02 0.51 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.864 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 t 44.76 41.83 5.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.856 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 64.81 121.02 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -50.61 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.257 . . . . 0.0 112.343 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 49.0 m -73.61 146.12 44.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 69.9 p -50.4 126.18 14.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.469 -179.997 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.6 t -61.1 88.69 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.893 0.378 . . . . 0.0 110.859 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 t -71.33 142.71 50.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.845 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.04 147.71 49.62 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.9 m -92.0 166.03 12.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.89 0.376 . . . . 0.0 110.843 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 30.4 t -105.27 -73.36 0.68 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.59 87.36 1.14 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.5 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 176.79 6.3 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.365 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 163.06 -27.78 0.24 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.457 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.508 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -94.98 28.07 2.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.416 ' C ' HD11 ' A' ' 99' ' ' LEU . 1.0 OUTLIER -98.02 171.43 8.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -74.39 108.45 7.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.23 158.02 21.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.923 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.9 p -137.83 148.68 45.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.7 mt -114.18 96.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -69.2 112.95 6.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.437 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -124.71 172.6 9.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.62 164.35 7.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.547 0.689 . . . . 0.0 111.091 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 2.41 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.329 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 24.74 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -95.4 132.13 40.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.91 0.386 . . . . 0.0 110.892 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.441 ' O ' ' C ' ' A' ' 23' ' ' LEU . 67.2 mtt180 -82.35 118.49 23.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.872 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.443 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.19 -51.63 0.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.952 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.82 28.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.5 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.443 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.4 pt -119.42 170.36 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 111.143 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.508 ' N ' ' O ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -132.61 166.86 21.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.44 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 19.7 pt -155.41 145.05 12.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ptt180 -124.02 124.76 43.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.76 -148.5 19.03 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.457 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 121.68 140.51 5.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.524 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -88.38 117.98 27.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.82 0.343 . . . . 0.0 111.125 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 58.3 mtp180 63.08 39.34 10.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.76 -88.57 0.48 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.514 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -116.21 119.67 36.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -48.0 124.56 7.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.096 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.38 -49.98 7.79 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.477 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.4 m-20 -118.31 140.76 28.53 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.587 0.708 . . . . 0.0 110.907 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.4 Cg_endo -69.77 -50.55 0.45 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.328 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.44 ' C ' ' O ' ' A' ' 38' ' ' PRO . 23.4 tpt180 -34.25 -72.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 48.0 m-20 -121.14 119.72 29.53 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.655 0.74 . . . . 0.0 110.854 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -1.41 8.42 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.3 p -85.56 26.93 0.88 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -124.31 114.21 19.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -113.66 28.43 8.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.61 144.04 43.21 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.449 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.457 HG12 ' N ' ' A' ' 30' ' ' GLY . 39.5 mt -115.34 119.49 61.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.867 0.365 . . . . 0.0 111.131 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.608 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -133.09 -174.7 3.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.918 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.48 ' CD1' HD21 ' A' ' 63' ' ' LEU . 54.8 mt -90.48 128.4 42.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.418 ' C ' HG11 ' A' ' 65' ' ' VAL . 2.6 t -105.21 -12.95 15.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.508 ' O ' ' N ' ' A' ' 26' ' ' SER . 39.4 ttmt -175.79 139.7 0.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.4 ' CG2' HG21 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -146.14 118.38 2.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.868 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 18.2 t -48.01 134.08 11.75 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.675 0.75 . . . . 0.0 110.881 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -16.12 37.39 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.728 2.286 . . . . 0.0 112.319 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.67 -6.98 13.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.173 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -63.79 174.24 11.84 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.468 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.463 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -52.88 -37.13 60.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.476 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -80.8 -60.38 2.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.115 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -36.56 -47.25 1.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.478 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.463 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 21.1 ptt180 -69.72 -36.4 75.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.36 . . . . 0.0 110.897 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ALA . 28.7 t70 -39.91 -56.12 1.87 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.81 -22.78 15.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -95.29 -44.66 7.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.841 0.353 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.48 HD21 ' CD1' ' A' ' 48' ' ' ILE . 0.7 OUTLIER -58.11 145.12 37.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 -179.956 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.416 ' N ' HD13 ' A' ' 67' ' ' LEU . 12.2 ptt-85 -175.23 146.61 0.85 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 57.4 t -57.89 105.49 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.106 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.72 -25.56 2.42 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.451 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.429 HD21 ' C ' ' A' ' 101' ' ' CYS . 11.4 mt -69.74 118.41 12.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.796 0.332 . . . . 0.0 110.933 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.562 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 25.4 ttt180 -68.85 123.25 20.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.476 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.6 mm? -74.24 110.03 8.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.933 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -85.61 -50.47 7.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -152.47 139.73 19.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.446 ' CG2' HD13 ' A' ' 69' ' ' LEU . 97.0 t -114.42 109.53 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.092 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.432 ' ND2' ' HB2' ' A' ' 96' ' ' LEU . 9.7 m-20 65.64 40.88 4.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 63.62 34.07 12.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 33.2 mt-30 -130.69 92.19 3.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 t -43.97 129.72 5.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 16.8 mt -89.65 10.14 24.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.884 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 1.5 tm? -80.88 122.57 27.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.15 -33.51 5.68 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.44 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -85.82 164.2 17.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.93 -179.934 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 82' ' ' HIS . 75.2 p -98.66 160.59 14.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.44 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.7 t-80 -33.67 -55.76 0.45 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -55.1 -46.99 76.17 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.466 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -62.86 -44.34 96.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 110.89 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.404 ' HA ' ' CD1' ' A' ' 80' ' ' LEU . . . -62.26 -51.77 66.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 38.2 t -49.45 -61.5 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.111 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.479 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 86.6 mm-40 -47.41 -24.08 0.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 tt -78.39 -33.03 49.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.897 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.9 -30.27 44.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.479 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.5 ptm180 -90.14 4.48 50.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.84 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.0 t -97.2 19.35 13.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.478 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 26.1 t -82.14 150.54 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.46 ' N ' HG13 ' A' ' 92' ' ' VAL . . . -94.64 -78.9 1.43 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -120.31 -22.35 6.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -160.23 131.94 6.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.134 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.478 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.1 pt? -113.09 171.5 7.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -121.19 97.65 5.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.149 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.54 130.13 44.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.416 HD11 ' C ' ' A' ' 11' ' ' ARG . 23.7 tp -104.11 33.9 3.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.476 HG13 ' CD2' ' A' ' 69' ' ' LEU . 2.4 m -66.51 -179.27 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.429 ' C ' HD21 ' A' ' 67' ' ' LEU . 1.2 p -173.09 158.15 3.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.46 104.42 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.897 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -91.82 -48.87 3.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -163.95 119.52 1.59 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.776 0.322 . . . . 0.0 110.891 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -63.62 131.77 49.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.888 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 38.3 p -43.65 -49.93 7.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.914 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.61 -166.22 42.21 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 108.74 2.14 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.734 2.289 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.8 t -54.77 -46.47 74.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.828 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 59.1 m -69.59 167.94 15.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.814 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.986 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.6 t -113.21 117.28 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.894 0.378 . . . . 0.0 110.859 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.5 m -86.53 148.85 25.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.837 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.81 -157.96 13.82 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.472 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.5 t -92.51 82.23 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.85 0.357 . . . . 0.0 110.833 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.9 m -121.73 43.77 2.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.839 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.23 79.72 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.474 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 156.15 64.17 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.707 2.272 . . . . 0.0 112.346 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.04 -37.01 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.444 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.51 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.53 16.12 1.83 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.812 0.339 . . . . 0.0 110.933 -179.935 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.5 mmt180 -85.63 160.92 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.918 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -70.44 113.82 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 19.6 mt -114.54 172.32 7.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.9 p -151.59 159.32 44.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.466 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 72.5 mt -129.12 112.43 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -80.33 127.44 32.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -139.92 173.62 11.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.472 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -61.4 169.18 2.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.593 0.711 . . . . 0.0 111.091 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.77 -3.07 11.29 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.333 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 34.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.8 tp10 -101.17 137.89 38.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.865 0.364 . . . . 0.0 110.9 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.482 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.3 mtp180 -81.86 118.68 23.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.859 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.482 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -31.55 -43.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.937 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.92 40.89 42.8 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.411 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.2 pt -119.92 161.62 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -130.6 135.68 48.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 18.2 pt -129.56 156.41 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -132.73 132.93 42.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.36 -137.72 5.84 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.68 155.43 10.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.469 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -63.74 -6.24 5.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.805 0.336 . . . . 0.0 111.083 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 33' ' ' GLY . 9.6 mmt85 -134.26 -33.59 1.0 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.909 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -34.02 109.37 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.504 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' C ' ' A' ' 35' ' ' ALA . 36.0 m170 -36.1 129.01 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 110.885 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . 35.06 41.6 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.073 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 35' ' ' ALA . . . -35.04 -49.18 0.79 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -79.52 126.53 80.66 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.656 0.741 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 0.59 5.42 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.702 2.268 . . . . 0.0 112.328 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -115.94 -49.19 2.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 0.7 OUTLIER -116.05 107.5 47.75 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.588 0.708 . . . . 0.0 110.9 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 53.5 Cg_endo -69.78 -13.85 35.2 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.347 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.8 t -102.41 5.98 39.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.117 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -122.46 110.84 16.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.899 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.7 mp0 -63.56 83.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -107.76 164.13 12.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.4 mt -132.34 117.02 30.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 111.142 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.09 155.77 45.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.818 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.471 HD13 ' CD2' ' A' ' 63' ' ' LEU . 77.7 mt -64.57 126.32 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.156 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -105.37 -18.25 14.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.462 ' CA ' HG23 ' A' ' 65' ' ' VAL . 8.9 tttp -165.76 154.35 11.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.422 HG22 ' C ' ' A' ' 50' ' ' LYS . 98.1 t -145.27 124.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -68.05 133.15 91.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.67 0.748 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -8.35 23.37 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.645 2.23 . . . . 0.0 112.332 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 54.9 p -111.13 -9.58 14.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.68 168.53 51.32 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.55 -35.01 67.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.78 0.324 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.479 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -74.33 -65.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.103 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.79 -40.08 2.08 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -77.01 -28.45 55.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.796 0.331 . . . . 0.0 110.892 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 57' ' ' ALA . 9.9 t0 -54.28 -64.03 0.96 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.06 -24.23 6.36 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -92.46 -66.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.813 0.339 . . . . 0.0 110.833 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.471 ' CD2' HD13 ' A' ' 48' ' ' ILE . 1.4 tm? -48.34 118.02 2.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.475 ' CG ' ' CD1' ' A' ' 67' ' ' LEU . 2.2 ptp180 -142.69 154.85 44.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.462 HG23 ' CA ' ' A' ' 50' ' ' LYS . 63.1 t -61.31 106.06 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 147.68 -27.18 1.48 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.459 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.475 ' CD1' ' CG ' ' A' ' 64' ' ' ARG . 7.6 mp -74.79 140.62 44.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.773 0.32 . . . . 0.0 110.892 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 57.2 ttt180 -87.61 121.01 29.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.826 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.457 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.0 mm? -67.87 105.97 2.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.949 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.422 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 1.7 mm? -80.15 -50.43 10.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.422 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 24.2 mt-10 -159.17 142.92 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.6 t -114.75 109.6 29.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.131 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.411 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.1 m-20 65.38 41.77 4.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.411 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 28.4 mt-30 64.6 34.04 10.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.26 90.59 3.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.941 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.5 t -46.1 129.19 9.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.879 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.0 mt -78.82 -0.49 30.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.06 116.7 17.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.59 -34.7 4.28 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.457 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.41 HD12 ' N ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -88.48 170.9 10.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.888 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 82' ' ' HIS . 42.0 p -107.8 160.92 15.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.095 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.446 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -32.97 -53.5 0.36 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.87 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.28 -49.96 57.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -64.38 -45.41 87.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.844 0.354 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.41 ' N ' HD12 ' A' ' 80' ' ' LEU . . . -57.67 -47.51 82.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 78.6 t -59.25 -58.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.476 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 74.7 mm-40 -51.24 -26.06 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 tt -72.3 -29.24 63.67 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.962 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.5 -29.59 46.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.895 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.476 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 2.4 ptm85 -92.51 0.77 57.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 21.6 t -98.99 36.24 1.73 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.88 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.501 HG23 ' CA ' ' A' ' 96' ' ' LEU . 2.1 p -111.6 144.94 18.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.09 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.481 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -64.8 -105.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 19' ' ' PRO . 1.3 t70 -103.39 -3.33 25.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.912 0.386 . . . . 0.0 110.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.426 ' O ' ' CG2' ' A' ' 92' ' ' VAL . 49.8 m -166.14 143.08 5.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.501 ' CA ' HG23 ' A' ' 92' ' ' VAL . 1.0 OUTLIER -120.8 168.41 11.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -120.33 98.18 5.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.16 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.2 m -98.65 130.37 47.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.104 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.4 tp -96.4 21.49 9.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.457 HG11 ' CD2' ' A' ' 69' ' ' LEU . 3.0 m -52.26 -175.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.106 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.5 p -175.96 157.58 1.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -52.65 100.82 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.32 -56.47 1.79 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.465 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -166.08 110.61 0.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 110.847 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -67.16 114.37 5.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.904 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.7 t -57.42 -44.02 84.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.897 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 141.61 146.02 4.64 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.486 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 173.84 10.34 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.708 2.272 . . . . 0.0 112.4 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 22.8 t -167.66 147.33 5.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.829 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 31.0 m -133.8 165.44 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.5 -179.964 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.1 t -84.99 112.05 20.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.869 0.366 . . . . 0.0 110.881 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.7 m -87.29 118.82 26.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.863 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.73 -158.61 28.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.4 t -45.19 106.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.85 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 79.1 p -42.24 -57.08 2.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 138.18 149.8 5.56 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.444 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.77 134.96 29.23 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.642 2.228 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 176.49 -28.48 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.521 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.496 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.3 29.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.796 0.332 . . . . 0.0 110.914 -179.924 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.48 ' CZ ' ' HB2' ' A' ' 11' ' ' ARG . 23.1 mtm105 -96.32 142.36 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.422 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.5 tt0 -53.35 114.9 1.65 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.69 163.49 16.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.943 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.7 p -146.09 153.72 41.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.431 ' CG2' ' HB2' ' A' ' 56' ' ' ALA . 82.7 mt -120.95 110.34 27.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.083 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -85.11 102.45 13.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.443 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 3.4 ptpp? -112.33 171.56 7.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.854 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.47 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.72 168.79 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.619 0.723 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.47 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.85 0.95 4.97 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.321 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.61 41.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.507 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -105.66 140.53 38.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 110.889 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.467 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.3 ptm180 -86.36 122.78 30.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.824 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.47 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.16 -46.9 0.17 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.32 44.76 51.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.47 HG12 ' CD1' ' A' ' 23' ' ' LEU . 0.9 OUTLIER -118.68 168.04 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.854 0.359 . . . . 0.0 111.111 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.414 ' C ' HG23 ' A' ' 27' ' ' ILE . 1.8 m -133.75 147.16 51.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.433 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.7 pt -138.32 155.63 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.152 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.5 ptt180 -126.83 124.54 39.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.857 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.55 -147.15 15.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.04 152.39 10.69 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -74.16 4.65 5.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.757 0.313 . . . . 0.0 111.08 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 28.9 ptt85 -131.05 16.53 5.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.916 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.28 164.67 14.43 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.5 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.45 ' O ' ' C ' ' A' ' 35' ' ' ALA . 54.7 p-80 -70.89 127.07 31.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.844 0.355 . . . . 0.0 110.852 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -34.24 123.9 0.5 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -55.3 -25.57 41.0 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.484 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -111.23 135.91 20.92 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.608 0.718 . . . . 0.0 110.919 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 -1.17 7.96 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.322 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 10.1 tpp180 -65.71 -69.79 0.28 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.72 120.98 31.11 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.641 0.734 . . . . 0.0 110.859 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.71 29.24 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.7 2.267 . . . . 0.0 112.302 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 77.9 p -105.17 55.71 0.69 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.139 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -137.79 112.25 8.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -89.25 34.16 0.8 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.16 149.26 49.92 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.497 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.8 mt -126.85 116.99 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.111 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.57 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -129.13 153.85 47.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.477 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 23.5 mt -62.78 138.26 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.1 t -118.18 -16.91 9.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.848 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.464 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 64.9 tttt -165.22 146.96 7.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.889 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 32.4 t -142.11 133.62 26.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.168 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 7.8 t -74.7 141.79 76.31 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.681 0.753 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -31.21 20.96 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.663 2.242 . . . . 0.0 112.324 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 47.8 p -93.56 -6.66 46.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.151 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.9 150.63 46.37 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.443 ' CB ' ' HB3' ' A' ' 17' ' ' LYS . . . -40.88 -31.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.809 0.338 . . . . 0.0 111.098 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.478 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -77.8 -65.55 0.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.088 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -41.11 -34.44 0.88 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -90.82 -23.22 20.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.478 ' N ' ' O ' ' A' ' 57' ' ' ALA . 10.7 t0 -52.58 -52.24 56.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.34 -7.94 40.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.518 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -115.39 -48.61 2.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.43 ' HB3' ' CB ' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -67.39 130.84 44.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.413 ' HD3' ' C ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER -161.52 157.41 24.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.849 179.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 80.5 t -59.67 105.89 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.31 -15.58 1.67 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.422 HD22 ' C ' ' A' ' 101' ' ' CYS . 58.1 mt -85.45 134.27 34.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.57 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 72.3 ttt180 -84.1 121.79 27.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.42 ' CD2' HG11 ' A' ' 100' ' ' VAL . 1.6 mm? -70.28 116.14 10.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 71.6 mt -96.87 -49.42 5.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.94 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -155.13 141.75 18.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 78.4 t -118.73 108.27 23.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.075 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 65.7 40.91 4.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 64.01 35.21 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -131.07 91.1 2.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.4 t -42.4 128.79 3.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.9 mt -80.68 9.01 6.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.933 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -83.09 137.6 34.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 97.76 -33.22 6.05 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.489 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.434 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -88.08 166.96 14.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.887 0.375 . . . . 0.0 110.91 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.0 p -106.92 165.43 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.439 ' C ' ' O ' ' A' ' 81' ' ' THR . 1.8 t-80 -33.82 -60.54 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.53 -47.68 22.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.434 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.3 mt-10 -66.01 -53.01 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.853 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -49.4 -49.35 45.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 61.2 t -59.1 -57.06 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -53.04 -17.51 1.54 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 tt -83.98 -28.08 28.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.424 HD11 ' CD1' ' A' ' 25' ' ' ILE . 0.6 OUTLIER -84.12 -27.4 28.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.9 ptm180 -97.03 5.74 49.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 m -102.27 32.43 3.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.885 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.459 HG21 ' N ' ' A' ' 93' ' ' GLY . 2.5 p -111.11 140.04 32.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.117 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.459 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -56.56 -100.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.487 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.408 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -113.17 -10.56 13.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.906 0.384 . . . . 0.0 110.868 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.1 m -151.64 135.39 16.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.131 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.451 ' CB ' HG22 ' A' ' 92' ' ' VAL . 1.1 pt? -124.17 171.26 9.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.422 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.4 m -120.69 96.6 5.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.2 m -94.25 128.64 45.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.162 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.6 tp -97.11 29.07 3.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.42 HG11 ' CD2' ' A' ' 69' ' ' LEU . 14.0 m -58.48 172.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.115 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.422 ' C ' HD22 ' A' ' 67' ' ' LEU . 2.8 p -162.27 148.47 13.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -51.16 110.62 0.45 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -100.25 -54.7 1.01 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -165.31 116.09 1.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.866 0.365 . . . . 0.0 110.861 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -62.98 -49.55 74.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 25.1 p 41.06 32.14 0.16 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.83 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -126.59 -150.6 7.6 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.526 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 121.43 8.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.709 2.273 . . . . 0.0 112.312 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 7.2 m -116.42 113.29 22.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.4 t -79.88 -47.26 15.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.884 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.467 179.972 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -130.62 129.98 43.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.847 0.356 . . . . 0.0 110.879 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.1 p -81.57 13.79 2.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.96 105.49 0.18 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.492 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.5 t -116.66 88.96 3.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.849 0.356 . . . . 0.0 110.858 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -59.84 103.11 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.59 162.36 27.34 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.469 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 172.35 12.78 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.714 2.276 . . . . 0.0 112.326 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.29 -52.44 0.13 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.531 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.481 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.21 33.94 0.51 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 110.939 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.432 ' O ' ' CD1' ' A' ' 13' ' ' LEU . 20.5 mtt-85 -99.28 165.03 11.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.421 ' CG ' HG23 ' A' ' 97' ' ' THR . 42.1 tt0 -77.84 110.18 12.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.432 ' CD1' ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -115.27 166.12 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.93 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.4 p -146.89 160.9 41.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.8 mt -124.1 115.17 44.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mp0 -85.21 113.11 21.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.6 ptpp? -126.89 165.41 19.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.472 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -47.65 169.12 0.13 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.472 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.78 -2.84 10.87 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.36 38.28 0.33 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.556 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 28.2 tp10 -103.53 140.64 37.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.815 0.34 . . . . 0.0 110.909 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.453 ' O ' ' C ' ' A' ' 23' ' ' LEU . 6.2 ptt85 -83.27 121.22 26.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -33.9 -54.12 0.47 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.37 40.51 9.98 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.439 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.431 ' CD1' HD13 ' A' ' 89' ' ' LEU . 4.1 pt -120.22 169.72 11.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.146 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.4 m -141.17 145.07 35.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.7 pt -134.85 158.96 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.118 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -131.4 133.29 45.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.73 -142.61 10.08 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 119.69 142.79 6.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.499 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -51.12 -16.73 0.51 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 111.139 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmm180 -127.44 -38.8 1.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -41.88 152.61 0.17 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.469 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -44.35 123.32 3.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.825 0.345 . . . . 0.0 110.841 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -44.85 123.59 3.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.98 -42.38 6.48 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.462 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -91.89 120.11 68.08 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.618 0.723 . . . . 0.0 110.889 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 1.37 4.46 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.722 2.281 . . . . 0.0 112.405 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -84.8 -64.2 1.2 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.48 124.57 32.28 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.595 0.712 . . . . 0.0 110.866 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -10.9 29.67 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.659 2.239 . . . . 0.0 112.353 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 68.2 p -89.11 41.08 1.01 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.096 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -134.92 89.49 2.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.875 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.439 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 5.9 mp0 -90.13 30.08 1.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.885 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.08 162.38 31.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 40.2 mt -129.51 118.34 45.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.864 0.364 . . . . 0.0 111.151 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -132.17 -177.74 4.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.476 ' CD1' ' CD1' ' A' ' 63' ' ' LEU . 54.8 mt -87.57 133.82 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.142 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -113.59 -14.55 12.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.47 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 24.6 tttm -172.51 145.21 1.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.944 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 65' ' ' VAL . 0.6 OUTLIER -152.92 110.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.15 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.4 t -53.83 129.6 56.12 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.678 0.751 . . . . 0.0 110.85 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 -6.36 18.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.712 2.274 . . . . 0.0 112.29 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 32.2 p -105.07 -18.43 14.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.173 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.24 179.81 14.15 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.49 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.428 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -57.69 -39.1 76.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.762 0.315 . . . . 0.0 111.08 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -74.99 -63.65 1.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.14 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.46 -48.56 1.69 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.441 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.428 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.5 ptt180 -70.63 -31.17 68.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 57' ' ' ALA . 31.2 t0 -44.55 -61.62 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.838 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.38 -20.34 10.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.477 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.6 mmp_? -99.61 -47.47 5.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.896 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.479 HD13 ' N ' ' A' ' 64' ' ' ARG . 0.5 OUTLIER -61.11 130.36 45.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.936 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.479 ' N ' HD13 ' A' ' 63' ' ' LEU . 16.8 ptt85 -162.01 146.0 12.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 82.7 t -53.87 106.58 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.156 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 143.09 -11.42 2.31 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.48 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 34.6 mt -86.52 124.02 32.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.854 0.359 . . . . 0.0 110.922 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.546 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 57.5 ttt180 -75.23 117.49 17.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.463 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.6 mm? -71.45 114.24 9.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 75.5 mt -90.43 -54.76 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.975 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -150.1 143.34 25.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.2 t -115.94 110.13 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.127 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 14.2 m-20 65.62 41.12 4.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 64.43 30.46 13.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 22.8 mt-30 -124.64 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 t -44.04 133.87 4.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.811 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.413 ' C ' HD23 ' A' ' 80' ' ' LEU . 13.3 mt -88.94 7.63 33.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.31 116.16 17.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.76 -33.25 5.3 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.463 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -86.4 164.54 16.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.91 0.386 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 82' ' ' HIS . 81.9 p -104.1 165.51 11.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.167 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -34.7 -59.92 0.46 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.834 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.09 -49.85 23.3 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.436 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.9 mt-10 -63.02 -51.7 65.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.89 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.01 -51.75 55.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.117 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 69.2 t -53.15 -60.45 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.471 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 78.1 mm-40 -50.36 -26.17 4.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tt -74.04 -29.95 62.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.923 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.431 HD13 ' CD1' ' A' ' 25' ' ' ILE . 0.6 OUTLIER -79.84 -27.11 40.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.471 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 0.6 OUTLIER -96.96 -3.17 42.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.86 179.94 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.4 m -89.76 29.94 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.872 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.472 HG21 ' N ' ' A' ' 93' ' ' GLY . 3.0 p -110.45 144.04 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.17 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.472 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -61.94 -101.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -111.39 -6.67 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.897 0.379 . . . . 0.0 110.854 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.7 m -155.24 136.47 13.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.468 ' CB ' HG22 ' A' ' 92' ' ' VAL . 1.0 OUTLIER -126.49 167.2 15.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.983 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.421 HG23 ' CG ' ' A' ' 12' ' ' GLU . 1.3 m -116.54 94.52 4.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.175 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.5 m -91.05 127.15 43.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.162 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 19.1 tp -95.97 33.03 1.77 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.878 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' A' ' 69' ' ' LEU . 5.9 m -60.98 174.62 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.146 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -167.78 155.12 8.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.83 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -51.5 107.6 0.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.852 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -97.72 -54.98 1.18 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.467 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.413 ' O ' ' C ' ' A' ' 105' ' ' GLU . 2.5 p90 -166.41 110.06 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.824 0.345 . . . . 0.0 110.851 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 104' ' ' PHE . 3.3 mp0 -37.61 -57.03 0.99 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.919 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 80.1 p 49.91 41.76 23.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.4 120.53 2.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 132.1 22.59 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.68 2.254 . . . . 0.0 112.343 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.1 m -59.84 122.79 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.863 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.5 m -162.95 146.06 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.832 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.486 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 t -94.75 -40.25 9.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.821 0.343 . . . . 0.0 110.836 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 m -117.35 72.48 0.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.824 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 67.62 -100.39 0.61 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.481 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 72.7 m -63.6 175.28 1.11 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.889 0.376 . . . . 0.0 110.866 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.4 m -85.03 173.0 10.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.889 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.73 166.49 22.69 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 158.47 56.88 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.388 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -156.79 -46.88 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.498 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.43 30.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.328 . . . . 0.0 110.907 -179.916 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 25.4 mtp180 -94.95 161.37 14.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -70.92 112.17 6.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.873 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.6 mt -116.88 159.52 22.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 3.0 m -142.45 159.66 41.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mt -125.58 114.57 40.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.173 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -88.6 107.66 19.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.416 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 1.0 OUTLIER -116.18 166.14 12.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.469 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.25 168.72 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.578 0.704 . . . . 0.0 111.097 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.79 3.35 2.83 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.703 2.268 . . . . 0.0 112.334 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -169.79 36.24 0.18 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.462 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.411 ' O ' ' CD ' ' A' ' 17' ' ' LYS . 17.7 tp10 -105.47 142.52 35.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.889 0.376 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' O ' ' C ' ' A' ' 23' ' ' LEU . 58.8 mtt180 -88.94 123.37 33.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.829 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.48 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -31.49 -49.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 77.41 32.48 47.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.487 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.466 HG12 ' CG ' ' A' ' 23' ' ' LEU . 1.5 pt -108.87 160.0 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.817 0.342 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.429 ' C ' HG21 ' A' ' 27' ' ' ILE . 0.5 OUTLIER -123.6 150.61 43.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.464 ' CD1' HG21 ' A' ' 86' ' ' VAL . 27.5 pt -140.36 150.92 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -128.47 131.85 48.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.9 -144.85 13.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.443 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 133.74 140.67 4.38 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.481 ' CB ' ' O ' ' A' ' 80' ' ' LEU . . . -59.84 -6.21 1.19 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.787 0.327 . . . . 0.0 111.13 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.458 ' O ' ' C ' ' A' ' 33' ' ' GLY . 22.9 mmm-85 -130.96 -31.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.869 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' O ' ' N ' ' A' ' 35' ' ' ALA . . . -33.88 124.14 0.41 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.462 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -37.55 -29.5 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.777 0.323 . . . . 0.0 110.806 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 33' ' ' GLY . . . -168.67 158.59 9.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -145.63 -39.35 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.532 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.439 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 32.4 t30 -110.87 132.14 21.78 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.581 0.705 . . . . 0.0 110.921 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -10.47 28.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.708 2.272 . . . . 0.0 112.358 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.439 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 23.5 mmm180 -91.73 -49.76 6.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -119.57 92.66 46.44 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.629 0.728 . . . . 0.0 110.841 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 -17.44 37.85 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.728 2.286 . . . . 0.0 112.348 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.3 t -97.94 11.62 36.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 45' ' ' GLY . 5.2 t0 -126.39 109.92 12.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.417 ' HB3' ' O ' ' A' ' 30' ' ' GLY . 19.5 mm-40 -57.14 84.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 43' ' ' ASP . . . -105.48 153.46 17.21 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.453 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.443 HG12 ' N ' ' A' ' 30' ' ' GLY . 26.8 mt -128.83 116.43 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.871 0.367 . . . . 0.0 111.133 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.6 m-85 -131.13 153.26 49.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.401 HD11 ' CD1' ' A' ' 63' ' ' LEU . 70.3 mt -62.67 128.22 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.419 ' C ' HG11 ' A' ' 65' ' ' VAL . 1.4 t -107.13 -18.89 13.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.483 ' CA ' HG21 ' A' ' 65' ' ' VAL . 8.4 tttp -159.89 153.41 22.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.46 HG23 ' CD1' ' A' ' 63' ' ' LEU . 78.7 t -143.28 127.52 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 29.1 t -66.24 140.29 96.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.726 0.774 . . . . 0.0 110.813 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -35.66 12.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.721 2.281 . . . . 0.0 112.328 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.02 -1.43 45.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.092 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -73.11 148.83 41.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.501 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.468 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -39.86 -35.18 0.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.82 0.343 . . . . 0.0 111.119 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.409 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -74.11 -59.66 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.082 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -47.89 -33.18 9.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.468 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.6 ptt-85 -84.97 -32.26 23.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.457 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 11.1 t0 -50.1 -61.57 2.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.839 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.22 -18.74 13.76 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.501 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -96.71 -42.81 7.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.828 0.347 . . . . 0.0 110.89 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.472 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.2 tm? -69.83 136.54 50.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.472 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -166.67 155.26 10.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.483 HG21 ' CA ' ' A' ' 50' ' ' LYS . 85.2 t -61.25 105.55 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.45 -24.74 1.22 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.533 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.426 HD23 ' C ' ' A' ' 101' ' ' CYS . 12.7 mt -74.85 135.88 41.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 45.8 ttt180 -85.69 117.59 24.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.873 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.473 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.3 mm? -68.11 116.07 8.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 75.8 mt -94.09 -52.29 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -152.13 145.71 24.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.873 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 75.9 t -119.5 108.38 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.118 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 17.5 m-20 65.12 41.54 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.9 mt-30 64.07 32.11 13.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -125.35 91.11 3.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 t -47.82 126.41 10.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.422 ' C ' HD21 ' A' ' 80' ' ' LEU . 11.4 mt -78.04 -0.37 27.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.863 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.37 115.38 11.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.922 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.93 -34.4 4.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.479 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.481 ' O ' ' CB ' ' A' ' 31' ' ' ALA . 0.2 OUTLIER -90.99 164.01 14.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.841 0.353 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 82' ' ' HIS . 38.1 p -102.18 163.39 12.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -34.32 -58.33 0.47 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.837 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.33 -45.68 21.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.46 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.435 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 10.3 mm-40 -70.93 -53.46 14.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.853 0.359 . . . . 0.0 110.838 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.463 ' N ' HD11 ' A' ' 80' ' ' LEU . . . -47.03 -49.01 21.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.049 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.464 HG21 ' CD1' ' A' ' 27' ' ' ILE . 70.0 t -57.34 -59.12 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.477 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 83.3 mm-40 -51.08 -22.79 2.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.917 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -75.62 -31.83 60.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.966 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.87 -27.93 49.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.962 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.477 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.9 ptm180 -94.41 1.5 55.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.866 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.9 t -94.62 30.92 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.407 HG22 ' N ' ' A' ' 93' ' ' GLY . 2.4 p -113.17 146.48 17.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.13 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.407 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -63.62 -95.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.492 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -119.55 -2.08 10.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.912 0.387 . . . . 0.0 110.9 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 m -157.14 132.01 8.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -122.95 164.37 18.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.944 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -113.07 94.14 4.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.74 129.04 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.0 tp -98.51 29.81 3.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.956 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.473 HG11 ' CD2' ' A' ' 69' ' ' LEU . 15.7 m -54.42 179.19 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.426 ' C ' HD23 ' A' ' 67' ' ' LEU . 3.3 p -171.52 148.75 2.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -41.19 113.61 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.849 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.19 -47.31 2.87 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.467 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.427 ' O ' ' C ' ' A' ' 105' ' ' GLU . 1.3 m-85 -144.99 116.66 8.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.821 0.343 . . . . 0.0 110.915 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.427 ' C ' ' O ' ' A' ' 104' ' ' PHE . 6.4 mp0 -36.28 -47.95 0.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.885 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.5 m 48.43 47.87 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.85 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -95.04 -167.12 35.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -32.19 19.04 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.728 2.285 . . . . 0.0 112.347 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 110' ' ' SER . 77.3 p -59.57 151.01 25.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 109' ' ' SER . 77.5 p -37.29 -44.97 0.63 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.506 -179.961 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.8 m -107.33 -45.01 4.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 110.848 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.7 m -86.21 128.3 34.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.877 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 169.47 -89.71 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 p -72.88 -4.84 34.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.909 0.385 . . . . 0.0 110.86 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.0 m -122.48 94.84 4.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.858 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.15 87.11 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 2.251 . . . . 0.0 112.352 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.418 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . -140.75 -36.79 0.1 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.448 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.477 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.37 41.39 0.61 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.794 0.331 . . . . 0.0 110.889 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.7 mmm180 -111.34 152.37 27.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.465 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 19.0 tt0 -68.38 109.18 3.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.909 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.6 mt -106.52 168.72 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -151.4 147.85 27.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.423 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 71.1 mt -118.66 120.23 63.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -88.46 125.61 34.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.8 ptpp? -138.68 168.56 19.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.471 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -48.69 168.9 0.17 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.585 0.707 . . . . 0.0 111.122 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.471 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.7 2.02 3.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.672 2.248 . . . . 0.0 112.379 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.58 35.53 0.17 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 21.5 tp10 -99.02 149.74 22.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' C ' ' A' ' 23' ' ' LEU . 86.4 mtt180 -89.46 121.6 31.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.461 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -32.91 -46.55 0.15 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.5 42.55 17.7 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.43 HG12 ' CD1' ' A' ' 23' ' ' LEU . 2.6 pt -126.01 168.66 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.842 0.353 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -138.91 142.73 38.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 39.6 pt -128.82 163.08 34.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.471 ' CG ' ' HB3' ' A' ' 49' ' ' SER . 22.6 ptt180 -134.56 124.71 25.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 158.81 -143.17 8.99 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 126.01 147.23 6.84 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -71.49 2.83 4.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.77 0.319 . . . . 0.0 111.132 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 79.7 mtt180 -135.01 14.62 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.61 154.71 21.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.503 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.457 ' O ' ' C ' ' A' ' 35' ' ' ALA . 13.5 m170 -72.15 125.77 28.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.779 0.323 . . . . 0.0 110.877 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 37' ' ' ASN . . . -32.38 108.01 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.147 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' A' ' 35' ' ' ALA . . . -34.32 -32.57 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.471 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.494 ' N ' ' O ' ' A' ' 35' ' ' ALA . 7.8 p-10 -89.0 146.89 37.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.77 9.01 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.717 2.278 . . . . 0.0 112.368 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 19.0 ttt180 -51.08 -72.18 0.05 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -143.4 107.06 5.15 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.588 0.708 . . . . 0.0 110.932 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -30.83 21.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.663 2.242 . . . . 0.0 112.371 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 7.0 t -64.25 -24.42 67.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.114 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -92.77 115.91 28.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.88 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 24.6 mp0 -75.36 49.57 0.48 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.53 168.85 54.59 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.8 mt -133.86 117.75 27.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.821 0.343 . . . . 0.0 111.132 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.1 m-85 -131.25 154.07 48.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.463 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 37.6 mt -58.99 138.14 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.471 ' HB3' ' CG ' ' A' ' 28' ' ' ARG . 60.7 p -117.48 -18.68 9.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.845 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.416 ' CA ' HG23 ' A' ' 65' ' ' VAL . 5.0 ttpm? -165.56 155.01 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.919 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.4 t -148.68 128.66 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 33.9 t -81.74 139.15 46.94 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.668 0.747 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.57 23.83 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.713 2.275 . . . . 0.0 112.356 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 59.7 p -80.83 -19.25 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.06 170.62 40.76 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.08 -33.65 72.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.326 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.488 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -71.2 -70.45 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.59 -40.95 0.76 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.471 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 10.7 ptt180 -75.68 -34.67 60.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.783 0.325 . . . . 0.0 110.829 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 57' ' ' ALA . 15.3 t0 -47.72 -64.7 0.72 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.36 -19.4 8.63 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.476 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 42.9 mtm180 -96.72 -61.55 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.888 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.476 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.8 tm? -46.4 133.4 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.476 ' N ' HD13 ' A' ' 63' ' ' LEU . 6.2 ptt180 -156.24 149.95 24.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.847 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.463 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 45.1 t -61.26 100.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.106 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 153.59 -19.89 0.7 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.445 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.429 HD22 ' C ' ' A' ' 101' ' ' CYS . 9.8 mt -77.81 140.74 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.783 0.325 . . . . 0.0 110.921 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 70.8 ttt180 -88.72 119.13 28.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.467 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.1 mm? -71.4 107.0 4.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.425 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 11.1 mp -83.45 -53.29 5.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.425 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -151.68 146.65 25.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 95.5 t -117.84 109.49 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 66.18 41.81 3.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.918 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.9 mt-30 64.64 29.96 12.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -122.9 89.04 3.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.1 t -40.49 129.03 2.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 83.9 mt -83.08 12.27 5.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.939 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -86.13 112.83 21.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.05 -38.97 2.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.442 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.1 OUTLIER -84.15 168.53 15.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 23.0 p -108.62 166.1 11.04 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.168 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -33.13 -61.77 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.4 -48.55 21.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.481 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.442 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.6 mt-10 -65.05 -55.98 15.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.87 0.366 . . . . 0.0 110.863 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -45.76 -50.36 14.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 71.2 t -55.64 -59.61 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.469 ' NE2' ' HD3' ' A' ' 90' ' ' ARG . 51.8 mm-40 -50.12 -25.41 3.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.886 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.1 tt -74.85 -32.16 61.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.881 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -77.96 -30.09 50.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.469 ' HD3' ' NE2' ' A' ' 87' ' ' GLN . 12.6 ptm180 -92.72 -7.13 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.874 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.5 m -87.84 30.01 0.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.471 HG21 ' CB ' ' A' ' 96' ' ' LEU . 2.9 p -106.69 143.73 16.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.466 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -62.51 -102.68 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.481 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -105.98 -13.41 15.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.886 0.374 . . . . 0.0 110.843 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.4 ' O ' ' CG2' ' A' ' 92' ' ' VAL . 3.3 m -153.89 141.29 19.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.177 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.471 ' CB ' HG21 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -124.01 169.52 11.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.465 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -122.02 99.35 6.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.9 m -96.14 130.99 44.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp -97.12 31.31 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.467 HG13 ' CD2' ' A' ' 69' ' ' LEU . 11.3 m -59.8 177.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.137 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.429 ' C ' HD22 ' A' ' 67' ' ' LEU . 13.2 p -175.23 143.06 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -38.69 104.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.871 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.05 -48.6 2.62 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.455 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.406 ' CE2' ' CD2' ' A' ' 47' ' ' PHE . 1.6 p90 -171.59 115.01 0.38 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -69.97 -52.48 23.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.856 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.4 m 56.28 40.89 29.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.63 -173.26 36.95 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 171.5 14.3 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 93.8 p -105.98 107.36 18.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.822 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.2 t 70.95 42.35 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.497 -179.963 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 p -110.01 102.51 11.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.865 0.364 . . . . 0.0 110.867 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.4 p -50.19 121.32 5.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.44 47.47 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.497 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.5 m -66.75 123.99 21.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.915 0.388 . . . . 0.0 110.859 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.4 m -119.15 78.04 1.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.849 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.58 153.5 23.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 160.38 49.93 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.312 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -164.08 -46.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.47 ' N ' HD23 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.17 39.87 0.6 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.915 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.8 mtp180 -111.76 148.13 34.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.434 ' CG ' ' CG2' ' A' ' 97' ' ' THR . 33.7 tt0 -61.89 111.29 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.5 mt -113.08 161.83 16.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -140.66 155.25 46.55 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 88.7 mt -123.01 108.71 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -84.53 114.98 22.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.411 ' NZ ' ' C ' ' A' ' 94' ' ' ASP . 0.5 OUTLIER -125.65 171.02 10.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.459 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.85 168.2 0.11 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.583 0.706 . . . . 0.0 111.07 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 2.81 3.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.704 2.27 . . . . 0.0 112.379 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -173.61 41.04 0.14 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.481 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -107.36 147.16 30.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.876 0.37 . . . . 0.0 110.899 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.7 mmt-85 -83.95 122.95 29.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.478 ' CD1' ' HB3' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.53 -47.58 0.23 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.16 41.48 13.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 3.0 pt -121.54 166.89 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.845 0.355 . . . . 0.0 111.154 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.444 ' C ' HG22 ' A' ' 27' ' ' ILE . 0.5 OUTLIER -130.3 149.76 51.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.85 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.444 HG22 ' C ' ' A' ' 26' ' ' SER . 30.1 pt -140.57 149.25 21.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.102 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.419 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 4.3 ptm85 -130.81 144.37 51.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 125.51 -155.48 18.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.454 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 165.56 -155.65 27.11 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 44' ' ' GLU . . . -129.16 -6.52 4.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.8 0.333 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -133.48 -40.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.97 -108.0 3.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -41.1 129.67 2.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.798 0.332 . . . . 0.0 110.845 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -98.57 -18.75 17.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.088 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.78 -39.14 2.85 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -112.61 127.85 26.32 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.655 0.74 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.66 5.34 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.681 2.254 . . . . 0.0 112.317 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -76.33 -67.72 0.66 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.909 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -128.62 111.86 19.14 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.58 0.705 . . . . 0.0 110.903 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 1.87 4.06 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.7 2.267 . . . . 0.0 112.339 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 43' ' ' ASP . 37.8 p -66.84 -68.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.127 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.417 ' N ' ' OG1' ' A' ' 42' ' ' THR . 14.0 t0 -63.8 112.87 3.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.437 ' CB ' ' HA ' ' A' ' 31' ' ' ALA . 35.7 mm-40 -81.43 75.91 8.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -93.47 169.87 30.65 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.497 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.454 HG12 ' N ' ' A' ' 30' ' ' GLY . 52.5 mt -139.95 116.65 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.874 0.368 . . . . 0.0 111.114 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 0.7 OUTLIER -133.46 156.17 48.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.861 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.46 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 82.9 mt -58.98 129.95 21.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.145 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.429 ' C ' HG12 ' A' ' 65' ' ' VAL . 11.2 p -103.89 -13.3 16.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.473 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 40.2 tttt -173.9 162.89 4.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.473 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 99.3 t -150.14 133.1 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.407 ' N ' HG12 ' A' ' 51' ' ' VAL . 8.2 t -75.35 142.3 74.72 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.678 0.751 . . . . 0.0 110.878 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -23.47 30.44 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.713 2.275 . . . . 0.0 112.343 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 80.0 p -103.52 -14.59 16.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.42 154.95 19.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.41 ' CB ' ' HB3' ' A' ' 17' ' ' LYS . . . -46.46 -33.75 4.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.821 0.343 . . . . 0.0 111.123 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.478 ' HB3' ' CD1' ' A' ' 23' ' ' LEU . . . -75.19 -60.52 2.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.35 -43.49 6.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -79.82 -21.88 43.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.77 0.319 . . . . 0.0 110.84 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 57' ' ' ALA . 12.9 t70 -55.02 -59.45 4.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.865 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.8 -4.19 14.56 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -118.48 -70.5 0.79 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 110.927 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.473 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -37.22 140.34 0.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.473 ' N ' HD13 ' A' ' 63' ' ' LEU . 9.0 ptm180 -167.04 161.4 14.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.46 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 18.7 t -70.27 102.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.125 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.68 -9.03 1.37 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 17.5 mt -89.25 128.22 35.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.331 . . . . 0.0 110.88 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.571 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -78.59 121.54 24.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.47 ' HB3' ' CD1' ' A' ' 77' ' ' LEU . 2.1 mm? -70.24 111.79 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.3 mt -89.24 -49.44 6.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.928 179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -155.17 141.87 18.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.937 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.456 ' HB ' ' CD2' ' A' ' 88' ' ' LEU . 72.7 t -118.67 109.31 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 65.43 40.65 4.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.7 mt-30 63.75 34.62 11.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.881 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -129.2 90.31 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.7 t -42.89 131.47 4.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.47 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 23.5 mt -89.81 9.04 28.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.953 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -77.32 131.5 38.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.943 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.03 -43.98 1.57 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.438 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -79.18 155.89 28.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.884 0.373 . . . . 0.0 110.948 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 68.7 p -93.71 -174.54 3.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -49.52 -61.91 1.84 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -46.35 -57.48 6.42 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 27.2 mt-10 -56.08 -42.05 76.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.902 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -60.91 -48.54 81.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.11 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 67.8 t -52.52 -57.78 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.122 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.469 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 57.3 mm-40 -52.67 -20.35 3.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.899 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.456 ' CD2' ' HB ' ' A' ' 72' ' ' VAL . 1.7 tt -79.71 -26.85 40.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.944 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.409 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -82.27 -22.43 35.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.844 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.469 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.0 ptm180 -96.74 -0.15 48.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 p -83.21 16.69 2.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.487 HG22 ' N ' ' A' ' 93' ' ' GLY . 4.5 p -106.8 141.05 22.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.487 ' N ' HG22 ' A' ' 92' ' ' VAL . . . -70.99 -86.51 0.15 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.48 179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.411 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 2.0 p30 -119.89 -12.54 9.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.2 m -149.3 132.65 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.175 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.461 ' CA ' HG23 ' A' ' 92' ' ' VAL . 0.8 OUTLIER -123.47 170.98 9.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.434 ' CG2' ' CG ' ' A' ' 12' ' ' GLU . 3.3 m -121.5 99.31 6.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.1 m -96.41 131.42 43.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 18.4 tp -98.32 31.3 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.953 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.467 HG13 ' CD2' ' A' ' 69' ' ' LEU . 5.8 m -62.59 176.88 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.112 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.1 p -171.67 145.23 1.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 p-10 -42.27 100.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.912 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -86.29 -44.24 5.98 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -166.37 109.6 0.76 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.807 0.337 . . . . 0.0 110.919 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -65.89 129.28 39.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.859 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 71.7 m -100.52 -44.13 5.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 147.88 120.33 1.14 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 111.75 2.91 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.651 2.234 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.4 m -130.11 113.84 15.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.913 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.8 t -38.84 -43.43 0.94 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.825 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.477 -179.995 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.4 m -125.94 43.41 3.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.87 0.367 . . . . 0.0 110.864 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -76.31 85.01 3.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.857 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.69 -123.43 0.99 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 m -83.36 100.98 11.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.958 0.409 . . . . 0.0 110.831 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -161.73 115.47 1.89 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.864 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.42 129.68 1.59 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.511 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 -169.79 0.35 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.737 2.291 . . . . 0.0 112.345 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . 167.54 -46.1 0.25 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.493 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.482 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.67 16.06 1.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.888 -179.909 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -89.44 149.29 23.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.416 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 30.3 tt0 -59.7 115.31 3.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.1 mt -116.69 160.66 20.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 2.7 m -139.93 157.39 45.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.403 ' C ' HG21 ' A' ' 95' ' ' THR . 34.8 mt -125.42 107.04 17.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -80.53 107.76 13.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -117.29 168.24 10.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.428 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -47.92 166.78 0.2 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.58 0.705 . . . . 0.0 111.103 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.428 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.4 Cg_endo -69.75 2.87 3.14 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.659 2.24 . . . . 0.0 112.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.24 38.18 0.19 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.482 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.5 tp10 -101.98 133.98 45.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.837 0.351 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 23' ' ' LEU . 91.3 mtt180 -78.95 116.87 19.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.475 HD13 ' CB ' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -34.02 -51.84 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.939 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.27 42.62 34.57 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.474 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.431 HG22 ' CD1' ' A' ' 23' ' ' LEU . 1.3 pt -116.26 177.59 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.881 0.372 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.493 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -141.91 157.53 44.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.409 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.3 pt -149.33 151.01 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -127.11 122.99 35.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.63 -156.91 28.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 131.09 166.98 11.85 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.6 1.62 57.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.815 0.34 . . . . 0.0 111.062 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -116.48 31.91 6.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.86 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.6 -138.92 15.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.502 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 60.34 36.72 20.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.861 0.362 . . . . 0.0 110.899 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -42.24 104.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.083 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.13 -58.73 13.08 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -97.09 139.7 21.66 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.72 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.9 Cg_endo -69.75 -28.98 24.67 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.699 2.266 . . . . 0.0 112.355 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -36.21 -54.32 0.81 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.959 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -136.74 116.84 10.82 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.642 0.734 . . . . 0.0 110.849 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -14.78 36.61 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.661 2.24 . . . . 0.0 112.329 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 80.8 p -97.61 51.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -133.0 114.43 13.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.853 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -84.99 27.36 0.77 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.926 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.44 148.02 50.36 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 62.9 mt -124.66 118.32 53.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.113 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CZ ' ' HD2' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.41 -175.6 3.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.468 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 96.4 mt -85.47 138.65 18.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.088 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 53.4 p -116.04 -16.44 11.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.493 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -171.83 150.94 2.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.467 ' CG1' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -160.95 110.24 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.092 179.836 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 40.1 t -58.12 137.75 84.23 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.742 . . . . 0.0 110.853 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -23.15 31.13 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.665 2.244 . . . . 0.0 112.353 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.5 p -89.24 -16.91 30.13 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.15 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.51 172.28 35.57 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.17 -38.84 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.78 0.324 . . . . 0.0 111.086 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.475 ' CB ' HD13 ' A' ' 23' ' ' LEU . . . -73.32 -59.33 2.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.072 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.17 -39.38 6.84 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.51 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 23.5 ptt180 -80.73 -20.76 42.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.844 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.402 ' N ' ' O ' ' A' ' 57' ' ' ALA . 13.9 t70 -60.53 -58.99 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.28 -15.71 32.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.476 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? -108.37 8.92 27.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.858 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.462 HD12 ' N ' ' A' ' 64' ' ' ARG . 0.9 OUTLIER -123.3 119.38 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.462 ' N ' HD12 ' A' ' 63' ' ' LEU . 28.2 mtp180 -145.3 165.64 27.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.468 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 77.9 t -77.11 97.17 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.49 -23.21 0.5 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.478 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 7.5 mp -71.75 159.93 33.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HD2' ' CZ ' ' A' ' 47' ' ' PHE . 29.8 ttt-85 -105.71 118.06 35.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.453 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.3 mm? -66.3 103.18 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.907 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.502 ' CD1' ' NH1' ' A' ' 68' ' ' ARG . 9.7 mp -82.42 -42.23 18.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 68.8 mt-10 -162.05 142.73 10.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 84.9 t -121.6 108.23 21.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.153 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.437 ' ND2' HG21 ' A' ' 92' ' ' VAL . 12.5 m-20 65.33 41.2 4.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 63.37 31.84 14.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -126.16 92.61 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.8 t -46.4 124.09 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.435 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 9.6 mt -81.29 3.46 23.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -78.66 122.67 26.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.87 -31.78 6.81 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.442 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -89.87 160.82 16.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.932 0.396 . . . . 0.0 110.901 -179.903 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 13.9 p -97.61 161.14 13.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.437 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.1 t-80 -33.91 -57.83 0.45 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.11 -44.05 56.71 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.495 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.442 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 23.5 mt-10 -67.17 -47.7 70.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.86 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -58.95 -55.71 31.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 91.9 t -43.54 -64.46 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.08 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.481 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 70.4 mm-40 -46.86 -25.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -75.85 -34.35 60.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.453 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -76.67 -29.03 56.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.962 179.85 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.481 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.2 ptm180 -93.82 4.49 53.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.897 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.6 t -96.3 29.71 2.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.475 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 12.4 t -94.5 150.58 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.472 ' N ' HG11 ' A' ' 92' ' ' VAL . . . -93.55 -75.15 1.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -121.27 -26.03 5.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 0.0 110.855 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.403 HG21 ' C ' ' A' ' 15' ' ' ILE . 32.1 m -155.81 138.74 15.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.138 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.475 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.0 OUTLIER -120.01 165.25 14.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.416 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.8 m -116.41 96.47 5.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.136 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.45 ' CG1' HD12 ' A' ' 96' ' ' LEU . 3.4 m -98.38 129.42 48.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . 0.412 ' CD1' ' HA ' ' A' ' 12' ' ' GLU . 22.6 tp -96.16 20.23 10.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.453 HG11 ' CD2' ' A' ' 69' ' ' LEU . 26.2 m -48.88 177.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.057 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -175.46 162.93 2.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.69 118.9 6.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -106.84 -38.58 2.16 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.472 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.2 p90 -170.8 111.42 0.37 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.828 0.347 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -59.09 127.72 33.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.875 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 67.0 m -53.3 -53.49 50.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.864 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 161.21 -165.79 35.52 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.511 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 0.14 6.08 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.653 2.235 . . . . 0.0 112.339 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 51.4 p -45.53 -41.97 10.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.5 t -140.06 108.78 5.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.873 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.949 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t 56.97 42.86 25.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.836 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.3 t -46.13 -55.19 7.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -48.52 -48.62 28.04 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.517 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.8 m -109.66 91.51 3.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.901 0.382 . . . . 0.0 110.848 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -165.39 117.48 1.14 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.869 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 102' ' ' ASP . . . 123.18 75.1 0.3 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.467 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 158.22 57.65 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.661 2.241 . . . . 0.0 112.317 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.21 24.4 0.22 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.489 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.452 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.88 36.86 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.791 0.329 . . . . 0.0 110.918 -179.919 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -108.31 173.86 6.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.447 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.4 tt0 -81.92 112.71 19.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.906 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.2 mp -117.26 168.92 9.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.899 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.5 p -148.29 157.02 43.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.416 ' CG2' ' HB3' ' A' ' 56' ' ' ALA . 86.8 mt -120.97 111.33 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -80.0 117.73 21.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.7 ptpt -132.18 166.47 21.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.86 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.466 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.0 168.63 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.551 0.691 . . . . 0.0 111.115 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.466 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.1 Cg_endo -69.83 -2.26 9.93 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 0.0 112.3 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.82 35.69 0.25 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 24.7 tp10 -99.84 147.14 25.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.915 0.388 . . . . 0.0 110.85 -179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 11.2 mtt-85 -86.93 123.67 32.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.847 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.458 ' CD1' HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -34.23 -52.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.68 41.3 9.01 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.458 HG12 ' CD1' ' A' ' 23' ' ' LEU . 3.5 pt -122.76 170.91 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.785 0.326 . . . . 0.0 111.16 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.423 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -130.36 160.79 32.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.829 -179.901 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.433 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 14.8 pt -151.2 145.62 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.169 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.457 ' CG ' ' HB2' ' A' ' 49' ' ' SER . 18.8 ptt85 -128.88 122.01 29.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 163.6 -149.41 16.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 129.51 156.19 8.73 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -60.83 -9.1 3.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.792 0.329 . . . . 0.0 111.044 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.407 ' O ' ' C ' ' A' ' 33' ' ' GLY . 3.2 mpt_? -131.9 -39.93 1.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -37.3 154.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.508 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.447 ' O ' ' C ' ' A' ' 35' ' ' ALA . 3.3 t-160 -63.01 124.78 21.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.804 0.335 . . . . 0.0 110.865 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -34.01 125.58 0.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.17 -36.18 0.52 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 46.2 m-20 -109.76 137.99 20.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.602 0.715 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -0.97 7.62 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.705 2.27 . . . . 0.0 112.354 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 16.0 tpp180 -66.4 -71.92 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -113.62 113.97 47.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.637 0.732 . . . . 0.0 110.884 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -7.77 21.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 75.0 p -95.51 41.96 1.09 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -134.22 94.17 3.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -80.81 44.45 0.74 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.48 167.76 47.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.465 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 30.3 mt -132.84 117.9 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 111.097 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.572 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -131.63 154.86 48.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.93 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.462 ' CG2' ' HA ' ' A' ' 65' ' ' VAL . 38.7 mt -58.2 134.44 22.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.156 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.457 ' HB2' ' CG ' ' A' ' 28' ' ' ARG . 36.8 t -112.47 -10.49 13.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.884 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.454 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 19.8 ttmt -173.79 148.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.454 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 86.7 t -138.3 114.36 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.126 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.4 t -64.59 140.69 98.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.711 0.767 . . . . 0.0 110.846 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -30.15 22.75 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 30.1 p -89.99 -4.16 57.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.442 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -76.87 155.88 45.22 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.514 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -47.0 -39.11 11.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.764 0.316 . . . . 0.0 111.098 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.464 ' CB ' ' HB3' ' A' ' 63' ' ' LEU . . . -72.78 -58.76 3.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -39.3 -43.88 2.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 27.8 ptt180 -82.43 -26.15 32.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 110.855 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.444 ' N ' ' O ' ' A' ' 57' ' ' ALA . 24.5 t70 -53.58 -69.28 0.12 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.862 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.01 -13.73 12.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -101.5 -17.96 16.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.464 ' HB3' ' CB ' ' A' ' 57' ' ' ALA . 2.0 tm? -103.33 125.5 49.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.456 ' N ' HD11 ' A' ' 63' ' ' LEU . 15.1 mtm-85 -139.5 174.81 10.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.462 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 8.0 t -82.64 90.01 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.69 -15.37 0.3 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 56.0 mt -74.35 132.7 42.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.572 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 55.4 ttt180 -81.7 119.58 24.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.467 ' HB3' ' CD1' ' A' ' 77' ' ' LEU . 2.3 mm? -72.19 108.27 5.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.945 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 11.1 mp -86.39 -52.46 5.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -151.41 141.81 22.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.867 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 66.9 t -115.77 110.0 30.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.13 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 13.3 m-20 65.65 40.56 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 64.03 30.08 14.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.7 mt-30 -125.26 90.86 3.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.938 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 35.9 t -40.2 130.29 2.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.854 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.467 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 24.9 mt -88.11 17.44 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.939 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.452 ' O ' ' CD2' ' A' ' 80' ' ' LEU . 1.1 tp -85.75 152.69 22.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.907 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.07 -31.77 2.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.498 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.452 ' CD2' ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -88.19 163.24 16.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.862 0.363 . . . . 0.0 110.923 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 56.7 p -99.06 -174.68 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.126 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.433 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.0 t-80 -52.66 -55.07 25.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.14 -50.19 63.3 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.415 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -58.75 -45.47 89.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.905 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -63.01 -48.76 77.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.0 t -53.96 -60.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.181 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.48 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 50.0 mm-40 -50.04 -23.42 2.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.957 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.9 tt -76.8 -30.76 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -78.96 -30.55 44.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.925 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.48 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.2 ptp180 -89.96 1.74 55.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.4 t -93.26 29.51 1.9 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.465 ' CG1' ' HB3' ' A' ' 96' ' ' LEU . 17.6 t -97.39 149.12 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.109 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.454 ' N ' HG13 ' A' ' 92' ' ' VAL . . . -88.57 -77.79 1.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -118.85 -23.88 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.889 0.376 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 8.2 m -158.12 143.09 16.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.145 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.465 ' HB3' ' CG1' ' A' ' 92' ' ' VAL . 1.2 pt? -124.05 168.97 12.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.447 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.7 m -120.57 98.84 6.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.144 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 6.5 m -95.62 131.19 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.107 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 17.6 tp -98.1 35.74 1.69 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.899 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.458 HG11 ' CD2' ' A' ' 69' ' ' LEU . 4.6 m -68.48 173.07 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.6 p -162.55 150.37 14.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.431 ' CG ' ' O ' ' A' ' 7' ' ' GLY . 0.3 OUTLIER -49.99 101.78 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -87.12 -63.24 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.476 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' CD1' ' N ' ' A' ' 104' ' ' PHE . 0.0 OUTLIER -169.25 108.14 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.902 -179.902 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -84.12 115.99 22.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.841 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.0 t -97.44 26.04 5.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.16 -109.64 1.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.489 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 152.42 69.0 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.65 2.233 . . . . 0.0 112.339 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 49.3 m -120.38 137.05 54.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.0 p -99.11 151.23 21.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.863 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.533 179.985 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m -129.46 161.63 29.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.371 . . . . 0.0 110.843 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.2 p 39.74 42.21 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.842 -179.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 48.91 -159.02 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.518 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 90.6 p -117.16 156.97 26.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.887 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.1 m -54.69 94.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.859 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.4 111.25 2.51 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.519 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 157.3 60.79 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.681 2.254 . . . . 0.0 112.346 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -128.9 -33.86 0.54 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.476 HD22 ' N ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.07 39.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 -179.894 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.429 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 5.3 mmm180 -113.76 158.27 21.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.404 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -67.43 109.66 3.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.7 mt -114.98 155.5 26.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 28.2 p -138.24 151.95 48.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.472 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 39.4 mt -115.06 116.44 52.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -87.95 120.52 29.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.91 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.448 ' CB ' ' HB2' ' A' ' 56' ' ' ALA . 0.5 OUTLIER -129.89 164.27 24.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.958 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.479 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -46.31 169.13 0.1 OUTLIER Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.596 0.712 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.479 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.81 3.15 2.97 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.687 2.258 . . . . 0.0 112.308 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.35 34.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -103.62 140.27 37.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.843 0.354 . . . . 0.0 110.908 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.0 mmp_? -85.83 123.93 31.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -34.05 -43.77 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.882 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 71.53 44.79 49.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.524 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.429 HG12 ' CD1' ' A' ' 23' ' ' LEU . 1.1 pt -125.76 177.58 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.809 0.338 . . . . 0.0 111.126 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.43 ' C ' HG23 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -141.02 154.29 45.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.433 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.2 pt -138.72 149.37 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.2 ptp180 -125.53 125.94 44.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.07 -150.79 22.6 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 122.74 152.74 8.64 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.492 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -61.83 -7.78 4.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.81 0.338 . . . . 0.0 111.104 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.6 mmm180 -131.11 -40.47 1.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . -52.09 155.08 4.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' ' N ' ' A' ' 36' ' ' GLY . 2.9 p80 -34.37 123.46 0.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.818 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -41.46 -23.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 100.5 -49.67 1.1 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.476 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -108.49 137.26 19.92 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.653 0.74 . . . . 0.0 110.846 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -37.96 8.46 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.257 . . . . 0.0 112.385 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 13.5 ttp85 -54.83 -56.67 16.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.899 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.13 85.4 4.28 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.622 0.725 . . . . 0.0 110.906 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -1.28 8.2 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.631 2.221 . . . . 0.0 112.35 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.3 p -106.73 28.59 7.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.436 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 0.2 OUTLIER -117.56 117.57 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 179.917 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -90.17 24.33 2.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.869 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.86 150.69 35.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 mt -123.38 118.13 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.896 0.379 . . . . 0.0 111.117 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.577 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -128.61 150.91 50.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.5 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 56.0 mt -56.37 146.36 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.104 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.474 ' N ' HG23 ' A' ' 48' ' ' ILE . 82.1 p -120.85 -24.53 5.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.856 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.466 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 24.5 ttmt -154.97 156.05 35.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.491 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 76.8 t -147.95 113.83 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 42.5 t -57.6 137.14 82.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.688 0.756 . . . . 0.0 110.844 -179.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -22.23 32.49 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.29 -9.22 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.77 155.86 53.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -44.15 -35.08 2.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 111.109 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -72.31 -56.47 5.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -51.5 -38.65 43.28 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.7 ptt-85 -76.73 -28.85 55.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.799 0.333 . . . . 0.0 110.86 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -55.27 -64.36 0.87 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.55 -6.02 16.6 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.468 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -109.44 -50.36 3.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.836 0.35 . . . . 0.0 110.91 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.5 ' CD2' ' CD1' ' A' ' 48' ' ' ILE . 1.6 tm? -64.59 122.54 17.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.432 ' N ' HD13 ' A' ' 63' ' ' LEU . 30.9 mtt180 -152.81 141.53 20.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.448 ' O ' ' CG2' ' A' ' 65' ' ' VAL . 0.1 OUTLIER -51.54 95.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 179.968 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.47 -12.82 0.5 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.492 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.449 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 50.5 mt -83.24 151.22 25.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.745 0.307 . . . . 0.0 110.95 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.577 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 74.6 ttt180 -95.68 114.79 26.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.463 ' CD2' HG11 ' A' ' 100' ' ' VAL . 3.3 mm? -72.71 108.11 5.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.411 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 10.1 mp -84.4 -45.73 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.411 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 39.2 mt-10 -158.64 146.64 18.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 72.3 t -119.37 108.17 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.165 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 13.3 m-20 65.68 41.38 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.0 mt-30 64.16 34.4 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -128.49 91.24 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.6 t -47.76 123.88 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.425 ' C ' HD21 ' A' ' 80' ' ' LEU . 10.9 mt -79.73 9.96 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.1 123.37 27.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.932 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 108.69 -35.97 4.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.478 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.436 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -81.66 166.29 20.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.895 0.378 . . . . 0.0 110.914 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.462 ' O ' ' C ' ' A' ' 82' ' ' HIS . 70.8 p -101.24 158.74 15.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.1 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.462 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.57 -52.82 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.8 -45.7 90.92 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.472 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.436 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.8 mm-40 -63.97 -46.55 84.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.931 0.396 . . . . 0.0 110.907 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.417 ' N ' HD11 ' A' ' 80' ' ' LEU . . . -58.74 -47.87 83.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 70.7 t -54.74 -63.16 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.128 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 7.1 mm-40 -47.5 -26.57 1.43 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.6 tt -72.65 -33.82 66.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.964 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -74.78 -33.61 62.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.939 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.0 ptt85 -91.62 9.62 31.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 33.4 t -99.26 28.44 4.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.852 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.444 HG23 ' CB ' ' A' ' 96' ' ' LEU . 19.0 t -96.16 166.52 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.416 ' N ' HG13 ' A' ' 92' ' ' VAL . . . -103.04 -66.21 0.74 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.515 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.61 -24.92 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.899 0.381 . . . . 0.0 110.89 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.426 HG22 ' C ' ' A' ' 15' ' ' ILE . 24.9 m -159.8 140.48 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.182 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.444 ' CB ' HG23 ' A' ' 92' ' ' VAL . 1.1 pt? -116.48 167.64 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.929 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.404 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.0 m -118.91 96.36 5.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.17 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.8 m -95.9 128.45 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.1 tp -93.14 36.55 1.04 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.463 HG11 ' CD2' ' A' ' 69' ' ' LEU . 5.8 m -66.45 168.2 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.1 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.445 ' O ' ' C ' ' A' ' 102' ' ' ASP . 28.7 p -166.01 133.29 2.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.449 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 2.4 p30 -34.52 108.27 0.06 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -101.26 -52.99 1.03 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.43 ' CZ ' ' CD2' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -172.77 135.7 0.67 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.775 0.321 . . . . 0.0 110.933 -179.828 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -97.92 127.94 44.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.2 m -86.88 35.12 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 109.59 169.45 20.25 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 151.89 69.51 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.679 2.252 . . . . 0.0 112.356 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.3 t -127.26 104.9 8.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.857 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 111' ' ' GLY . 89.0 p -162.01 156.25 21.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.845 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 110' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.521 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.6 p -68.11 129.52 40.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.946 0.403 . . . . 0.0 110.835 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 75.4 m -101.84 42.0 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -92.71 101.03 2.73 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.469 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.3 p -162.3 140.91 9.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.818 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.3 t -105.36 155.64 18.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.77 89.99 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.49 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 148.58 65.49 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.73 2.287 . . . . 0.0 112.298 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.89 -40.53 0.46 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.55 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -86.4 26.54 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 18.0 mmm180 -92.89 169.68 10.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.876 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.455 ' CG ' HG21 ' A' ' 97' ' ' THR . 34.5 tt0 -80.06 110.44 15.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.3 mp -116.34 166.8 11.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.7 p -144.47 156.92 44.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.864 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.65 108.82 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.121 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -79.53 118.47 21.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.913 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.472 ' HZ2' ' N ' ' A' ' 95' ' ' THR . 0.4 OUTLIER -128.87 171.05 12.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.456 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -49.58 168.07 0.21 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.632 0.729 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.456 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.74 2.9 3.11 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.313 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.62 34.82 0.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.5 tp10 -104.11 130.59 51.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.877 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 9.3 ptt-85 -80.3 117.46 21.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.484 ' CD2' HG12 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -33.36 -50.67 0.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.933 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.73 47.52 8.64 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.477 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.484 HG12 ' CD2' ' A' ' 23' ' ' LEU . 2.9 pt -112.39 158.1 12.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 111.168 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -125.08 134.9 52.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.2 pt -126.86 163.51 29.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.4 ptt180 -136.23 125.75 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.61 -144.64 11.37 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.57 157.08 12.28 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.505 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.423 ' HA ' ' CG ' ' A' ' 44' ' ' GLU . . . -68.74 -6.09 24.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.725 0.297 . . . . 0.0 111.034 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -133.05 -38.66 0.96 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . -47.28 134.83 12.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.47 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 33' ' ' GLY . 23.3 m80 -34.67 114.34 0.22 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.879 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -35.96 112.59 0.18 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -45.38 -48.86 11.22 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.524 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.427 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 32.7 t30 -89.27 126.07 59.83 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.68 21.77 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.671 2.247 . . . . 0.0 112.325 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.427 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 81.2 mtt180 -44.11 -69.66 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.865 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -115.07 119.34 39.0 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.614 0.721 . . . . 0.0 110.841 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -18.07 37.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.687 2.258 . . . . 0.0 112.363 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 37.5 p -88.75 42.37 1.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -129.85 104.97 7.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.841 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.423 ' CG ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 mp0 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.887 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.44 150.88 46.87 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.454 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 33.1 mt -125.74 117.6 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.851 0.358 . . . . 0.0 111.087 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.86 154.26 46.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.893 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.464 ' CD1' HD22 ' A' ' 63' ' ' LEU . 85.2 mt -64.23 126.58 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.101 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 4.9 t -103.97 -18.13 14.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.461 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 17.4 ttmt -165.56 160.75 17.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.927 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.444 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 95.6 t -157.07 127.98 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.105 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -67.94 141.99 94.99 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.658 0.742 . . . . 0.0 110.902 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -35.3 12.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.628 2.219 . . . . 0.0 112.403 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.2 p -91.25 3.65 54.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -78.49 161.5 48.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.437 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.4 ' HB2' ' CD1' ' A' ' 23' ' ' LEU . . . -51.12 -32.76 23.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.751 0.31 . . . . 0.0 111.104 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -80.54 -64.06 1.27 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.097 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.28 -33.4 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.475 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.434 ' HG3' ' N ' ' A' ' 60' ' ' ASP . 12.1 ptt180 -81.24 -47.09 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.868 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.434 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 17.2 t0 -40.95 -66.37 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.871 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 -13.52 13.85 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.466 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -97.76 -12.64 22.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.464 HD22 ' CD1' ' A' ' 48' ' ' ILE . 1.5 tm? -111.16 134.63 52.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.417 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -154.84 159.04 40.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.895 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 42.7 t -64.5 97.65 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.202 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.03 -20.91 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.46 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 66.3 mt -77.1 136.35 38.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.82 0.343 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.579 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 63.0 ttt180 -84.02 123.65 30.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.46 ' CD2' HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -72.77 111.62 8.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.42 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 49.1 mt -89.4 -49.36 6.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.42 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 13.5 mt-10 -158.28 140.86 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.419 ' CG1' HD11 ' A' ' 96' ' ' LEU . 84.0 t -112.09 111.2 35.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.0 m-20 65.23 40.96 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 40.4 mt-30 64.36 32.12 12.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -127.56 90.03 3.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 t -42.94 130.31 4.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.858 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 14.7 mt -81.31 6.93 12.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.95 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.62 123.96 27.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.943 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 112.13 -37.19 3.78 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.413 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -84.99 168.88 14.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.933 -179.925 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' C ' ' A' ' 82' ' ' HIS . 77.8 p -106.69 161.27 14.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.471 ' C ' ' O ' ' A' ' 81' ' ' THR . 4.3 t-80 -32.81 -55.8 0.37 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.31 -47.32 56.3 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.464 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.42 ' N ' ' O ' ' A' ' 81' ' ' THR . 11.1 mm-40 -66.51 -49.88 65.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.838 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -50.17 -50.15 49.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 68.9 t -56.16 -57.3 9.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.122 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.468 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 9.9 mm-40 -52.17 -23.33 5.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.912 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 tt -76.41 -27.15 56.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.408 HD12 ' CG1' ' A' ' 25' ' ' ILE . 0.5 OUTLIER -82.84 -25.12 32.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.861 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.468 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.4 ptm180 -97.63 -3.57 39.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 31.2 t -89.6 28.82 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.902 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.461 HG21 ' CA ' ' A' ' 96' ' ' LEU . 3.3 p -109.26 147.66 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.23 -98.49 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.495 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.464 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 0.8 OUTLIER -112.4 -11.31 13.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.89 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.472 ' N ' ' HZ2' ' A' ' 17' ' ' LYS . 6.4 m -153.03 137.22 16.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.104 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.461 ' CA ' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -121.65 169.42 10.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.455 HG21 ' CG ' ' A' ' 12' ' ' GLU . 1.3 m -117.28 95.58 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.4 m -91.98 128.87 43.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.148 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.9 21.13 10.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.923 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 69' ' ' LEU . 22.6 m -49.8 177.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.405 ' C ' HD23 ' A' ' 67' ' ' LEU . 1.8 p -169.26 147.62 3.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.46 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 0.7 OUTLIER -43.07 113.4 0.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.464 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -95.66 -43.55 3.36 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.508 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.464 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.2 OUTLIER -157.31 124.43 5.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.904 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -37.96 -47.62 1.09 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.929 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.5 m 49.86 42.16 23.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -100.49 147.44 18.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.484 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 176.43 6.78 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.696 2.264 . . . . 0.0 112.34 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.7 t -125.72 138.38 53.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.8 p -50.6 147.36 4.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.822 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.7 m -141.75 144.13 33.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.915 0.388 . . . . 0.0 110.854 -179.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.4 m -120.54 131.72 54.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.815 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.29 105.49 0.54 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.47 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -139.81 141.54 36.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.916 0.388 . . . . 0.0 110.898 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.8 m -117.26 85.66 2.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.855 -179.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 65.78 150.22 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.403 ' HB2' ' CG ' ' A' ' 11' ' ' ARG . 54.1 Cg_endo -69.75 147.31 62.63 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.708 2.272 . . . . 0.0 112.349 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -115.85 -25.49 3.61 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.475 ' N ' HD21 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.16 31.21 0.5 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.742 0.306 . . . . 0.0 110.854 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.403 ' CG ' ' HB2' ' A' ' 8' ' ' PRO . 13.6 mmm180 -104.91 162.48 13.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.46 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 50.2 tt0 -73.31 113.17 10.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.46 ' O ' ' CG2' ' A' ' 97' ' ' THR . 26.2 mt -105.46 -174.87 2.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.909 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' SG ' ' O ' ' A' ' 96' ' ' LEU . 1.7 t -164.47 153.28 13.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 19.5 mt -125.82 118.72 52.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -94.04 115.68 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -128.65 164.53 22.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.469 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -45.12 168.75 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.578 0.704 . . . . 0.0 111.092 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.469 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.83 1.19 4.71 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.679 2.253 . . . . 0.0 112.325 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.48 42.88 0.23 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 17.1 tp10 -107.77 141.24 39.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.903 0.383 . . . . 0.0 110.875 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.9 mtt180 -83.59 120.72 26.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.468 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.1 OUTLIER -32.55 -56.97 0.35 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.56 41.1 7.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.545 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.468 ' CD1' HD13 ' A' ' 89' ' ' LEU . 2.7 pt -121.68 171.17 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.414 ' C ' HG21 ' A' ' 27' ' ' ILE . 1.5 m -142.92 146.47 34.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.414 HG21 ' C ' ' A' ' 26' ' ' SER . 28.8 pt -136.41 161.32 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.153 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.417 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 4.4 ptm85 -132.14 140.42 48.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.417 ' HA2' ' C ' ' A' ' 34' ' ' HIS . . . 140.11 -155.35 24.45 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 139.22 172.48 12.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.411 ' HB3' ' CG2' ' A' ' 81' ' ' THR . . . -97.28 15.22 23.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.728 0.299 . . . . 0.0 111.068 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -127.37 40.66 3.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.869 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.458 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . 111.2 -77.32 0.23 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.458 ' C ' ' O ' ' A' ' 33' ' ' GLY . 24.7 m170 -33.19 125.81 0.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.856 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -147.27 148.89 31.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.536 ' HA3' ' CD1' ' A' ' 47' ' ' PHE . . . -44.08 -74.31 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.462 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -83.07 122.0 77.47 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.588 0.709 . . . . 0.0 110.908 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 -7.71 21.76 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.674 2.249 . . . . 0.0 112.355 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 63.6 ttp85 -49.19 -51.55 32.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.851 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -138.98 111.26 7.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.89 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -18.72 36.85 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.722 2.281 . . . . 0.0 112.342 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 72.3 p -56.04 -37.91 69.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -83.56 110.22 18.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.859 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 17.9 mp0 -75.56 65.19 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.15 148.59 21.53 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 86.6 mt -127.81 117.95 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.837 0.351 . . . . 0.0 111.178 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.2 m-85 -131.49 -176.67 4.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.494 ' CD1' ' CD1' ' A' ' 63' ' ' LEU . 78.6 mt -84.74 139.92 16.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.136 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 24.4 p -119.07 -12.07 9.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.468 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 22.0 tttp -175.78 149.84 0.98 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.898 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.47 ' CG1' HG21 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -156.1 117.57 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.099 179.887 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.7 t -66.25 137.79 95.72 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.67 0.748 . . . . 0.0 110.846 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -26.45 27.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.354 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 67.5 p -82.33 -26.37 33.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.153 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.96 174.31 2.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.483 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.3 -32.3 73.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.845 0.355 . . . . 0.0 111.134 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 60' ' ' ASP . . . -77.45 -69.33 0.54 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.19 -45.63 1.23 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.447 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.9 ptt180 -68.04 -35.27 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ALA . 32.0 t70 -45.29 -64.77 0.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.49 -19.35 6.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -98.34 -51.47 3.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.494 ' CD1' ' CD1' ' A' ' 48' ' ' ILE . 0.2 OUTLIER -55.31 130.43 42.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.896 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -162.69 151.23 14.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.481 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 64.7 t -59.92 104.89 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.541 ' HA2' ' CE1' ' A' ' 104' ' ' PHE . . . 144.67 -8.43 1.8 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.47 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.425 HD23 ' C ' ' A' ' 101' ' ' CYS . 23.5 mt -89.95 129.29 36.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.579 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 62.2 ttt180 -79.31 124.24 28.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.886 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.469 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.4 mm? -75.31 114.14 13.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.427 HD11 ' N ' ' A' ' 70' ' ' LEU . 7.4 mp -91.16 -50.69 5.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.917 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -155.4 141.98 18.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.459 ' CG1' HD11 ' A' ' 96' ' ' LEU . 88.0 t -114.58 108.38 25.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 65.93 42.06 3.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.925 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 64.43 29.86 13.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 -123.47 89.88 3.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.6 t -42.99 130.92 4.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.466 ' CD1' ' HB3' ' A' ' 69' ' ' LEU . 36.7 mt -85.25 7.68 21.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -77.41 126.66 31.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.41 -36.11 4.62 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.492 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.457 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -85.73 162.51 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.846 0.355 . . . . 0.0 110.928 -179.889 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 82' ' ' HIS . 43.0 p -105.68 167.38 9.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.54 -65.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -41.77 -48.1 5.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.6 mt-10 -66.86 -50.91 61.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.852 0.358 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.25 -55.27 22.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 88.4 t -51.37 -61.7 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.17 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.474 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.1 mm-40 -50.07 -24.78 2.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.6 -30.9 61.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.468 HD13 ' CD1' ' A' ' 25' ' ' ILE . 0.7 OUTLIER -78.42 -28.9 46.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.474 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.9 ptp180 -93.61 1.16 56.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.1 t -95.05 31.3 1.92 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.477 HG23 ' N ' ' A' ' 93' ' ' GLY . 2.8 p -112.89 142.93 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.477 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -60.08 -101.48 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 20.0 p-10 -114.81 0.24 13.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 0.0 110.876 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.441 ' O ' ' CG2' ' A' ' 92' ' ' VAL . 19.3 m -159.02 135.72 9.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.128 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.464 ' CB ' HG21 ' A' ' 92' ' ' VAL . 0.6 OUTLIER -132.13 157.21 44.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.894 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' THR . . . . . 0.46 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 9.6 m -107.99 103.53 12.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.128 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.413 ' O ' ' CG2' ' A' ' 98' ' ' VAL . 2.9 m -97.1 126.31 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.0 tp -91.89 29.41 1.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.469 HG11 ' CD2' ' A' ' 69' ' ' LEU . 11.7 m -61.07 166.43 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.169 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.425 ' C ' HD23 ' A' ' 67' ' ' LEU . 25.0 p -164.34 146.01 8.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.832 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -42.63 119.96 1.58 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -112.75 -36.47 1.54 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.517 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.541 ' CE1' ' HA2' ' A' ' 66' ' ' GLY . 3.2 p90 -173.72 118.47 0.27 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -73.93 122.79 23.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.881 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.4 t -75.84 -45.89 33.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 145.85 7.37 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 117.32 5.01 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.1 t 62.06 44.51 7.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.827 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.6 m 57.38 49.67 12.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.509 179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.4 t -123.66 90.89 3.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.897 0.379 . . . . 0.0 110.88 -179.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.6 p -130.07 84.83 2.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.908 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -42.6 160.24 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.507 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 p -90.2 118.0 29.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 0.0 110.822 -179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.6 m -146.23 122.58 10.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.861 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.81 89.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.481 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.75 143.77 51.94 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 166.96 -42.16 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.518 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.94 23.53 1.46 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.791 0.329 . . . . 0.0 110.93 -179.935 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.429 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 4.7 mmm180 -93.1 157.65 16.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -65.71 106.84 1.59 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mt -109.25 170.73 7.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.936 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.9 p -150.59 155.35 39.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 34.4 mt -120.73 120.51 62.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.153 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -92.26 115.34 27.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.931 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.422 ' CB ' ' HB1' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -128.17 164.62 22.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.895 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.468 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.33 168.65 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.562 0.696 . . . . 0.0 111.06 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.468 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.78 3.49 2.75 Favored 'Trans proline' 0 N--CA 1.466 -0.146 0 C-N-CA 122.698 2.265 . . . . 0.0 112.321 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.18 37.84 0.16 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.7 tp10 -100.29 138.41 37.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.463 ' O ' ' C ' ' A' ' 23' ' ' LEU . 30.1 mmt-85 -81.07 116.71 21.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.463 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.0 OUTLIER -32.56 -46.79 0.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.81 42.82 52.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.43 HG12 ' CG ' ' A' ' 23' ' ' LEU . 1.3 pt -119.56 166.54 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.338 . . . . 0.0 111.135 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.437 ' C ' HG21 ' A' ' 27' ' ' ILE . 0.6 OUTLIER -130.51 150.37 51.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.437 HG21 ' C ' ' A' ' 26' ' ' SER . 30.7 pt -139.53 151.39 22.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.114 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -129.07 124.67 35.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . 155.36 -150.83 22.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.485 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 139.41 144.01 4.49 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.451 ' CB ' ' O ' ' A' ' 80' ' ' LEU . . . -73.17 5.62 3.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.075 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 3.2 ptm85 -115.06 47.87 1.23 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.846 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.432 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . 100.14 -72.25 0.46 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.448 ' O ' ' C ' ' A' ' 29' ' ' GLY . 56.7 m-70 -35.6 101.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.771 0.32 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -93.52 -18.87 21.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 75.16 -47.36 1.95 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.675 ' ND2' ' CE1' ' A' ' 104' ' ' PHE . 20.7 t-20 -95.18 131.57 29.72 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.622 0.725 . . . . 0.0 110.912 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -6.93 19.76 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.446 ' NE ' ' HA ' ' A' ' 39' ' ' ARG . 8.4 mmp_? -55.42 -70.7 0.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.826 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 79.8 m-20 -121.8 99.47 44.45 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.586 0.708 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -22.67 31.69 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.316 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.0 t -83.37 -9.59 58.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.167 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -107.29 110.63 22.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.914 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -62.69 84.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.3 163.86 13.63 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.443 HG12 ' N ' ' A' ' 30' ' ' GLY . 36.6 mt -135.72 115.95 17.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.592 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.59 149.97 51.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.461 HD12 ' CD1' ' A' ' 63' ' ' LEU . 18.1 mt -55.59 140.95 12.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.129 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 49.8 p -114.15 -26.55 8.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.429 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 37.5 tttm -158.61 157.05 31.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.429 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 85.8 t -150.79 116.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.114 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.5 t -62.91 140.48 97.48 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.679 0.752 . . . . 0.0 110.853 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -16.46 37.82 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.707 2.271 . . . . 0.0 112.353 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.9 p -105.62 -6.28 19.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.117 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' ALA . . . -76.72 145.9 31.94 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.503 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.487 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -37.51 -33.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 111.094 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.425 ' CB ' HD11 ' A' ' 23' ' ' LEU . . . -74.98 -62.71 1.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.02 -40.22 6.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.502 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 1.6 ptt-85 -73.91 -29.94 62.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.866 0.365 . . . . 0.0 110.893 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . 0.422 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 6.5 t70 -55.16 -69.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.71 -22.01 4.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -96.28 -52.64 3.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.82 0.343 . . . . 0.0 110.905 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.461 ' CD1' HD12 ' A' ' 48' ' ' ILE . 0.6 OUTLIER -61.9 110.85 1.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.944 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 5.1 ptp180 -152.8 136.3 15.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.836 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.438 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 0.2 OUTLIER -39.59 99.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.123 179.944 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.66 -32.41 0.52 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.54 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.448 HD23 ' CG2' ' A' ' 100' ' ' VAL . 7.8 mp -73.73 151.82 40.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.845 0.355 . . . . 0.0 110.882 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 61.5 ttt180 -97.66 116.54 30.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.449 ' CD2' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -66.09 105.64 1.42 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 9.5 mp -80.5 -49.64 11.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.941 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -158.94 145.12 16.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.869 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 79.3 t -115.31 110.21 31.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.11 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.404 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.7 m-20 64.88 40.56 5.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.404 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 35.4 mt-30 64.61 29.85 12.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.955 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.8 mm100 -123.64 90.76 3.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.885 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.1 t -44.96 130.86 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.82 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.6 mt -79.85 0.26 31.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -74.7 118.4 17.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.6 -34.02 4.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.5 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -92.98 171.38 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.945 0.402 . . . . 0.0 110.903 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.7 p -109.85 162.5 14.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.162 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.33 -55.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -49.83 -49.53 34.73 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.494 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -68.01 -51.75 43.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.878 0.37 . . . . 0.0 110.862 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.47 ' N ' HD12 ' A' ' 80' ' ' LEU . . . -47.81 -48.62 30.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 98.3 t -57.96 -54.24 34.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.135 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.476 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 61.6 mm-40 -56.79 -22.0 32.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 tt -76.42 -27.07 56.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.412 HD11 ' CD1' ' A' ' 25' ' ' ILE . 0.7 OUTLIER -82.71 -29.1 30.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.964 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.476 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.7 ptm180 -92.49 0.81 57.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.871 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 44.4 t -94.25 28.06 2.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.834 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 93' ' ' GLY . 3.0 p -108.77 140.28 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.164 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.475 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -59.59 -98.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.518 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -114.16 -11.87 12.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.883 0.373 . . . . 0.0 110.858 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 2.0 m -150.29 137.11 19.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.116 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.434 ' CB ' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -125.95 167.94 14.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.936 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 m -115.98 97.54 6.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.1 m -97.04 130.6 45.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.136 179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.78 24.07 6.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.449 HG12 ' CD2' ' A' ' 69' ' ' LEU . 21.7 m -51.59 -176.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.111 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 5.3 p -175.45 153.93 1.58 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -55.68 105.38 0.18 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -96.75 -55.78 1.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.675 ' CE1' ' ND2' ' A' ' 37' ' ' ASN . 2.4 p90 -164.44 110.01 1.0 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.846 0.355 . . . . 0.0 110.863 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 25.5 mp0 -84.75 124.01 31.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 21.5 t -48.99 -52.17 26.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 160.54 172.42 27.79 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.448 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -2.47 10.21 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.667 2.245 . . . . 0.0 112.372 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 15.6 m -39.62 -47.91 2.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 29.0 t -57.26 134.06 55.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.822 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.498 179.991 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.6 m -65.92 155.38 36.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.877 0.37 . . . . 0.0 110.858 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.5 m -59.27 157.13 11.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.83 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.63 83.24 0.22 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m 51.23 47.24 25.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.883 0.373 . . . . 0.0 110.887 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -98.74 -53.91 3.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.851 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.21 146.43 9.49 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -168.02 0.25 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 166.98 -45.23 0.26 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.463 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.46 ' C ' ' CD2' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.46 18.47 1.47 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.928 -179.894 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.0 mmm180 -87.35 165.33 15.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.853 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -72.18 115.12 11.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -123.62 160.14 27.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 14.3 p -143.33 156.35 44.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.856 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 59.0 mt -117.74 102.66 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -77.31 117.85 19.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.403 ' NZ ' HD11 ' A' ' 23' ' ' LEU . 0.5 OUTLIER -134.03 165.4 25.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.837 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.455 ' CB ' ' HD2' ' A' ' 19' ' ' PRO . . . -43.38 168.43 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.633 0.73 . . . . 0.0 111.091 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.455 ' HD2' ' CB ' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.82 -0.15 6.54 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.626 2.217 . . . . 0.0 112.338 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -171.04 33.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 22.8 tp10 -92.1 126.05 37.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.866 0.365 . . . . 0.0 110.85 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.488 ' O ' ' C ' ' A' ' 23' ' ' LEU . 62.5 mtt180 -70.82 97.01 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.887 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.488 ' C ' ' O ' ' A' ' 22' ' ' ARG . 0.2 OUTLIER -30.95 -48.85 0.12 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.6 47.64 7.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.47 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 4.8 pt -117.61 153.67 19.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.83 0.348 . . . . 0.0 111.161 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.422 ' C ' HG23 ' A' ' 27' ' ' ILE . 0.9 OUTLIER -122.04 151.77 40.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.888 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.0 pt -137.28 145.96 28.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.099 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.415 ' HB2' ' NH1' ' A' ' 28' ' ' ARG . 1.5 ptm85 -122.76 137.21 54.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.845 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.96 -145.57 17.54 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.491 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.58 132.71 5.4 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.424 ' C ' ' HD3' ' A' ' 32' ' ' ARG . . . -63.28 115.14 4.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.784 0.325 . . . . 0.0 111.078 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . 0.424 ' HD3' ' C ' ' A' ' 31' ' ' ALA . 1.6 mpp_? 64.01 39.98 7.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -163.28 105.62 0.26 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.508 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.438 ' O ' ' C ' ' A' ' 35' ' ' ALA . 46.1 m-70 65.63 54.09 1.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.764 0.316 . . . . 0.0 110.891 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.438 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -33.71 113.07 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.06 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -51.54 -78.09 0.11 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -83.05 128.49 65.04 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.611 0.719 . . . . 0.0 110.883 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.8 27.0 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.647 2.231 . . . . 0.0 112.351 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.0 mtt85 -59.33 -72.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.26 116.32 20.1 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.615 0.722 . . . . 0.0 110.837 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.81 -2.86 10.92 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.348 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 67.1 p -70.16 -53.84 15.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -81.07 94.24 6.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -88.12 94.86 9.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.891 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -102.49 161.9 16.87 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.463 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 mt -126.22 119.53 54.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.886 0.374 . . . . 0.0 111.1 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.6 OUTLIER -132.04 150.68 52.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.858 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.475 HD13 ' CD1' ' A' ' 63' ' ' LEU . 44.1 mt -60.25 139.43 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.407 ' N ' HG22 ' A' ' 48' ' ' ILE . 1.3 t -112.01 -24.53 9.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.418 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 23.9 tttp -155.1 154.87 33.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.418 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 80.4 t -148.71 120.59 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 42.9 t -58.79 138.02 86.86 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.652 0.739 . . . . 0.0 110.877 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -38.42 7.66 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.645 2.23 . . . . 0.0 112.36 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.9 p -92.95 -2.95 55.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.55 172.86 38.12 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.14 -34.04 74.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.75 0.31 . . . . 0.0 111.063 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.478 ' CB ' HD21 ' A' ' 23' ' ' LEU . . . -76.83 -60.97 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.41 -42.75 4.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -77.74 -27.96 50.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -53.55 -66.98 0.3 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.85 -5.7 22.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.509 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.414 ' HA ' ' NH1' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -115.22 -7.76 12.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.38 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.475 ' CD1' HD13 ' A' ' 48' ' ' ILE . 1.3 tm? -114.55 124.63 52.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.467 ' N ' HD12 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.91 151.73 25.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 179.956 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -55.8 107.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.57 -25.54 1.67 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.424 HD21 ' C ' ' A' ' 101' ' ' CYS . 12.5 mt -70.89 142.36 51.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.927 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.525 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 75.5 ttt180 -88.91 112.89 23.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.466 ' CD2' HG11 ' A' ' 100' ' ' VAL . 2.9 mm? -64.94 103.06 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.924 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -79.61 -52.37 8.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -155.72 136.98 13.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 97.3 t -107.44 110.35 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.15 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.403 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.5 m-20 64.79 41.72 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . 0.403 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 29.6 mt-30 64.17 30.36 13.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -126.42 90.55 3.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.7 t -42.67 133.26 3.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.824 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.1 mt -87.62 13.19 10.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.941 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -80.74 133.18 35.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 101.18 -36.15 4.39 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.438 ' HB2' ' CB ' ' A' ' 84' ' ' GLU . 0.2 OUTLIER -87.12 156.92 19.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.865 0.364 . . . . 0.0 110.925 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 30.7 p -92.06 -177.26 4.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . 0.435 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 3.2 t-80 -51.33 -56.12 14.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.868 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -53.29 -51.47 46.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.494 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 6.8 mm-40 -58.54 -45.92 87.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.881 0.372 . . . . 0.0 110.871 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . 0.424 ' HA ' ' CD1' ' A' ' 80' ' ' LEU . . . -57.87 -49.62 76.07 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 55.4 t -53.08 -56.92 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.473 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.7 mm-40 -52.1 -22.84 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 tt -78.92 -28.04 43.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.929 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . 0.402 ' CD1' ' C ' ' A' ' 89' ' ' LEU . 0.5 OUTLIER -83.09 -26.36 31.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.864 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.473 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.5 ptp180 -95.05 0.89 54.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 24.9 t -96.36 33.28 1.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.455 HG21 ' N ' ' A' ' 93' ' ' GLY . 2.0 p -112.0 145.57 17.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.455 ' N ' HG21 ' A' ' 92' ' ' VAL . . . -64.63 -100.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.452 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -112.47 -1.69 14.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.884 0.373 . . . . 0.0 110.893 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 26.8 m -162.96 136.6 5.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.143 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.438 ' CA ' HG22 ' A' ' 92' ' ' VAL . 1.2 pt? -119.39 166.83 12.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.6 m -115.68 96.08 5.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.131 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.6 m -93.49 133.0 36.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.119 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -103.09 26.53 8.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.466 HG11 ' CD2' ' A' ' 69' ' ' LEU . 2.5 m -60.28 178.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.095 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.424 ' C ' HD21 ' A' ' 67' ' ' LEU . 2.4 p -171.65 146.02 2.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -37.89 109.98 0.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -104.01 -50.05 1.03 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.462 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -168.46 117.13 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.81 0.338 . . . . 0.0 110.907 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -53.67 -62.08 1.89 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.931 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 6.7 t 55.23 41.66 31.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -89.48 127.99 8.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.487 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 169.15 19.52 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.655 2.237 . . . . 0.0 112.339 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.5 t -105.51 118.0 35.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 48.6 p -109.08 138.61 45.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.466 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.3 m -90.3 -57.09 2.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.855 0.36 . . . . 0.0 110.858 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -52.12 132.87 33.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 39.94 43.81 2.57 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.497 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 40.9 t -68.17 147.25 52.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.829 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 m -103.18 110.93 23.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.866 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 155.17 175.48 26.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 142.5 47.85 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.661 2.241 . . . . 0.0 112.304 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 160.84 -47.61 0.38 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.551 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.458 ' N ' HD21 ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.33 32.43 0.5 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.799 0.333 . . . . 0.0 110.913 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -99.39 150.65 21.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.77 113.77 2.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.4 mt -117.37 167.35 11.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 23.0 p -146.42 158.9 43.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.418 ' C ' HG22 ' A' ' 95' ' ' THR . 22.6 mt -125.85 106.25 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.116 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -81.31 107.33 14.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.412 ' NZ ' ' HB3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -118.81 172.74 7.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.48 165.09 0.3 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.609 0.718 . . . . 0.0 111.099 179.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.424 ' HA ' ' CG ' ' A' ' 94' ' ' ASP . 53.6 Cg_endo -69.83 1.87 4.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.337 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.55 32.1 0.18 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.466 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 33.5 tp10 -97.92 153.34 18.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.876 0.369 . . . . 0.0 110.886 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.81 125.65 35.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . 0.47 ' CD1' ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -37.58 -52.46 1.2 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.911 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.44 40.9 14.35 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 7.5 pt -121.26 157.43 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 111.096 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.413 ' C ' HG23 ' A' ' 27' ' ' ILE . 1.6 m -122.16 144.1 49.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.413 HG23 ' C ' ' A' ' 26' ' ' SER . 21.1 pt -135.85 149.27 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.114 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.0 ptt180 -128.67 135.1 48.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 139.95 -140.93 11.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.82 135.43 6.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.402 ' O ' ' CG2' ' A' ' 81' ' ' THR . . . -61.68 114.29 3.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.736 0.303 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 15.9 mmm180 64.24 25.84 13.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.56 -91.26 2.16 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 15.1 m80 -108.15 109.68 21.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.813 0.339 . . . . 0.0 110.819 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -55.31 102.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.067 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -79.24 -58.01 3.04 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.475 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 56.4 t30 -90.38 118.93 69.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.621 0.724 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -30.93 21.16 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.637 2.225 . . . . 0.0 112.344 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 53.5 mtt85 -42.59 -63.26 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.911 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -123.19 117.14 28.3 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.604 0.716 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 2.76 3.25 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.348 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 17.2 p -102.17 -26.76 13.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.156 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.38 108.0 9.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.894 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -102.41 104.18 14.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.928 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -119.28 165.23 13.19 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.508 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.26 117.76 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.857 0.36 . . . . 0.0 111.132 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -131.04 149.61 52.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.471 HD11 ' CD1' ' A' ' 63' ' ' LEU . 65.1 mt -58.14 123.71 10.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.155 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.9 t -99.3 -10.8 21.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.855 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.452 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 13.1 ttmt -175.06 160.35 2.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.915 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.452 ' N ' ' CG ' ' A' ' 50' ' ' LYS . 58.8 t -144.42 114.09 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.6 t -61.54 138.28 94.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.681 0.753 . . . . 0.0 110.821 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -25.1 28.9 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.252 . . . . 0.0 112.329 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.3 p -94.99 1.22 55.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.78 158.94 34.07 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.484 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -50.25 -44.09 53.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.47 ' HB2' ' CD1' ' A' ' 23' ' ' LEU . . . -63.75 -58.76 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.089 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.11 -42.15 5.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.47 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 30.2 ptt180 -85.01 -24.22 28.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 110.914 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -54.42 -69.13 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.37 -13.54 15.9 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -101.38 -7.46 22.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.811 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.471 ' CD1' HD11 ' A' ' 48' ' ' ILE . 2.4 tm? -108.79 135.17 50.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.908 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.42 ' N ' HD11 ' A' ' 63' ' ' LEU . 2.5 mmp_? -140.5 158.09 44.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.413 HG11 ' N ' ' A' ' 50' ' ' LYS . 5.4 t -73.82 88.95 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 155.8 -17.76 0.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 13.0 mt -65.72 130.35 42.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.803 0.335 . . . . 0.0 110.901 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.569 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 60.4 ttt180 -78.6 122.1 25.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.451 ' CD2' HG13 ' A' ' 100' ' ' VAL . 2.2 mm? -73.86 111.87 9.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.953 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.448 ' N ' HD13 ' A' ' 70' ' ' LEU . 9.0 mp -87.48 -52.94 5.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.91 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -156.73 135.77 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 53.0 t -108.66 111.72 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.101 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 65.46 40.58 4.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 63.98 36.38 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.928 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -134.77 90.91 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.0 t -41.11 139.13 0.98 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.832 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.43 ' C ' HD22 ' A' ' 80' ' ' LEU . 11.5 mt -86.11 9.78 16.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.958 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.471 ' O ' ' CD2' ' A' ' 80' ' ' LEU . 6.8 tt -83.69 156.64 22.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 79.71 -19.51 6.1 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' LEU . . . . . 0.471 ' CD2' ' O ' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -110.38 155.06 22.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.381 . . . . 0.0 110.907 -179.91 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.402 ' CG2' ' O ' ' A' ' 31' ' ' ALA . 65.5 p -91.75 179.03 5.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -48.62 -58.11 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.84 -49.87 27.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.45 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.0 mt-10 -61.72 -46.84 87.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.841 0.353 . . . . 0.0 110.923 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -54.63 -51.64 64.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.085 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.422 HG13 ' NE2' ' A' ' 87' ' ' GLN . 65.0 t -48.22 -58.01 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.101 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLN . . . . . 0.721 HE21 ' N ' ' A' ' 87' ' ' GLN . 0.9 OUTLIER -51.49 -24.89 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.911 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.421 HD13 ' CD2' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -74.84 -32.19 61.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.914 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.83 -24.75 55.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.473 ' CZ ' ' OE1' ' A' ' 87' ' ' GLN . 4.2 ptt180 -96.55 -0.11 49.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 p -83.36 20.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.475 HG23 ' N ' ' A' ' 93' ' ' GLY . 2.4 p -106.42 145.84 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.162 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.475 ' N ' HG23 ' A' ' 92' ' ' VAL . . . -78.47 -80.66 0.71 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.501 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ASP . . . . . 0.424 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -121.13 -13.74 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.863 0.364 . . . . 0.0 110.852 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.418 HG22 ' C ' ' A' ' 15' ' ' ILE . 14.3 m -157.1 134.61 10.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -118.88 -179.24 3.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.926 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -126.61 95.92 4.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.4 m -96.92 129.31 47.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -94.96 21.6 7.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.451 HG13 ' CD2' ' A' ' 69' ' ' LEU . 20.8 m -49.65 169.29 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 8.6 p -161.6 154.08 20.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -48.8 111.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.853 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . 0.437 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -102.56 -46.33 1.54 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.437 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.5 OUTLIER -155.19 115.29 3.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 110.875 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLU . . . . . 0.453 ' O ' ' C ' ' A' ' 106' ' ' SER . 18.7 mt-10 -83.91 34.28 0.5 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.913 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' SER . . . . . 0.453 ' C ' ' O ' ' A' ' 105' ' ' GLU . 25.6 t -34.49 -39.44 0.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.873 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.2 153.14 8.67 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 140.55 43.16 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.356 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 88.5 p -64.81 134.56 54.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.838 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 60.7 p -51.09 152.86 2.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.839 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.538 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.672 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -97.77 33.06 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.929 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.623 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.6 mmm180 -104.12 177.82 4.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.419 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.6 tt0 -78.0 112.22 14.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.907 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.2 mt -119.85 163.38 17.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 96' ' ' LEU . 18.9 p -144.3 159.47 42.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.87 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.6 mt -122.34 112.96 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -84.47 115.39 22.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -127.41 166.77 17.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.889 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.06 168.27 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.543 0.687 . . . . 0.0 111.118 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.8 -2.01 9.48 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.653 2.235 . . . . 0.0 112.333 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.49 37.89 0.27 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 40.8 tp10 -102.68 143.58 32.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.864 0.364 . . . . 0.0 110.893 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.6 ptt180 -84.13 121.5 27.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.849 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.751 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -33.63 -53.16 0.42 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 41.12 9.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.751 HG12 HD12 ' A' ' 23' ' ' LEU . 3.3 pt -121.35 162.57 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.5 m -130.57 145.13 51.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.819 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.565 HD12 HG21 ' A' ' 46' ' ' ILE . 21.1 pt -136.2 156.2 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.107 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -132.48 132.9 43.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.873 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.07 -142.32 9.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.507 -179.927 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.565 HG21 HD12 ' A' ' 27' ' ' ILE . 30.8 mt -126.88 119.2 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.385 . . . . 0.0 111.106 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.72 149.12 52.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.833 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.541 HD13 HD11 ' A' ' 63' ' ' LEU . 94.7 mt -54.59 132.76 17.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.43 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.4 p -108.59 -13.41 14.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.412 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 28.4 tttm -175.5 156.47 1.96 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.853 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.56 HG13 HG22 ' A' ' 25' ' ' ILE . 93.4 t -143.63 123.24 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.109 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 t -69.22 143.15 93.49 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.684 0.754 . . . . 0.0 110.858 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -35.6 12.15 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.33 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.3 p -88.27 0.95 55.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.449 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -80.57 153.05 34.54 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.604 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -45.18 -38.9 5.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.769 0.319 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -73.32 -64.0 1.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -35.44 -44.56 0.62 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.8 ptt180 -79.3 -37.24 38.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 57' ' ' ALA . 22.1 t0 -40.66 -64.57 0.51 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.38 -9.75 22.23 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.24 -24.35 11.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.0 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.29 126.25 37.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -142.6 174.46 10.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 6.4 t -82.62 92.33 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.68 -13.66 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.47 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.611 HD12 HD22 ' A' ' 63' ' ' LEU . 52.7 mt -77.05 118.71 19.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.559 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 46.5 ttt180 -69.12 122.69 19.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.688 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -72.95 108.96 6.15 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.434 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 4.4 mm? -84.31 -52.37 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.951 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.434 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 11.3 mt-10 -157.85 134.99 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.837 HG13 HD12 ' A' ' 96' ' ' LEU . 88.8 t -106.58 110.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.075 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 18.6 m-20 64.73 41.66 5.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 64.17 31.89 12.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -128.86 91.05 3.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.887 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 36.2 t -50.45 130.89 24.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.3 mt -80.29 5.14 15.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.402 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -73.04 114.95 11.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.932 179.918 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -37.39 3.17 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.494 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.585 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -86.42 167.89 14.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.904 0.383 . . . . 0.0 110.917 -179.934 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 61.8 p -104.37 160.59 14.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.1 -55.19 0.39 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.821 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.24 -46.11 51.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 81' ' ' THR . 29.4 mm-40 -70.03 -47.87 60.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.863 0.364 . . . . 0.0 110.857 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -54.18 -48.76 70.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 82' ' ' HIS . 75.2 t -55.57 -55.22 18.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 19.8 mm100 -54.27 -27.3 34.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -70.43 -29.59 66.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.958 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.67 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.41 -30.5 47.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.921 179.879 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.8 ptp180 -93.36 -1.14 56.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.83 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -90.64 30.0 1.23 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.636 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.6 p -112.1 144.66 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.154 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.73 -94.51 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -119.52 -8.78 9.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 m -152.92 134.68 14.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.837 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -122.8 171.87 8.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.419 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.4 m -120.8 98.64 6.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.158 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.46 131.91 40.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.623 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.1 tp -101.15 31.47 3.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.688 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.5 m -65.96 175.47 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.133 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.4 p -165.17 154.23 12.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -46.26 101.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.478 -179.925 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.748 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -83.31 20.19 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.892 -179.906 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.472 ' O ' HD12 ' A' ' 99' ' ' LEU . 15.3 mmt180 -90.24 168.01 12.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.458 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 31.9 tt0 -74.25 114.84 13.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.893 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.8 mt -118.58 160.06 22.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.6 p -139.5 155.77 47.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 95' ' ' THR . 31.0 mt -122.97 109.78 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.19 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -80.31 115.93 20.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.482 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -131.98 178.26 6.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -56.83 163.62 2.71 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.554 0.692 . . . . 0.0 111.093 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.2 Cg_endo -69.8 1.23 4.65 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.688 2.259 . . . . 0.0 112.328 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -162.59 26.14 0.23 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.488 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.1 tp10 -94.43 142.22 27.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.909 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.9 mpt_? -86.32 123.72 31.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.722 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -46.53 0.24 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.58 41.18 30.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.527 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -121.41 162.97 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 0.0 111.143 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -120.12 159.1 25.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.835 -179.894 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 86' ' ' VAL . 14.4 pt -151.69 145.65 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.11 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -129.26 132.14 47.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.929 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.67 -146.19 15.17 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.478 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.464 -179.907 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 60.3 mt -139.18 115.86 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 111.135 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.4 OUTLIER -132.54 163.5 28.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.959 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.736 HD11 HD21 ' A' ' 63' ' ' LEU . 27.4 mt -67.72 125.49 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 82.7 p -96.85 -11.02 25.36 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.823 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 16.8 ttmm -175.86 167.25 3.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 64.5 t -150.06 114.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.139 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.5 t -67.27 140.01 95.17 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.61 0.719 . . . . 0.0 110.85 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.74 21.68 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.646 2.231 . . . . 0.0 112.361 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.5 p -86.57 -8.57 57.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.137 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -75.56 158.2 50.07 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.408 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -50.17 -39.39 43.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.766 0.317 . . . . 0.0 111.087 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -70.34 -60.26 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.079 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.63 -42.88 2.84 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.408 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 23.3 ptt180 -80.29 -31.53 38.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.83 0.348 . . . . 0.0 110.886 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -50.17 -72.29 0.05 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 119.72 -9.58 11.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.492 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -104.32 -10.93 17.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.876 0.37 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.83 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.4 tm? -105.83 134.0 49.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.707 ' N ' HD13 ' A' ' 63' ' ' LEU . 19.7 mtp180 -144.28 178.97 7.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 51' ' ' VAL . 9.1 t -88.02 92.86 3.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.138 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 151.91 -13.16 0.74 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.465 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.557 ' HB2' HD12 ' A' ' 48' ' ' ILE . 32.6 mt -73.0 110.41 7.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.803 0.335 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 16.6 ttm180 -62.34 122.8 16.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.858 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.67 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -71.24 107.03 4.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.495 ' O ' ' CG ' ' A' ' 71' ' ' GLU . 1.7 mm? -86.37 -42.14 13.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 40.3 mt-10 -161.82 139.55 8.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.885 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.745 HG13 HD12 ' A' ' 96' ' ' LEU . 66.7 t -117.6 108.0 23.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.089 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.476 ' ND2' HG22 ' A' ' 92' ' ' VAL . 11.5 m-20 65.44 41.35 4.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 63.65 36.66 10.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -131.92 91.16 2.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.3 t -47.55 127.04 10.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.436 ' HA ' HD21 ' A' ' 80' ' ' LEU . 12.8 mt -78.01 1.06 22.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.442 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -72.12 111.39 7.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.964 179.805 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.92 -37.28 2.73 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.524 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.501 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -87.16 167.03 14.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.953 0.406 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 81.0 p -102.66 -179.97 4.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.64 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -50.32 -51.48 44.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.85 -45.57 79.54 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.1 mt-10 -67.1 -58.36 5.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.819 0.342 . . . . 0.0 110.889 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -44.27 -46.79 9.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.123 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.746 ' HA ' HD23 ' A' ' 89' ' ' LEU . 74.5 t -57.05 -60.45 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.11 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.482 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.3 mm-40 -50.39 -26.27 4.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.902 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -74.73 -32.12 62.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.746 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -79.08 -31.66 44.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.482 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.4 ptm180 -90.81 3.54 54.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.897 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 5.5 m -96.59 29.23 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.639 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.4 t -94.25 149.94 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.59 -76.7 1.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -123.28 -17.76 6.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.84 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.426 HG23 ' O ' ' A' ' 15' ' ' ILE . 56.2 m -163.16 137.04 5.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.093 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.745 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.0 169.08 10.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.458 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.1 m -119.71 100.15 7.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.428 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.0 m -96.72 130.66 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.472 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.7 tp -99.19 24.83 7.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.7 m -61.84 172.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.122 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.3 p -163.35 163.02 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -54.31 95.15 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.485 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.31 28.81 0.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.813 0.339 . . . . 0.0 110.934 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -98.5 161.93 13.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 35.2 tt0 -68.21 107.37 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.869 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 98' ' ' VAL . 18.9 mt -113.48 157.49 21.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 20.6 p -139.36 165.33 27.5 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.404 HG22 ' HB1' ' A' ' 56' ' ' ALA . 52.4 mt -128.99 105.62 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -80.68 117.55 21.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.4 ptpp? -126.91 168.6 14.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.51 168.34 0.12 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 0.0 111.103 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.823 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 1.61 4.27 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.727 2.285 . . . . 0.0 112.339 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.32 43.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 38.8 tp10 -111.59 142.7 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.814 0.34 . . . . 0.0 110.86 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -86.6 124.5 32.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 -179.926 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.777 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.46 -52.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 41.04 13.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.505 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.685 HG23 HD12 ' A' ' 23' ' ' LEU . 3.1 pt -119.39 157.33 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.813 0.339 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -123.5 140.06 53.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.628 HD12 HG21 ' A' ' 46' ' ' ILE . 21.5 pt -132.79 157.09 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.121 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.445 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 3.3 ptm85 -132.58 138.87 47.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.23 -144.75 13.2 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 -179.957 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.628 HG21 HD12 ' A' ' 27' ' ' ILE . 39.6 mt -125.21 117.63 50.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.829 0.347 . . . . 0.0 111.136 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.06 156.53 43.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 HD11 ' A' ' 63' ' ' LEU . 65.3 mt -64.19 130.46 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.158 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 43.5 t -110.23 -14.57 14.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.837 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.474 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 11.2 tttm -167.02 161.21 14.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.659 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -152.78 129.28 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.144 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.1 t -72.52 137.65 80.72 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.611 0.719 . . . . 0.0 110.867 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -25.29 28.84 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.676 2.251 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -101.71 12.88 36.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.187 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -91.92 161.94 27.21 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.506 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.491 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -50.04 -35.51 25.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.17 -57.11 4.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.123 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.27 -43.85 4.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.497 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -80.83 -26.25 37.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.821 0.343 . . . . 0.0 110.889 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -48.58 -58.23 5.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.79 -25.12 11.19 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.468 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -94.73 -53.48 3.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.855 0.36 . . . . 0.0 110.883 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.811 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.4 OUTLIER -58.6 132.49 53.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.627 ' N ' HD13 ' A' ' 63' ' ' LEU . 3.6 ptp180 -165.33 147.57 7.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 62.0 t -49.79 106.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.153 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.13 -26.3 2.03 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.696 HD23 ' C ' ' A' ' 101' ' ' CYS . 20.3 mt -75.25 118.55 18.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.765 0.316 . . . . 0.0 110.942 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.56 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -69.61 131.66 45.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.602 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -80.29 111.75 16.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 4.0 mm? -88.84 -49.78 6.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.957 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.416 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -158.39 140.41 13.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.923 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.847 HG13 HD12 ' A' ' 96' ' ' LEU . 88.4 t -111.84 109.77 29.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.159 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 65.07 41.9 4.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 64.21 32.99 12.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.21 90.54 3.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.912 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.8 t -47.3 130.08 13.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.618 ' HA ' HD21 ' A' ' 80' ' ' LEU . 5.8 mt -83.31 8.34 13.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.965 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.5 OUTLIER -76.97 115.45 16.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.886 179.894 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.11 -32.52 5.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.468 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.618 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -88.04 167.12 13.96 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.918 0.389 . . . . 0.0 110.9 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.441 ' O ' ' N ' ' A' ' 84' ' ' GLU . 44.5 p -105.94 162.92 13.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.102 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.598 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.7 t-80 -34.82 -55.96 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.62 -41.12 49.23 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.442 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -73.16 -48.6 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.856 0.36 . . . . 0.0 110.868 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.4 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.3 -51.64 64.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.152 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.0 t -53.17 -62.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.125 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 15.9 mm-40 -49.51 -23.44 1.6 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -75.07 -33.47 61.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.773 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.2 -32.76 56.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 8.2 ptm180 -89.24 -3.36 58.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.1 m -91.41 33.52 0.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.84 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.3 p -112.88 145.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.115 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.25 -98.15 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -116.15 -6.96 11.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.923 0.392 . . . . 0.0 110.918 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.4 m -156.17 130.64 8.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.172 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.847 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.99 168.2 10.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.6 m -116.85 97.77 6.14 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.113 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 13' ' ' LEU . 3.3 m -95.43 129.32 45.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.152 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.3 tp -99.51 34.17 2.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.602 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.0 m -69.91 173.0 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.696 ' C ' HD23 ' A' ' 67' ' ' LEU . 7.9 p -165.15 168.34 17.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -52.51 114.32 1.34 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.494 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.443 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.707 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.79 38.99 0.73 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.924 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 53.8 mtp180 -109.68 144.95 37.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.438 ' OE2' HG21 ' A' ' 97' ' ' THR . 52.9 tt0 -55.52 110.09 0.65 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.5 mt -105.1 168.67 8.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.944 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.696 ' SG ' HG22 ' A' ' 95' ' ' THR . 7.2 t -150.35 144.22 25.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.931 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.814 ' O ' HG23 ' A' ' 95' ' ' THR . 15.6 mt -120.71 127.2 75.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -97.72 113.54 25.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -124.83 170.5 10.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.89 168.05 0.17 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.582 0.706 . . . . 0.0 111.1 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.813 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.81 2.37 3.62 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.344 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.05 39.43 0.17 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.6 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 26.1 tp10 -101.73 144.19 30.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.812 0.339 . . . . 0.0 110.926 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 25.5 mtt-85 -83.75 120.23 25.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.753 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -49.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.35 42.6 18.12 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.471 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.753 HG12 HD12 ' A' ' 23' ' ' LEU . 2.2 pt -122.74 161.5 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.803 0.335 . . . . 0.0 111.133 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.471 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -119.17 160.37 22.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.891 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 46' ' ' ILE . 17.7 pt -151.55 147.27 15.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.169 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.473 ' NH1' ' CB ' ' A' ' 49' ' ' SER . 6.1 ptt-85 -125.09 139.42 53.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 137.87 -149.93 20.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.514 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.542 -179.893 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.439 HG21 HD12 ' A' ' 27' ' ' ILE . 48.6 mt -123.62 118.69 55.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.844 0.354 . . . . 0.0 111.117 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.75 147.51 50.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.701 HD13 HD11 ' A' ' 63' ' ' LEU . 95.3 mt -55.88 135.66 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.149 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.473 ' CB ' ' NH1' ' A' ' 28' ' ' ARG . 70.0 p -113.87 -13.39 12.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.853 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.517 ' N ' HG13 ' A' ' 65' ' ' VAL . 17.9 ttmm -170.38 161.23 7.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.684 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.08 121.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -68.01 139.27 92.89 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 110.871 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -29.91 23.26 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.716 2.277 . . . . 0.0 112.367 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.3 p -92.7 4.49 53.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -85.45 161.45 35.46 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.447 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -51.39 -39.55 57.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.795 0.331 . . . . 0.0 111.116 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.65 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -70.55 -59.36 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -38.69 -42.43 1.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 24.9 ptt180 -82.95 -30.09 28.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.8 0.333 . . . . 0.0 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 57' ' ' ALA . 48.2 t0 -45.9 -56.97 4.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.876 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.4 -20.23 40.43 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.36 -20.52 18.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.845 0.355 . . . . 0.0 110.865 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.701 HD11 HD13 ' A' ' 48' ' ' ILE . 1.1 tm? -89.55 134.35 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.569 ' N ' HD13 ' A' ' 63' ' ' LEU . 14.2 mmm-85 -143.15 154.12 43.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.887 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 51' ' ' VAL . 18.3 t -70.49 87.21 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.99 -17.35 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.499 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.547 HD12 HD22 ' A' ' 63' ' ' LEU . 18.0 mt -67.82 124.64 23.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 36.2 ttt180 -71.84 119.74 16.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.766 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -67.04 111.43 3.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.887 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 70' ' ' LEU . 2.0 mm? -86.79 -54.24 4.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.92 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -156.58 133.6 10.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.782 HG13 HD12 ' A' ' 96' ' ' LEU . 93.1 t -106.76 110.92 33.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.505 ' ND2' HG22 ' A' ' 92' ' ' VAL . 15.0 m-20 64.91 41.06 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 37.4 mt-30 63.86 31.55 13.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -129.38 91.24 3.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -46.4 138.97 5.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 18.2 mt -91.52 5.17 50.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.4 117.97 17.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 117.28 -39.62 2.6 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.544 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.461 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -82.8 167.36 18.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.888 0.375 . . . . 0.0 110.894 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 72.5 p -103.84 162.06 13.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.672 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.83 -56.02 0.47 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.04 55.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.525 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.441 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.7 mm-40 -69.04 -49.02 61.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.829 0.347 . . . . 0.0 110.875 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.461 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.87 -45.34 74.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.734 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.7 t -57.2 -58.18 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.487 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 66.6 mm-40 -52.09 -22.48 4.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.4 tt -79.37 -28.24 41.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.906 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.734 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.7 OUTLIER -83.76 -25.86 30.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.896 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.487 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.8 ptm180 -96.04 0.91 52.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.834 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 32.6 t -93.68 28.04 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.684 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.1 t -92.81 148.91 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.76 -77.76 1.3 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.499 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -125.16 -17.72 5.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.916 0.388 . . . . 0.0 110.869 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.814 HG23 ' O ' ' A' ' 15' ' ' ILE . 5.0 m -158.38 137.28 11.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.782 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -122.69 160.65 25.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.912 179.986 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.438 HG21 ' OE2' ' A' ' 12' ' ' GLU . 3.4 m -113.24 96.62 6.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.103 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.563 HG23 HG22 ' A' ' 100' ' ' VAL . 3.0 m -91.96 130.01 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.1 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.7 tp -97.08 17.77 16.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.872 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.766 HG12 HD22 ' A' ' 69' ' ' LEU . 35.9 m -49.38 178.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.443 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 1.9 p -167.62 161.58 13.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -60.77 102.28 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.509 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.97 19.78 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -88.71 162.26 16.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.848 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.467 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -73.18 110.78 7.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.3 161.57 15.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.0 p -143.01 153.2 42.74 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.3 mt -121.85 120.94 62.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.111 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -93.12 110.59 22.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.575 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.1 179.75 4.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.764 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -59.18 166.4 2.84 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.566 0.698 . . . . 0.0 111.088 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.9 Cg_endo -69.71 -0.28 6.65 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.65 2.233 . . . . 0.0 112.369 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.59 29.34 0.22 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.688 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 52.2 tp10 -94.25 140.42 29.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.924 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 5.9 ptt-85 -82.95 120.57 25.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.715 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.99 -49.15 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.94 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.24 42.07 24.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 89' ' ' LEU . 1.5 pt -121.19 164.41 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.143 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.97 150.9 50.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.407 ' C ' ' HE2' ' A' ' 82' ' ' HIS . 30.2 pt -140.36 149.39 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.097 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 35.0 ptt180 -125.14 123.16 39.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.04 -141.87 8.49 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.475 -179.914 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.459 -0.257 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.7 mt -128.76 119.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.911 0.386 . . . . 0.0 111.152 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.5 OUTLIER -132.14 -179.94 5.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.905 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.832 HD13 HD11 ' A' ' 63' ' ' LEU . 69.9 mt -88.01 121.4 38.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.5 t -97.32 -17.36 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.453 ' HA ' HG21 ' A' ' 65' ' ' VAL . 12.3 ttmt -166.23 160.09 15.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 84.0 t -149.31 115.08 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.136 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.6 t -60.3 134.37 90.95 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.694 0.759 . . . . 0.0 110.859 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -19.52 35.75 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.702 2.268 . . . . 0.0 112.351 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 19.4 p -102.24 3.47 38.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.16 172.89 49.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.73 -39.7 85.57 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.808 0.337 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.689 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -69.3 -61.5 1.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.83 -39.94 2.07 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 14.5 ptt180 -82.24 -25.06 34.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 0.0 110.852 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.472 ' N ' ' O ' ' A' ' 57' ' ' ALA . 30.3 t0 -53.27 -62.01 1.93 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 111.57 -16.24 26.56 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.1 -29.05 11.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.872 0.367 . . . . 0.0 110.866 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.1 tm? -87.4 134.16 33.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.966 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.924 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.72 150.2 24.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.463 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 44.2 t -56.63 104.48 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.33 -13.25 1.62 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.454 HD12 HD22 ' A' ' 63' ' ' LEU . 87.7 mt -83.49 123.75 30.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.547 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 36.7 ttt180 -72.55 125.39 27.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.65 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -74.35 107.56 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.835 HD12 ' O ' ' A' ' 99' ' ' LEU . 70.3 mt -86.58 -48.91 7.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.958 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.443 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 20.0 mt-10 -158.92 138.47 11.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.734 HG13 HD12 ' A' ' 96' ' ' LEU . 93.0 t -112.99 110.37 31.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.8 m-20 65.49 40.55 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 36.5 mt-30 64.4 32.13 12.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.929 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -127.23 89.58 2.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.0 t -44.26 132.23 5.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.458 ' HA ' HD21 ' A' ' 80' ' ' LEU . 19.8 mt -79.4 0.07 30.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.416 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.7 OUTLIER -72.99 119.94 17.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 179.885 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.416 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 116.31 -34.73 4.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.562 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -92.42 158.8 15.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.902 -179.91 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.5 p -92.04 178.94 5.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.407 ' HE2' ' C ' ' A' ' 27' ' ' ILE . 4.0 t-80 -50.06 -53.85 24.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.49 -48.69 63.89 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.484 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.468 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 22.4 mt-10 -61.04 -51.96 66.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.867 0.365 . . . . 0.0 110.887 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.562 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.19 -50.85 48.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.089 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.7 t -52.3 -58.84 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.479 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 59.9 mm-40 -53.11 -21.22 4.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.6 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.7 tt -78.03 -26.75 48.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.764 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -84.02 -28.47 27.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.479 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.3 ptm180 -93.72 1.19 56.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 46.3 t -96.24 33.1 1.81 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.841 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -111.28 136.53 47.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.163 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -57.46 -101.57 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.518 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -112.55 -3.71 14.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.868 0.366 . . . . 0.0 110.841 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 m -158.47 135.31 9.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.841 ' HB3' HG21 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -123.82 168.16 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.918 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.467 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -118.14 96.24 5.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.118 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -93.93 129.84 43.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.835 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.7 tp -99.18 25.19 7.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.934 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.65 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.7 m -62.43 166.84 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.119 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.9 p -158.37 152.84 24.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.446 ' HA ' HD23 ' A' ' 67' ' ' LEU . 3.8 m-20 -43.83 104.61 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.53 -179.959 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.693 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -94.98 28.07 2.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' HD12 ' A' ' 99' ' ' LEU . 1.0 OUTLIER -98.02 171.43 8.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.409 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 41.4 tt0 -74.39 108.45 7.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.23 158.02 21.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.923 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.9 p -137.83 148.68 45.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 57' ' ' ALA . 40.7 mt -114.18 96.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -69.2 112.95 6.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.437 ' HZ1' ' CD2' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.71 172.6 9.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -60.62 164.35 7.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.547 0.689 . . . . 0.0 111.091 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.717 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.77 2.41 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.329 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 24.74 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.774 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 9.1 tp10 -95.4 132.13 40.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.91 0.386 . . . . 0.0 110.892 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.441 ' O ' ' C ' ' A' ' 23' ' ' LEU . 67.2 mtt180 -82.35 118.49 23.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.872 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.783 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.19 -51.63 0.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.952 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.82 28.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.5 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.612 HG12 HD12 ' A' ' 23' ' ' LEU . 1.4 pt -119.42 170.36 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 111.143 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -132.61 166.86 21.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.44 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 19.7 pt -155.41 145.05 12.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ptt180 -124.02 124.76 43.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.76 -148.5 19.03 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.47 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.524 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.47 HG12 ' N ' ' A' ' 30' ' ' GLY . 39.5 mt -115.34 119.49 61.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.867 0.365 . . . . 0.0 111.131 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.608 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -133.09 -174.7 3.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.918 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.76 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -90.48 128.4 42.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.6 t -105.21 -12.95 15.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' O ' ' N ' ' A' ' 26' ' ' SER . 39.4 ttmt -175.79 139.7 0.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.76 HG21 HD12 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -146.14 118.38 2.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.868 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 18.2 t -48.01 134.08 11.75 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.675 0.75 . . . . 0.0 110.881 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -16.12 37.39 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.728 2.286 . . . . 0.0 112.319 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.67 -6.98 13.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.173 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -63.79 174.24 11.84 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.468 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.511 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -52.88 -37.13 60.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.783 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -80.8 -60.38 2.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.115 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -36.56 -47.25 1.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.478 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.478 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 21.1 ptt180 -69.72 -36.4 75.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.36 . . . . 0.0 110.897 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ALA . 28.7 t70 -39.91 -56.12 1.87 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.81 -22.78 15.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -95.29 -44.66 7.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.841 0.353 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.76 HD11 HD13 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -58.11 145.12 37.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 -179.956 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.724 ' N ' HD13 ' A' ' 63' ' ' LEU . 12.2 ptt-85 -175.23 146.61 0.85 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.483 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 57.4 t -57.89 105.49 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.106 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.72 -25.56 2.42 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.451 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.714 HD23 ' C ' ' A' ' 101' ' ' CYS . 11.4 mt -69.74 118.41 12.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.796 0.332 . . . . 0.0 110.933 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.551 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 25.4 ttt180 -68.85 123.25 20.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.576 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -74.24 110.03 8.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.933 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.434 ' HA ' HD13 ' A' ' 70' ' ' LEU . 2.1 mm? -85.61 -50.47 7.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -152.47 139.73 19.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.677 HG13 HD12 ' A' ' 96' ' ' LEU . 97.0 t -114.42 109.53 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.092 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.522 ' ND2' HG22 ' A' ' 92' ' ' VAL . 9.7 m-20 65.64 40.88 4.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 63.62 34.07 12.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 33.2 mt-30 -130.69 92.19 3.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 t -43.97 129.72 5.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.674 HD11 HG23 ' A' ' 72' ' ' VAL . 16.8 mt -89.65 10.14 24.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.884 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.576 HD13 ' N ' ' A' ' 79' ' ' GLY . 1.5 tm? -80.88 122.57 27.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.576 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.15 -33.51 5.68 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.541 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -85.82 164.2 17.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.93 -179.934 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 82' ' ' HIS . 75.2 p -98.66 160.59 14.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.44 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.7 t-80 -33.67 -55.76 0.45 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -55.1 -46.99 76.17 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.466 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -62.86 -44.34 96.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 110.89 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.525 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -62.26 -51.77 66.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.56 ' HA ' HD23 ' A' ' 89' ' ' LEU . 38.2 t -49.45 -61.5 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.111 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.49 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 86.6 mm-40 -47.41 -24.08 0.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.556 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.4 tt -78.39 -33.03 49.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.897 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.597 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -78.9 -30.27 44.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 179.923 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.49 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.5 ptm180 -90.14 4.48 50.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.84 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.0 t -97.2 19.35 13.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 96' ' ' LEU . 26.1 t -82.14 150.54 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.64 -78.9 1.43 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -120.31 -22.35 6.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -160.23 131.94 6.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.134 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.677 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -113.09 171.5 7.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.409 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.0 m -121.19 97.65 5.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.3 m -95.54 130.13 44.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.7 tp -104.11 33.9 3.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.576 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.4 m -66.51 -179.27 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.714 ' C ' HD23 ' A' ' 67' ' ' LEU . 1.2 p -173.09 158.15 3.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.46 104.42 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.897 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 -179.921 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.53 16.12 1.83 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.812 0.339 . . . . 0.0 110.933 -179.935 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.5 mmt180 -85.63 160.92 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.918 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -70.44 113.82 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 19.6 mt -114.54 172.32 7.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.9 p -151.59 159.32 44.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.479 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 72.5 mt -129.12 112.43 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -80.33 127.44 32.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -139.92 173.62 11.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.851 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -61.4 169.18 2.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.593 0.711 . . . . 0.0 111.091 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.851 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.77 -3.07 11.29 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.333 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 34.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.623 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.8 tp10 -101.17 137.89 38.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.865 0.364 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.482 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.3 mtp180 -81.86 118.68 23.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.859 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.736 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.55 -43.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.937 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.92 40.89 42.8 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.727 HD11 HD13 ' A' ' 89' ' ' LEU . 1.2 pt -119.92 161.62 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -130.6 135.68 48.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.625 HD12 HG21 ' A' ' 46' ' ' ILE . 18.2 pt -129.56 156.41 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -132.73 132.93 42.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.36 -137.72 5.84 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.469 -179.931 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.625 HG21 HD12 ' A' ' 27' ' ' ILE . 26.4 mt -132.34 117.02 30.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 111.142 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.09 155.77 45.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.818 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.897 HD13 HD11 ' A' ' 63' ' ' LEU . 77.7 mt -64.57 126.32 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.156 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -105.37 -18.25 14.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.508 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.9 tttp -165.76 154.35 11.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 25' ' ' ILE . 98.1 t -145.27 124.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -68.05 133.15 91.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.67 0.748 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -8.35 23.37 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.645 2.23 . . . . 0.0 112.332 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 54.9 p -111.13 -9.58 14.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.68 168.53 51.32 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.55 -35.01 67.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.78 0.324 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.736 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.33 -65.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.103 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.79 -40.08 2.08 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -77.01 -28.45 55.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.796 0.331 . . . . 0.0 110.892 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 57' ' ' ALA . 9.9 t0 -54.28 -64.03 0.96 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.06 -24.23 6.36 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -92.46 -66.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.813 0.339 . . . . 0.0 110.833 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.897 HD11 HD13 ' A' ' 48' ' ' ILE . 1.4 tm? -48.34 118.02 2.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.579 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.2 ptp180 -142.69 154.85 44.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.508 HG21 ' HA ' ' A' ' 50' ' ' LYS . 63.1 t -61.31 106.06 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 147.68 -27.18 1.48 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.459 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.735 HD23 HG23 ' A' ' 100' ' ' VAL . 7.6 mp -74.79 140.62 44.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.773 0.32 . . . . 0.0 110.892 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 57.2 ttt180 -87.61 121.01 29.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.826 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.599 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.0 mm? -67.87 105.97 2.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.949 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.438 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 1.7 mm? -80.15 -50.43 10.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 24.2 mt-10 -159.17 142.92 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.908 HG13 HD12 ' A' ' 96' ' ' LEU . 95.6 t -114.75 109.6 29.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.131 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.1 m-20 65.38 41.77 4.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 28.4 mt-30 64.6 34.04 10.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.26 90.59 3.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.941 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.421 ' O ' HD21 ' A' ' 80' ' ' LEU . 38.5 t -46.1 129.19 9.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.879 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.456 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.0 mt -78.82 -0.49 30.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.06 116.7 17.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.59 -34.7 4.28 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.457 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.498 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -88.48 170.9 10.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.888 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 82' ' ' HIS . 42.0 p -107.8 160.92 15.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.095 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.486 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 t-80 -32.97 -53.5 0.36 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.87 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.28 -49.96 57.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.416 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 3.1 mm-40 -64.38 -45.41 87.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.844 0.354 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.498 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.67 -47.51 82.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 82' ' ' HIS . 78.6 t -59.25 -58.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 74.7 mm-40 -51.24 -26.06 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.1 tt -72.3 -29.24 63.67 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.962 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.727 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.5 -29.59 46.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.895 179.883 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 2.4 ptm85 -92.51 0.77 57.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 21.6 t -98.99 36.24 1.73 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.88 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.552 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.1 p -111.6 144.94 18.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.09 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.8 -105.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 19' ' ' PRO . 1.3 t70 -103.39 -3.33 25.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.912 0.386 . . . . 0.0 110.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.469 ' C ' HG21 ' A' ' 92' ' ' VAL . 49.8 m -166.14 143.08 5.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.908 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.8 168.41 11.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -120.33 98.18 5.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.16 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.469 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.2 m -98.65 130.37 47.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.104 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.4 tp -96.4 21.49 9.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.735 HG23 HD23 ' A' ' 67' ' ' LEU . 3.0 m -52.26 -175.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.106 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.5 p -175.96 157.58 1.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -52.65 100.82 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.465 -179.905 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.701 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.3 29.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.796 0.332 . . . . 0.0 110.914 -179.924 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 11' ' ' ARG . 23.1 mtm105 -96.32 142.36 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.442 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.5 tt0 -53.35 114.9 1.65 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.69 163.49 16.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.943 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.7 p -146.09 153.72 41.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.427 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 82.7 mt -120.95 110.34 27.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.083 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -85.11 102.45 13.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.464 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 3.4 ptpp? -112.33 171.56 7.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.854 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.842 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.72 168.79 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.619 0.723 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.842 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.85 0.95 4.97 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.321 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.61 41.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.507 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 48.9 tp10 -105.66 140.53 38.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.467 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.3 ptm180 -86.36 122.78 30.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.824 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.851 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.16 -46.9 0.17 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.32 44.76 51.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.911 HG22 HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -118.68 168.04 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.854 0.359 . . . . 0.0 111.111 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.8 m -133.75 147.16 51.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.52 HD12 HG21 ' A' ' 46' ' ' ILE . 28.7 pt -138.32 155.63 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.152 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.5 ptt180 -126.83 124.54 39.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.857 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.55 -147.15 15.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.52 HG21 HD12 ' A' ' 27' ' ' ILE . 26.8 mt -126.85 116.99 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.111 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.553 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -129.13 153.85 47.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.636 HD13 HD11 ' A' ' 63' ' ' LEU . 23.5 mt -62.78 138.26 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.1 t -118.18 -16.91 9.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.848 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.53 ' HA ' HG21 ' A' ' 65' ' ' VAL . 64.9 tttt -165.22 146.96 7.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.889 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 25' ' ' ILE . 32.4 t -142.11 133.62 26.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.168 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 7.8 t -74.7 141.79 76.31 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.681 0.753 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -31.21 20.96 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.663 2.242 . . . . 0.0 112.324 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 47.8 p -93.56 -6.66 46.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.151 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.9 150.63 46.37 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.72 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -40.88 -31.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.809 0.338 . . . . 0.0 111.098 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.8 -65.55 0.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.088 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -41.11 -34.44 0.88 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -90.82 -23.22 20.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.478 ' N ' ' O ' ' A' ' 57' ' ' ALA . 10.7 t0 -52.58 -52.24 56.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.34 -7.94 40.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.518 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -115.39 -48.61 2.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.869 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -67.39 130.84 44.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.598 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -161.52 157.41 24.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.849 179.968 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.53 HG21 ' HA ' ' A' ' 50' ' ' LYS . 80.5 t -59.67 105.89 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.31 -15.58 1.67 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.61 HD23 ' HA ' ' A' ' 102' ' ' ASP . 58.1 mt -85.45 134.27 34.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.553 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 72.3 ttt180 -84.1 121.79 27.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.69 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -70.28 116.14 10.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 99' ' ' LEU . 71.6 mt -96.87 -49.42 5.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.94 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -155.13 141.75 18.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.694 HG13 HD12 ' A' ' 96' ' ' LEU . 78.4 t -118.73 108.27 23.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.075 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 72' ' ' VAL . 15.0 m-20 65.7 40.91 4.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 64.01 35.21 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -131.07 91.1 2.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.4 t -42.4 128.79 3.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.548 ' HA ' HD11 ' A' ' 80' ' ' LEU . 9.9 mt -80.68 9.01 6.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.933 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.679 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -83.09 137.6 34.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.679 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 97.76 -33.22 6.05 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.489 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.548 HD11 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -88.08 166.96 14.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.887 0.375 . . . . 0.0 110.91 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.0 p -106.92 165.43 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.512 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.82 -60.54 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.53 -47.68 22.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.3 mt-10 -66.01 -53.01 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.853 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.401 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -49.4 -49.35 45.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.1 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.2 t -59.1 -57.06 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -53.04 -17.51 1.54 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.5 tt -83.98 -28.08 28.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.834 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -84.12 -27.4 28.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.9 ptm180 -97.03 5.74 49.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 m -102.27 32.43 3.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.885 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.5 p -111.11 140.04 32.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.117 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -56.56 -100.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.451 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -113.17 -10.56 13.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.906 0.384 . . . . 0.0 110.868 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.1 m -151.64 135.39 16.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.131 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.803 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -124.17 171.26 9.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.442 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.4 m -120.69 96.6 5.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.2 m -94.25 128.64 45.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.162 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.686 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.6 tp -97.11 29.07 3.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.69 HG12 HD22 ' A' ' 69' ' ' LEU . 14.0 m -58.48 172.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.115 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.8 p -162.27 148.47 13.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.61 ' HA ' HD23 ' A' ' 67' ' ' LEU . 4.9 m-20 -51.16 110.62 0.45 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.921 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.706 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.21 33.94 0.51 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 110.939 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.822 ' O ' HD12 ' A' ' 13' ' ' LEU . 20.5 mtt-85 -99.28 165.03 11.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 42.1 tt0 -77.84 110.18 12.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.822 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -115.27 166.12 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.93 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.4 p -146.89 160.9 41.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.8 mt -124.1 115.17 44.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mp0 -85.21 113.11 21.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.6 ptpp? -126.89 165.41 19.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.65 169.12 0.13 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.78 -2.84 10.87 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.36 38.28 0.33 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.556 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.69 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 28.2 tp10 -103.53 140.64 37.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.815 0.34 . . . . 0.0 110.909 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.453 ' O ' ' C ' ' A' ' 23' ' ' LEU . 6.2 ptt85 -83.27 121.22 26.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.87 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -33.9 -54.12 0.47 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.37 40.51 9.98 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.439 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.928 HD11 HD13 ' A' ' 89' ' ' LEU . 4.1 pt -120.22 169.72 11.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.146 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.4 m -141.17 145.07 35.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.566 HD12 ' CG2' ' A' ' 46' ' ' ILE . 30.7 pt -134.85 158.96 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -131.4 133.29 45.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.73 -142.61 10.08 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.499 -179.929 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.566 ' CG2' HD12 ' A' ' 27' ' ' ILE . 40.2 mt -129.51 118.34 45.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.864 0.364 . . . . 0.0 111.151 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -132.17 -177.74 4.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.932 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -87.57 133.82 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.142 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -113.59 -14.55 12.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 24.6 tttm -172.51 145.21 1.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.944 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.596 HG12 HG23 ' A' ' 65' ' ' VAL . 0.6 OUTLIER -152.92 110.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.15 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.4 t -53.83 129.6 56.12 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.678 0.751 . . . . 0.0 110.85 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.403 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.5 Cg_endo -69.78 -6.36 18.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.712 2.274 . . . . 0.0 112.29 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 32.2 p -105.07 -18.43 14.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.173 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.24 179.81 14.15 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.49 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.441 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -57.69 -39.1 76.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.762 0.315 . . . . 0.0 111.08 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.87 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.99 -63.65 1.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.14 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.46 -48.56 1.69 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.441 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.441 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.5 ptt180 -70.63 -31.17 68.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 57' ' ' ALA . 31.2 t0 -44.55 -61.62 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.838 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.38 -20.34 10.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.477 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.6 mmp_? -99.61 -47.47 5.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.896 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.932 HD11 HD13 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -61.11 130.36 45.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.936 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.64 ' N ' HD13 ' A' ' 63' ' ' LEU . 16.8 ptt85 -162.01 146.0 12.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.596 HG23 HG12 ' A' ' 51' ' ' VAL . 82.7 t -53.87 106.58 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.156 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 143.09 -11.42 2.31 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.48 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.474 HD12 ' H ' ' A' ' 64' ' ' ARG . 34.6 mt -86.52 124.02 32.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.854 0.359 . . . . 0.0 110.922 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.533 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 57.5 ttt180 -75.23 117.49 17.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.733 HD22 HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -71.45 114.24 9.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.526 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.5 mt -90.43 -54.76 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.975 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -150.1 143.34 25.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 95.2 t -115.94 110.13 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.127 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 65.62 41.12 4.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.7 mt-30 64.43 30.46 13.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.956 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 22.8 mt-30 -124.64 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 t -44.04 133.87 4.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.811 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.756 ' HA ' HD21 ' A' ' 80' ' ' LEU . 13.3 mt -88.94 7.63 33.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.421 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.9 OUTLIER -77.31 116.16 17.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.76 -33.25 5.3 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.463 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.756 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -86.4 164.54 16.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.91 0.386 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 82' ' ' HIS . 81.9 p -104.1 165.51 11.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.167 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -34.7 -59.92 0.46 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.834 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.09 -49.85 23.3 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.9 mt-10 -63.02 -51.7 65.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.89 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.46 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -52.01 -51.75 55.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.117 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.549 ' HA ' HD23 ' A' ' 89' ' ' LEU . 69.2 t -53.15 -60.45 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 78.1 mm-40 -50.36 -26.17 4.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.3 tt -74.04 -29.95 62.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.923 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.928 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -79.84 -27.11 40.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 0.6 OUTLIER -96.96 -3.17 42.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.86 179.94 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.4 m -89.76 29.94 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.872 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.76 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -110.45 144.04 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.17 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.94 -101.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -111.39 -6.67 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.897 0.379 . . . . 0.0 110.854 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.7 m -155.24 136.47 13.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -126.49 167.2 15.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.983 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.41 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -116.54 94.52 4.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.175 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.5 m -91.05 127.15 43.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.162 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.526 ' O ' HD12 ' A' ' 70' ' ' LEU . 19.1 tp -95.97 33.03 1.77 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.878 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.733 HG12 HD22 ' A' ' 69' ' ' LEU . 5.9 m -60.98 174.62 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.146 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -167.78 155.12 8.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.83 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.417 ' HA ' HD23 ' A' ' 67' ' ' LEU . 5.6 p-10 -51.5 107.6 0.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.852 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.467 -179.948 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.263 0 N-CA-C 112.489 -0.245 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.733 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.43 30.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.328 . . . . 0.0 110.907 -179.916 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.411 ' O ' HD12 ' A' ' 99' ' ' LEU . 25.4 mtp180 -94.95 161.37 14.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -70.92 112.17 6.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.873 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.6 mt -116.88 159.52 22.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.581 ' SG ' HG23 ' A' ' 97' ' ' THR . 3.0 m -142.45 159.66 41.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 23' ' ' LEU . 40.5 mt -125.58 114.57 40.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.173 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -88.6 107.66 19.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.511 ' CB ' ' HB2' ' A' ' 56' ' ' ALA . 1.0 OUTLIER -116.18 166.14 12.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.836 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.25 168.72 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.578 0.704 . . . . 0.0 111.097 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.836 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.79 3.35 2.83 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.703 2.268 . . . . 0.0 112.334 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -169.79 36.24 0.18 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.462 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.614 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.7 tp10 -105.47 142.52 35.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.889 0.376 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' O ' ' C ' ' A' ' 23' ' ' LEU . 58.8 mtt180 -88.94 123.37 33.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.829 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.86 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.49 -49.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 77.41 32.48 47.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.487 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.697 HG23 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -108.87 160.0 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.817 0.342 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.495 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -123.6 150.61 43.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 27.5 pt -140.36 150.92 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -128.47 131.85 48.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.9 -144.85 13.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 26.8 mt -128.83 116.43 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.871 0.367 . . . . 0.0 111.133 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.554 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.6 m-85 -131.13 153.26 49.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.731 HD13 HD11 ' A' ' 63' ' ' LEU . 70.3 mt -62.67 128.22 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.4 t -107.13 -18.89 13.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.4 tttp -159.89 153.41 22.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 50' ' ' LYS . 78.7 t -143.28 127.52 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 29.1 t -66.24 140.29 96.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.726 0.774 . . . . 0.0 110.813 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -35.66 12.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.721 2.281 . . . . 0.0 112.328 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.02 -1.43 45.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.092 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -73.11 148.83 41.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.501 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.513 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -39.86 -35.18 0.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.82 0.343 . . . . 0.0 111.119 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.86 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.11 -59.66 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.082 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -47.89 -33.18 9.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.475 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.6 ptt-85 -84.97 -32.26 23.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 11.1 t0 -50.1 -61.57 2.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.839 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.22 -18.74 13.76 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.501 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -96.71 -42.81 7.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.828 0.347 . . . . 0.0 110.89 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.772 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.2 tm? -69.83 136.54 50.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.631 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -166.67 155.26 10.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 50' ' ' LYS . 85.2 t -61.25 105.55 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.45 -24.74 1.22 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.533 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.462 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.7 mt -74.85 135.88 41.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.554 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 45.8 ttt180 -85.69 117.59 24.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.873 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.782 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -68.11 116.07 8.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.8 mt -94.09 -52.29 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -152.13 145.71 24.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.873 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.874 HG13 HD12 ' A' ' 96' ' ' LEU . 75.9 t -119.5 108.38 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.118 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.5 m-20 65.12 41.54 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.9 mt-30 64.07 32.11 13.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -125.35 91.11 3.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 t -47.82 126.41 10.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD21 ' A' ' 80' ' ' LEU . 11.4 mt -78.04 -0.37 27.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.863 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.37 115.38 11.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.922 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.93 -34.4 4.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.479 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.552 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -90.99 164.01 14.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.841 0.353 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 82' ' ' HIS . 38.1 p -102.18 163.39 12.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -34.32 -58.33 0.47 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.837 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.33 -45.68 21.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.46 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 10.3 mm-40 -70.93 -53.46 14.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.853 0.359 . . . . 0.0 110.838 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.533 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.03 -49.01 21.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.049 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.565 ' HA ' HD23 ' A' ' 89' ' ' LEU . 70.0 t -57.34 -59.12 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.489 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 83.3 mm-40 -51.08 -22.79 2.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.917 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.557 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.62 -31.83 60.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.627 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.87 -27.93 49.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.962 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.489 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.9 ptm180 -94.41 1.5 55.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.866 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.9 t -94.62 30.92 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.583 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -113.17 146.48 17.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.13 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.62 -95.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -119.55 -2.08 10.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.912 0.387 . . . . 0.0 110.9 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 m -157.14 132.01 8.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.874 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -122.95 164.37 18.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.944 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.581 HG23 ' SG ' ' A' ' 14' ' ' CYS . 1.6 m -113.07 94.14 4.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.443 HG12 HD11 ' A' ' 96' ' ' LEU . 3.2 m -90.74 129.04 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.615 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.0 tp -98.51 29.81 3.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.956 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.782 HG12 HD22 ' A' ' 69' ' ' LEU . 15.7 m -54.42 179.19 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 3.3 p -171.52 148.75 2.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -41.19 113.61 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.849 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.467 -179.949 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.445 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.734 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.37 41.39 0.61 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.794 0.331 . . . . 0.0 110.889 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.7 mmm180 -111.34 152.37 27.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.484 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 19.0 tt0 -68.38 109.18 3.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.909 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.6 mt -106.52 168.72 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -151.4 147.85 27.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 95' ' ' THR . 71.1 mt -118.66 120.23 63.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -88.46 125.61 34.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.8 ptpp? -138.68 168.56 19.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.844 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -48.69 168.9 0.17 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.585 0.707 . . . . 0.0 111.122 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.844 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.7 2.02 3.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.672 2.248 . . . . 0.0 112.379 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.58 35.53 0.17 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.7 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 21.5 tp10 -99.02 149.74 22.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' C ' ' A' ' 23' ' ' LEU . 86.4 mtt180 -89.46 121.6 31.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -32.91 -46.55 0.15 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.5 42.55 17.7 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.766 HG22 HG13 ' A' ' 51' ' ' VAL . 2.6 pt -126.01 168.66 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.842 0.353 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -138.91 142.73 38.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.492 HD12 HG21 ' A' ' 46' ' ' ILE . 39.6 pt -128.82 163.08 34.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.488 ' CG ' ' HB3' ' A' ' 49' ' ' SER . 22.6 ptt180 -134.56 124.71 25.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 158.81 -143.17 8.99 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 -179.913 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.492 HG21 HD12 ' A' ' 27' ' ' ILE . 38.8 mt -133.86 117.75 27.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.821 0.343 . . . . 0.0 111.132 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.563 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.1 m-85 -131.25 154.07 48.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 63' ' ' LEU . 37.6 mt -58.99 138.14 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.488 ' HB3' ' CG ' ' A' ' 28' ' ' ARG . 60.7 p -117.48 -18.68 9.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.845 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 5.0 ttpm? -165.56 155.01 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.766 HG13 HG22 ' A' ' 25' ' ' ILE . 98.4 t -148.68 128.66 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 33.9 t -81.74 139.15 46.94 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.668 0.747 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.57 23.83 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.713 2.275 . . . . 0.0 112.356 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 59.7 p -80.83 -19.25 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.06 170.62 40.76 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.08 -33.65 72.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.326 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.615 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -71.2 -70.45 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.59 -40.95 0.76 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.471 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 10.7 ptt180 -75.68 -34.67 60.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.783 0.325 . . . . 0.0 110.829 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 57' ' ' ALA . 15.3 t0 -47.72 -64.7 0.72 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.36 -19.4 8.63 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.476 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 42.9 mtm180 -96.72 -61.55 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.888 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.586 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.8 tm? -46.4 133.4 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.553 ' H ' HD12 ' A' ' 67' ' ' LEU . 6.2 ptt180 -156.24 149.95 24.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.847 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.476 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 45.1 t -61.26 100.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.106 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 153.59 -19.89 0.7 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.445 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.553 HD12 ' H ' ' A' ' 64' ' ' ARG . 9.8 mt -77.81 140.74 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.783 0.325 . . . . 0.0 110.921 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 70.8 ttt180 -88.72 119.13 28.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.678 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -71.4 107.0 4.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.441 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 11.1 mp -83.45 -53.29 5.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.441 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -151.68 146.65 25.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.819 HG13 HD12 ' A' ' 96' ' ' LEU . 95.5 t -117.84 109.49 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.414 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 66.18 41.81 3.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.918 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.9 mt-30 64.64 29.96 12.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -122.9 89.04 3.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.1 t -40.49 129.03 2.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 83.9 mt -83.08 12.27 5.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.939 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -86.13 112.83 21.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.05 -38.97 2.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.57 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -84.15 168.53 15.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 23.0 p -108.62 166.1 11.04 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.168 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -33.13 -61.77 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.4 -48.55 21.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.481 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.465 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.6 mt-10 -65.05 -55.98 15.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.87 0.366 . . . . 0.0 110.863 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.5 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -45.76 -50.36 14.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.405 ' HA ' HD23 ' A' ' 89' ' ' LEU . 71.2 t -55.64 -59.61 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.486 ' NE2' ' HD3' ' A' ' 90' ' ' ARG . 51.8 mm-40 -50.12 -25.41 3.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.886 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.1 tt -74.85 -32.16 61.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.805 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.5 OUTLIER -77.96 -30.09 50.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.486 ' HD3' ' NE2' ' A' ' 87' ' ' GLN . 12.6 ptm180 -92.72 -7.13 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.874 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.5 m -87.84 30.01 0.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.709 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.9 p -106.69 143.73 16.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.51 -102.68 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.481 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -105.98 -13.41 15.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.886 0.374 . . . . 0.0 110.843 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 15' ' ' ILE . 3.3 m -153.89 141.29 19.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.177 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.819 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -124.01 169.52 11.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.484 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -122.02 99.35 6.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.9 m -96.14 130.99 44.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp -97.12 31.31 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.678 HG12 HD22 ' A' ' 69' ' ' LEU . 11.3 m -59.8 177.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.137 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.445 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 13.2 p -175.23 143.06 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -38.69 104.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.871 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.455 -179.954 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.739 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.17 39.87 0.6 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.915 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.8 mtp180 -111.76 148.13 34.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 33.7 tt0 -61.89 111.29 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.5 mt -113.08 161.83 16.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -140.66 155.25 46.55 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.434 HG22 ' HB1' ' A' ' 56' ' ' ALA . 88.7 mt -123.01 108.71 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -84.53 114.98 22.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 0.5 OUTLIER -125.65 171.02 10.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.85 168.2 0.11 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.583 0.706 . . . . 0.0 111.07 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.82 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 2.81 3.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.704 2.27 . . . . 0.0 112.379 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -173.61 41.04 0.14 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.481 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 32.7 tp10 -107.36 147.16 30.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.876 0.37 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.7 mmt-85 -83.95 122.95 29.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.658 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.53 -47.58 0.23 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.16 41.48 13.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.583 HG23 HD12 ' A' ' 23' ' ' LEU . 3.0 pt -121.54 166.89 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.845 0.355 . . . . 0.0 111.154 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.426 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -130.3 149.76 51.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.85 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 pt -140.57 149.25 21.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.102 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.432 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.3 ptm85 -130.81 144.37 51.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 125.51 -155.48 18.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.468 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.468 HG12 ' N ' ' A' ' 30' ' ' GLY . 52.5 mt -139.95 116.65 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.874 0.368 . . . . 0.0 111.114 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.558 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 0.7 OUTLIER -133.46 156.17 48.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.861 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.548 HD11 HD21 ' A' ' 63' ' ' LEU . 82.9 mt -58.98 129.95 21.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.145 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.2 p -103.89 -13.3 16.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.473 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 40.2 tttt -173.9 162.89 4.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.509 HG13 HG22 ' A' ' 25' ' ' ILE . 99.3 t -150.14 133.1 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -75.35 142.3 74.72 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.678 0.751 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -23.47 30.44 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.713 2.275 . . . . 0.0 112.343 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 80.0 p -103.52 -14.59 16.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.42 154.95 19.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -46.46 -33.75 4.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.821 0.343 . . . . 0.0 111.123 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.961 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -75.19 -60.52 2.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.35 -43.49 6.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -79.82 -21.88 43.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.77 0.319 . . . . 0.0 110.84 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 57' ' ' ALA . 12.9 t70 -55.02 -59.45 4.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.865 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.8 -4.19 14.56 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -118.48 -70.5 0.79 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 110.927 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.961 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -37.22 140.34 0.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.629 ' N ' HD13 ' A' ' 63' ' ' LEU . 9.0 ptm180 -167.04 161.4 14.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.47 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 18.7 t -70.27 102.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.125 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.68 -9.03 1.37 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 102' ' ' ASP . 17.5 mt -89.25 128.22 35.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.331 . . . . 0.0 110.88 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.558 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -78.59 121.54 24.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.604 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -70.24 111.79 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.668 HD12 ' O ' ' A' ' 99' ' ' LEU . 58.3 mt -89.24 -49.44 6.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -155.17 141.87 18.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.937 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.881 HG13 HD12 ' A' ' 96' ' ' LEU . 72.7 t -118.67 109.31 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 65.43 40.65 4.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.7 mt-30 63.75 34.62 11.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.881 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.832 ' HB2' HD21 ' A' ' 88' ' ' LEU . 59.1 mt-30 -129.2 90.31 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.7 t -42.89 131.47 4.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.691 HD23 HD13 ' A' ' 88' ' ' LEU . 23.5 mt -89.81 9.04 28.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.953 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -77.32 131.5 38.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.943 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.577 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 103.03 -43.98 1.57 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.657 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -79.18 155.89 28.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.884 0.373 . . . . 0.0 110.948 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 68.7 p -93.71 -174.54 3.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -49.52 -61.91 1.84 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -46.35 -57.48 6.42 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.459 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 27.2 mt-10 -56.08 -42.05 76.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.902 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -60.91 -48.54 81.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.11 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 67.8 t -52.52 -57.78 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.122 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.481 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 57.3 mm-40 -52.67 -20.35 3.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.899 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.842 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.7 tt -79.71 -26.85 40.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.944 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -82.27 -22.43 35.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.844 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.481 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.0 ptm180 -96.74 -0.15 48.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 p -83.21 16.69 2.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.814 HG21 ' HB3' ' A' ' 96' ' ' LEU . 4.5 p -106.8 141.05 22.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.99 -86.51 0.15 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.48 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.411 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 2.0 p30 -119.89 -12.54 9.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.2 m -149.3 132.65 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.175 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.881 HD12 HG13 ' A' ' 72' ' ' VAL . 0.8 OUTLIER -123.47 170.98 9.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.439 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -121.5 99.31 6.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.431 HG12 HD11 ' A' ' 96' ' ' LEU . 3.1 m -96.41 131.42 43.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.668 ' O ' HD12 ' A' ' 70' ' ' LEU . 18.4 tp -98.32 31.3 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.953 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 69' ' ' LEU . 5.8 m -62.59 176.88 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.112 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.1 p -171.67 145.23 1.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.597 ' HA ' HD23 ' A' ' 67' ' ' LEU . 2.2 p-10 -42.27 100.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.912 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.53 -179.956 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.339 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.67 16.06 1.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.888 -179.909 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -89.44 149.29 23.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.431 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 30.3 tt0 -59.7 115.31 3.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.1 mt -116.69 160.66 20.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.478 ' SG ' HG23 ' A' ' 97' ' ' THR . 2.7 m -139.93 157.39 45.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 57' ' ' ALA . 34.8 mt -125.42 107.04 17.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -80.53 107.76 13.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.403 ' HA ' ' NH2' ' A' ' 59' ' ' ARG . 0.9 OUTLIER -117.29 168.24 10.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.776 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.92 166.78 0.2 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.58 0.705 . . . . 0.0 111.103 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.776 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.4 Cg_endo -69.75 2.87 3.14 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.659 2.24 . . . . 0.0 112.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.24 38.18 0.19 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.482 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.679 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.5 tp10 -101.98 133.98 45.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.837 0.351 . . . . 0.0 110.869 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 23' ' ' LEU . 91.3 mtt180 -78.95 116.87 19.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.831 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -34.02 -51.84 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.939 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.27 42.62 34.57 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.474 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -116.26 177.59 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.881 0.372 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.501 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -141.91 157.53 44.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.414 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.3 pt -149.33 151.01 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -127.11 122.99 35.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.63 -156.91 28.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.486 -0.245 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 ' N ' ' A' ' 30' ' ' GLY . 62.9 mt -124.66 118.32 53.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.113 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CZ ' ' HD2' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.41 -175.6 3.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.696 HD13 ' CD1' ' A' ' 63' ' ' LEU . 96.4 mt -85.47 138.65 18.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.088 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 53.4 p -116.04 -16.44 11.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -171.83 150.94 2.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.517 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -160.95 110.24 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.092 179.836 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 40.1 t -58.12 137.75 84.23 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.742 . . . . 0.0 110.853 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.9 Cg_endo -69.76 -23.15 31.13 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.665 2.244 . . . . 0.0 112.353 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.5 p -89.24 -16.91 30.13 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.15 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.51 172.28 35.57 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.17 -38.84 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.78 0.324 . . . . 0.0 111.086 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.831 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -73.32 -59.33 2.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.072 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 53' ' ' PRO . . . -45.17 -39.38 6.84 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.51 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.403 ' NH2' ' HA ' ' A' ' 17' ' ' LYS . 23.5 ptt180 -80.73 -20.76 42.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.844 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.402 ' N ' ' O ' ' A' ' 57' ' ' ALA . 13.9 t70 -60.53 -58.99 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.28 -15.71 32.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.476 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? -108.37 8.92 27.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.858 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.696 ' CD1' HD13 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -123.3 119.38 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.493 ' O ' HD12 ' A' ' 48' ' ' ILE . 28.2 mtp180 -145.3 165.64 27.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.517 HG23 HG12 ' A' ' 51' ' ' VAL . 77.9 t -77.11 97.17 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.49 -23.21 0.5 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.478 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.432 ' N ' HD12 ' A' ' 67' ' ' LEU . 7.5 mp -71.75 159.93 33.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HD2' ' CZ ' ' A' ' 47' ' ' PHE . 29.8 ttt-85 -105.71 118.06 35.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.838 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -66.3 103.18 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.907 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.502 ' CD1' ' NH1' ' A' ' 68' ' ' ARG . 9.7 mp -82.42 -42.23 18.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 68.8 mt-10 -162.05 142.73 10.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.723 HG13 HD12 ' A' ' 96' ' ' LEU . 84.9 t -121.6 108.23 21.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.153 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.426 ' ND2' HG22 ' A' ' 92' ' ' VAL . 12.5 m-20 65.33 41.2 4.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 63.37 31.84 14.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.543 ' O ' HD23 ' A' ' 77' ' ' LEU . 27.7 mt-30 -126.16 92.61 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.8 t -46.4 124.09 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.577 ' HA ' HD21 ' A' ' 80' ' ' LEU . 9.6 mt -81.29 3.46 23.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.451 ' HA ' HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -78.66 122.67 26.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.87 -31.78 6.81 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -89.87 160.82 16.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.932 0.396 . . . . 0.0 110.901 -179.903 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 13.9 p -97.61 161.14 13.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.56 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.1 t-80 -33.91 -57.83 0.45 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.11 -44.05 56.71 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.495 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 23.5 mt-10 -67.17 -47.7 70.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.86 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.561 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.95 -55.71 31.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 82' ' ' HIS . 91.9 t -43.54 -64.46 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.08 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.493 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 24.2 mm100 -46.86 -25.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.523 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.85 -34.35 60.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -76.67 -29.03 56.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.962 179.85 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.493 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.2 ptm180 -93.82 4.49 53.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.897 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.6 t -96.3 29.71 2.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.662 HG11 ' HB3' ' A' ' 96' ' ' LEU . 12.4 t -94.5 150.58 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -93.55 -75.15 1.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -121.27 -26.03 5.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 0.0 110.855 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 15' ' ' ILE . 32.1 m -155.81 138.74 15.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.138 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.723 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.01 165.25 14.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.478 HG23 ' SG ' ' A' ' 14' ' ' CYS . 2.8 m -116.41 96.47 5.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.136 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' A' ' 96' ' ' LEU . 3.4 m -98.38 129.42 48.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.413 ' CD1' ' HA ' ' A' ' 12' ' ' GLU . 22.6 tp -96.16 20.23 10.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.838 HG12 HD22 ' A' ' 69' ' ' LEU . 26.2 m -48.88 177.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.057 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -175.46 162.93 2.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.69 118.9 6.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.472 -179.933 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.715 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.88 36.86 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.791 0.329 . . . . 0.0 110.918 -179.919 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.689 ' O ' HD12 ' A' ' 13' ' ' LEU . 55.7 mtp180 -108.31 173.86 6.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.464 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.4 tt0 -81.92 112.71 19.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.906 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.689 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -117.26 168.92 9.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.899 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.5 p -148.29 157.02 43.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.422 ' O ' HG23 ' A' ' 95' ' ' THR . 86.8 mt -120.97 111.33 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -80.0 117.73 21.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.47 ' NZ ' HD23 ' A' ' 23' ' ' LEU . 1.7 ptpt -132.18 166.47 21.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.86 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.0 168.63 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.551 0.691 . . . . 0.0 111.115 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.828 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.1 Cg_endo -69.83 -2.26 9.93 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 0.0 112.3 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.82 35.69 0.25 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.669 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 24.7 tp10 -99.84 147.14 25.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.915 0.388 . . . . 0.0 110.85 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 11.2 mtt-85 -86.93 123.67 32.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.847 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.768 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -34.23 -52.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.68 41.3 9.01 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.768 HG12 HD12 ' A' ' 23' ' ' LEU . 3.5 pt -122.76 170.91 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.785 0.326 . . . . 0.0 111.16 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.425 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -130.36 160.79 32.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.829 -179.901 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.438 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 14.8 pt -151.2 145.62 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.169 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.466 ' CG ' ' HB2' ' A' ' 49' ' ' SER . 18.8 ptt85 -128.88 122.01 29.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 163.6 -149.41 16.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.408 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.26 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.408 HG12 ' N ' ' A' ' 30' ' ' GLY . 30.3 mt -132.84 117.9 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 111.097 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -131.63 154.86 48.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.93 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.679 HD11 HD21 ' A' ' 63' ' ' LEU . 38.7 mt -58.2 134.44 22.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.156 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.466 ' HB2' ' CG ' ' A' ' 28' ' ' ARG . 36.8 t -112.47 -10.49 13.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.884 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.469 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 19.8 ttmt -173.79 148.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.632 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -138.3 114.36 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.126 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.4 t -64.59 140.69 98.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.711 0.767 . . . . 0.0 110.846 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -30.15 22.75 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 30.1 p -89.99 -4.16 57.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.442 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -76.87 155.88 45.22 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.514 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.584 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -47.0 -39.11 11.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.764 0.316 . . . . 0.0 111.098 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.975 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.78 -58.76 3.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -39.3 -43.88 2.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 27.8 ptt180 -82.43 -26.15 32.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 110.855 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.444 ' N ' ' O ' ' A' ' 57' ' ' ALA . 24.5 t70 -53.58 -69.28 0.12 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.862 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.01 -13.73 12.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -101.5 -17.96 16.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.975 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.0 tm? -103.33 125.5 49.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.726 ' N ' HD13 ' A' ' 63' ' ' LEU . 15.1 mtm-85 -139.5 174.81 10.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 51' ' ' VAL . 8.0 t -82.64 90.01 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.69 -15.37 0.3 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.572 ' HB2' HD12 ' A' ' 48' ' ' ILE . 56.0 mt -74.35 132.7 42.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.56 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 55.4 ttt180 -81.7 119.58 24.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.624 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -72.19 108.27 5.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.945 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 11.1 mp -86.39 -52.46 5.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -151.41 141.81 22.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.867 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 66.9 t -115.77 110.0 30.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.493 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.65 40.56 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 64.03 30.08 14.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.7 mt-30 -125.26 90.86 3.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.938 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 35.9 t -40.2 130.29 2.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.854 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD11 ' A' ' 80' ' ' LEU . 24.9 mt -88.11 17.44 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.939 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.822 ' O ' HD23 ' A' ' 80' ' ' LEU . 1.1 tp -85.75 152.69 22.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.907 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.07 -31.77 2.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.498 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -88.19 163.24 16.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.862 0.363 . . . . 0.0 110.923 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 56.7 p -99.06 -174.68 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.126 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.519 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.0 t-80 -52.66 -55.07 25.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.14 -50.19 63.3 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -58.75 -45.47 89.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.905 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.475 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -63.01 -48.76 77.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 82' ' ' HIS . 54.0 t -53.96 -60.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.181 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.491 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 18.7 mm100 -50.04 -23.42 2.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.957 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.571 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -76.8 -30.76 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.601 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -78.96 -30.55 44.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.925 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.491 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.2 ptp180 -89.96 1.74 55.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.4 t -93.26 29.51 1.9 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.666 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.6 t -97.39 149.12 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.109 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.57 -77.79 1.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -118.85 -23.88 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.889 0.376 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 15' ' ' ILE . 8.2 m -158.12 143.09 16.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.145 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -124.05 168.97 12.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.464 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.7 m -120.57 98.84 6.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.144 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.402 ' HB ' HG13 ' A' ' 100' ' ' VAL . 6.5 m -95.62 131.19 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.107 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 11' ' ' ARG . 17.6 tp -98.1 35.74 1.69 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.624 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.6 m -68.48 173.07 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.6 p -162.55 150.37 14.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -49.99 101.78 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.476 -179.898 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.721 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.07 39.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 -179.894 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.42 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 5.3 mmm180 -113.76 158.27 21.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.424 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -67.43 109.66 3.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.7 mt -114.98 155.5 26.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 96' ' ' LEU . 28.2 p -138.24 151.95 48.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.742 ' O ' HG23 ' A' ' 95' ' ' THR . 39.4 mt -115.06 116.44 52.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -87.95 120.52 29.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.91 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.89 164.27 24.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.31 169.13 0.1 OUTLIER Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.596 0.712 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.81 3.15 2.97 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.687 2.258 . . . . 0.0 112.308 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.35 34.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.546 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 11.1 tp10 -103.62 140.27 37.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.843 0.354 . . . . 0.0 110.908 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.0 mmp_? -85.83 123.93 31.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.751 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.05 -43.77 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.882 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 71.53 44.79 49.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.524 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.713 HG12 HD12 ' A' ' 23' ' ' LEU . 1.1 pt -125.76 177.58 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.809 0.338 . . . . 0.0 111.126 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -141.02 154.29 45.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.434 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.2 pt -138.72 149.37 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.419 ' HE ' ' CB ' ' A' ' 49' ' ' SER . 8.2 ptp180 -125.53 125.94 44.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.07 -150.79 22.6 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.492 -179.861 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 mt -123.38 118.13 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.896 0.379 . . . . 0.0 111.117 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -128.61 150.91 50.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.61 HD11 HD21 ' A' ' 63' ' ' LEU . 56.0 mt -56.37 146.36 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.104 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.419 ' CB ' ' HE ' ' A' ' 28' ' ' ARG . 82.1 p -120.85 -24.53 5.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.856 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 24.5 ttmt -154.97 156.05 35.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.491 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 76.8 t -147.95 113.83 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 42.5 t -57.6 137.14 82.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.688 0.756 . . . . 0.0 110.844 -179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -22.23 32.49 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.29 -9.22 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.77 155.86 53.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.494 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -44.15 -35.08 2.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 111.109 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.825 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.31 -56.47 5.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -51.5 -38.65 43.28 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.7 ptt-85 -76.73 -28.85 55.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.799 0.333 . . . . 0.0 110.86 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -55.27 -64.36 0.87 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.55 -6.02 16.6 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.468 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.432 ' O ' HD11 ' A' ' 67' ' ' LEU . 2.8 mmp_? -109.44 -50.36 3.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.836 0.35 . . . . 0.0 110.91 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.825 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.6 tm? -64.59 122.54 17.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.636 ' N ' HD13 ' A' ' 63' ' ' LEU . 30.9 mtt180 -152.81 141.53 20.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.727 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.1 OUTLIER -51.54 95.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 179.968 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.47 -12.82 0.5 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.492 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.457 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 50.5 mt -83.24 151.22 25.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.745 0.307 . . . . 0.0 110.95 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 74.6 ttt180 -95.68 114.79 26.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.698 HD22 HG12 ' A' ' 100' ' ' VAL . 3.3 mm? -72.71 108.11 5.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.429 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 10.1 mp -84.4 -45.73 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.429 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 39.2 mt-10 -158.64 146.64 18.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 72.3 t -119.37 108.17 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.165 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.51 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.68 41.38 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.0 mt-30 64.16 34.4 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLN . . . . . 0.405 ' HB3' HD11 ' A' ' 88' ' ' LEU . 26.6 mt-30 -128.49 91.24 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.6 t -47.76 123.88 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.67 ' HA ' HD21 ' A' ' 80' ' ' LEU . 10.9 mt -79.73 9.96 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.498 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -80.1 123.37 27.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.932 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.498 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 108.69 -35.97 4.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.478 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.67 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -81.66 166.29 20.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.895 0.378 . . . . 0.0 110.914 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.462 ' O ' ' C ' ' A' ' 82' ' ' HIS . 70.8 p -101.24 158.74 15.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.1 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.51 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -33.57 -52.82 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.8 -45.7 90.92 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.472 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.8 mm-40 -63.97 -46.55 84.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.931 0.396 . . . . 0.0 110.907 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.52 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.74 -47.87 83.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 82' ' ' HIS . 70.7 t -54.74 -63.16 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.128 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 7.1 mm-40 -47.5 -26.57 1.43 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.567 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -72.65 -33.82 66.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.964 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.612 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -74.78 -33.61 62.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.939 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.0 ptt85 -91.62 9.62 31.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 33.4 t -99.26 28.44 4.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.852 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.766 HG21 ' HB3' ' A' ' 96' ' ' LEU . 19.0 t -96.16 166.52 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.598 ' N ' HG12 ' A' ' 92' ' ' VAL . . . -103.04 -66.21 0.74 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.515 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.61 -24.92 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.899 0.381 . . . . 0.0 110.89 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.742 HG23 ' O ' ' A' ' 15' ' ' ILE . 24.9 m -159.8 140.48 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.182 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.48 167.64 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.929 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.424 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.0 m -118.91 96.36 5.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.17 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.8 m -95.9 128.45 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.1 tp -93.14 36.55 1.04 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.698 HG12 HD22 ' A' ' 69' ' ' LEU . 5.8 m -66.45 168.2 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.1 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.445 ' O ' ' C ' ' A' ' 102' ' ' ASP . 28.7 p -166.01 133.29 2.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.457 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 2.4 p30 -34.52 108.27 0.06 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 -179.91 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.616 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -86.4 26.54 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.744 ' O ' HD12 ' A' ' 13' ' ' LEU . 18.0 mmm180 -92.89 169.68 10.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 34.5 tt0 -80.06 110.44 15.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.744 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.3 mp -116.34 166.8 11.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.7 p -144.47 156.92 44.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.864 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.65 108.82 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.121 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -79.53 118.47 21.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.913 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.627 ' HZ2' ' C ' ' A' ' 94' ' ' ASP . 0.4 OUTLIER -128.87 171.05 12.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.808 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -49.58 168.07 0.21 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.632 0.729 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.808 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.74 2.9 3.11 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.313 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.62 34.82 0.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 49.5 tp10 -104.11 130.59 51.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.877 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 9.3 ptt-85 -80.3 117.46 21.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.651 HD23 HG12 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -33.36 -50.67 0.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.933 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.73 47.52 8.64 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.477 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.775 HD11 HD13 ' A' ' 89' ' ' LEU . 2.9 pt -112.39 158.1 12.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 111.168 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -125.08 134.9 52.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 46' ' ' ILE . 33.2 pt -126.86 163.51 29.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.4 ptt180 -136.23 125.75 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.61 -144.64 11.37 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.505 -179.915 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.454 -0.259 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.447 HG21 HD12 ' A' ' 27' ' ' ILE . 33.1 mt -125.74 117.6 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.851 0.358 . . . . 0.0 111.087 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.565 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.86 154.26 46.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.893 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.807 HD13 HD11 ' A' ' 63' ' ' LEU . 85.2 mt -64.23 126.58 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.101 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' SER . . . . . 0.419 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.9 t -103.97 -18.13 14.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.47 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 17.4 ttmt -165.56 160.75 17.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.927 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.706 HG13 HG22 ' A' ' 25' ' ' ILE . 95.6 t -157.07 127.98 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.105 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -67.94 141.99 94.99 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.658 0.742 . . . . 0.0 110.902 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -35.3 12.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.628 2.219 . . . . 0.0 112.403 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.2 p -91.25 3.65 54.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -78.49 161.5 48.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.437 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -51.12 -32.76 23.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.751 0.31 . . . . 0.0 111.104 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.711 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -80.54 -64.06 1.27 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.097 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.28 -33.4 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.475 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 60' ' ' ASP . 12.1 ptt180 -81.24 -47.09 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.868 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.451 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 17.2 t0 -40.95 -66.37 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.871 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 -13.52 13.85 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.466 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -97.76 -12.64 22.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.9 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.5 tm? -111.16 134.63 52.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.9 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -154.84 159.04 40.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.895 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 42.7 t -64.5 97.65 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.202 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.03 -20.91 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.518 HD12 HD22 ' A' ' 63' ' ' LEU . 66.3 mt -77.1 136.35 38.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.82 0.343 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.565 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 63.0 ttt180 -84.02 123.65 30.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.764 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -72.77 111.62 8.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 99' ' ' LEU . 49.1 mt -89.4 -49.36 6.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 13.5 mt-10 -158.28 140.86 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.849 HG13 HD12 ' A' ' 96' ' ' LEU . 84.0 t -112.09 111.2 35.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.0 m-20 65.23 40.96 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 40.4 mt-30 64.36 32.12 12.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -127.56 90.03 3.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 t -42.94 130.31 4.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.858 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.411 HD21 HG23 ' A' ' 72' ' ' VAL . 14.7 mt -81.31 6.93 12.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.95 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.546 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.3 OUTLIER -77.62 123.96 27.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.943 179.907 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.546 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.13 -37.19 3.78 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -84.99 168.88 14.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.933 -179.925 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' C ' ' A' ' 82' ' ' HIS . 77.8 p -106.69 161.27 14.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.471 ' C ' ' O ' ' A' ' 81' ' ' THR . 4.3 t-80 -32.81 -55.8 0.37 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.31 -47.32 56.3 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.464 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.434 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 11.1 mm-40 -66.51 -49.88 65.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.838 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.17 -50.15 49.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 68.9 t -56.16 -57.3 9.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.122 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.48 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 9.9 mm-40 -52.17 -23.33 5.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.912 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.562 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.5 tt -76.41 -27.15 56.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.775 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -82.84 -25.12 32.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.861 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.48 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.4 ptm180 -97.63 -3.57 39.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 31.2 t -89.6 28.82 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.902 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.3 p -109.26 147.66 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.23 -98.49 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.495 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.627 ' C ' ' HZ2' ' A' ' 17' ' ' LYS . 0.8 OUTLIER -112.4 -11.31 13.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.89 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.425 ' C ' HG21 ' A' ' 92' ' ' VAL . 6.4 m -153.03 137.22 16.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.104 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.849 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -121.65 169.42 10.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -117.28 95.58 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.412 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -91.98 128.87 43.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.148 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.523 HD12 ' O ' ' A' ' 11' ' ' ARG . 20.9 tp -96.9 21.13 10.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.764 HG12 HD22 ' A' ' 69' ' ' LEU . 22.6 m -49.8 177.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.8 p -169.26 147.62 3.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.517 ' HA ' HD23 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -43.07 113.4 0.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.508 -179.921 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.727 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.16 31.21 0.5 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.742 0.306 . . . . 0.0 110.854 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 -104.91 162.48 13.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.865 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.48 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 50.2 tt0 -73.31 113.17 10.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 97' ' ' THR . 26.2 mt -105.46 -174.87 2.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.909 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.516 ' SG ' HG22 ' A' ' 95' ' ' THR . 1.7 t -164.47 153.28 13.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 95' ' ' THR . 19.5 mt -125.82 118.72 52.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -94.04 115.68 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -128.65 164.53 22.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.12 168.75 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.578 0.704 . . . . 0.0 111.092 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.83 1.19 4.71 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.679 2.253 . . . . 0.0 112.325 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.48 42.88 0.23 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.1 tp10 -107.77 141.24 39.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.903 0.383 . . . . 0.0 110.875 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.9 mtt180 -83.59 120.72 26.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.909 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -32.55 -56.97 0.35 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.56 41.1 7.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.545 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.819 HD11 HD13 ' A' ' 89' ' ' LEU . 2.7 pt -121.68 171.17 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.408 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.5 m -142.92 146.47 34.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 28.8 pt -136.41 161.32 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.153 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.431 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.4 ptm85 -132.14 140.42 48.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.11 -155.35 24.45 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.911 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 86.6 mt -127.81 117.95 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.837 0.351 . . . . 0.0 111.178 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.562 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.2 m-85 -131.49 -176.67 4.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.72 HD13 HD11 ' A' ' 63' ' ' LEU . 78.6 mt -84.74 139.92 16.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.136 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 24.4 p -119.07 -12.07 9.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.476 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 22.0 tttp -175.78 149.84 0.98 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.898 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.584 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -156.1 117.57 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.099 179.887 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.7 t -66.25 137.79 95.72 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.67 0.748 . . . . 0.0 110.846 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 54.0 Cg_endo -69.8 -26.45 27.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.354 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 67.5 p -82.33 -26.37 33.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.153 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.96 174.31 2.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.483 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.3 -32.3 73.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.845 0.355 . . . . 0.0 111.134 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.909 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -77.45 -69.33 0.54 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.19 -45.63 1.23 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.447 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.9 ptt180 -68.04 -35.27 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ALA . 32.0 t70 -45.29 -64.77 0.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.49 -19.35 6.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -98.34 -51.47 3.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.72 HD11 HD13 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -55.31 130.43 42.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.896 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.58 ' N ' HD13 ' A' ' 63' ' ' LEU . 5.2 ptp180 -162.69 151.23 14.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.584 HG23 HG12 ' A' ' 51' ' ' VAL . 64.7 t -59.92 104.89 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.67 -8.43 1.8 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.47 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.671 HD23 ' HA ' ' A' ' 102' ' ' ASP . 23.5 mt -89.95 129.29 36.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.562 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 62.2 ttt180 -79.31 124.24 28.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.886 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.78 HD22 HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -75.31 114.14 13.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 7.4 mp -91.16 -50.69 5.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -155.4 141.98 18.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.829 HG13 HD12 ' A' ' 96' ' ' LEU . 88.0 t -114.58 108.38 25.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 12.7 m-20 65.93 42.06 3.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 34.3 mt-30 64.43 29.86 13.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 -123.47 89.88 3.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.6 t -42.99 130.92 4.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.523 ' HA ' HD21 ' A' ' 80' ' ' LEU . 36.7 mt -85.25 7.68 21.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.522 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -77.41 126.66 31.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 105.41 -36.11 4.62 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.492 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.682 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -85.73 162.51 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.846 0.355 . . . . 0.0 110.928 -179.889 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 82' ' ' HIS . 43.0 p -105.68 167.38 9.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.54 -65.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -41.77 -48.1 5.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.477 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.6 mt-10 -66.86 -50.91 61.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.852 0.358 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.25 -55.27 22.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.537 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.4 t -51.37 -61.7 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.17 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.485 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.1 mm-40 -50.07 -24.78 2.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -74.6 -30.9 61.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.819 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -78.42 -28.9 46.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.485 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.9 ptp180 -93.61 1.16 56.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.1 t -95.05 31.3 1.92 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.8 p -112.89 142.93 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.08 -101.48 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.404 ' HB3' ' HA ' ' A' ' 19' ' ' PRO . 20.0 p-10 -114.81 0.24 13.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.516 HG22 ' SG ' ' A' ' 14' ' ' CYS . 19.3 m -159.02 135.72 9.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.128 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.829 HD12 HG13 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -132.13 157.21 44.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.894 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 97' ' ' THR . . . . . 0.77 HG23 ' O ' ' A' ' 13' ' ' LEU . 9.6 m -107.99 103.53 12.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.128 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 98' ' ' VAL . 2.9 m -97.1 126.31 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 99' ' ' LEU . 20.0 tp -91.89 29.41 1.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.78 HG12 HD22 ' A' ' 69' ' ' LEU . 11.7 m -61.07 166.43 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.169 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 25.0 p -164.34 146.01 8.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.832 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.671 ' HA ' HD23 ' A' ' 67' ' ' LEU . 1.4 t70 -42.63 119.96 1.58 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.517 -179.951 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.652 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.94 23.53 1.46 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.791 0.329 . . . . 0.0 110.93 -179.935 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.422 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 4.7 mmm180 -93.1 157.65 16.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -65.71 106.84 1.59 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mt -109.25 170.73 7.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.936 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.9 p -150.59 155.35 39.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.438 ' O ' HG23 ' A' ' 95' ' ' THR . 34.4 mt -120.73 120.51 62.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.153 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -92.26 115.34 27.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.931 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.401 ' O ' ' O ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -128.17 164.62 22.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.895 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.832 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.33 168.65 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.562 0.696 . . . . 0.0 111.06 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.832 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.78 3.49 2.75 Favored 'Trans proline' 0 N--CA 1.466 -0.146 0 C-N-CA 122.698 2.265 . . . . 0.0 112.321 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.18 37.84 0.16 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.7 tp10 -100.29 138.41 37.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.463 ' O ' ' C ' ' A' ' 23' ' ' LEU . 30.1 mmt-85 -81.07 116.71 21.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.745 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -32.56 -46.79 0.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.81 42.82 52.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.838 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -119.56 166.54 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.338 . . . . 0.0 111.135 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.6 OUTLIER -130.51 150.37 51.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.416 HD11 HG22 ' A' ' 86' ' ' VAL . 30.7 pt -139.53 151.39 22.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.114 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -129.07 124.67 35.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.36 -150.83 22.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.485 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 36.6 mt -135.72 115.95 17.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.592 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.59 149.97 51.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 26' ' ' SER . 18.1 mt -55.59 140.95 12.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.129 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 49.8 p -114.15 -26.55 8.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 37.5 tttm -158.61 157.05 31.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.553 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.79 116.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.114 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.5 t -62.91 140.48 97.48 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.679 0.752 . . . . 0.0 110.853 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -16.46 37.82 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.707 2.271 . . . . 0.0 112.353 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.9 p -105.62 -6.28 19.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.117 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' ALA . . . -76.72 145.9 31.94 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.503 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.495 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -37.51 -33.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 111.094 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -74.98 -62.71 1.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.02 -40.22 6.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.502 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.495 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 1.6 ptt-85 -73.91 -29.94 62.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.866 0.365 . . . . 0.0 110.893 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 6.5 t70 -55.16 -69.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.71 -22.01 4.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -96.28 -52.64 3.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.82 0.343 . . . . 0.0 110.905 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.883 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -61.9 110.85 1.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.944 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.411 ' HG3' ' CD1' ' A' ' 67' ' ' LEU . 5.1 ptp180 -152.8 136.3 15.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.836 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -39.59 99.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.123 179.944 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.66 -32.41 0.52 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.54 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.493 ' HB2' HD12 ' A' ' 48' ' ' ILE . 7.8 mp -73.73 151.82 40.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.845 0.355 . . . . 0.0 110.882 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 61.5 ttt180 -97.66 116.54 30.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.812 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -66.09 105.64 1.42 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.403 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 9.5 mp -80.5 -49.64 11.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.941 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.403 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 31.4 mt-10 -158.94 145.12 16.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.81 HG13 HD12 ' A' ' 96' ' ' LEU . 79.3 t -115.31 110.21 31.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.7 m-20 64.88 40.56 5.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 35.4 mt-30 64.61 29.85 12.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.955 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.8 mm100 -123.64 90.76 3.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.885 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.1 t -44.96 130.86 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.82 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.6 mt -79.85 0.26 31.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.527 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -74.7 118.4 17.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.881 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 119.6 -34.02 4.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.5 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.5 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -92.98 171.38 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.945 0.402 . . . . 0.0 110.903 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.7 p -109.85 162.5 14.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.162 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.543 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.6 t-80 -33.33 -55.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -49.83 -49.53 34.73 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.494 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -68.01 -51.75 43.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.878 0.37 . . . . 0.0 110.862 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.5 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.81 -48.62 30.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 82' ' ' HIS . 98.3 t -57.96 -54.24 34.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.135 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 61.6 mm-40 -56.79 -22.0 32.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.8 tt -76.42 -27.07 56.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.838 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -82.71 -29.1 30.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.964 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.7 ptm180 -92.49 0.81 57.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.871 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 44.4 t -94.25 28.06 2.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.834 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.825 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -108.77 140.28 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.164 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -59.59 -98.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.518 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -114.16 -11.87 12.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.883 0.373 . . . . 0.0 110.858 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 15' ' ' ILE . 2.0 m -150.29 137.11 19.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.116 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.825 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -125.95 167.94 14.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.936 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 m -115.98 97.54 6.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 98' ' ' VAL . 10.1 m -97.04 130.6 45.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.136 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.78 24.07 6.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.812 HG12 HD22 ' A' ' 69' ' ' LEU . 21.7 m -51.59 -176.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.111 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 5.3 p -175.45 153.93 1.58 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -55.68 105.38 0.18 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.749 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.46 18.47 1.47 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.928 -179.894 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.404 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.0 mmm180 -87.35 165.33 15.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.853 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -72.18 115.12 11.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -123.62 160.14 27.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 14.3 p -143.33 156.35 44.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.856 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HG23 ' A' ' 95' ' ' THR . 59.0 mt -117.74 102.66 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -77.31 117.85 19.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.511 ' NZ ' HD12 ' A' ' 23' ' ' LEU . 0.5 OUTLIER -134.03 165.4 25.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.837 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.841 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.38 168.43 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.633 0.73 . . . . 0.0 111.091 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.841 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.82 -0.15 6.54 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.626 2.217 . . . . 0.0 112.338 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -171.04 33.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.66 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.8 tp10 -92.1 126.05 37.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.866 0.365 . . . . 0.0 110.85 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.488 ' O ' ' C ' ' A' ' 23' ' ' LEU . 62.5 mtt180 -70.82 97.01 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.887 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.84 ' HG ' ' HB3' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -30.95 -48.85 0.12 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.6 47.64 7.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.47 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.543 HG22 HG13 ' A' ' 51' ' ' VAL . 4.8 pt -117.61 153.67 19.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.83 0.348 . . . . 0.0 111.161 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.57 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -122.04 151.77 40.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.888 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.0 pt -137.28 145.96 28.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.099 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.422 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 1.5 ptm85 -122.76 137.21 54.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.845 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.96 -145.57 17.54 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.491 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.367 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 -179.89 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 mt -126.22 119.53 54.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.886 0.374 . . . . 0.0 111.1 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.6 OUTLIER -132.04 150.68 52.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.858 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.571 HD13 HD11 ' A' ' 63' ' ' LEU . 44.1 mt -60.25 139.43 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.3 t -112.01 -24.53 9.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 23.9 tttp -155.1 154.87 33.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.543 HG13 HG22 ' A' ' 25' ' ' ILE . 80.4 t -148.71 120.59 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 42.9 t -58.79 138.02 86.86 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.652 0.739 . . . . 0.0 110.877 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -38.42 7.66 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.645 2.23 . . . . 0.0 112.36 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.9 p -92.95 -2.95 55.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.55 172.86 38.12 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.84 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -61.14 -34.04 74.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.75 0.31 . . . . 0.0 111.063 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.816 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -76.83 -60.97 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.41 -42.75 4.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.406 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.8 ptt180 -77.74 -27.96 50.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -53.55 -66.98 0.3 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.85 -5.7 22.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.509 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.425 ' HA ' ' NH1' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -115.22 -7.76 12.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.38 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.805 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.3 tm? -114.55 124.63 52.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.747 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.91 151.73 25.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 179.956 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.429 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -55.8 107.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.97 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.57 -25.54 1.67 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.675 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.5 mt -70.89 142.36 51.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.927 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.536 ' O ' HD22 ' A' ' 70' ' ' LEU . 75.5 ttt180 -88.91 112.89 23.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.705 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.9 mm? -64.94 103.06 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.924 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.536 HD22 ' O ' ' A' ' 68' ' ' ARG . 1.6 mm? -79.61 -52.37 8.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -155.72 136.98 13.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 97.3 t -107.44 110.35 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.15 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.5 m-20 64.79 41.72 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 29.6 mt-30 64.17 30.36 13.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -126.42 90.55 3.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.7 t -42.67 133.26 3.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.824 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.535 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.1 mt -87.62 13.19 10.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.941 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.634 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -80.74 133.18 35.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 179.88 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.634 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 101.18 -36.15 4.39 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.589 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -87.12 156.92 19.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.865 0.364 . . . . 0.0 110.925 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 30.7 p -92.06 -177.26 4.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' HIS . . . . . 0.435 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 3.2 t-80 -51.33 -56.12 14.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.868 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -53.29 -51.47 46.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.494 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 6.8 mm-40 -58.54 -45.92 87.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.881 0.372 . . . . 0.0 110.871 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.541 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.87 -49.62 76.07 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 55.4 t -53.08 -56.92 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.484 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 17.1 mm100 -52.1 -22.84 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -78.92 -28.04 43.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.618 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -83.09 -26.36 31.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.864 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.484 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.5 ptp180 -95.05 0.89 54.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 24.9 t -96.36 33.28 1.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.0 p -112.0 145.57 17.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.63 -100.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.452 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -112.47 -1.69 14.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.884 0.373 . . . . 0.0 110.893 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.401 HG23 ' C ' ' A' ' 15' ' ' ILE . 26.8 m -162.96 136.6 5.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.143 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.39 166.83 12.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.6 m -115.68 96.08 5.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.131 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.454 ' HB ' HG13 ' A' ' 100' ' ' VAL . 5.6 m -93.49 133.0 36.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.404 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.8 tp -103.09 26.53 8.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.5 m -60.28 178.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.095 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.4 p -171.65 146.02 2.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -37.89 109.98 0.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.462 -179.918 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.738 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.33 32.43 0.5 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.799 0.333 . . . . 0.0 110.913 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -99.39 150.65 21.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.77 113.77 2.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.4 mt -117.37 167.35 11.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 23.0 p -146.42 158.9 43.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.423 ' C ' HG23 ' A' ' 95' ' ' THR . 22.6 mt -125.85 106.25 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.116 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -81.31 107.33 14.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.624 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -118.81 172.74 7.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.806 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -49.48 165.09 0.3 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.609 0.718 . . . . 0.0 111.099 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.83 1.87 4.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.337 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.55 32.1 0.18 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.466 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.806 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 33.5 tp10 -97.92 153.34 18.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.876 0.369 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.81 125.65 35.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . 0.698 HD12 HG23 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -37.58 -52.46 1.2 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.911 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.44 40.9 14.35 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.698 HG23 HD12 ' A' ' 23' ' ' LEU . 7.5 pt -121.26 157.43 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 111.096 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.506 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -122.16 144.1 49.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.1 pt -135.85 149.27 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.114 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.0 ptt180 -128.67 135.1 48.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 139.95 -140.93 11.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.26 117.76 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.857 0.36 . . . . 0.0 111.132 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.555 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -131.04 149.61 52.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.806 HD11 HD21 ' A' ' 63' ' ' LEU . 65.1 mt -58.14 123.71 10.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.155 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.9 t -99.3 -10.8 21.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.855 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.523 ' N ' HG13 ' A' ' 65' ' ' VAL . 13.1 ttmt -175.06 160.35 2.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.915 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.688 HG23 HG22 ' A' ' 65' ' ' VAL . 58.8 t -144.42 114.09 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.6 t -61.54 138.28 94.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.681 0.753 . . . . 0.0 110.821 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -25.1 28.9 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.252 . . . . 0.0 112.329 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.3 p -94.99 1.22 55.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.78 158.94 34.07 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.484 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -50.25 -44.09 53.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -63.75 -58.76 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.089 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.11 -42.15 5.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.47 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 30.2 ptt180 -85.01 -24.22 28.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 110.914 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -54.42 -69.13 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.37 -13.54 15.9 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -101.38 -7.46 22.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.811 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 HD11 ' A' ' 48' ' ' ILE . 2.4 tm? -108.79 135.17 50.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.908 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.716 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.5 mmp_? -140.5 158.09 44.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 51' ' ' VAL . 5.4 t -73.82 88.95 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 155.8 -17.76 0.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.464 ' HB2' HD12 ' A' ' 48' ' ' ILE . 13.0 mt -65.72 130.35 42.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.803 0.335 . . . . 0.0 110.901 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.555 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 60.4 ttt180 -78.6 122.1 25.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.775 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -73.86 111.87 9.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.953 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 9.0 mp -87.48 -52.94 5.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.91 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -156.73 135.77 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.989 HG13 HD12 ' A' ' 96' ' ' LEU . 53.0 t -108.66 111.72 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.101 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 65.46 40.58 4.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 63.98 36.38 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.928 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -134.77 90.91 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.0 t -41.11 139.13 0.98 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.832 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.475 ' CD2' HD13 ' A' ' 88' ' ' LEU . 11.5 mt -86.11 9.78 16.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.958 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.8 tt -83.69 156.64 22.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 79.71 -19.51 6.1 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -110.38 155.06 22.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.381 . . . . 0.0 110.907 -179.91 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 65.5 p -91.75 179.03 5.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -48.62 -58.11 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.84 -49.87 27.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.0 mt-10 -61.72 -46.84 87.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.841 0.353 . . . . 0.0 110.923 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.43 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.63 -51.64 64.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.085 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 89' ' ' LEU . 65.0 t -48.22 -58.01 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.101 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLN . . . . . 0.623 ' NE2' ' CZ ' ' A' ' 90' ' ' ARG . 3.5 mm100 -51.49 -24.89 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.911 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.475 HD13 ' CD2' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -74.84 -32.19 61.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.914 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.574 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -75.83 -24.75 55.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.623 ' CZ ' ' NE2' ' A' ' 87' ' ' GLN . 4.2 ptt180 -96.55 -0.11 49.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 p -83.36 20.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -106.42 145.84 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.162 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -78.47 -80.66 0.71 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.501 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ASP . . . . . 0.446 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -121.13 -13.74 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.863 0.364 . . . . 0.0 110.852 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' C ' ' A' ' 15' ' ' ILE . 14.3 m -157.1 134.61 10.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.989 HD12 HG13 ' A' ' 72' ' ' VAL . 1.3 pt? -118.88 -179.24 3.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.926 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -126.61 95.92 4.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.4 m -96.92 129.31 47.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -94.96 21.6 7.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.775 HG12 HD22 ' A' ' 69' ' ' LEU . 20.8 m -49.65 169.29 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 8.6 p -161.6 154.08 20.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -48.8 111.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.853 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.512 -0.235 . . . . 0.0 112.512 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.1 t -82.58 135.23 35.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.829 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -147.44 138.94 23.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.862 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -117.28 -74.91 0.52 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.6 m -69.02 -64.55 0.85 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.88 0.372 . . . . 0.0 110.857 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.2 t 69.78 37.16 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.61 145.28 10.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.499 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 157.79 59.06 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.693 2.262 . . . . 0.0 112.326 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -141.4 -39.68 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.672 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -97.77 33.06 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.929 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.623 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.6 mmm180 -104.12 177.82 4.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.419 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.6 tt0 -78.0 112.22 14.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.907 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.2 mt -119.85 163.38 17.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 96' ' ' LEU . 18.9 p -144.3 159.47 42.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.87 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.6 mt -122.34 112.96 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -84.47 115.39 22.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -127.41 166.77 17.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.889 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.06 168.27 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.543 0.687 . . . . 0.0 111.118 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.8 -2.01 9.48 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.653 2.235 . . . . 0.0 112.333 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.49 37.89 0.27 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 40.8 tp10 -102.68 143.58 32.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.864 0.364 . . . . 0.0 110.893 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.6 ptt180 -84.13 121.5 27.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.849 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.751 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -33.63 -53.16 0.42 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 41.12 9.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.751 HG12 HD12 ' A' ' 23' ' ' LEU . 3.3 pt -121.35 162.57 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.5 m -130.57 145.13 51.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.819 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.565 HD12 HG21 ' A' ' 46' ' ' ILE . 21.1 pt -136.2 156.2 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.107 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -132.48 132.9 43.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.873 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.07 -142.32 9.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.95 149.89 9.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.507 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.452 ' O ' ' CD ' ' A' ' 44' ' ' GLU . . . -57.86 -11.09 2.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 111.105 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 33' ' ' GLY . 42.6 mtp180 -130.17 -44.76 1.14 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -35.39 150.5 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' C ' ' O ' ' A' ' 33' ' ' GLY . 7.9 p80 -35.67 129.23 0.6 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -43.27 110.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.097 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.31 -40.11 22.02 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -88.35 118.96 70.07 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.569 0.7 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -11.91 31.86 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.718 2.278 . . . . 0.0 112.342 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 -81.17 -60.66 2.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.91 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -111.49 125.22 30.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.65 0.738 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -14.46 36.21 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.694 2.263 . . . . 0.0 112.342 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 p -87.43 33.64 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.161 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -124.91 115.79 21.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.452 ' CD ' ' O ' ' A' ' 31' ' ' ALA . 24.8 mt-10 -107.67 18.47 21.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -52.55 162.86 2.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.486 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.565 HG21 HD12 ' A' ' 27' ' ' ILE . 30.8 mt -126.88 119.2 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.385 . . . . 0.0 111.106 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.72 149.12 52.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.833 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.541 HD13 HD11 ' A' ' 63' ' ' LEU . 94.7 mt -54.59 132.76 17.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.43 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.4 p -108.59 -13.41 14.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.412 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 28.4 tttm -175.5 156.47 1.96 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.853 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.56 HG13 HG22 ' A' ' 25' ' ' ILE . 93.4 t -143.63 123.24 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.109 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 t -69.22 143.15 93.49 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.684 0.754 . . . . 0.0 110.858 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -35.6 12.15 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.33 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.3 p -88.27 0.95 55.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.449 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -80.57 153.05 34.54 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.604 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -45.18 -38.9 5.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.769 0.319 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -73.32 -64.0 1.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -35.44 -44.56 0.62 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.8 ptt180 -79.3 -37.24 38.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 57' ' ' ALA . 22.1 t0 -40.66 -64.57 0.51 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.38 -9.75 22.23 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.24 -24.35 11.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.0 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.29 126.25 37.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -142.6 174.46 10.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 6.4 t -82.62 92.33 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.555 ' HA2' ' CE2' ' A' ' 104' ' ' PHE . . . 154.68 -13.66 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.47 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.611 HD12 HD22 ' A' ' 63' ' ' LEU . 52.7 mt -77.05 118.71 19.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.559 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 46.5 ttt180 -69.12 122.69 19.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.688 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -72.95 108.96 6.15 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.434 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 4.4 mm? -84.31 -52.37 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.951 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.434 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 11.3 mt-10 -157.85 134.99 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.837 HG13 HD12 ' A' ' 96' ' ' LEU . 88.8 t -106.58 110.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.075 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 18.6 m-20 64.73 41.66 5.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 64.17 31.89 12.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -128.86 91.05 3.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.887 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 36.2 t -50.45 130.89 24.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.3 mt -80.29 5.14 15.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.402 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -73.04 114.95 11.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.932 179.918 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -37.39 3.17 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.494 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.585 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -86.42 167.89 14.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.904 0.383 . . . . 0.0 110.917 -179.934 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 61.8 p -104.37 160.59 14.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.1 -55.19 0.39 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.821 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.24 -46.11 51.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 81' ' ' THR . 29.4 mm-40 -70.03 -47.87 60.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.863 0.364 . . . . 0.0 110.857 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -54.18 -48.76 70.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 82' ' ' HIS . 75.2 t -55.57 -55.22 18.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 19.8 mm100 -54.27 -27.3 34.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -70.43 -29.59 66.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.958 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.67 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.41 -30.5 47.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.921 179.879 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.8 ptp180 -93.36 -1.14 56.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.83 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -90.64 30.0 1.23 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.636 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.6 p -112.1 144.66 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.154 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.73 -94.51 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -119.52 -8.78 9.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 m -152.92 134.68 14.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.837 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -122.8 171.87 8.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.419 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.4 m -120.8 98.64 6.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.158 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.46 131.91 40.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.623 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.1 tp -101.15 31.47 3.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.688 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.5 m -65.96 175.47 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.133 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.4 p -165.17 154.23 12.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -46.26 101.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -96.5 -51.73 1.66 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.478 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.555 ' CE2' ' HA2' ' A' ' 66' ' ' GLY . 6.0 p90 -168.34 121.87 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.795 0.331 . . . . 0.0 110.865 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -69.84 133.82 47.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 76.5 p -100.56 40.51 1.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 80.79 -176.53 54.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 155.98 64.6 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.701 2.267 . . . . 0.0 112.362 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 23.4 t -130.37 170.12 14.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 5.1 t -122.04 146.61 47.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.859 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.485 180.0 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 81.1 p -84.99 122.44 29.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.361 . . . . 0.0 110.874 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 31.4 m -112.09 -57.83 2.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.02 -151.52 20.02 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.465 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 97.5 p -85.25 -51.72 6.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.852 0.358 . . . . 0.0 110.859 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 99.0 p -68.49 117.14 9.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -110.18 -78.56 1.0 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.513 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.82 158.54 56.53 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.688 2.259 . . . . 0.0 112.307 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -140.01 -36.5 0.12 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.485 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.748 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -83.31 20.19 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.892 -179.906 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.472 ' O ' HD12 ' A' ' 99' ' ' LEU . 15.3 mmt180 -90.24 168.01 12.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.458 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 31.9 tt0 -74.25 114.84 13.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.893 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.8 mt -118.58 160.06 22.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.6 p -139.5 155.77 47.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 95' ' ' THR . 31.0 mt -122.97 109.78 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.19 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -80.31 115.93 20.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.482 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -131.98 178.26 6.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -56.83 163.62 2.71 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.554 0.692 . . . . 0.0 111.093 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.2 Cg_endo -69.8 1.23 4.65 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.688 2.259 . . . . 0.0 112.328 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -162.59 26.14 0.23 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.488 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.1 tp10 -94.43 142.22 27.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.909 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.9 mpt_? -86.32 123.72 31.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.722 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -46.53 0.24 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.58 41.18 30.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.527 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -121.41 162.97 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 0.0 111.143 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -120.12 159.1 25.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.835 -179.894 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 86' ' ' VAL . 14.4 pt -151.69 145.65 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.11 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -129.26 132.14 47.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.929 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.67 -146.19 15.17 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.478 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 125.69 139.27 5.11 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -52.91 -14.74 0.61 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 111.107 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.546 ' NE ' HG21 ' A' ' 81' ' ' THR . 12.1 ptp180 -123.53 -28.51 3.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.86 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -35.51 124.48 0.69 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' GLY . 91.9 m-70 -37.83 -34.56 0.11 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 110.844 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.96 173.87 2.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.09 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 32.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.467 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 24.9 t30 -155.2 117.29 2.39 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 0.0 110.911 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 2.19 3.73 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.73 2.287 . . . . 0.0 112.317 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -103.86 -47.67 4.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -140.41 116.88 7.87 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.605 0.717 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -29.21 24.25 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.69 2.26 . . . . 0.0 112.357 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 p -82.39 44.57 0.89 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.139 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -143.71 115.55 8.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.852 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.485 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 14.2 mp0 -81.31 41.58 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.23 175.7 48.19 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.466 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 60.3 mt -139.18 115.86 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 111.135 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.4 OUTLIER -132.54 163.5 28.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.959 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.736 HD11 HD21 ' A' ' 63' ' ' LEU . 27.4 mt -67.72 125.49 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 82.7 p -96.85 -11.02 25.36 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.823 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 16.8 ttmm -175.86 167.25 3.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 64.5 t -150.06 114.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.139 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.5 t -67.27 140.01 95.17 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.61 0.719 . . . . 0.0 110.85 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.74 21.68 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.646 2.231 . . . . 0.0 112.361 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.5 p -86.57 -8.57 57.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.137 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -75.56 158.2 50.07 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.408 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -50.17 -39.39 43.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.766 0.317 . . . . 0.0 111.087 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -70.34 -60.26 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.079 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.63 -42.88 2.84 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.408 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 23.3 ptt180 -80.29 -31.53 38.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.83 0.348 . . . . 0.0 110.886 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -50.17 -72.29 0.05 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 119.72 -9.58 11.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.492 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -104.32 -10.93 17.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.876 0.37 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.83 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.4 tm? -105.83 134.0 49.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.707 ' N ' HD13 ' A' ' 63' ' ' LEU . 19.7 mtp180 -144.28 178.97 7.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 51' ' ' VAL . 9.1 t -88.02 92.86 3.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.138 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 151.91 -13.16 0.74 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.465 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.557 ' HB2' HD12 ' A' ' 48' ' ' ILE . 32.6 mt -73.0 110.41 7.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.803 0.335 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 16.6 ttm180 -62.34 122.8 16.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.858 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.67 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -71.24 107.03 4.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.495 ' O ' ' CG ' ' A' ' 71' ' ' GLU . 1.7 mm? -86.37 -42.14 13.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 40.3 mt-10 -161.82 139.55 8.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.885 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.745 HG13 HD12 ' A' ' 96' ' ' LEU . 66.7 t -117.6 108.0 23.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.089 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.476 ' ND2' HG22 ' A' ' 92' ' ' VAL . 11.5 m-20 65.44 41.35 4.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 63.65 36.66 10.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -131.92 91.16 2.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.3 t -47.55 127.04 10.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.436 ' HA ' HD21 ' A' ' 80' ' ' LEU . 12.8 mt -78.01 1.06 22.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.442 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -72.12 111.39 7.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.964 179.805 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.92 -37.28 2.73 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.524 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.501 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -87.16 167.03 14.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.953 0.406 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.546 HG21 ' NE ' ' A' ' 32' ' ' ARG . 81.0 p -102.66 -179.97 4.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.64 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -50.32 -51.48 44.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.85 -45.57 79.54 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.1 mt-10 -67.1 -58.36 5.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.819 0.342 . . . . 0.0 110.889 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -44.27 -46.79 9.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.123 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.746 ' HA ' HD23 ' A' ' 89' ' ' LEU . 74.5 t -57.05 -60.45 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.11 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.482 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.3 mm-40 -50.39 -26.27 4.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.902 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -74.73 -32.12 62.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.746 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -79.08 -31.66 44.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.482 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.4 ptm180 -90.81 3.54 54.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.897 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 5.5 m -96.59 29.23 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.639 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.4 t -94.25 149.94 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.59 -76.7 1.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -123.28 -17.76 6.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.84 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.426 HG23 ' O ' ' A' ' 15' ' ' ILE . 56.2 m -163.16 137.04 5.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.093 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.745 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.0 169.08 10.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.458 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.1 m -119.71 100.15 7.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.428 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.0 m -96.72 130.66 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.472 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.7 tp -99.19 24.83 7.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.7 m -61.84 172.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.122 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.3 p -163.35 163.02 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -54.31 95.15 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -89.11 -47.44 4.13 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.485 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 7.9 p90 -171.51 117.49 0.43 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.817 0.342 . . . . 0.0 110.898 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -80.06 129.4 34.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 88.0 p -60.85 -44.73 96.61 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.835 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.17 142.6 4.34 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 154.69 67.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.707 2.271 . . . . 0.0 112.388 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.1 t -169.44 156.46 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 26.7 p -62.67 127.49 31.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.503 -179.969 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 m -100.28 117.65 34.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.901 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.5 m -53.16 -56.03 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.858 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.38 -121.22 6.25 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.534 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.3 t -121.41 87.94 2.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.827 0.346 . . . . 0.0 110.856 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 65.2 m -65.26 156.38 32.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.22 144.37 3.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.509 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 153.95 68.55 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.703 2.268 . . . . 0.0 112.381 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . 172.65 -43.34 0.17 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.31 28.81 0.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.813 0.339 . . . . 0.0 110.934 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -98.5 161.93 13.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 35.2 tt0 -68.21 107.37 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.869 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 98' ' ' VAL . 18.9 mt -113.48 157.49 21.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 20.6 p -139.36 165.33 27.5 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.404 HG22 ' HB1' ' A' ' 56' ' ' ALA . 52.4 mt -128.99 105.62 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -80.68 117.55 21.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.4 ptpp? -126.91 168.6 14.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.51 168.34 0.12 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 0.0 111.103 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.823 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 1.61 4.27 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.727 2.285 . . . . 0.0 112.339 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.32 43.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 38.8 tp10 -111.59 142.7 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.814 0.34 . . . . 0.0 110.86 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -86.6 124.5 32.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 -179.926 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.777 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.46 -52.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 41.04 13.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.505 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.685 HG23 HD12 ' A' ' 23' ' ' LEU . 3.1 pt -119.39 157.33 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.813 0.339 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -123.5 140.06 53.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.628 HD12 HG21 ' A' ' 46' ' ' ILE . 21.5 pt -132.79 157.09 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.121 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.445 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 3.3 ptm85 -132.58 138.87 47.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.23 -144.75 13.2 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.79 162.87 12.97 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.16 -1.99 57.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.772 0.32 . . . . 0.0 111.077 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 28.9 mmt180 -130.72 -31.18 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.43 -156.17 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.47 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.493 ' O ' ' N ' ' A' ' 36' ' ' GLY . 9.8 m170 -81.26 43.24 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.845 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.714 ' HB1' ' O ' ' A' ' 43' ' ' ASP . . . 36.37 30.18 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.07 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 38.24 40.3 0.86 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -172.58 114.84 0.38 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.656 0.741 . . . . 0.0 110.926 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.63 24.09 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.26 . . . . 0.0 112.352 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.5 tpt180 -87.99 -57.44 2.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.429 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 5.8 m-20 -121.69 103.63 40.41 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.592 0.71 . . . . 0.0 110.868 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.652 ' HA ' ' HB3' ' A' ' 35' ' ' ALA . 53.8 Cg_endo -69.69 1.85 4.01 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -89.2 -29.88 18.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.714 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 36.4 t70 -69.11 100.39 1.25 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.889 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 50.2 mp0 -80.62 13.9 2.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -59.95 150.4 39.71 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.628 HG21 HD12 ' A' ' 27' ' ' ILE . 39.6 mt -125.21 117.63 50.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.829 0.347 . . . . 0.0 111.136 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.06 156.53 43.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 HD11 ' A' ' 63' ' ' LEU . 65.3 mt -64.19 130.46 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.158 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 43.5 t -110.23 -14.57 14.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.837 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.474 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 11.2 tttm -167.02 161.21 14.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.659 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -152.78 129.28 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.144 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.1 t -72.52 137.65 80.72 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.611 0.719 . . . . 0.0 110.867 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -25.29 28.84 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.676 2.251 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -101.71 12.88 36.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.187 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -91.92 161.94 27.21 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.506 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.491 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -50.04 -35.51 25.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.17 -57.11 4.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.123 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.27 -43.85 4.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.497 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -80.83 -26.25 37.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.821 0.343 . . . . 0.0 110.889 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -48.58 -58.23 5.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.79 -25.12 11.19 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.468 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -94.73 -53.48 3.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.855 0.36 . . . . 0.0 110.883 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.811 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.4 OUTLIER -58.6 132.49 53.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.627 ' N ' HD13 ' A' ' 63' ' ' LEU . 3.6 ptp180 -165.33 147.57 7.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 62.0 t -49.79 106.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.153 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.13 -26.3 2.03 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.696 HD23 ' C ' ' A' ' 101' ' ' CYS . 20.3 mt -75.25 118.55 18.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.765 0.316 . . . . 0.0 110.942 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.56 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -69.61 131.66 45.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.602 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -80.29 111.75 16.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 4.0 mm? -88.84 -49.78 6.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.957 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.416 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -158.39 140.41 13.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.923 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.847 HG13 HD12 ' A' ' 96' ' ' LEU . 88.4 t -111.84 109.77 29.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.159 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 65.07 41.9 4.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 64.21 32.99 12.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.21 90.54 3.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.912 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.8 t -47.3 130.08 13.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.618 ' HA ' HD21 ' A' ' 80' ' ' LEU . 5.8 mt -83.31 8.34 13.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.965 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.5 OUTLIER -76.97 115.45 16.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.886 179.894 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.11 -32.52 5.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.468 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.618 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -88.04 167.12 13.96 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.918 0.389 . . . . 0.0 110.9 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.441 ' O ' ' N ' ' A' ' 84' ' ' GLU . 44.5 p -105.94 162.92 13.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.102 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.598 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.7 t-80 -34.82 -55.96 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.62 -41.12 49.23 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.442 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -73.16 -48.6 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.856 0.36 . . . . 0.0 110.868 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.4 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.3 -51.64 64.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.152 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.0 t -53.17 -62.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.125 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 15.9 mm-40 -49.51 -23.44 1.6 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -75.07 -33.47 61.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.773 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.2 -32.76 56.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 8.2 ptm180 -89.24 -3.36 58.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.1 m -91.41 33.52 0.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.84 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.3 p -112.88 145.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.115 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.25 -98.15 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -116.15 -6.96 11.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.923 0.392 . . . . 0.0 110.918 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.4 m -156.17 130.64 8.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.172 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.847 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.99 168.2 10.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.6 m -116.85 97.77 6.14 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.113 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 13' ' ' LEU . 3.3 m -95.43 129.32 45.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.152 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.3 tp -99.51 34.17 2.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.602 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.0 m -69.91 173.0 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.696 ' C ' HD23 ' A' ' 67' ' ' LEU . 7.9 p -165.15 168.34 17.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -52.51 114.32 1.34 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.435 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -107.53 -36.73 2.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.494 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.435 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.6 OUTLIER -156.23 109.86 2.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.36 . . . . 0.0 110.892 -179.85 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 60.6 mt-10 -44.08 -45.24 7.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 80.3 p 43.73 34.91 0.93 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.819 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.75 -158.02 3.27 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.456 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 112.61 3.12 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.671 2.247 . . . . 0.0 112.366 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.9 t -84.64 113.91 21.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 12.2 t -144.74 111.47 5.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.95 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 76.6 p -42.15 -44.43 3.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.877 0.37 . . . . 0.0 110.852 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 55.2 m -46.9 101.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.872 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.38 -136.85 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.445 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.7 m -110.56 124.87 52.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.896 0.379 . . . . 0.0 110.85 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 78.8 p -134.47 172.82 12.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.884 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.84 166.52 22.84 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.456 ' CB ' ' HD2' ' A' ' 11' ' ' ARG . 53.8 Cg_endo -69.81 158.22 57.62 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.681 2.254 . . . . 0.0 112.331 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.443 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . -145.13 -36.94 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.496 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.707 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.79 38.99 0.73 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.924 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.456 ' HD2' ' CB ' ' A' ' 8' ' ' PRO . 53.8 mtp180 -109.68 144.95 37.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.438 ' OE2' HG21 ' A' ' 97' ' ' THR . 52.9 tt0 -55.52 110.09 0.65 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.5 mt -105.1 168.67 8.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.944 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.696 ' SG ' HG22 ' A' ' 95' ' ' THR . 7.2 t -150.35 144.22 25.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.931 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.814 ' O ' HG23 ' A' ' 95' ' ' THR . 15.6 mt -120.71 127.2 75.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -97.72 113.54 25.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -124.83 170.5 10.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.89 168.05 0.17 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.582 0.706 . . . . 0.0 111.1 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.813 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.81 2.37 3.62 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.344 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.05 39.43 0.17 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.6 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 26.1 tp10 -101.73 144.19 30.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.812 0.339 . . . . 0.0 110.926 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 25.5 mtt-85 -83.75 120.23 25.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.753 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -49.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.35 42.6 18.12 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.471 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.753 HG12 HD12 ' A' ' 23' ' ' LEU . 2.2 pt -122.74 161.5 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.803 0.335 . . . . 0.0 111.133 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.471 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -119.17 160.37 22.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.891 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 46' ' ' ILE . 17.7 pt -151.55 147.27 15.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.169 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.473 ' NH1' ' CB ' ' A' ' 49' ' ' SER . 6.1 ptt-85 -125.09 139.42 53.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 137.87 -149.93 20.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.514 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.22 141.56 7.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.542 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.473 ' HA ' ' CG ' ' A' ' 44' ' ' GLU . . . -63.05 -7.98 6.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.719 0.295 . . . . 0.0 111.089 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.5 mtt180 -126.73 23.43 6.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.38 172.42 18.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.506 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' A' ' 35' ' ' ALA . 46.0 m170 -76.97 125.03 28.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.774 0.321 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.432 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . -35.71 120.8 0.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' HD2' ' A' ' 28' ' ' ARG . . . -35.78 -52.11 1.13 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.514 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.441 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 21.1 t30 -88.79 134.23 34.2 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.576 0.703 . . . . 0.0 110.93 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -1.49 8.53 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.691 2.261 . . . . 0.0 112.32 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.441 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 9.5 tpp85 -66.17 -49.65 66.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 35' ' ' ALA . 26.3 m-20 -139.78 112.15 7.58 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.593 0.711 . . . . 0.0 110.827 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HA ' ' HB3' ' A' ' 35' ' ' ALA . 54.0 Cg_endo -69.75 -0.01 6.28 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.664 2.243 . . . . 0.0 112.351 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 75.9 p -101.17 49.49 0.88 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.117 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -138.86 111.52 7.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.473 ' CG ' ' HA ' ' A' ' 31' ' ' ALA . 5.3 mp0 -84.75 3.19 38.61 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -53.98 153.43 9.06 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.503 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.439 HG21 HD12 ' A' ' 27' ' ' ILE . 48.6 mt -123.62 118.69 55.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.844 0.354 . . . . 0.0 111.117 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.75 147.51 50.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.701 HD13 HD11 ' A' ' 63' ' ' LEU . 95.3 mt -55.88 135.66 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.149 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.473 ' CB ' ' NH1' ' A' ' 28' ' ' ARG . 70.0 p -113.87 -13.39 12.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.853 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.517 ' N ' HG13 ' A' ' 65' ' ' VAL . 17.9 ttmm -170.38 161.23 7.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.684 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.08 121.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -68.01 139.27 92.89 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 110.871 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -29.91 23.26 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.716 2.277 . . . . 0.0 112.367 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.3 p -92.7 4.49 53.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -85.45 161.45 35.46 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.447 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -51.39 -39.55 57.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.795 0.331 . . . . 0.0 111.116 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.65 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -70.55 -59.36 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -38.69 -42.43 1.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 24.9 ptt180 -82.95 -30.09 28.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.8 0.333 . . . . 0.0 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 57' ' ' ALA . 48.2 t0 -45.9 -56.97 4.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.876 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.4 -20.23 40.43 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.36 -20.52 18.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.845 0.355 . . . . 0.0 110.865 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.701 HD11 HD13 ' A' ' 48' ' ' ILE . 1.1 tm? -89.55 134.35 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.569 ' N ' HD13 ' A' ' 63' ' ' LEU . 14.2 mmm-85 -143.15 154.12 43.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.887 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 51' ' ' VAL . 18.3 t -70.49 87.21 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.99 -17.35 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.499 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.547 HD12 HD22 ' A' ' 63' ' ' LEU . 18.0 mt -67.82 124.64 23.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 36.2 ttt180 -71.84 119.74 16.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.766 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -67.04 111.43 3.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.887 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 70' ' ' LEU . 2.0 mm? -86.79 -54.24 4.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.92 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -156.58 133.6 10.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.782 HG13 HD12 ' A' ' 96' ' ' LEU . 93.1 t -106.76 110.92 33.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.505 ' ND2' HG22 ' A' ' 92' ' ' VAL . 15.0 m-20 64.91 41.06 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 37.4 mt-30 63.86 31.55 13.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -129.38 91.24 3.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -46.4 138.97 5.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 18.2 mt -91.52 5.17 50.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.4 117.97 17.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 117.28 -39.62 2.6 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.544 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.461 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -82.8 167.36 18.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.888 0.375 . . . . 0.0 110.894 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.449 HG22 ' HB3' ' A' ' 31' ' ' ALA . 72.5 p -103.84 162.06 13.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.672 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.83 -56.02 0.47 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.04 55.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.525 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.441 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.7 mm-40 -69.04 -49.02 61.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.829 0.347 . . . . 0.0 110.875 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.461 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.87 -45.34 74.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.734 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.7 t -57.2 -58.18 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.487 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 66.6 mm-40 -52.09 -22.48 4.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.4 tt -79.37 -28.24 41.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.906 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.734 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.7 OUTLIER -83.76 -25.86 30.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.896 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.487 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.8 ptm180 -96.04 0.91 52.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.834 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 32.6 t -93.68 28.04 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.684 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.1 t -92.81 148.91 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.76 -77.76 1.3 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.499 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -125.16 -17.72 5.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.916 0.388 . . . . 0.0 110.869 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.814 HG23 ' O ' ' A' ' 15' ' ' ILE . 5.0 m -158.38 137.28 11.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.782 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -122.69 160.65 25.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.912 179.986 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.438 HG21 ' OE2' ' A' ' 12' ' ' GLU . 3.4 m -113.24 96.62 6.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.103 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.563 HG23 HG22 ' A' ' 100' ' ' VAL . 3.0 m -91.96 130.01 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.1 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.7 tp -97.08 17.77 16.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.872 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.766 HG12 HD22 ' A' ' 69' ' ' LEU . 35.9 m -49.38 178.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.443 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 1.9 p -167.62 161.58 13.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -60.77 102.28 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -92.56 -60.29 1.23 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.509 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -164.39 113.39 1.15 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.862 0.363 . . . . 0.0 110.883 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -54.79 -55.61 28.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.4 m 58.59 51.4 7.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -138.65 -126.89 2.44 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.483 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -7.24 20.57 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.343 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 96.0 p -53.0 -28.98 26.61 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 10.7 m -50.03 -52.59 32.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.842 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.481 -179.988 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 t -47.22 -58.68 3.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.868 0.366 . . . . 0.0 110.869 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 68.5 p -75.98 75.09 2.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -103.95 -71.45 0.85 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.514 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.3 m -98.29 142.75 29.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.876 0.37 . . . . 0.0 110.866 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 m -97.18 56.17 1.35 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.86 145.81 17.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.481 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 176.59 6.59 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.669 2.246 . . . . 0.0 112.315 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 169.26 -55.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.48 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.97 19.78 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -88.71 162.26 16.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.848 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.467 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -73.18 110.78 7.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.3 161.57 15.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.0 p -143.01 153.2 42.74 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.3 mt -121.85 120.94 62.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.111 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -93.12 110.59 22.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.575 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.1 179.75 4.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.764 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -59.18 166.4 2.84 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.566 0.698 . . . . 0.0 111.088 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.9 Cg_endo -69.71 -0.28 6.65 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.65 2.233 . . . . 0.0 112.369 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.59 29.34 0.22 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.688 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 52.2 tp10 -94.25 140.42 29.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.924 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 5.9 ptt-85 -82.95 120.57 25.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.715 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.99 -49.15 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.94 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.24 42.07 24.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 89' ' ' LEU . 1.5 pt -121.19 164.41 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.143 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.97 150.9 50.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.407 ' C ' ' HE2' ' A' ' 82' ' ' HIS . 30.2 pt -140.36 149.39 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.097 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 35.0 ptt180 -125.14 123.16 39.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.04 -141.87 8.49 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 119.34 133.62 4.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.475 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.443 ' O ' HG22 ' A' ' 81' ' ' THR . . . -70.82 112.1 6.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.741 0.305 . . . . 0.0 111.124 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 mtp180 70.11 27.83 4.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -99.26 -101.35 2.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 35' ' ' ALA . 9.7 p80 -128.52 116.37 19.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.826 0.346 . . . . 0.0 110.873 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.426 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -35.97 125.68 0.73 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.056 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.37 -52.57 0.87 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.0 m-20 -88.9 127.76 54.68 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.656 0.741 . . . . 0.0 110.877 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.8 Cg_endo -69.75 -43.57 2.58 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.729 2.286 . . . . 0.0 112.323 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.441 ' C ' ' O ' ' A' ' 38' ' ' PRO . 16.0 mmm180 -34.21 -70.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.846 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -119.06 119.89 31.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.632 0.729 . . . . 0.0 110.848 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -24.42 29.7 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.356 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 59.9 p -89.04 41.73 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.153 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -136.85 111.3 8.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.853 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.507 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 7.2 mp0 -101.3 71.36 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.912 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.88 162.5 24.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.459 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.7 mt -128.76 119.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.911 0.386 . . . . 0.0 111.152 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.5 OUTLIER -132.14 -179.94 5.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.905 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.832 HD13 HD11 ' A' ' 63' ' ' LEU . 69.9 mt -88.01 121.4 38.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.5 t -97.32 -17.36 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.453 ' HA ' HG21 ' A' ' 65' ' ' VAL . 12.3 ttmt -166.23 160.09 15.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 84.0 t -149.31 115.08 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.136 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.6 t -60.3 134.37 90.95 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.694 0.759 . . . . 0.0 110.859 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -19.52 35.75 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.702 2.268 . . . . 0.0 112.351 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 19.4 p -102.24 3.47 38.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.16 172.89 49.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.73 -39.7 85.57 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.808 0.337 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.689 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -69.3 -61.5 1.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.83 -39.94 2.07 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 14.5 ptt180 -82.24 -25.06 34.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 0.0 110.852 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.472 ' N ' ' O ' ' A' ' 57' ' ' ALA . 30.3 t0 -53.27 -62.01 1.93 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 111.57 -16.24 26.56 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.1 -29.05 11.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.872 0.367 . . . . 0.0 110.866 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.1 tm? -87.4 134.16 33.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.966 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.924 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.72 150.2 24.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.463 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 44.2 t -56.63 104.48 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.33 -13.25 1.62 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.454 HD12 HD22 ' A' ' 63' ' ' LEU . 87.7 mt -83.49 123.75 30.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.547 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 36.7 ttt180 -72.55 125.39 27.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.65 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -74.35 107.56 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.835 HD12 ' O ' ' A' ' 99' ' ' LEU . 70.3 mt -86.58 -48.91 7.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.958 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.443 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 20.0 mt-10 -158.92 138.47 11.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.734 HG13 HD12 ' A' ' 96' ' ' LEU . 93.0 t -112.99 110.37 31.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.8 m-20 65.49 40.55 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 36.5 mt-30 64.4 32.13 12.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.929 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -127.23 89.58 2.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.0 t -44.26 132.23 5.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.458 ' HA ' HD21 ' A' ' 80' ' ' LEU . 19.8 mt -79.4 0.07 30.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.416 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.7 OUTLIER -72.99 119.94 17.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 179.885 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.416 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 116.31 -34.73 4.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.562 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -92.42 158.8 15.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.902 -179.91 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.443 HG22 ' O ' ' A' ' 31' ' ' ALA . 49.5 p -92.04 178.94 5.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.407 ' HE2' ' C ' ' A' ' 27' ' ' ILE . 4.0 t-80 -50.06 -53.85 24.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.49 -48.69 63.89 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.484 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.468 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 22.4 mt-10 -61.04 -51.96 66.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.867 0.365 . . . . 0.0 110.887 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.562 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.19 -50.85 48.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.089 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.7 t -52.3 -58.84 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.479 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 59.9 mm-40 -53.11 -21.22 4.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.6 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.7 tt -78.03 -26.75 48.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.764 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -84.02 -28.47 27.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.479 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.3 ptm180 -93.72 1.19 56.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 46.3 t -96.24 33.1 1.81 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.841 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -111.28 136.53 47.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.163 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -57.46 -101.57 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.518 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -112.55 -3.71 14.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.868 0.366 . . . . 0.0 110.841 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 m -158.47 135.31 9.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.841 ' HB3' HG21 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -123.82 168.16 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.918 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.467 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -118.14 96.24 5.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.118 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -93.93 129.84 43.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.835 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.7 tp -99.18 25.19 7.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.934 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.65 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.7 m -62.43 166.84 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.119 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.9 p -158.37 152.84 24.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.446 ' HA ' HD23 ' A' ' 67' ' ' LEU . 3.8 m-20 -43.83 104.61 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.81 -41.81 5.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.53 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -144.96 106.75 4.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.86 0.362 . . . . 0.0 110.84 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -39.05 -39.02 0.51 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.864 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 t 44.76 41.83 5.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.856 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 64.81 121.02 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -50.61 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.257 . . . . 0.0 112.343 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 49.0 m -73.61 146.12 44.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 69.9 p -50.4 126.18 14.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.469 -179.997 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.6 t -61.1 88.69 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.893 0.378 . . . . 0.0 110.859 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 t -71.33 142.71 50.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.845 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.04 147.71 49.62 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.9 m -92.0 166.03 12.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.89 0.376 . . . . 0.0 110.843 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 30.4 t -105.27 -73.36 0.68 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.59 87.36 1.14 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.5 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 176.79 6.3 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.365 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 163.06 -27.78 0.24 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.457 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.693 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -94.98 28.07 2.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' HD12 ' A' ' 99' ' ' LEU . 1.0 OUTLIER -98.02 171.43 8.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.409 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 41.4 tt0 -74.39 108.45 7.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.23 158.02 21.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.923 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.9 p -137.83 148.68 45.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 57' ' ' ALA . 40.7 mt -114.18 96.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -69.2 112.95 6.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.437 ' HZ1' ' CD2' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.71 172.6 9.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -60.62 164.35 7.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.547 0.689 . . . . 0.0 111.091 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.717 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.77 2.41 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.329 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 24.74 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.774 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 9.1 tp10 -95.4 132.13 40.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.91 0.386 . . . . 0.0 110.892 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.441 ' O ' ' C ' ' A' ' 23' ' ' LEU . 67.2 mtt180 -82.35 118.49 23.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.872 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.783 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.19 -51.63 0.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.952 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.82 28.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.5 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.612 HG12 HD12 ' A' ' 23' ' ' LEU . 1.4 pt -119.42 170.36 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 111.143 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -132.61 166.86 21.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.44 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 19.7 pt -155.41 145.05 12.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ptt180 -124.02 124.76 43.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.76 -148.5 19.03 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.47 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 121.68 140.51 5.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.524 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.931 ' O ' HG22 ' A' ' 81' ' ' THR . . . -88.38 117.98 27.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.82 0.343 . . . . 0.0 111.125 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 58.3 mtp180 63.08 39.34 10.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.76 -88.57 0.48 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.514 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -116.21 119.67 36.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -48.0 124.56 7.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.096 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.38 -49.98 7.79 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.477 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.4 m-20 -118.31 140.76 28.53 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.587 0.708 . . . . 0.0 110.907 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.4 Cg_endo -69.77 -50.55 0.45 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.328 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.44 ' C ' ' O ' ' A' ' 38' ' ' PRO . 23.4 tpt180 -34.25 -72.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 48.0 m-20 -121.14 119.72 29.53 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.655 0.74 . . . . 0.0 110.854 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -1.41 8.42 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.3 p -85.56 26.93 0.88 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -124.31 114.21 19.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -113.66 28.43 8.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.61 144.04 43.21 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.449 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.47 HG12 ' N ' ' A' ' 30' ' ' GLY . 39.5 mt -115.34 119.49 61.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.867 0.365 . . . . 0.0 111.131 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.608 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -133.09 -174.7 3.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.918 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.76 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -90.48 128.4 42.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.6 t -105.21 -12.95 15.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' O ' ' N ' ' A' ' 26' ' ' SER . 39.4 ttmt -175.79 139.7 0.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.76 HG21 HD12 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -146.14 118.38 2.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.868 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 18.2 t -48.01 134.08 11.75 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.675 0.75 . . . . 0.0 110.881 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -16.12 37.39 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.728 2.286 . . . . 0.0 112.319 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.67 -6.98 13.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.173 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -63.79 174.24 11.84 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.468 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.511 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -52.88 -37.13 60.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.783 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -80.8 -60.38 2.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.115 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -36.56 -47.25 1.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.478 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.478 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 21.1 ptt180 -69.72 -36.4 75.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.36 . . . . 0.0 110.897 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ALA . 28.7 t70 -39.91 -56.12 1.87 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.81 -22.78 15.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -95.29 -44.66 7.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.841 0.353 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.76 HD11 HD13 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -58.11 145.12 37.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 -179.956 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.724 ' N ' HD13 ' A' ' 63' ' ' LEU . 12.2 ptt-85 -175.23 146.61 0.85 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.483 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 57.4 t -57.89 105.49 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.106 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.72 -25.56 2.42 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.451 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.714 HD23 ' C ' ' A' ' 101' ' ' CYS . 11.4 mt -69.74 118.41 12.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.796 0.332 . . . . 0.0 110.933 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.551 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 25.4 ttt180 -68.85 123.25 20.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.576 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -74.24 110.03 8.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.933 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.434 ' HA ' HD13 ' A' ' 70' ' ' LEU . 2.1 mm? -85.61 -50.47 7.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -152.47 139.73 19.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.677 HG13 HD12 ' A' ' 96' ' ' LEU . 97.0 t -114.42 109.53 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.092 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.522 ' ND2' HG22 ' A' ' 92' ' ' VAL . 9.7 m-20 65.64 40.88 4.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 63.62 34.07 12.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 33.2 mt-30 -130.69 92.19 3.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 t -43.97 129.72 5.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.674 HD11 HG23 ' A' ' 72' ' ' VAL . 16.8 mt -89.65 10.14 24.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.884 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.576 HD13 ' N ' ' A' ' 79' ' ' GLY . 1.5 tm? -80.88 122.57 27.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.576 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.15 -33.51 5.68 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.541 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -85.82 164.2 17.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.93 -179.934 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.931 HG22 ' O ' ' A' ' 31' ' ' ALA . 75.2 p -98.66 160.59 14.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.44 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.7 t-80 -33.67 -55.76 0.45 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -55.1 -46.99 76.17 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.466 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -62.86 -44.34 96.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 110.89 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.525 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -62.26 -51.77 66.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.56 ' HA ' HD23 ' A' ' 89' ' ' LEU . 38.2 t -49.45 -61.5 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.111 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.49 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 86.6 mm-40 -47.41 -24.08 0.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.556 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.4 tt -78.39 -33.03 49.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.897 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.597 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -78.9 -30.27 44.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 179.923 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.49 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.5 ptm180 -90.14 4.48 50.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.84 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.0 t -97.2 19.35 13.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 96' ' ' LEU . 26.1 t -82.14 150.54 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.64 -78.9 1.43 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -120.31 -22.35 6.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -160.23 131.94 6.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.134 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.677 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -113.09 171.5 7.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.409 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.0 m -121.19 97.65 5.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.3 m -95.54 130.13 44.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.7 tp -104.11 33.9 3.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.576 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.4 m -66.51 -179.27 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.714 ' C ' HD23 ' A' ' 67' ' ' LEU . 1.2 p -173.09 158.15 3.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.46 104.42 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.897 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -91.82 -48.87 3.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -163.95 119.52 1.59 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.776 0.322 . . . . 0.0 110.891 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -63.62 131.77 49.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.888 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 38.3 p -43.65 -49.93 7.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.914 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.61 -166.22 42.21 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 108.74 2.14 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.734 2.289 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.8 t -54.77 -46.47 74.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.828 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 59.1 m -69.59 167.94 15.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.814 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.986 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.6 t -113.21 117.28 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.894 0.378 . . . . 0.0 110.859 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.5 m -86.53 148.85 25.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.837 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.81 -157.96 13.82 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.472 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.5 t -92.51 82.23 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.85 0.357 . . . . 0.0 110.833 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.9 m -121.73 43.77 2.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.839 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.23 79.72 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.474 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 156.15 64.17 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.707 2.272 . . . . 0.0 112.346 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.04 -37.01 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.444 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.53 16.12 1.83 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.812 0.339 . . . . 0.0 110.933 -179.935 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.5 mmt180 -85.63 160.92 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.918 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -70.44 113.82 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 19.6 mt -114.54 172.32 7.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.9 p -151.59 159.32 44.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.479 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 72.5 mt -129.12 112.43 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -80.33 127.44 32.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -139.92 173.62 11.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.851 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -61.4 169.18 2.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.593 0.711 . . . . 0.0 111.091 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.851 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.77 -3.07 11.29 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.333 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 34.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.623 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.8 tp10 -101.17 137.89 38.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.865 0.364 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.482 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.3 mtp180 -81.86 118.68 23.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.859 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.736 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.55 -43.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.937 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.92 40.89 42.8 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.727 HD11 HD13 ' A' ' 89' ' ' LEU . 1.2 pt -119.92 161.62 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -130.6 135.68 48.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.625 HD12 HG21 ' A' ' 46' ' ' ILE . 18.2 pt -129.56 156.41 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -132.73 132.93 42.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.36 -137.72 5.84 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.68 155.43 10.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.469 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.509 ' HB3' HG22 ' A' ' 81' ' ' THR . . . -63.74 -6.24 5.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.805 0.336 . . . . 0.0 111.083 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 33' ' ' GLY . 9.6 mmt85 -134.26 -33.59 1.0 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.909 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -34.02 109.37 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.504 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' C ' ' A' ' 35' ' ' ALA . 36.0 m170 -36.1 129.01 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 110.885 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . 35.06 41.6 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.073 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 35' ' ' ALA . . . -35.04 -49.18 0.79 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -79.52 126.53 80.66 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.656 0.741 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 0.59 5.42 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.702 2.268 . . . . 0.0 112.328 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -115.94 -49.19 2.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.433 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 0.7 OUTLIER -116.05 107.5 47.75 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.588 0.708 . . . . 0.0 110.9 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 53.5 Cg_endo -69.78 -13.85 35.2 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.347 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.8 t -102.41 5.98 39.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.117 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -122.46 110.84 16.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.899 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.429 ' H ' ' CD ' ' A' ' 44' ' ' GLU . 4.7 mp0 -63.56 83.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -107.76 164.13 12.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.625 HG21 HD12 ' A' ' 27' ' ' ILE . 26.4 mt -132.34 117.02 30.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 111.142 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.09 155.77 45.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.818 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.897 HD13 HD11 ' A' ' 63' ' ' LEU . 77.7 mt -64.57 126.32 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.156 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -105.37 -18.25 14.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.508 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.9 tttp -165.76 154.35 11.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 25' ' ' ILE . 98.1 t -145.27 124.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -68.05 133.15 91.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.67 0.748 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -8.35 23.37 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.645 2.23 . . . . 0.0 112.332 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 54.9 p -111.13 -9.58 14.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.68 168.53 51.32 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.55 -35.01 67.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.78 0.324 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.736 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.33 -65.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.103 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.79 -40.08 2.08 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -77.01 -28.45 55.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.796 0.331 . . . . 0.0 110.892 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 57' ' ' ALA . 9.9 t0 -54.28 -64.03 0.96 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.06 -24.23 6.36 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -92.46 -66.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.813 0.339 . . . . 0.0 110.833 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.897 HD11 HD13 ' A' ' 48' ' ' ILE . 1.4 tm? -48.34 118.02 2.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.579 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.2 ptp180 -142.69 154.85 44.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.508 HG21 ' HA ' ' A' ' 50' ' ' LYS . 63.1 t -61.31 106.06 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 147.68 -27.18 1.48 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.459 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.735 HD23 HG23 ' A' ' 100' ' ' VAL . 7.6 mp -74.79 140.62 44.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.773 0.32 . . . . 0.0 110.892 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 57.2 ttt180 -87.61 121.01 29.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.826 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.599 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.0 mm? -67.87 105.97 2.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.949 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.438 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 1.7 mm? -80.15 -50.43 10.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 24.2 mt-10 -159.17 142.92 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.908 HG13 HD12 ' A' ' 96' ' ' LEU . 95.6 t -114.75 109.6 29.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.131 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.1 m-20 65.38 41.77 4.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 28.4 mt-30 64.6 34.04 10.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.26 90.59 3.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.941 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.421 ' O ' HD21 ' A' ' 80' ' ' LEU . 38.5 t -46.1 129.19 9.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.879 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.456 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.0 mt -78.82 -0.49 30.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.06 116.7 17.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.59 -34.7 4.28 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.457 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.498 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -88.48 170.9 10.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.888 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.509 HG22 ' HB3' ' A' ' 31' ' ' ALA . 42.0 p -107.8 160.92 15.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.095 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.486 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 t-80 -32.97 -53.5 0.36 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.87 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.28 -49.96 57.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.416 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 3.1 mm-40 -64.38 -45.41 87.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.844 0.354 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.498 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.67 -47.51 82.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 82' ' ' HIS . 78.6 t -59.25 -58.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 74.7 mm-40 -51.24 -26.06 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.1 tt -72.3 -29.24 63.67 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.962 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.727 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.5 -29.59 46.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.895 179.883 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 2.4 ptm85 -92.51 0.77 57.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 21.6 t -98.99 36.24 1.73 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.88 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.552 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.1 p -111.6 144.94 18.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.09 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.8 -105.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 19' ' ' PRO . 1.3 t70 -103.39 -3.33 25.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.912 0.386 . . . . 0.0 110.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.469 ' C ' HG21 ' A' ' 92' ' ' VAL . 49.8 m -166.14 143.08 5.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.908 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.8 168.41 11.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -120.33 98.18 5.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.16 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.469 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.2 m -98.65 130.37 47.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.104 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.4 tp -96.4 21.49 9.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.735 HG23 HD23 ' A' ' 67' ' ' LEU . 3.0 m -52.26 -175.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.106 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.5 p -175.96 157.58 1.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -52.65 100.82 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.32 -56.47 1.79 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.465 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -166.08 110.61 0.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 110.847 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -67.16 114.37 5.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.904 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.7 t -57.42 -44.02 84.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.897 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 141.61 146.02 4.64 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.486 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 173.84 10.34 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.708 2.272 . . . . 0.0 112.4 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 22.8 t -167.66 147.33 5.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.829 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 31.0 m -133.8 165.44 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.5 -179.964 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.1 t -84.99 112.05 20.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.869 0.366 . . . . 0.0 110.881 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.7 m -87.29 118.82 26.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.863 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.73 -158.61 28.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.4 t -45.19 106.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.85 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 79.1 p -42.24 -57.08 2.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 138.18 149.8 5.56 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.444 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.77 134.96 29.23 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.642 2.228 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 176.49 -28.48 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.521 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.701 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.3 29.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.796 0.332 . . . . 0.0 110.914 -179.924 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 11' ' ' ARG . 23.1 mtm105 -96.32 142.36 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.442 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.5 tt0 -53.35 114.9 1.65 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.69 163.49 16.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.943 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.7 p -146.09 153.72 41.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.427 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 82.7 mt -120.95 110.34 27.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.083 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -85.11 102.45 13.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.464 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 3.4 ptpp? -112.33 171.56 7.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.854 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.842 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.72 168.79 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.619 0.723 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.842 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.85 0.95 4.97 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.321 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.61 41.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.507 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 48.9 tp10 -105.66 140.53 38.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.467 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.3 ptm180 -86.36 122.78 30.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.824 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.851 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.16 -46.9 0.17 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.32 44.76 51.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.911 HG22 HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -118.68 168.04 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.854 0.359 . . . . 0.0 111.111 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.8 m -133.75 147.16 51.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.52 HD12 HG21 ' A' ' 46' ' ' ILE . 28.7 pt -138.32 155.63 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.152 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.5 ptt180 -126.83 124.54 39.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.857 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.55 -147.15 15.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.04 152.39 10.69 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -74.16 4.65 5.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.757 0.313 . . . . 0.0 111.08 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.452 ' HD3' HG21 ' A' ' 81' ' ' THR . 28.9 ptt85 -131.05 16.53 5.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.28 164.67 14.43 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.5 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.45 ' O ' ' C ' ' A' ' 35' ' ' ALA . 54.7 p-80 -70.89 127.07 31.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.844 0.355 . . . . 0.0 110.852 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -34.24 123.9 0.5 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -55.3 -25.57 41.0 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.484 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -111.23 135.91 20.92 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.608 0.718 . . . . 0.0 110.919 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 -1.17 7.96 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.322 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 10.1 tpp180 -65.71 -69.79 0.28 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.72 120.98 31.11 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.641 0.734 . . . . 0.0 110.859 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.71 29.24 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.7 2.267 . . . . 0.0 112.302 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 77.9 p -105.17 55.71 0.69 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.139 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -137.79 112.25 8.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -89.25 34.16 0.8 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.16 149.26 49.92 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.497 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.52 HG21 HD12 ' A' ' 27' ' ' ILE . 26.8 mt -126.85 116.99 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.111 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.553 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -129.13 153.85 47.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.636 HD13 HD11 ' A' ' 63' ' ' LEU . 23.5 mt -62.78 138.26 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.1 t -118.18 -16.91 9.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.848 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.53 ' HA ' HG21 ' A' ' 65' ' ' VAL . 64.9 tttt -165.22 146.96 7.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.889 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 25' ' ' ILE . 32.4 t -142.11 133.62 26.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.168 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 7.8 t -74.7 141.79 76.31 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.681 0.753 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -31.21 20.96 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.663 2.242 . . . . 0.0 112.324 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 47.8 p -93.56 -6.66 46.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.151 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.9 150.63 46.37 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.72 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -40.88 -31.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.809 0.338 . . . . 0.0 111.098 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.8 -65.55 0.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.088 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -41.11 -34.44 0.88 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -90.82 -23.22 20.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.478 ' N ' ' O ' ' A' ' 57' ' ' ALA . 10.7 t0 -52.58 -52.24 56.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.34 -7.94 40.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.518 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -115.39 -48.61 2.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.869 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -67.39 130.84 44.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.598 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -161.52 157.41 24.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.849 179.968 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.53 HG21 ' HA ' ' A' ' 50' ' ' LYS . 80.5 t -59.67 105.89 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.31 -15.58 1.67 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.61 HD23 ' HA ' ' A' ' 102' ' ' ASP . 58.1 mt -85.45 134.27 34.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.553 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 72.3 ttt180 -84.1 121.79 27.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.69 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -70.28 116.14 10.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 99' ' ' LEU . 71.6 mt -96.87 -49.42 5.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.94 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -155.13 141.75 18.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.694 HG13 HD12 ' A' ' 96' ' ' LEU . 78.4 t -118.73 108.27 23.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.075 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 72' ' ' VAL . 15.0 m-20 65.7 40.91 4.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 64.01 35.21 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -131.07 91.1 2.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.4 t -42.4 128.79 3.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.548 ' HA ' HD11 ' A' ' 80' ' ' LEU . 9.9 mt -80.68 9.01 6.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.933 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.679 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -83.09 137.6 34.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.679 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 97.76 -33.22 6.05 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.489 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.548 HD11 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -88.08 166.96 14.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.887 0.375 . . . . 0.0 110.91 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.452 HG21 ' HD3' ' A' ' 32' ' ' ARG . 33.0 p -106.92 165.43 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.512 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.82 -60.54 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.53 -47.68 22.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.3 mt-10 -66.01 -53.01 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.853 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.401 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -49.4 -49.35 45.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.1 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.2 t -59.1 -57.06 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -53.04 -17.51 1.54 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.5 tt -83.98 -28.08 28.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.834 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -84.12 -27.4 28.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.9 ptm180 -97.03 5.74 49.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 m -102.27 32.43 3.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.885 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.5 p -111.11 140.04 32.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.117 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -56.56 -100.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.451 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -113.17 -10.56 13.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.906 0.384 . . . . 0.0 110.868 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.1 m -151.64 135.39 16.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.131 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.803 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -124.17 171.26 9.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.442 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.4 m -120.69 96.6 5.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.2 m -94.25 128.64 45.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.162 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.686 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.6 tp -97.11 29.07 3.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.69 HG12 HD22 ' A' ' 69' ' ' LEU . 14.0 m -58.48 172.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.115 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.8 p -162.27 148.47 13.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.61 ' HA ' HD23 ' A' ' 67' ' ' LEU . 4.9 m-20 -51.16 110.62 0.45 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -100.25 -54.7 1.01 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -165.31 116.09 1.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.866 0.365 . . . . 0.0 110.861 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -62.98 -49.55 74.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 25.1 p 41.06 32.14 0.16 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.83 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.402 ' HA3' ' HD2' ' A' ' 108' ' ' PRO . . . -126.59 -150.6 7.6 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.526 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.402 ' HD2' ' HA3' ' A' ' 107' ' ' GLY . 53.6 Cg_endo -69.8 121.43 8.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.709 2.273 . . . . 0.0 112.312 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 7.2 m -116.42 113.29 22.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.4 t -79.88 -47.26 15.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.884 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.467 179.972 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -130.62 129.98 43.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.847 0.356 . . . . 0.0 110.879 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.1 p -81.57 13.79 2.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.96 105.49 0.18 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.492 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.5 t -116.66 88.96 3.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.849 0.356 . . . . 0.0 110.858 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -59.84 103.11 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.59 162.36 27.34 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.469 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 172.35 12.78 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.714 2.276 . . . . 0.0 112.326 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.29 -52.44 0.13 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.531 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.706 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.21 33.94 0.51 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 110.939 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.822 ' O ' HD12 ' A' ' 13' ' ' LEU . 20.5 mtt-85 -99.28 165.03 11.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 42.1 tt0 -77.84 110.18 12.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.822 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -115.27 166.12 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.93 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.4 p -146.89 160.9 41.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.8 mt -124.1 115.17 44.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mp0 -85.21 113.11 21.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.6 ptpp? -126.89 165.41 19.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.65 169.12 0.13 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.78 -2.84 10.87 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.36 38.28 0.33 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.556 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.69 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 28.2 tp10 -103.53 140.64 37.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.815 0.34 . . . . 0.0 110.909 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.453 ' O ' ' C ' ' A' ' 23' ' ' LEU . 6.2 ptt85 -83.27 121.22 26.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.87 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -33.9 -54.12 0.47 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.37 40.51 9.98 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.439 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.928 HD11 HD13 ' A' ' 89' ' ' LEU . 4.1 pt -120.22 169.72 11.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.146 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.4 m -141.17 145.07 35.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.566 HD12 ' CG2' ' A' ' 46' ' ' ILE . 30.7 pt -134.85 158.96 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -131.4 133.29 45.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.73 -142.61 10.08 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 119.69 142.79 6.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.499 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.428 ' HB3' HG22 ' A' ' 81' ' ' THR . . . -51.12 -16.73 0.51 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 111.139 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmm180 -127.44 -38.8 1.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -41.88 152.61 0.17 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.469 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -44.35 123.32 3.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.825 0.345 . . . . 0.0 110.841 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -44.85 123.59 3.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.98 -42.38 6.48 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.462 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -91.89 120.11 68.08 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.618 0.723 . . . . 0.0 110.889 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 1.37 4.46 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.722 2.281 . . . . 0.0 112.405 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -84.8 -64.2 1.2 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.48 124.57 32.28 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.595 0.712 . . . . 0.0 110.866 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -10.9 29.67 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.659 2.239 . . . . 0.0 112.353 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 68.2 p -89.11 41.08 1.01 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.096 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -134.92 89.49 2.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.875 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.439 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 5.9 mp0 -90.13 30.08 1.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.885 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.08 162.38 31.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.566 ' CG2' HD12 ' A' ' 27' ' ' ILE . 40.2 mt -129.51 118.34 45.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.864 0.364 . . . . 0.0 111.151 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -132.17 -177.74 4.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.932 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -87.57 133.82 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.142 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -113.59 -14.55 12.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 24.6 tttm -172.51 145.21 1.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.944 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.596 HG12 HG23 ' A' ' 65' ' ' VAL . 0.6 OUTLIER -152.92 110.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.15 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.4 t -53.83 129.6 56.12 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.678 0.751 . . . . 0.0 110.85 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.403 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.5 Cg_endo -69.78 -6.36 18.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.712 2.274 . . . . 0.0 112.29 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 32.2 p -105.07 -18.43 14.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.173 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.24 179.81 14.15 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.49 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.441 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -57.69 -39.1 76.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.762 0.315 . . . . 0.0 111.08 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.87 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.99 -63.65 1.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.14 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.46 -48.56 1.69 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.441 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.441 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.5 ptt180 -70.63 -31.17 68.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 57' ' ' ALA . 31.2 t0 -44.55 -61.62 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.838 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.38 -20.34 10.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.477 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.6 mmp_? -99.61 -47.47 5.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.896 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.932 HD11 HD13 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -61.11 130.36 45.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.936 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.64 ' N ' HD13 ' A' ' 63' ' ' LEU . 16.8 ptt85 -162.01 146.0 12.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.596 HG23 HG12 ' A' ' 51' ' ' VAL . 82.7 t -53.87 106.58 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.156 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 143.09 -11.42 2.31 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.48 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.474 HD12 ' H ' ' A' ' 64' ' ' ARG . 34.6 mt -86.52 124.02 32.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.854 0.359 . . . . 0.0 110.922 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.533 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 57.5 ttt180 -75.23 117.49 17.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.733 HD22 HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -71.45 114.24 9.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.526 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.5 mt -90.43 -54.76 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.975 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -150.1 143.34 25.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 95.2 t -115.94 110.13 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.127 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 65.62 41.12 4.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.7 mt-30 64.43 30.46 13.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.956 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 22.8 mt-30 -124.64 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 t -44.04 133.87 4.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.811 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.756 ' HA ' HD21 ' A' ' 80' ' ' LEU . 13.3 mt -88.94 7.63 33.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.421 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.9 OUTLIER -77.31 116.16 17.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.76 -33.25 5.3 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.463 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.756 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -86.4 164.54 16.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.91 0.386 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.428 HG22 ' HB3' ' A' ' 31' ' ' ALA . 81.9 p -104.1 165.51 11.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.167 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -34.7 -59.92 0.46 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.834 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.09 -49.85 23.3 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.9 mt-10 -63.02 -51.7 65.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.89 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.46 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -52.01 -51.75 55.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.117 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.549 ' HA ' HD23 ' A' ' 89' ' ' LEU . 69.2 t -53.15 -60.45 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 78.1 mm-40 -50.36 -26.17 4.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.3 tt -74.04 -29.95 62.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.923 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.928 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -79.84 -27.11 40.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 0.6 OUTLIER -96.96 -3.17 42.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.86 179.94 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.4 m -89.76 29.94 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.872 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.76 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -110.45 144.04 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.17 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.94 -101.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -111.39 -6.67 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.897 0.379 . . . . 0.0 110.854 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.7 m -155.24 136.47 13.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -126.49 167.2 15.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.983 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.41 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -116.54 94.52 4.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.175 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.5 m -91.05 127.15 43.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.162 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.526 ' O ' HD12 ' A' ' 70' ' ' LEU . 19.1 tp -95.97 33.03 1.77 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.878 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.733 HG12 HD22 ' A' ' 69' ' ' LEU . 5.9 m -60.98 174.62 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.146 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -167.78 155.12 8.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.83 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.417 ' HA ' HD23 ' A' ' 67' ' ' LEU . 5.6 p-10 -51.5 107.6 0.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.852 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -97.72 -54.98 1.18 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.467 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.413 ' O ' ' C ' ' A' ' 105' ' ' GLU . 2.5 p90 -166.41 110.06 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.824 0.345 . . . . 0.0 110.851 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 104' ' ' PHE . 3.3 mp0 -37.61 -57.03 0.99 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.919 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 80.1 p 49.91 41.76 23.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.4 120.53 2.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 132.1 22.59 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.68 2.254 . . . . 0.0 112.343 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.1 m -59.84 122.79 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.863 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.5 m -162.95 146.06 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.832 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.486 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 t -94.75 -40.25 9.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.821 0.343 . . . . 0.0 110.836 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 m -117.35 72.48 0.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.824 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 67.62 -100.39 0.61 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.481 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 72.7 m -63.6 175.28 1.11 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.889 0.376 . . . . 0.0 110.866 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.4 m -85.03 173.0 10.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.889 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.73 166.49 22.69 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 158.47 56.88 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.388 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -156.79 -46.88 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.733 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.43 30.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.328 . . . . 0.0 110.907 -179.916 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.411 ' O ' HD12 ' A' ' 99' ' ' LEU . 25.4 mtp180 -94.95 161.37 14.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -70.92 112.17 6.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.873 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.6 mt -116.88 159.52 22.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.581 ' SG ' HG23 ' A' ' 97' ' ' THR . 3.0 m -142.45 159.66 41.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 23' ' ' LEU . 40.5 mt -125.58 114.57 40.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.173 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -88.6 107.66 19.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.511 ' CB ' ' HB2' ' A' ' 56' ' ' ALA . 1.0 OUTLIER -116.18 166.14 12.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.836 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.25 168.72 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.578 0.704 . . . . 0.0 111.097 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.836 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.79 3.35 2.83 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.703 2.268 . . . . 0.0 112.334 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -169.79 36.24 0.18 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.462 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.614 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.7 tp10 -105.47 142.52 35.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.889 0.376 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' O ' ' C ' ' A' ' 23' ' ' LEU . 58.8 mtt180 -88.94 123.37 33.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.829 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.86 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.49 -49.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 77.41 32.48 47.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.487 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.697 HG23 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -108.87 160.0 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.817 0.342 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.495 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -123.6 150.61 43.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 27.5 pt -140.36 150.92 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -128.47 131.85 48.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.9 -144.85 13.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 133.74 140.67 4.38 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.481 ' CB ' ' O ' ' A' ' 80' ' ' LEU . . . -59.84 -6.21 1.19 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.787 0.327 . . . . 0.0 111.13 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.458 ' O ' ' C ' ' A' ' 33' ' ' GLY . 22.9 mmm-85 -130.96 -31.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.869 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' O ' ' N ' ' A' ' 35' ' ' ALA . . . -33.88 124.14 0.41 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.462 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -37.55 -29.5 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.777 0.323 . . . . 0.0 110.806 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 33' ' ' GLY . . . -168.67 158.59 9.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -145.63 -39.35 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.532 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.432 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 32.4 t30 -110.87 132.14 21.78 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.581 0.705 . . . . 0.0 110.921 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -10.47 28.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.708 2.272 . . . . 0.0 112.358 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.432 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 23.5 mmm180 -91.73 -49.76 6.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -119.57 92.66 46.44 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.629 0.728 . . . . 0.0 110.841 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 -17.44 37.85 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.728 2.286 . . . . 0.0 112.348 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.3 t -97.94 11.62 36.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 45' ' ' GLY . 5.2 t0 -126.39 109.92 12.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' ' 30' ' ' GLY . 19.5 mm-40 -57.14 84.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 43' ' ' ASP . . . -105.48 153.46 17.21 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.453 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 26.8 mt -128.83 116.43 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.871 0.367 . . . . 0.0 111.133 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.554 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.6 m-85 -131.13 153.26 49.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.731 HD13 HD11 ' A' ' 63' ' ' LEU . 70.3 mt -62.67 128.22 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.4 t -107.13 -18.89 13.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.4 tttp -159.89 153.41 22.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 50' ' ' LYS . 78.7 t -143.28 127.52 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 29.1 t -66.24 140.29 96.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.726 0.774 . . . . 0.0 110.813 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -35.66 12.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.721 2.281 . . . . 0.0 112.328 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.02 -1.43 45.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.092 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -73.11 148.83 41.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.501 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.513 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -39.86 -35.18 0.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.82 0.343 . . . . 0.0 111.119 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.86 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.11 -59.66 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.082 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -47.89 -33.18 9.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.475 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.6 ptt-85 -84.97 -32.26 23.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 11.1 t0 -50.1 -61.57 2.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.839 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.22 -18.74 13.76 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.501 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -96.71 -42.81 7.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.828 0.347 . . . . 0.0 110.89 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.772 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.2 tm? -69.83 136.54 50.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.631 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -166.67 155.26 10.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 50' ' ' LYS . 85.2 t -61.25 105.55 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.45 -24.74 1.22 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.533 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.462 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.7 mt -74.85 135.88 41.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.554 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 45.8 ttt180 -85.69 117.59 24.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.873 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.782 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -68.11 116.07 8.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.8 mt -94.09 -52.29 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -152.13 145.71 24.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.873 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.874 HG13 HD12 ' A' ' 96' ' ' LEU . 75.9 t -119.5 108.38 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.118 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.5 m-20 65.12 41.54 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.9 mt-30 64.07 32.11 13.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 9.8 mt-30 -125.35 91.11 3.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 t -47.82 126.41 10.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD21 ' A' ' 80' ' ' LEU . 11.4 mt -78.04 -0.37 27.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.863 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.37 115.38 11.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.922 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.93 -34.4 4.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.479 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.552 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -90.99 164.01 14.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.841 0.353 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 82' ' ' HIS . 38.1 p -102.18 163.39 12.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -34.32 -58.33 0.47 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.837 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.33 -45.68 21.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.46 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 10.3 mm-40 -70.93 -53.46 14.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.853 0.359 . . . . 0.0 110.838 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.533 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.03 -49.01 21.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.049 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.565 ' HA ' HD23 ' A' ' 89' ' ' LEU . 70.0 t -57.34 -59.12 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.489 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 83.3 mm-40 -51.08 -22.79 2.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.917 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.557 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.62 -31.83 60.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.627 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.87 -27.93 49.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.962 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.489 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.9 ptm180 -94.41 1.5 55.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.866 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.9 t -94.62 30.92 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.583 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -113.17 146.48 17.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.13 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.62 -95.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -119.55 -2.08 10.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.912 0.387 . . . . 0.0 110.9 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 m -157.14 132.01 8.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.874 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -122.95 164.37 18.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.944 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.581 HG23 ' SG ' ' A' ' 14' ' ' CYS . 1.6 m -113.07 94.14 4.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.443 HG12 HD11 ' A' ' 96' ' ' LEU . 3.2 m -90.74 129.04 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.615 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.0 tp -98.51 29.81 3.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.956 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.782 HG12 HD22 ' A' ' 69' ' ' LEU . 15.7 m -54.42 179.19 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 3.3 p -171.52 148.75 2.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -41.19 113.61 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.849 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.19 -47.31 2.87 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.467 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.427 ' O ' ' C ' ' A' ' 105' ' ' GLU . 1.3 m-85 -144.99 116.66 8.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.821 0.343 . . . . 0.0 110.915 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.427 ' C ' ' O ' ' A' ' 104' ' ' PHE . 6.4 mp0 -36.28 -47.95 0.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.885 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.5 m 48.43 47.87 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.85 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -95.04 -167.12 35.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -32.19 19.04 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.728 2.285 . . . . 0.0 112.347 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 110' ' ' SER . 77.3 p -59.57 151.01 25.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 109' ' ' SER . 77.5 p -37.29 -44.97 0.63 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.506 -179.961 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.8 m -107.33 -45.01 4.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 110.848 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.7 m -86.21 128.3 34.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.877 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 169.47 -89.71 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 p -72.88 -4.84 34.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.909 0.385 . . . . 0.0 110.86 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.0 m -122.48 94.84 4.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.858 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.15 87.11 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 2.251 . . . . 0.0 112.352 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.445 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . -140.75 -36.79 0.1 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.448 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.734 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.37 41.39 0.61 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.794 0.331 . . . . 0.0 110.889 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.7 mmm180 -111.34 152.37 27.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.484 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 19.0 tt0 -68.38 109.18 3.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.909 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.6 mt -106.52 168.72 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -151.4 147.85 27.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 95' ' ' THR . 71.1 mt -118.66 120.23 63.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -88.46 125.61 34.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.8 ptpp? -138.68 168.56 19.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.844 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -48.69 168.9 0.17 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.585 0.707 . . . . 0.0 111.122 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.844 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.7 2.02 3.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.672 2.248 . . . . 0.0 112.379 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.58 35.53 0.17 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.7 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 21.5 tp10 -99.02 149.74 22.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' C ' ' A' ' 23' ' ' LEU . 86.4 mtt180 -89.46 121.6 31.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -32.91 -46.55 0.15 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.5 42.55 17.7 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.766 HG22 HG13 ' A' ' 51' ' ' VAL . 2.6 pt -126.01 168.66 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.842 0.353 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -138.91 142.73 38.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.492 HD12 HG21 ' A' ' 46' ' ' ILE . 39.6 pt -128.82 163.08 34.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.488 ' CG ' ' HB3' ' A' ' 49' ' ' SER . 22.6 ptt180 -134.56 124.71 25.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 158.81 -143.17 8.99 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 126.01 147.23 6.84 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -71.49 2.83 4.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.77 0.319 . . . . 0.0 111.132 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 79.7 mtt180 -135.01 14.62 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.61 154.71 21.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.503 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.457 ' O ' ' C ' ' A' ' 35' ' ' ALA . 13.5 m170 -72.15 125.77 28.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.779 0.323 . . . . 0.0 110.877 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 37' ' ' ASN . . . -32.38 108.01 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.147 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' A' ' 35' ' ' ALA . . . -34.32 -32.57 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.471 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.494 ' N ' ' O ' ' A' ' 35' ' ' ALA . 7.8 p-10 -89.0 146.89 37.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.77 9.01 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.717 2.278 . . . . 0.0 112.368 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 19.0 ttt180 -51.08 -72.18 0.05 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -143.4 107.06 5.15 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.588 0.708 . . . . 0.0 110.932 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -30.83 21.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.663 2.242 . . . . 0.0 112.371 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 7.0 t -64.25 -24.42 67.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.114 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -92.77 115.91 28.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.88 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.43 ' H ' ' CD ' ' A' ' 44' ' ' GLU . 24.6 mp0 -75.36 49.57 0.48 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.53 168.85 54.59 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.492 HG21 HD12 ' A' ' 27' ' ' ILE . 38.8 mt -133.86 117.75 27.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.821 0.343 . . . . 0.0 111.132 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.563 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.1 m-85 -131.25 154.07 48.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 63' ' ' LEU . 37.6 mt -58.99 138.14 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.488 ' HB3' ' CG ' ' A' ' 28' ' ' ARG . 60.7 p -117.48 -18.68 9.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.845 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 5.0 ttpm? -165.56 155.01 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.766 HG13 HG22 ' A' ' 25' ' ' ILE . 98.4 t -148.68 128.66 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 33.9 t -81.74 139.15 46.94 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.668 0.747 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.57 23.83 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.713 2.275 . . . . 0.0 112.356 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 59.7 p -80.83 -19.25 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.06 170.62 40.76 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.08 -33.65 72.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.326 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.615 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -71.2 -70.45 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.59 -40.95 0.76 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.471 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 10.7 ptt180 -75.68 -34.67 60.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.783 0.325 . . . . 0.0 110.829 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 57' ' ' ALA . 15.3 t0 -47.72 -64.7 0.72 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.36 -19.4 8.63 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.476 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 42.9 mtm180 -96.72 -61.55 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.888 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.586 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.8 tm? -46.4 133.4 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.553 ' H ' HD12 ' A' ' 67' ' ' LEU . 6.2 ptt180 -156.24 149.95 24.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.847 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.476 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 45.1 t -61.26 100.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.106 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 153.59 -19.89 0.7 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.445 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.553 HD12 ' H ' ' A' ' 64' ' ' ARG . 9.8 mt -77.81 140.74 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.783 0.325 . . . . 0.0 110.921 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 70.8 ttt180 -88.72 119.13 28.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.678 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -71.4 107.0 4.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.441 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 11.1 mp -83.45 -53.29 5.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.441 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -151.68 146.65 25.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.819 HG13 HD12 ' A' ' 96' ' ' LEU . 95.5 t -117.84 109.49 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.414 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 66.18 41.81 3.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.918 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.9 mt-30 64.64 29.96 12.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -122.9 89.04 3.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.1 t -40.49 129.03 2.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 83.9 mt -83.08 12.27 5.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.939 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -86.13 112.83 21.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.05 -38.97 2.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.57 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -84.15 168.53 15.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 23.0 p -108.62 166.1 11.04 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.168 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -33.13 -61.77 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.4 -48.55 21.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.481 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.465 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.6 mt-10 -65.05 -55.98 15.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.87 0.366 . . . . 0.0 110.863 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.5 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -45.76 -50.36 14.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.405 ' HA ' HD23 ' A' ' 89' ' ' LEU . 71.2 t -55.64 -59.61 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.486 ' NE2' ' HD3' ' A' ' 90' ' ' ARG . 51.8 mm-40 -50.12 -25.41 3.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.886 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.1 tt -74.85 -32.16 61.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.805 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.5 OUTLIER -77.96 -30.09 50.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.486 ' HD3' ' NE2' ' A' ' 87' ' ' GLN . 12.6 ptm180 -92.72 -7.13 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.874 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.5 m -87.84 30.01 0.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.709 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.9 p -106.69 143.73 16.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.51 -102.68 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.481 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -105.98 -13.41 15.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.886 0.374 . . . . 0.0 110.843 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 15' ' ' ILE . 3.3 m -153.89 141.29 19.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.177 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.819 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -124.01 169.52 11.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.484 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -122.02 99.35 6.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.9 m -96.14 130.99 44.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp -97.12 31.31 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.678 HG12 HD22 ' A' ' 69' ' ' LEU . 11.3 m -59.8 177.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.137 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.445 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 13.2 p -175.23 143.06 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -38.69 104.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.871 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.05 -48.6 2.62 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.455 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.406 ' CE2' ' CD2' ' A' ' 47' ' ' PHE . 1.6 p90 -171.59 115.01 0.38 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -69.97 -52.48 23.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.856 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.4 m 56.28 40.89 29.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.63 -173.26 36.95 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 171.5 14.3 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 93.8 p -105.98 107.36 18.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.822 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.2 t 70.95 42.35 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.497 -179.963 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 p -110.01 102.51 11.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.865 0.364 . . . . 0.0 110.867 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.4 p -50.19 121.32 5.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.44 47.47 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.497 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.5 m -66.75 123.99 21.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.915 0.388 . . . . 0.0 110.859 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.4 m -119.15 78.04 1.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.849 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.58 153.5 23.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 160.38 49.93 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.312 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -164.08 -46.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.739 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.17 39.87 0.6 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.915 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.8 mtp180 -111.76 148.13 34.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 33.7 tt0 -61.89 111.29 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.5 mt -113.08 161.83 16.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -140.66 155.25 46.55 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.434 HG22 ' HB1' ' A' ' 56' ' ' ALA . 88.7 mt -123.01 108.71 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -84.53 114.98 22.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 0.5 OUTLIER -125.65 171.02 10.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.85 168.2 0.11 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.583 0.706 . . . . 0.0 111.07 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.82 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 2.81 3.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.704 2.27 . . . . 0.0 112.379 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -173.61 41.04 0.14 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.481 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 32.7 tp10 -107.36 147.16 30.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.876 0.37 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.7 mmt-85 -83.95 122.95 29.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.658 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.53 -47.58 0.23 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.16 41.48 13.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.583 HG23 HD12 ' A' ' 23' ' ' LEU . 3.0 pt -121.54 166.89 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.845 0.355 . . . . 0.0 111.154 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.426 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -130.3 149.76 51.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.85 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 pt -140.57 149.25 21.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.102 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.432 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.3 ptm85 -130.81 144.37 51.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 125.51 -155.48 18.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.468 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 165.56 -155.65 27.11 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.63 ' HB2' ' O ' ' A' ' 80' ' ' LEU . . . -129.16 -6.52 4.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.8 0.333 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -133.48 -40.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.97 -108.0 3.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -41.1 129.67 2.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.798 0.332 . . . . 0.0 110.845 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.412 ' HB1' ' O ' ' A' ' 43' ' ' ASP . . . -98.57 -18.75 17.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.088 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.78 -39.14 2.85 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -112.61 127.85 26.32 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.655 0.74 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.66 5.34 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.681 2.254 . . . . 0.0 112.317 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -76.33 -67.72 0.66 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.909 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -128.62 111.86 19.14 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.58 0.705 . . . . 0.0 110.903 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 1.87 4.06 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.7 2.267 . . . . 0.0 112.339 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 43' ' ' ASP . 37.8 p -66.84 -68.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.127 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.417 ' N ' ' OG1' ' A' ' 42' ' ' THR . 14.0 t0 -63.8 112.87 3.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.455 ' CB ' ' HA ' ' A' ' 31' ' ' ALA . 35.7 mm-40 -81.43 75.91 8.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -93.47 169.87 30.65 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.497 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.468 HG12 ' N ' ' A' ' 30' ' ' GLY . 52.5 mt -139.95 116.65 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.874 0.368 . . . . 0.0 111.114 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.558 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 0.7 OUTLIER -133.46 156.17 48.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.861 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.548 HD11 HD21 ' A' ' 63' ' ' LEU . 82.9 mt -58.98 129.95 21.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.145 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.2 p -103.89 -13.3 16.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.473 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 40.2 tttt -173.9 162.89 4.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.509 HG13 HG22 ' A' ' 25' ' ' ILE . 99.3 t -150.14 133.1 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -75.35 142.3 74.72 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.678 0.751 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -23.47 30.44 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.713 2.275 . . . . 0.0 112.343 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 80.0 p -103.52 -14.59 16.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.42 154.95 19.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -46.46 -33.75 4.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.821 0.343 . . . . 0.0 111.123 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.961 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -75.19 -60.52 2.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.35 -43.49 6.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -79.82 -21.88 43.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.77 0.319 . . . . 0.0 110.84 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 57' ' ' ALA . 12.9 t70 -55.02 -59.45 4.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.865 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.8 -4.19 14.56 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -118.48 -70.5 0.79 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 110.927 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.961 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -37.22 140.34 0.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.629 ' N ' HD13 ' A' ' 63' ' ' LEU . 9.0 ptm180 -167.04 161.4 14.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.47 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 18.7 t -70.27 102.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.125 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.68 -9.03 1.37 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 102' ' ' ASP . 17.5 mt -89.25 128.22 35.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.331 . . . . 0.0 110.88 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.558 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -78.59 121.54 24.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.604 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -70.24 111.79 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.668 HD12 ' O ' ' A' ' 99' ' ' LEU . 58.3 mt -89.24 -49.44 6.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -155.17 141.87 18.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.937 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.881 HG13 HD12 ' A' ' 96' ' ' LEU . 72.7 t -118.67 109.31 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 65.43 40.65 4.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.7 mt-30 63.75 34.62 11.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.881 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.832 ' HB2' HD21 ' A' ' 88' ' ' LEU . 59.1 mt-30 -129.2 90.31 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.7 t -42.89 131.47 4.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.691 HD23 HD13 ' A' ' 88' ' ' LEU . 23.5 mt -89.81 9.04 28.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.953 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -77.32 131.5 38.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.943 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.577 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 103.03 -43.98 1.57 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.657 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -79.18 155.89 28.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.884 0.373 . . . . 0.0 110.948 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 68.7 p -93.71 -174.54 3.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -49.52 -61.91 1.84 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -46.35 -57.48 6.42 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.459 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 27.2 mt-10 -56.08 -42.05 76.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.902 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -60.91 -48.54 81.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.11 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 67.8 t -52.52 -57.78 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.122 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.481 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 57.3 mm-40 -52.67 -20.35 3.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.899 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.842 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.7 tt -79.71 -26.85 40.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.944 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -82.27 -22.43 35.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.844 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.481 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.0 ptm180 -96.74 -0.15 48.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 p -83.21 16.69 2.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.814 HG21 ' HB3' ' A' ' 96' ' ' LEU . 4.5 p -106.8 141.05 22.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.99 -86.51 0.15 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.48 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.411 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 2.0 p30 -119.89 -12.54 9.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.2 m -149.3 132.65 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.175 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.881 HD12 HG13 ' A' ' 72' ' ' VAL . 0.8 OUTLIER -123.47 170.98 9.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.439 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -121.5 99.31 6.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.431 HG12 HD11 ' A' ' 96' ' ' LEU . 3.1 m -96.41 131.42 43.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.668 ' O ' HD12 ' A' ' 70' ' ' LEU . 18.4 tp -98.32 31.3 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.953 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 69' ' ' LEU . 5.8 m -62.59 176.88 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.112 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.1 p -171.67 145.23 1.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.597 ' HA ' HD23 ' A' ' 67' ' ' LEU . 2.2 p-10 -42.27 100.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.912 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -86.29 -44.24 5.98 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -166.37 109.6 0.76 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.807 0.337 . . . . 0.0 110.919 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -65.89 129.28 39.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.859 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 71.7 m -100.52 -44.13 5.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 147.88 120.33 1.14 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 111.75 2.91 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.651 2.234 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.4 m -130.11 113.84 15.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.913 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.8 t -38.84 -43.43 0.94 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.825 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.477 -179.995 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.4 m -125.94 43.41 3.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.87 0.367 . . . . 0.0 110.864 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -76.31 85.01 3.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.857 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.69 -123.43 0.99 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 m -83.36 100.98 11.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.958 0.409 . . . . 0.0 110.831 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -161.73 115.47 1.89 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.864 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.42 129.68 1.59 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.511 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 -169.79 0.35 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.737 2.291 . . . . 0.0 112.345 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . 167.54 -46.1 0.25 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.493 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.67 16.06 1.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.888 -179.909 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -89.44 149.29 23.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.431 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 30.3 tt0 -59.7 115.31 3.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.1 mt -116.69 160.66 20.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.478 ' SG ' HG23 ' A' ' 97' ' ' THR . 2.7 m -139.93 157.39 45.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 57' ' ' ALA . 34.8 mt -125.42 107.04 17.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -80.53 107.76 13.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.403 ' HA ' ' NH2' ' A' ' 59' ' ' ARG . 0.9 OUTLIER -117.29 168.24 10.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.776 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.92 166.78 0.2 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.58 0.705 . . . . 0.0 111.103 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.776 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.4 Cg_endo -69.75 2.87 3.14 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.659 2.24 . . . . 0.0 112.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.24 38.18 0.19 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.482 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.679 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.5 tp10 -101.98 133.98 45.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.837 0.351 . . . . 0.0 110.869 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 23' ' ' LEU . 91.3 mtt180 -78.95 116.87 19.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.831 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -34.02 -51.84 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.939 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.27 42.62 34.57 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.474 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -116.26 177.59 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.881 0.372 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.501 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -141.91 157.53 44.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.414 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.3 pt -149.33 151.01 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -127.11 122.99 35.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.63 -156.91 28.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 131.09 166.98 11.85 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.6 1.62 57.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.815 0.34 . . . . 0.0 111.062 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -116.48 31.91 6.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.86 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.6 -138.92 15.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.502 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 60.34 36.72 20.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.861 0.362 . . . . 0.0 110.899 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -42.24 104.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.083 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.13 -58.73 13.08 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -97.09 139.7 21.66 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.72 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.9 Cg_endo -69.75 -28.98 24.67 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.699 2.266 . . . . 0.0 112.355 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -36.21 -54.32 0.81 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.959 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -136.74 116.84 10.82 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.642 0.734 . . . . 0.0 110.849 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -14.78 36.61 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.661 2.24 . . . . 0.0 112.329 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 80.8 p -97.61 51.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -133.0 114.43 13.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.853 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -84.99 27.36 0.77 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.926 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.44 148.02 50.36 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 ' N ' ' A' ' 30' ' ' GLY . 62.9 mt -124.66 118.32 53.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.113 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CZ ' ' HD2' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.41 -175.6 3.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.696 HD13 ' CD1' ' A' ' 63' ' ' LEU . 96.4 mt -85.47 138.65 18.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.088 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 53.4 p -116.04 -16.44 11.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -171.83 150.94 2.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.517 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -160.95 110.24 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.092 179.836 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 40.1 t -58.12 137.75 84.23 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.742 . . . . 0.0 110.853 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.9 Cg_endo -69.76 -23.15 31.13 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.665 2.244 . . . . 0.0 112.353 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.5 p -89.24 -16.91 30.13 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.15 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.51 172.28 35.57 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.17 -38.84 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.78 0.324 . . . . 0.0 111.086 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.831 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -73.32 -59.33 2.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.072 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 53' ' ' PRO . . . -45.17 -39.38 6.84 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.51 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.403 ' NH2' ' HA ' ' A' ' 17' ' ' LYS . 23.5 ptt180 -80.73 -20.76 42.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.844 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.402 ' N ' ' O ' ' A' ' 57' ' ' ALA . 13.9 t70 -60.53 -58.99 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.28 -15.71 32.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.476 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? -108.37 8.92 27.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.858 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.696 ' CD1' HD13 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -123.3 119.38 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.493 ' O ' HD12 ' A' ' 48' ' ' ILE . 28.2 mtp180 -145.3 165.64 27.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.517 HG23 HG12 ' A' ' 51' ' ' VAL . 77.9 t -77.11 97.17 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.49 -23.21 0.5 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.478 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.432 ' N ' HD12 ' A' ' 67' ' ' LEU . 7.5 mp -71.75 159.93 33.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HD2' ' CZ ' ' A' ' 47' ' ' PHE . 29.8 ttt-85 -105.71 118.06 35.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.838 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -66.3 103.18 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.907 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.502 ' CD1' ' NH1' ' A' ' 68' ' ' ARG . 9.7 mp -82.42 -42.23 18.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 68.8 mt-10 -162.05 142.73 10.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.723 HG13 HD12 ' A' ' 96' ' ' LEU . 84.9 t -121.6 108.23 21.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.153 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.426 ' ND2' HG22 ' A' ' 92' ' ' VAL . 12.5 m-20 65.33 41.2 4.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 63.37 31.84 14.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.543 ' O ' HD23 ' A' ' 77' ' ' LEU . 27.7 mt-30 -126.16 92.61 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.8 t -46.4 124.09 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.577 ' HA ' HD21 ' A' ' 80' ' ' LEU . 9.6 mt -81.29 3.46 23.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.451 ' HA ' HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -78.66 122.67 26.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.87 -31.78 6.81 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -89.87 160.82 16.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.932 0.396 . . . . 0.0 110.901 -179.903 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 13.9 p -97.61 161.14 13.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.56 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.1 t-80 -33.91 -57.83 0.45 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.11 -44.05 56.71 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.495 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 23.5 mt-10 -67.17 -47.7 70.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.86 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.561 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.95 -55.71 31.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 82' ' ' HIS . 91.9 t -43.54 -64.46 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.08 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.493 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 24.2 mm100 -46.86 -25.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.523 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.85 -34.35 60.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -76.67 -29.03 56.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.962 179.85 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.493 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.2 ptm180 -93.82 4.49 53.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.897 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.6 t -96.3 29.71 2.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.662 HG11 ' HB3' ' A' ' 96' ' ' LEU . 12.4 t -94.5 150.58 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -93.55 -75.15 1.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -121.27 -26.03 5.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 0.0 110.855 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 15' ' ' ILE . 32.1 m -155.81 138.74 15.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.138 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.723 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.01 165.25 14.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.478 HG23 ' SG ' ' A' ' 14' ' ' CYS . 2.8 m -116.41 96.47 5.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.136 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' A' ' 96' ' ' LEU . 3.4 m -98.38 129.42 48.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.413 ' CD1' ' HA ' ' A' ' 12' ' ' GLU . 22.6 tp -96.16 20.23 10.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.838 HG12 HD22 ' A' ' 69' ' ' LEU . 26.2 m -48.88 177.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.057 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -175.46 162.93 2.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.69 118.9 6.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -106.84 -38.58 2.16 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.472 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.2 p90 -170.8 111.42 0.37 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.828 0.347 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -59.09 127.72 33.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.875 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 67.0 m -53.3 -53.49 50.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.864 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 161.21 -165.79 35.52 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.511 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 0.14 6.08 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.653 2.235 . . . . 0.0 112.339 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 51.4 p -45.53 -41.97 10.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.5 t -140.06 108.78 5.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.873 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.949 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t 56.97 42.86 25.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.836 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.3 t -46.13 -55.19 7.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -48.52 -48.62 28.04 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.517 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.8 m -109.66 91.51 3.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.901 0.382 . . . . 0.0 110.848 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -165.39 117.48 1.14 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.869 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 102' ' ' ASP . . . 123.18 75.1 0.3 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.467 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 158.22 57.65 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.661 2.241 . . . . 0.0 112.317 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.21 24.4 0.22 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.489 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.715 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.88 36.86 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.791 0.329 . . . . 0.0 110.918 -179.919 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.689 ' O ' HD12 ' A' ' 13' ' ' LEU . 55.7 mtp180 -108.31 173.86 6.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.464 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.4 tt0 -81.92 112.71 19.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.906 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.689 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -117.26 168.92 9.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.899 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.5 p -148.29 157.02 43.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.422 ' O ' HG23 ' A' ' 95' ' ' THR . 86.8 mt -120.97 111.33 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -80.0 117.73 21.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.47 ' NZ ' HD23 ' A' ' 23' ' ' LEU . 1.7 ptpt -132.18 166.47 21.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.86 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.0 168.63 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.551 0.691 . . . . 0.0 111.115 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.828 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.1 Cg_endo -69.83 -2.26 9.93 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 0.0 112.3 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.82 35.69 0.25 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.669 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 24.7 tp10 -99.84 147.14 25.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.915 0.388 . . . . 0.0 110.85 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 11.2 mtt-85 -86.93 123.67 32.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.847 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.768 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -34.23 -52.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.68 41.3 9.01 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.768 HG12 HD12 ' A' ' 23' ' ' LEU . 3.5 pt -122.76 170.91 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.785 0.326 . . . . 0.0 111.16 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.425 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -130.36 160.79 32.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.829 -179.901 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.438 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 14.8 pt -151.2 145.62 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.169 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.466 ' CG ' ' HB2' ' A' ' 49' ' ' SER . 18.8 ptt85 -128.88 122.01 29.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 163.6 -149.41 16.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.408 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 129.51 156.19 8.73 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -60.83 -9.1 3.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.792 0.329 . . . . 0.0 111.044 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.407 ' O ' ' C ' ' A' ' 33' ' ' GLY . 3.2 mpt_? -131.9 -39.93 1.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -37.3 154.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.508 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.447 ' O ' ' C ' ' A' ' 35' ' ' ALA . 3.6 t-80 -63.01 124.78 21.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.804 0.335 . . . . 0.0 110.865 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -34.01 125.58 0.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.17 -36.18 0.52 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 46.2 m-20 -109.76 137.99 20.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.602 0.715 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -0.97 7.62 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.705 2.27 . . . . 0.0 112.354 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 16.0 tpp180 -66.4 -71.92 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 0.5 OUTLIER -113.62 113.97 47.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.637 0.732 . . . . 0.0 110.884 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 54.1 Cg_endo -69.77 -7.77 21.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 75.0 p -95.51 41.96 1.09 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -134.22 94.17 3.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -80.81 44.45 0.74 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.48 167.76 47.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.465 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.408 HG12 ' N ' ' A' ' 30' ' ' GLY . 30.3 mt -132.84 117.9 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 111.097 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -131.63 154.86 48.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.93 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.679 HD11 HD21 ' A' ' 63' ' ' LEU . 38.7 mt -58.2 134.44 22.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.156 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.466 ' HB2' ' CG ' ' A' ' 28' ' ' ARG . 36.8 t -112.47 -10.49 13.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.884 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.469 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 19.8 ttmt -173.79 148.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.632 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -138.3 114.36 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.126 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.4 t -64.59 140.69 98.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.711 0.767 . . . . 0.0 110.846 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -30.15 22.75 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 30.1 p -89.99 -4.16 57.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.442 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -76.87 155.88 45.22 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.514 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.584 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -47.0 -39.11 11.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.764 0.316 . . . . 0.0 111.098 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.975 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.78 -58.76 3.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -39.3 -43.88 2.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 27.8 ptt180 -82.43 -26.15 32.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 110.855 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.444 ' N ' ' O ' ' A' ' 57' ' ' ALA . 24.5 t70 -53.58 -69.28 0.12 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.862 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.01 -13.73 12.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -101.5 -17.96 16.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.975 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.0 tm? -103.33 125.5 49.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.726 ' N ' HD13 ' A' ' 63' ' ' LEU . 15.1 mtm-85 -139.5 174.81 10.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 51' ' ' VAL . 8.0 t -82.64 90.01 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.69 -15.37 0.3 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.572 ' HB2' HD12 ' A' ' 48' ' ' ILE . 56.0 mt -74.35 132.7 42.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.56 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 55.4 ttt180 -81.7 119.58 24.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.624 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -72.19 108.27 5.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.945 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 11.1 mp -86.39 -52.46 5.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -151.41 141.81 22.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.867 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 66.9 t -115.77 110.0 30.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.493 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.65 40.56 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 64.03 30.08 14.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.7 mt-30 -125.26 90.86 3.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.938 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 35.9 t -40.2 130.29 2.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.854 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD11 ' A' ' 80' ' ' LEU . 24.9 mt -88.11 17.44 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.939 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.822 ' O ' HD23 ' A' ' 80' ' ' LEU . 1.1 tp -85.75 152.69 22.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.907 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.07 -31.77 2.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.498 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -88.19 163.24 16.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.862 0.363 . . . . 0.0 110.923 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 56.7 p -99.06 -174.68 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.126 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.519 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.0 t-80 -52.66 -55.07 25.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.14 -50.19 63.3 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -58.75 -45.47 89.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.905 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.475 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -63.01 -48.76 77.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 82' ' ' HIS . 54.0 t -53.96 -60.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.181 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.491 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 18.7 mm100 -50.04 -23.42 2.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.957 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.571 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -76.8 -30.76 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.601 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -78.96 -30.55 44.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.925 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.491 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.2 ptp180 -89.96 1.74 55.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.4 t -93.26 29.51 1.9 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.666 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.6 t -97.39 149.12 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.109 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.57 -77.79 1.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -118.85 -23.88 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.889 0.376 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 15' ' ' ILE . 8.2 m -158.12 143.09 16.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.145 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -124.05 168.97 12.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.464 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.7 m -120.57 98.84 6.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.144 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.402 ' HB ' HG13 ' A' ' 100' ' ' VAL . 6.5 m -95.62 131.19 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.107 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 11' ' ' ARG . 17.6 tp -98.1 35.74 1.69 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.624 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.6 m -68.48 173.07 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.6 p -162.55 150.37 14.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.431 ' CG ' ' O ' ' A' ' 7' ' ' GLY . 0.3 OUTLIER -49.99 101.78 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -87.12 -63.24 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.476 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 104' ' ' PHE . 0.0 OUTLIER -169.25 108.14 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.902 -179.902 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -84.12 115.99 22.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.841 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.0 t -97.44 26.04 5.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.16 -109.64 1.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.489 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 152.42 69.0 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.65 2.233 . . . . 0.0 112.339 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 49.3 m -120.38 137.05 54.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.0 p -99.11 151.23 21.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.863 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.533 179.985 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m -129.46 161.63 29.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.371 . . . . 0.0 110.843 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.2 p 39.74 42.21 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.842 -179.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 48.91 -159.02 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.518 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 90.6 p -117.16 156.97 26.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.887 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.1 m -54.69 94.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.859 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.4 111.25 2.51 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.519 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 157.3 60.79 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.681 2.254 . . . . 0.0 112.346 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -128.9 -33.86 0.54 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.721 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.07 39.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 -179.894 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.42 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 5.3 mmm180 -113.76 158.27 21.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.424 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -67.43 109.66 3.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.7 mt -114.98 155.5 26.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 96' ' ' LEU . 28.2 p -138.24 151.95 48.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.742 ' O ' HG23 ' A' ' 95' ' ' THR . 39.4 mt -115.06 116.44 52.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -87.95 120.52 29.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.91 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.89 164.27 24.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.31 169.13 0.1 OUTLIER Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.596 0.712 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.81 3.15 2.97 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.687 2.258 . . . . 0.0 112.308 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.35 34.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.546 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 11.1 tp10 -103.62 140.27 37.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.843 0.354 . . . . 0.0 110.908 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.0 mmp_? -85.83 123.93 31.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.751 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.05 -43.77 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.882 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 71.53 44.79 49.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.524 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.713 HG12 HD12 ' A' ' 23' ' ' LEU . 1.1 pt -125.76 177.58 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.809 0.338 . . . . 0.0 111.126 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -141.02 154.29 45.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.434 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.2 pt -138.72 149.37 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.419 ' HE ' ' CB ' ' A' ' 49' ' ' SER . 8.2 ptp180 -125.53 125.94 44.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.07 -150.79 22.6 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 122.74 152.74 8.64 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.492 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -61.83 -7.78 4.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.81 0.338 . . . . 0.0 111.104 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.6 mmm180 -131.11 -40.47 1.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . -52.09 155.08 4.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' ' N ' ' A' ' 36' ' ' GLY . 4.1 p-80 -34.37 123.46 0.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.818 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -41.46 -23.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 100.5 -49.67 1.1 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.476 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -108.49 137.26 19.92 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.653 0.74 . . . . 0.0 110.846 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -37.96 8.46 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.257 . . . . 0.0 112.385 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 13.5 ttp85 -54.83 -56.67 16.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.899 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.13 85.4 4.28 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.622 0.725 . . . . 0.0 110.906 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -1.28 8.2 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.631 2.221 . . . . 0.0 112.35 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.3 p -106.73 28.59 7.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.436 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 0.2 OUTLIER -117.56 117.57 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 179.917 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -90.17 24.33 2.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.869 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.86 150.69 35.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 mt -123.38 118.13 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.896 0.379 . . . . 0.0 111.117 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -128.61 150.91 50.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.61 HD11 HD21 ' A' ' 63' ' ' LEU . 56.0 mt -56.37 146.36 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.104 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.419 ' CB ' ' HE ' ' A' ' 28' ' ' ARG . 82.1 p -120.85 -24.53 5.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.856 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 24.5 ttmt -154.97 156.05 35.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.491 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 76.8 t -147.95 113.83 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 42.5 t -57.6 137.14 82.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.688 0.756 . . . . 0.0 110.844 -179.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -22.23 32.49 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.29 -9.22 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.77 155.86 53.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.494 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -44.15 -35.08 2.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 111.109 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.825 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.31 -56.47 5.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -51.5 -38.65 43.28 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.7 ptt-85 -76.73 -28.85 55.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.799 0.333 . . . . 0.0 110.86 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -55.27 -64.36 0.87 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.55 -6.02 16.6 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.468 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.432 ' O ' HD11 ' A' ' 67' ' ' LEU . 2.8 mmp_? -109.44 -50.36 3.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.836 0.35 . . . . 0.0 110.91 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.825 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.6 tm? -64.59 122.54 17.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.636 ' N ' HD13 ' A' ' 63' ' ' LEU . 30.9 mtt180 -152.81 141.53 20.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.727 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.1 OUTLIER -51.54 95.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 179.968 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.47 -12.82 0.5 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.492 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.457 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 50.5 mt -83.24 151.22 25.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.745 0.307 . . . . 0.0 110.95 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 74.6 ttt180 -95.68 114.79 26.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.698 HD22 HG12 ' A' ' 100' ' ' VAL . 3.3 mm? -72.71 108.11 5.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.429 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 10.1 mp -84.4 -45.73 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.429 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 39.2 mt-10 -158.64 146.64 18.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 72.3 t -119.37 108.17 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.165 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.51 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.68 41.38 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.0 mt-30 64.16 34.4 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLN . . . . . 0.405 ' HB3' HD11 ' A' ' 88' ' ' LEU . 26.6 mt-30 -128.49 91.24 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.6 t -47.76 123.88 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.67 ' HA ' HD21 ' A' ' 80' ' ' LEU . 10.9 mt -79.73 9.96 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.498 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -80.1 123.37 27.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.932 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.498 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 108.69 -35.97 4.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.478 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.67 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -81.66 166.29 20.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.895 0.378 . . . . 0.0 110.914 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.462 ' O ' ' C ' ' A' ' 82' ' ' HIS . 70.8 p -101.24 158.74 15.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.1 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.51 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -33.57 -52.82 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.8 -45.7 90.92 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.472 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.8 mm-40 -63.97 -46.55 84.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.931 0.396 . . . . 0.0 110.907 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.52 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.74 -47.87 83.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 82' ' ' HIS . 70.7 t -54.74 -63.16 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.128 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 7.1 mm-40 -47.5 -26.57 1.43 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.567 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -72.65 -33.82 66.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.964 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.612 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -74.78 -33.61 62.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.939 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.0 ptt85 -91.62 9.62 31.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 33.4 t -99.26 28.44 4.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.852 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.766 HG21 ' HB3' ' A' ' 96' ' ' LEU . 19.0 t -96.16 166.52 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.598 ' N ' HG12 ' A' ' 92' ' ' VAL . . . -103.04 -66.21 0.74 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.515 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.61 -24.92 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.899 0.381 . . . . 0.0 110.89 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.742 HG23 ' O ' ' A' ' 15' ' ' ILE . 24.9 m -159.8 140.48 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.182 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.48 167.64 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.929 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.424 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.0 m -118.91 96.36 5.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.17 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.8 m -95.9 128.45 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.1 tp -93.14 36.55 1.04 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.698 HG12 HD22 ' A' ' 69' ' ' LEU . 5.8 m -66.45 168.2 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.1 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.445 ' O ' ' C ' ' A' ' 102' ' ' ASP . 28.7 p -166.01 133.29 2.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.457 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 2.4 p30 -34.52 108.27 0.06 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -101.26 -52.99 1.03 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.43 ' CZ ' ' CD2' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -172.77 135.7 0.67 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.775 0.321 . . . . 0.0 110.933 -179.828 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -97.92 127.94 44.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.2 m -86.88 35.12 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 109.59 169.45 20.25 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 151.89 69.51 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.679 2.252 . . . . 0.0 112.356 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.3 t -127.26 104.9 8.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.857 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 111' ' ' GLY . 89.0 p -162.01 156.25 21.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.845 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 110' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.521 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.6 p -68.11 129.52 40.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.946 0.403 . . . . 0.0 110.835 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 75.4 m -101.84 42.0 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -92.71 101.03 2.73 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.469 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.3 p -162.3 140.91 9.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.818 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.3 t -105.36 155.64 18.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.77 89.99 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.49 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 148.58 65.49 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.73 2.287 . . . . 0.0 112.298 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.89 -40.53 0.46 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.616 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -86.4 26.54 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.744 ' O ' HD12 ' A' ' 13' ' ' LEU . 18.0 mmm180 -92.89 169.68 10.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 34.5 tt0 -80.06 110.44 15.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.744 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.3 mp -116.34 166.8 11.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.7 p -144.47 156.92 44.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.864 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.65 108.82 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.121 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -79.53 118.47 21.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.913 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.627 ' HZ2' ' C ' ' A' ' 94' ' ' ASP . 0.4 OUTLIER -128.87 171.05 12.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.808 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -49.58 168.07 0.21 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.632 0.729 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.808 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.74 2.9 3.11 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.313 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.62 34.82 0.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 49.5 tp10 -104.11 130.59 51.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.877 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 9.3 ptt-85 -80.3 117.46 21.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.651 HD23 HG12 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -33.36 -50.67 0.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.933 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.73 47.52 8.64 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.477 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.775 HD11 HD13 ' A' ' 89' ' ' LEU . 2.9 pt -112.39 158.1 12.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 111.168 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -125.08 134.9 52.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 46' ' ' ILE . 33.2 pt -126.86 163.51 29.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.4 ptt180 -136.23 125.75 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.61 -144.64 11.37 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.57 157.08 12.28 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.505 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.438 ' HA ' ' CG ' ' A' ' 44' ' ' GLU . . . -68.74 -6.09 24.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.725 0.297 . . . . 0.0 111.034 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -133.05 -38.66 0.96 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . -47.28 134.83 12.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.47 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 33' ' ' GLY . 23.3 m80 -34.67 114.34 0.22 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.879 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -35.96 112.59 0.18 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -45.38 -48.86 11.22 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.524 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.423 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 32.7 t30 -89.27 126.07 59.83 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.68 21.77 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.671 2.247 . . . . 0.0 112.325 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.423 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 81.2 mtt180 -44.11 -69.66 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.865 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -115.07 119.34 39.0 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.614 0.721 . . . . 0.0 110.841 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -18.07 37.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.687 2.258 . . . . 0.0 112.363 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 37.5 p -88.75 42.37 1.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -129.85 104.97 7.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.841 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.438 ' CG ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 mp0 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.887 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.44 150.88 46.87 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.454 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.447 HG21 HD12 ' A' ' 27' ' ' ILE . 33.1 mt -125.74 117.6 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.851 0.358 . . . . 0.0 111.087 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.565 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.86 154.26 46.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.893 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.807 HD13 HD11 ' A' ' 63' ' ' LEU . 85.2 mt -64.23 126.58 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.101 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.419 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.9 t -103.97 -18.13 14.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.47 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 17.4 ttmt -165.56 160.75 17.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.927 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.706 HG13 HG22 ' A' ' 25' ' ' ILE . 95.6 t -157.07 127.98 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.105 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -67.94 141.99 94.99 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.658 0.742 . . . . 0.0 110.902 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -35.3 12.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.628 2.219 . . . . 0.0 112.403 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.2 p -91.25 3.65 54.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -78.49 161.5 48.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.437 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -51.12 -32.76 23.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.751 0.31 . . . . 0.0 111.104 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.711 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -80.54 -64.06 1.27 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.097 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.28 -33.4 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.475 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 60' ' ' ASP . 12.1 ptt180 -81.24 -47.09 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.868 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.451 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 17.2 t0 -40.95 -66.37 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.871 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 -13.52 13.85 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.466 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -97.76 -12.64 22.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.9 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.5 tm? -111.16 134.63 52.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.9 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -154.84 159.04 40.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.895 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 42.7 t -64.5 97.65 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.202 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.03 -20.91 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.518 HD12 HD22 ' A' ' 63' ' ' LEU . 66.3 mt -77.1 136.35 38.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.82 0.343 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.565 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 63.0 ttt180 -84.02 123.65 30.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.764 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -72.77 111.62 8.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 99' ' ' LEU . 49.1 mt -89.4 -49.36 6.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 13.5 mt-10 -158.28 140.86 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.849 HG13 HD12 ' A' ' 96' ' ' LEU . 84.0 t -112.09 111.2 35.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.0 m-20 65.23 40.96 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 40.4 mt-30 64.36 32.12 12.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -127.56 90.03 3.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 t -42.94 130.31 4.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.858 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.411 HD21 HG23 ' A' ' 72' ' ' VAL . 14.7 mt -81.31 6.93 12.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.95 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.546 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.3 OUTLIER -77.62 123.96 27.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.943 179.907 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.546 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.13 -37.19 3.78 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -84.99 168.88 14.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.933 -179.925 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' C ' ' A' ' 82' ' ' HIS . 77.8 p -106.69 161.27 14.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.471 ' C ' ' O ' ' A' ' 81' ' ' THR . 4.3 t-80 -32.81 -55.8 0.37 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.31 -47.32 56.3 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.464 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.434 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 11.1 mm-40 -66.51 -49.88 65.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.838 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.17 -50.15 49.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 68.9 t -56.16 -57.3 9.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.122 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.48 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 9.9 mm-40 -52.17 -23.33 5.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.912 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.562 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.5 tt -76.41 -27.15 56.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.775 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -82.84 -25.12 32.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.861 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.48 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.4 ptm180 -97.63 -3.57 39.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 31.2 t -89.6 28.82 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.902 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.3 p -109.26 147.66 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.23 -98.49 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.495 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.627 ' C ' ' HZ2' ' A' ' 17' ' ' LYS . 0.8 OUTLIER -112.4 -11.31 13.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.89 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.425 ' C ' HG21 ' A' ' 92' ' ' VAL . 6.4 m -153.03 137.22 16.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.104 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.849 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -121.65 169.42 10.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -117.28 95.58 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.412 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -91.98 128.87 43.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.148 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.523 HD12 ' O ' ' A' ' 11' ' ' ARG . 20.9 tp -96.9 21.13 10.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.764 HG12 HD22 ' A' ' 69' ' ' LEU . 22.6 m -49.8 177.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.8 p -169.26 147.62 3.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.517 ' HA ' HD23 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -43.07 113.4 0.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.464 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -95.66 -43.55 3.36 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.508 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.464 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.2 OUTLIER -157.31 124.43 5.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.904 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -37.96 -47.62 1.09 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.929 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.5 m 49.86 42.16 23.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -100.49 147.44 18.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.484 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 176.43 6.78 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.696 2.264 . . . . 0.0 112.34 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.7 t -125.72 138.38 53.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.8 p -50.6 147.36 4.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.822 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.7 m -141.75 144.13 33.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.915 0.388 . . . . 0.0 110.854 -179.711 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.4 m -120.54 131.72 54.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.815 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.29 105.49 0.54 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.47 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -139.81 141.54 36.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.916 0.388 . . . . 0.0 110.898 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.8 m -117.26 85.66 2.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.855 -179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 65.78 150.22 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.421 ' HB2' ' CG ' ' A' ' 11' ' ' ARG . 54.1 Cg_endo -69.75 147.31 62.63 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.708 2.272 . . . . 0.0 112.349 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -115.85 -25.49 3.61 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.727 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.16 31.21 0.5 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.742 0.306 . . . . 0.0 110.854 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.421 ' CG ' ' HB2' ' A' ' 8' ' ' PRO . 13.6 mmm180 -104.91 162.48 13.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.48 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 50.2 tt0 -73.31 113.17 10.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 97' ' ' THR . 26.2 mt -105.46 -174.87 2.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.909 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.516 ' SG ' HG22 ' A' ' 95' ' ' THR . 1.7 t -164.47 153.28 13.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 95' ' ' THR . 19.5 mt -125.82 118.72 52.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -94.04 115.68 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -128.65 164.53 22.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.12 168.75 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.578 0.704 . . . . 0.0 111.092 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.83 1.19 4.71 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.679 2.253 . . . . 0.0 112.325 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.48 42.88 0.23 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.1 tp10 -107.77 141.24 39.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.903 0.383 . . . . 0.0 110.875 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.9 mtt180 -83.59 120.72 26.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.909 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -32.55 -56.97 0.35 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.56 41.1 7.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.545 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.819 HD11 HD13 ' A' ' 89' ' ' LEU . 2.7 pt -121.68 171.17 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.408 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.5 m -142.92 146.47 34.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 28.8 pt -136.41 161.32 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.153 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.431 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.4 ptm85 -132.14 140.42 48.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.421 ' HA2' ' C ' ' A' ' 34' ' ' HIS . . . 140.11 -155.35 24.45 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 139.22 172.48 12.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.736 ' HB3' HG22 ' A' ' 81' ' ' THR . . . -97.28 15.22 23.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.728 0.299 . . . . 0.0 111.068 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -127.37 40.66 3.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.869 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.458 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . 111.2 -77.32 0.23 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.458 ' C ' ' O ' ' A' ' 33' ' ' GLY . 24.7 m170 -33.19 125.81 0.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.856 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -147.27 148.89 31.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.546 ' HA3' ' CD1' ' A' ' 47' ' ' PHE . . . -44.08 -74.31 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.462 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -83.07 122.0 77.47 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.588 0.709 . . . . 0.0 110.908 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 -7.71 21.76 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.674 2.249 . . . . 0.0 112.355 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 63.6 ttp85 -49.19 -51.55 32.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.851 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -138.98 111.26 7.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.89 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -18.72 36.85 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.722 2.281 . . . . 0.0 112.342 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 72.3 p -56.04 -37.91 69.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -83.56 110.22 18.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.859 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 17.9 mp0 -75.56 65.19 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.15 148.59 21.53 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 86.6 mt -127.81 117.95 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.837 0.351 . . . . 0.0 111.178 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.562 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.2 m-85 -131.49 -176.67 4.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.72 HD13 HD11 ' A' ' 63' ' ' LEU . 78.6 mt -84.74 139.92 16.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.136 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 24.4 p -119.07 -12.07 9.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.476 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 22.0 tttp -175.78 149.84 0.98 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.898 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.584 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -156.1 117.57 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.099 179.887 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.7 t -66.25 137.79 95.72 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.67 0.748 . . . . 0.0 110.846 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 54.0 Cg_endo -69.8 -26.45 27.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.354 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 67.5 p -82.33 -26.37 33.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.153 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.96 174.31 2.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.483 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.3 -32.3 73.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.845 0.355 . . . . 0.0 111.134 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.909 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -77.45 -69.33 0.54 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.19 -45.63 1.23 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.447 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.9 ptt180 -68.04 -35.27 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ALA . 32.0 t70 -45.29 -64.77 0.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.49 -19.35 6.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -98.34 -51.47 3.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.72 HD11 HD13 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -55.31 130.43 42.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.896 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.58 ' N ' HD13 ' A' ' 63' ' ' LEU . 5.2 ptp180 -162.69 151.23 14.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.584 HG23 HG12 ' A' ' 51' ' ' VAL . 64.7 t -59.92 104.89 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.554 ' HA2' ' CE1' ' A' ' 104' ' ' PHE . . . 144.67 -8.43 1.8 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.47 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.671 HD23 ' HA ' ' A' ' 102' ' ' ASP . 23.5 mt -89.95 129.29 36.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.562 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 62.2 ttt180 -79.31 124.24 28.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.886 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.78 HD22 HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -75.31 114.14 13.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 7.4 mp -91.16 -50.69 5.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -155.4 141.98 18.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.829 HG13 HD12 ' A' ' 96' ' ' LEU . 88.0 t -114.58 108.38 25.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 12.7 m-20 65.93 42.06 3.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 34.3 mt-30 64.43 29.86 13.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 -123.47 89.88 3.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.6 t -42.99 130.92 4.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.523 ' HA ' HD21 ' A' ' 80' ' ' LEU . 36.7 mt -85.25 7.68 21.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.522 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -77.41 126.66 31.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 105.41 -36.11 4.62 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.492 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.682 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -85.73 162.51 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.846 0.355 . . . . 0.0 110.928 -179.889 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.736 HG22 ' HB3' ' A' ' 31' ' ' ALA . 43.0 p -105.68 167.38 9.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.54 -65.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -41.77 -48.1 5.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.477 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.6 mt-10 -66.86 -50.91 61.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.852 0.358 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.25 -55.27 22.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.537 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.4 t -51.37 -61.7 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.17 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.485 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.1 mm-40 -50.07 -24.78 2.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -74.6 -30.9 61.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.819 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -78.42 -28.9 46.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.485 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.9 ptp180 -93.61 1.16 56.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.1 t -95.05 31.3 1.92 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.8 p -112.89 142.93 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.08 -101.48 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.404 ' HB3' ' HA ' ' A' ' 19' ' ' PRO . 20.0 p-10 -114.81 0.24 13.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.516 HG22 ' SG ' ' A' ' 14' ' ' CYS . 19.3 m -159.02 135.72 9.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.128 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.829 HD12 HG13 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -132.13 157.21 44.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.894 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 97' ' ' THR . . . . . 0.77 HG23 ' O ' ' A' ' 13' ' ' LEU . 9.6 m -107.99 103.53 12.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.128 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 98' ' ' VAL . 2.9 m -97.1 126.31 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 99' ' ' LEU . 20.0 tp -91.89 29.41 1.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.78 HG12 HD22 ' A' ' 69' ' ' LEU . 11.7 m -61.07 166.43 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.169 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 25.0 p -164.34 146.01 8.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.832 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.671 ' HA ' HD23 ' A' ' 67' ' ' LEU . 1.4 t70 -42.63 119.96 1.58 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -112.75 -36.47 1.54 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.517 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.554 ' CE1' ' HA2' ' A' ' 66' ' ' GLY . 3.2 p90 -173.72 118.47 0.27 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -73.93 122.79 23.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.881 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.4 t -75.84 -45.89 33.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 145.85 7.37 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 117.32 5.01 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.1 t 62.06 44.51 7.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.827 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.6 m 57.38 49.67 12.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.509 179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.4 t -123.66 90.89 3.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.897 0.379 . . . . 0.0 110.88 -179.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.6 p -130.07 84.83 2.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.908 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -42.6 160.24 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.507 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 p -90.2 118.0 29.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 0.0 110.822 -179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.6 m -146.23 122.58 10.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.861 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.81 89.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.481 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.75 143.77 51.94 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 166.96 -42.16 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.652 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.94 23.53 1.46 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.791 0.329 . . . . 0.0 110.93 -179.935 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.422 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 4.7 mmm180 -93.1 157.65 16.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -65.71 106.84 1.59 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mt -109.25 170.73 7.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.936 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.9 p -150.59 155.35 39.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.438 ' O ' HG23 ' A' ' 95' ' ' THR . 34.4 mt -120.73 120.51 62.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.153 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -92.26 115.34 27.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.931 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.401 ' O ' ' O ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -128.17 164.62 22.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.895 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.832 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.33 168.65 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.562 0.696 . . . . 0.0 111.06 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.832 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.78 3.49 2.75 Favored 'Trans proline' 0 N--CA 1.466 -0.146 0 C-N-CA 122.698 2.265 . . . . 0.0 112.321 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.18 37.84 0.16 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.7 tp10 -100.29 138.41 37.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.463 ' O ' ' C ' ' A' ' 23' ' ' LEU . 30.1 mmt-85 -81.07 116.71 21.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.745 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -32.56 -46.79 0.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.81 42.82 52.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.838 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -119.56 166.54 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.338 . . . . 0.0 111.135 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.6 OUTLIER -130.51 150.37 51.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.416 HD11 HG22 ' A' ' 86' ' ' VAL . 30.7 pt -139.53 151.39 22.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.114 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -129.07 124.67 35.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . 155.36 -150.83 22.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.485 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 139.41 144.01 4.49 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.451 ' CB ' ' O ' ' A' ' 80' ' ' LEU . . . -73.17 5.62 3.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.075 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.478 ' HD2' HG21 ' A' ' 81' ' ' THR . 3.2 ptm85 -115.06 47.87 1.23 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.432 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . 100.14 -72.25 0.46 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.448 ' O ' ' C ' ' A' ' 29' ' ' GLY . 56.7 m-70 -35.6 101.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.771 0.32 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -93.52 -18.87 21.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 75.16 -47.36 1.95 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.675 ' ND2' ' CE1' ' A' ' 104' ' ' PHE . 20.7 t-20 -95.18 131.57 29.72 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.622 0.725 . . . . 0.0 110.912 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -6.93 19.76 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.453 ' HA ' ' NE ' ' A' ' 39' ' ' ARG . 8.4 mmp_? -55.42 -70.7 0.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.826 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.41 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 79.8 m-20 -121.8 99.47 44.45 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.586 0.708 . . . . 0.0 110.917 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 53.3 Cg_endo -69.77 -22.67 31.69 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.316 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.0 t -83.37 -9.59 58.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.167 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -107.29 110.63 22.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.914 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' A' ' 44' ' ' GLU . 4.4 mp0 -62.69 84.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.3 163.86 13.63 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 36.6 mt -135.72 115.95 17.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.592 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.59 149.97 51.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 26' ' ' SER . 18.1 mt -55.59 140.95 12.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.129 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 49.8 p -114.15 -26.55 8.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 37.5 tttm -158.61 157.05 31.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.553 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.79 116.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.114 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.5 t -62.91 140.48 97.48 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.679 0.752 . . . . 0.0 110.853 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -16.46 37.82 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.707 2.271 . . . . 0.0 112.353 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.9 p -105.62 -6.28 19.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.117 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' ALA . . . -76.72 145.9 31.94 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.503 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.495 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -37.51 -33.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 111.094 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -74.98 -62.71 1.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.02 -40.22 6.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.502 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.495 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 1.6 ptt-85 -73.91 -29.94 62.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.866 0.365 . . . . 0.0 110.893 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 6.5 t70 -55.16 -69.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.71 -22.01 4.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -96.28 -52.64 3.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.82 0.343 . . . . 0.0 110.905 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.883 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -61.9 110.85 1.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.944 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.411 ' HG3' ' CD1' ' A' ' 67' ' ' LEU . 5.1 ptp180 -152.8 136.3 15.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.836 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -39.59 99.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.123 179.944 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.66 -32.41 0.52 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.54 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.493 ' HB2' HD12 ' A' ' 48' ' ' ILE . 7.8 mp -73.73 151.82 40.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.845 0.355 . . . . 0.0 110.882 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 61.5 ttt180 -97.66 116.54 30.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.812 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -66.09 105.64 1.42 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.403 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 9.5 mp -80.5 -49.64 11.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.941 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.403 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 31.4 mt-10 -158.94 145.12 16.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.81 HG13 HD12 ' A' ' 96' ' ' LEU . 79.3 t -115.31 110.21 31.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.7 m-20 64.88 40.56 5.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 35.4 mt-30 64.61 29.85 12.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.955 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.8 mm100 -123.64 90.76 3.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.885 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.1 t -44.96 130.86 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.82 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.6 mt -79.85 0.26 31.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.527 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -74.7 118.4 17.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.881 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 119.6 -34.02 4.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.5 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.5 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -92.98 171.38 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.945 0.402 . . . . 0.0 110.903 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.478 HG21 ' HD2' ' A' ' 32' ' ' ARG . 33.7 p -109.85 162.5 14.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.162 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.543 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.6 t-80 -33.33 -55.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -49.83 -49.53 34.73 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.494 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -68.01 -51.75 43.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.878 0.37 . . . . 0.0 110.862 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.5 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.81 -48.62 30.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 82' ' ' HIS . 98.3 t -57.96 -54.24 34.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.135 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 61.6 mm-40 -56.79 -22.0 32.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.8 tt -76.42 -27.07 56.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.838 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -82.71 -29.1 30.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.964 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.7 ptm180 -92.49 0.81 57.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.871 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 44.4 t -94.25 28.06 2.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.834 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.825 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -108.77 140.28 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.164 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -59.59 -98.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.518 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -114.16 -11.87 12.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.883 0.373 . . . . 0.0 110.858 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 15' ' ' ILE . 2.0 m -150.29 137.11 19.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.116 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.825 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -125.95 167.94 14.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.936 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 m -115.98 97.54 6.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 98' ' ' VAL . 10.1 m -97.04 130.6 45.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.136 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.78 24.07 6.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.812 HG12 HD22 ' A' ' 69' ' ' LEU . 21.7 m -51.59 -176.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.111 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 5.3 p -175.45 153.93 1.58 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -55.68 105.38 0.18 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -96.75 -55.78 1.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.675 ' CE1' ' ND2' ' A' ' 37' ' ' ASN . 2.4 p90 -164.44 110.01 1.0 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.846 0.355 . . . . 0.0 110.863 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 25.5 mp0 -84.75 124.01 31.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 21.5 t -48.99 -52.17 26.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 160.54 172.42 27.79 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.448 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -2.47 10.21 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.667 2.245 . . . . 0.0 112.372 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 15.6 m -39.62 -47.91 2.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 29.0 t -57.26 134.06 55.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.822 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.498 179.991 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.6 m -65.92 155.38 36.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.877 0.37 . . . . 0.0 110.858 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.5 m -59.27 157.13 11.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.83 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.63 83.24 0.22 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m 51.23 47.24 25.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.883 0.373 . . . . 0.0 110.887 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -98.74 -53.91 3.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.851 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.21 146.43 9.49 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -168.02 0.25 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 166.98 -45.23 0.26 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.463 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.749 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.46 18.47 1.47 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.928 -179.894 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.404 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.0 mmm180 -87.35 165.33 15.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.853 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -72.18 115.12 11.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -123.62 160.14 27.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 14.3 p -143.33 156.35 44.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.856 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HG23 ' A' ' 95' ' ' THR . 59.0 mt -117.74 102.66 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -77.31 117.85 19.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.511 ' NZ ' HD12 ' A' ' 23' ' ' LEU . 0.5 OUTLIER -134.03 165.4 25.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.837 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.841 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.38 168.43 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.633 0.73 . . . . 0.0 111.091 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.841 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.82 -0.15 6.54 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.626 2.217 . . . . 0.0 112.338 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -171.04 33.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.66 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.8 tp10 -92.1 126.05 37.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.866 0.365 . . . . 0.0 110.85 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.488 ' O ' ' C ' ' A' ' 23' ' ' LEU . 62.5 mtt180 -70.82 97.01 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.887 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.84 ' HG ' ' HB3' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -30.95 -48.85 0.12 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.6 47.64 7.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.47 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.543 HG22 HG13 ' A' ' 51' ' ' VAL . 4.8 pt -117.61 153.67 19.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.83 0.348 . . . . 0.0 111.161 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.57 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -122.04 151.77 40.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.888 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.0 pt -137.28 145.96 28.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.099 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.422 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 1.5 ptm85 -122.76 137.21 54.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.845 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.96 -145.57 17.54 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.491 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.58 132.71 5.4 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.659 ' O ' HG22 ' A' ' 81' ' ' THR . . . -63.28 115.14 4.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.784 0.325 . . . . 0.0 111.078 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD3' ' C ' ' A' ' 31' ' ' ALA . 1.6 mpp_? 64.01 39.98 7.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -163.28 105.62 0.26 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.508 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.438 ' O ' ' C ' ' A' ' 35' ' ' ALA . 46.1 m-70 65.63 54.09 1.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.764 0.316 . . . . 0.0 110.891 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.438 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -33.71 113.07 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.06 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -51.54 -78.09 0.11 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -83.05 128.49 65.04 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.611 0.719 . . . . 0.0 110.883 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.8 27.0 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.647 2.231 . . . . 0.0 112.351 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.0 mtt85 -59.33 -72.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.26 116.32 20.1 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.615 0.722 . . . . 0.0 110.837 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.81 -2.86 10.92 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.348 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 67.1 p -70.16 -53.84 15.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -81.07 94.24 6.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -88.12 94.86 9.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.891 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -102.49 161.9 16.87 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.463 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 mt -126.22 119.53 54.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.886 0.374 . . . . 0.0 111.1 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.6 OUTLIER -132.04 150.68 52.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.858 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.571 HD13 HD11 ' A' ' 63' ' ' LEU . 44.1 mt -60.25 139.43 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.3 t -112.01 -24.53 9.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 23.9 tttp -155.1 154.87 33.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.543 HG13 HG22 ' A' ' 25' ' ' ILE . 80.4 t -148.71 120.59 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 42.9 t -58.79 138.02 86.86 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.652 0.739 . . . . 0.0 110.877 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -38.42 7.66 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.645 2.23 . . . . 0.0 112.36 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.9 p -92.95 -2.95 55.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.55 172.86 38.12 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.84 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -61.14 -34.04 74.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.75 0.31 . . . . 0.0 111.063 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.816 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -76.83 -60.97 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.41 -42.75 4.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.406 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.8 ptt180 -77.74 -27.96 50.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -53.55 -66.98 0.3 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.85 -5.7 22.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.509 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.425 ' HA ' ' NH1' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -115.22 -7.76 12.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.38 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.805 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.3 tm? -114.55 124.63 52.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.747 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.91 151.73 25.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 179.956 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.429 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -55.8 107.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.97 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.57 -25.54 1.67 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.675 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.5 mt -70.89 142.36 51.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.927 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.536 ' O ' HD22 ' A' ' 70' ' ' LEU . 75.5 ttt180 -88.91 112.89 23.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.705 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.9 mm? -64.94 103.06 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.924 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.536 HD22 ' O ' ' A' ' 68' ' ' ARG . 1.6 mm? -79.61 -52.37 8.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -155.72 136.98 13.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 97.3 t -107.44 110.35 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.15 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.5 m-20 64.79 41.72 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 29.6 mt-30 64.17 30.36 13.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -126.42 90.55 3.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.7 t -42.67 133.26 3.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.824 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.535 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.1 mt -87.62 13.19 10.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.941 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.634 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -80.74 133.18 35.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 179.88 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.634 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 101.18 -36.15 4.39 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.589 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -87.12 156.92 19.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.865 0.364 . . . . 0.0 110.925 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.659 HG22 ' O ' ' A' ' 31' ' ' ALA . 30.7 p -92.06 -177.26 4.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' HIS . . . . . 0.435 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 3.2 t-80 -51.33 -56.12 14.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.868 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -53.29 -51.47 46.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.494 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 6.8 mm-40 -58.54 -45.92 87.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.881 0.372 . . . . 0.0 110.871 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.541 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.87 -49.62 76.07 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 55.4 t -53.08 -56.92 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.484 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 17.1 mm100 -52.1 -22.84 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -78.92 -28.04 43.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.618 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -83.09 -26.36 31.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.864 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.484 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.5 ptp180 -95.05 0.89 54.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 24.9 t -96.36 33.28 1.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.0 p -112.0 145.57 17.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.63 -100.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.452 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -112.47 -1.69 14.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.884 0.373 . . . . 0.0 110.893 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.401 HG23 ' C ' ' A' ' 15' ' ' ILE . 26.8 m -162.96 136.6 5.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.143 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.39 166.83 12.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.6 m -115.68 96.08 5.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.131 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.454 ' HB ' HG13 ' A' ' 100' ' ' VAL . 5.6 m -93.49 133.0 36.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.404 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.8 tp -103.09 26.53 8.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.5 m -60.28 178.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.095 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.4 p -171.65 146.02 2.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -37.89 109.98 0.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -104.01 -50.05 1.03 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.462 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -168.46 117.13 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.81 0.338 . . . . 0.0 110.907 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -53.67 -62.08 1.89 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.931 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 6.7 t 55.23 41.66 31.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -89.48 127.99 8.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.487 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 169.15 19.52 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.655 2.237 . . . . 0.0 112.339 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.5 t -105.51 118.0 35.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 48.6 p -109.08 138.61 45.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.466 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.3 m -90.3 -57.09 2.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.855 0.36 . . . . 0.0 110.858 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -52.12 132.87 33.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 39.94 43.81 2.57 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.497 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 40.9 t -68.17 147.25 52.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.829 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 m -103.18 110.93 23.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.866 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 155.17 175.48 26.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 142.5 47.85 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.661 2.241 . . . . 0.0 112.304 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 160.84 -47.61 0.38 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.551 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.738 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.33 32.43 0.5 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.799 0.333 . . . . 0.0 110.913 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -99.39 150.65 21.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.77 113.77 2.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.4 mt -117.37 167.35 11.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 23.0 p -146.42 158.9 43.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.423 ' C ' HG23 ' A' ' 95' ' ' THR . 22.6 mt -125.85 106.25 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.116 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -81.31 107.33 14.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.624 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -118.81 172.74 7.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.806 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -49.48 165.09 0.3 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.609 0.718 . . . . 0.0 111.099 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.83 1.87 4.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.337 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.55 32.1 0.18 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.466 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.806 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 33.5 tp10 -97.92 153.34 18.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.876 0.369 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.81 125.65 35.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . 0.698 HD12 HG23 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -37.58 -52.46 1.2 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.911 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.44 40.9 14.35 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.698 HG23 HD12 ' A' ' 23' ' ' LEU . 7.5 pt -121.26 157.43 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 111.096 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.506 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -122.16 144.1 49.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.1 pt -135.85 149.27 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.114 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.0 ptt180 -128.67 135.1 48.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 139.95 -140.93 11.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.82 135.43 6.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.942 ' O ' HG22 ' A' ' 81' ' ' THR . . . -61.68 114.29 3.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.736 0.303 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 15.9 mmm180 64.24 25.84 13.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.56 -91.26 2.16 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 15.1 m80 -108.15 109.68 21.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.813 0.339 . . . . 0.0 110.819 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -55.31 102.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.067 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -79.24 -58.01 3.04 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.475 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 56.4 t30 -90.38 118.93 69.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.621 0.724 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -30.93 21.16 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.637 2.225 . . . . 0.0 112.344 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 53.5 mtt85 -42.59 -63.26 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.911 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -123.19 117.14 28.3 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.604 0.716 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 2.76 3.25 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.348 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 17.2 p -102.17 -26.76 13.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.156 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.38 108.0 9.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.894 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -102.41 104.18 14.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.928 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -119.28 165.23 13.19 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.508 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.26 117.76 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.857 0.36 . . . . 0.0 111.132 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.555 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -131.04 149.61 52.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.806 HD11 HD21 ' A' ' 63' ' ' LEU . 65.1 mt -58.14 123.71 10.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.155 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.9 t -99.3 -10.8 21.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.855 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.523 ' N ' HG13 ' A' ' 65' ' ' VAL . 13.1 ttmt -175.06 160.35 2.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.915 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.688 HG23 HG22 ' A' ' 65' ' ' VAL . 58.8 t -144.42 114.09 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.6 t -61.54 138.28 94.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.681 0.753 . . . . 0.0 110.821 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -25.1 28.9 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.252 . . . . 0.0 112.329 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.3 p -94.99 1.22 55.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.78 158.94 34.07 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.484 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -50.25 -44.09 53.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -63.75 -58.76 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.089 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.11 -42.15 5.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.47 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 30.2 ptt180 -85.01 -24.22 28.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 110.914 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -54.42 -69.13 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.37 -13.54 15.9 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -101.38 -7.46 22.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.811 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 HD11 ' A' ' 48' ' ' ILE . 2.4 tm? -108.79 135.17 50.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.908 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.716 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.5 mmp_? -140.5 158.09 44.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 51' ' ' VAL . 5.4 t -73.82 88.95 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 155.8 -17.76 0.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.464 ' HB2' HD12 ' A' ' 48' ' ' ILE . 13.0 mt -65.72 130.35 42.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.803 0.335 . . . . 0.0 110.901 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.555 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 60.4 ttt180 -78.6 122.1 25.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.775 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -73.86 111.87 9.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.953 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 9.0 mp -87.48 -52.94 5.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.91 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -156.73 135.77 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.989 HG13 HD12 ' A' ' 96' ' ' LEU . 53.0 t -108.66 111.72 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.101 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 65.46 40.58 4.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 63.98 36.38 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.928 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -134.77 90.91 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.0 t -41.11 139.13 0.98 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.832 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.475 ' CD2' HD13 ' A' ' 88' ' ' LEU . 11.5 mt -86.11 9.78 16.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.958 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.8 tt -83.69 156.64 22.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 79.71 -19.51 6.1 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -110.38 155.06 22.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.381 . . . . 0.0 110.907 -179.91 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.942 HG22 ' O ' ' A' ' 31' ' ' ALA . 65.5 p -91.75 179.03 5.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -48.62 -58.11 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.84 -49.87 27.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.0 mt-10 -61.72 -46.84 87.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.841 0.353 . . . . 0.0 110.923 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.43 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.63 -51.64 64.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.085 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 89' ' ' LEU . 65.0 t -48.22 -58.01 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.101 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLN . . . . . 0.623 ' NE2' ' CZ ' ' A' ' 90' ' ' ARG . 3.5 mm100 -51.49 -24.89 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.911 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.475 HD13 ' CD2' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -74.84 -32.19 61.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.914 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.574 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -75.83 -24.75 55.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.623 ' CZ ' ' NE2' ' A' ' 87' ' ' GLN . 4.2 ptt180 -96.55 -0.11 49.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 p -83.36 20.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -106.42 145.84 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.162 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -78.47 -80.66 0.71 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.501 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ASP . . . . . 0.446 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -121.13 -13.74 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.863 0.364 . . . . 0.0 110.852 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' C ' ' A' ' 15' ' ' ILE . 14.3 m -157.1 134.61 10.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.989 HD12 HG13 ' A' ' 72' ' ' VAL . 1.3 pt? -118.88 -179.24 3.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.926 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -126.61 95.92 4.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.4 m -96.92 129.31 47.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -94.96 21.6 7.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.775 HG12 HD22 ' A' ' 69' ' ' LEU . 20.8 m -49.65 169.29 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 8.6 p -161.6 154.08 20.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -48.8 111.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.853 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLY . . . . . 0.437 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -102.56 -46.33 1.54 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.437 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.5 OUTLIER -155.19 115.29 3.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 110.875 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLU . . . . . 0.453 ' O ' ' C ' ' A' ' 106' ' ' SER . 18.7 mt-10 -83.91 34.28 0.5 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.913 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.453 ' C ' ' O ' ' A' ' 105' ' ' GLU . 25.6 t -34.49 -39.44 0.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.873 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.2 153.14 8.67 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 140.55 43.16 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.356 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 88.5 p -64.81 134.56 54.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.838 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 60.7 p -51.09 152.86 2.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.839 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.538 -179.983 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.672 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -97.77 33.06 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.929 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.623 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.6 mmm180 -104.12 177.82 4.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.419 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.6 tt0 -78.0 112.22 14.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.907 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.2 mt -119.85 163.38 17.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 96' ' ' LEU . 18.9 p -144.3 159.47 42.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.87 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.6 mt -122.34 112.96 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -84.47 115.39 22.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -127.41 166.77 17.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.889 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.06 168.27 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.543 0.687 . . . . 0.0 111.118 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.8 -2.01 9.48 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.653 2.235 . . . . 0.0 112.333 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.49 37.89 0.27 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 40.8 tp10 -102.68 143.58 32.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.864 0.364 . . . . 0.0 110.893 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.6 ptt180 -84.13 121.5 27.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.849 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.751 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -33.63 -53.16 0.42 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 41.12 9.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.751 HG12 HD12 ' A' ' 23' ' ' LEU . 3.3 pt -121.35 162.57 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.5 m -130.57 145.13 51.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.819 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.565 HD12 HG21 ' A' ' 46' ' ' ILE . 21.1 pt -136.2 156.2 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.107 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -132.48 132.9 43.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.873 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.07 -142.32 9.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.507 -179.927 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.565 HG21 HD12 ' A' ' 27' ' ' ILE . 30.8 mt -126.88 119.2 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.385 . . . . 0.0 111.106 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.72 149.12 52.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.833 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.541 HD13 HD11 ' A' ' 63' ' ' LEU . 94.7 mt -54.59 132.76 17.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.43 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.4 p -108.59 -13.41 14.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.412 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 28.4 tttm -175.5 156.47 1.96 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.853 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.56 HG13 HG22 ' A' ' 25' ' ' ILE . 93.4 t -143.63 123.24 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.109 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 t -69.22 143.15 93.49 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.684 0.754 . . . . 0.0 110.858 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -35.6 12.15 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.33 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.3 p -88.27 0.95 55.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.449 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -80.57 153.05 34.54 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.604 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -45.18 -38.9 5.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.769 0.319 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -73.32 -64.0 1.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -35.44 -44.56 0.62 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.8 ptt180 -79.3 -37.24 38.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 57' ' ' ALA . 22.1 t0 -40.66 -64.57 0.51 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.38 -9.75 22.23 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.24 -24.35 11.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.0 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.29 126.25 37.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -142.6 174.46 10.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 6.4 t -82.62 92.33 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.68 -13.66 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.47 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.611 HD12 HD22 ' A' ' 63' ' ' LEU . 52.7 mt -77.05 118.71 19.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.559 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 46.5 ttt180 -69.12 122.69 19.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.688 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -72.95 108.96 6.15 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.434 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 4.4 mm? -84.31 -52.37 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.951 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.434 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 11.3 mt-10 -157.85 134.99 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.837 HG13 HD12 ' A' ' 96' ' ' LEU . 88.8 t -106.58 110.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.075 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 18.6 m-20 64.73 41.66 5.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 64.17 31.89 12.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -128.86 91.05 3.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.887 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 36.2 t -50.45 130.89 24.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.3 mt -80.29 5.14 15.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.402 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -73.04 114.95 11.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.932 179.918 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -37.39 3.17 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.494 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.585 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -86.42 167.89 14.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.904 0.383 . . . . 0.0 110.917 -179.934 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 61.8 p -104.37 160.59 14.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.1 -55.19 0.39 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.821 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.24 -46.11 51.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 81' ' ' THR . 29.4 mm-40 -70.03 -47.87 60.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.863 0.364 . . . . 0.0 110.857 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -54.18 -48.76 70.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 82' ' ' HIS . 75.2 t -55.57 -55.22 18.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.9 mm-40 -54.27 -27.3 34.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -70.43 -29.59 66.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.958 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.67 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.41 -30.5 47.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.921 179.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.8 ptp180 -93.36 -1.14 56.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.83 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -90.64 30.0 1.23 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.636 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.6 p -112.1 144.66 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.154 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.73 -94.51 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -119.52 -8.78 9.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 m -152.92 134.68 14.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.837 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -122.8 171.87 8.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.419 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.4 m -120.8 98.64 6.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.158 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.46 131.91 40.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.623 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.1 tp -101.15 31.47 3.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.688 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.5 m -65.96 175.47 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.133 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.4 p -165.17 154.23 12.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -46.26 101.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.478 -179.925 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.748 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -83.31 20.19 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.892 -179.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.472 ' O ' HD12 ' A' ' 99' ' ' LEU . 15.3 mmt180 -90.24 168.01 12.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.458 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 31.9 tt0 -74.25 114.84 13.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.893 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.8 mt -118.58 160.06 22.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.6 p -139.5 155.77 47.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 95' ' ' THR . 31.0 mt -122.97 109.78 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.19 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -80.31 115.93 20.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.482 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -131.98 178.26 6.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -56.83 163.62 2.71 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.554 0.692 . . . . 0.0 111.093 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.2 Cg_endo -69.8 1.23 4.65 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.688 2.259 . . . . 0.0 112.328 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -162.59 26.14 0.23 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.488 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.1 tp10 -94.43 142.22 27.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.909 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.9 mpt_? -86.32 123.72 31.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.722 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -46.53 0.24 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.58 41.18 30.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.527 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -121.41 162.97 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 0.0 111.143 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -120.12 159.1 25.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.835 -179.894 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 86' ' ' VAL . 14.4 pt -151.69 145.65 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.11 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -129.26 132.14 47.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.929 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.67 -146.19 15.17 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.478 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.464 -179.907 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 60.3 mt -139.18 115.86 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 111.135 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.4 OUTLIER -132.54 163.5 28.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.959 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.736 HD11 HD21 ' A' ' 63' ' ' LEU . 27.4 mt -67.72 125.49 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 82.7 p -96.85 -11.02 25.36 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.823 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 16.8 ttmm -175.86 167.25 3.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 64.5 t -150.06 114.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.139 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.5 t -67.27 140.01 95.17 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.61 0.719 . . . . 0.0 110.85 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.74 21.68 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.646 2.231 . . . . 0.0 112.361 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.5 p -86.57 -8.57 57.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.137 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -75.56 158.2 50.07 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.408 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -50.17 -39.39 43.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.766 0.317 . . . . 0.0 111.087 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -70.34 -60.26 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.079 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.63 -42.88 2.84 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.408 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 23.3 ptt180 -80.29 -31.53 38.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.83 0.348 . . . . 0.0 110.886 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -50.17 -72.29 0.05 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 119.72 -9.58 11.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.492 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -104.32 -10.93 17.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.876 0.37 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.83 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.4 tm? -105.83 134.0 49.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.707 ' N ' HD13 ' A' ' 63' ' ' LEU . 19.7 mtp180 -144.28 178.97 7.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 51' ' ' VAL . 9.1 t -88.02 92.86 3.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.138 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 151.91 -13.16 0.74 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.465 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.557 ' HB2' HD12 ' A' ' 48' ' ' ILE . 32.6 mt -73.0 110.41 7.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.803 0.335 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 16.6 ttm180 -62.34 122.8 16.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.858 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.67 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -71.24 107.03 4.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.495 ' O ' ' CG ' ' A' ' 71' ' ' GLU . 1.7 mm? -86.37 -42.14 13.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 40.3 mt-10 -161.82 139.55 8.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.885 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.745 HG13 HD12 ' A' ' 96' ' ' LEU . 66.7 t -117.6 108.0 23.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.089 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.476 ' ND2' HG22 ' A' ' 92' ' ' VAL . 11.5 m-20 65.44 41.35 4.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 63.65 36.66 10.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -131.92 91.16 2.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.3 t -47.55 127.04 10.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.436 ' HA ' HD21 ' A' ' 80' ' ' LEU . 12.8 mt -78.01 1.06 22.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.442 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -72.12 111.39 7.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.964 179.805 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.92 -37.28 2.73 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.524 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.501 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -87.16 167.03 14.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.953 0.406 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 81.0 p -102.66 -179.97 4.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.64 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -50.32 -51.48 44.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.85 -45.57 79.54 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.1 mt-10 -67.1 -58.36 5.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.819 0.342 . . . . 0.0 110.889 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -44.27 -46.79 9.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.123 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.746 ' HA ' HD23 ' A' ' 89' ' ' LEU . 74.5 t -57.05 -60.45 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.11 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.482 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.3 mm-40 -50.39 -26.27 4.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.902 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -74.73 -32.12 62.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.746 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -79.08 -31.66 44.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.482 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.4 ptm180 -90.81 3.54 54.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.897 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 5.5 m -96.59 29.23 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.639 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.4 t -94.25 149.94 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.59 -76.7 1.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -123.28 -17.76 6.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.84 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.426 HG23 ' O ' ' A' ' 15' ' ' ILE . 56.2 m -163.16 137.04 5.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.093 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.745 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.0 169.08 10.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.458 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.1 m -119.71 100.15 7.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.428 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.0 m -96.72 130.66 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.472 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.7 tp -99.19 24.83 7.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.7 m -61.84 172.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.122 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.3 p -163.35 163.02 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -54.31 95.15 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.485 -179.908 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.356 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.31 28.81 0.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.813 0.339 . . . . 0.0 110.934 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -98.5 161.93 13.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 35.2 tt0 -68.21 107.37 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.869 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 98' ' ' VAL . 18.9 mt -113.48 157.49 21.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 20.6 p -139.36 165.33 27.5 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.404 HG22 ' HB1' ' A' ' 56' ' ' ALA . 52.4 mt -128.99 105.62 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -80.68 117.55 21.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.4 ptpp? -126.91 168.6 14.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.51 168.34 0.12 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 0.0 111.103 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.823 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 1.61 4.27 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.727 2.285 . . . . 0.0 112.339 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.32 43.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 38.8 tp10 -111.59 142.7 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.814 0.34 . . . . 0.0 110.86 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -86.6 124.5 32.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 -179.926 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.777 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.46 -52.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 41.04 13.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.505 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.685 HG23 HD12 ' A' ' 23' ' ' LEU . 3.1 pt -119.39 157.33 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.813 0.339 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -123.5 140.06 53.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.628 HD12 HG21 ' A' ' 46' ' ' ILE . 21.5 pt -132.79 157.09 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.121 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.445 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 3.3 ptm85 -132.58 138.87 47.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.23 -144.75 13.2 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 -179.957 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.628 HG21 HD12 ' A' ' 27' ' ' ILE . 39.6 mt -125.21 117.63 50.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.829 0.347 . . . . 0.0 111.136 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.06 156.53 43.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 HD11 ' A' ' 63' ' ' LEU . 65.3 mt -64.19 130.46 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.158 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 43.5 t -110.23 -14.57 14.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.837 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.474 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 11.2 tttm -167.02 161.21 14.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.659 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -152.78 129.28 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.144 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.1 t -72.52 137.65 80.72 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.611 0.719 . . . . 0.0 110.867 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -25.29 28.84 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.676 2.251 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -101.71 12.88 36.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.187 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -91.92 161.94 27.21 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.506 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.491 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -50.04 -35.51 25.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.17 -57.11 4.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.123 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.27 -43.85 4.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.497 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -80.83 -26.25 37.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.821 0.343 . . . . 0.0 110.889 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -48.58 -58.23 5.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.79 -25.12 11.19 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.468 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -94.73 -53.48 3.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.855 0.36 . . . . 0.0 110.883 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.811 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.4 OUTLIER -58.6 132.49 53.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.627 ' N ' HD13 ' A' ' 63' ' ' LEU . 3.6 ptp180 -165.33 147.57 7.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 62.0 t -49.79 106.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.153 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.13 -26.3 2.03 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.696 HD23 ' C ' ' A' ' 101' ' ' CYS . 20.3 mt -75.25 118.55 18.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.765 0.316 . . . . 0.0 110.942 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.56 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -69.61 131.66 45.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.602 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -80.29 111.75 16.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 4.0 mm? -88.84 -49.78 6.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.957 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.416 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -158.39 140.41 13.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.923 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.847 HG13 HD12 ' A' ' 96' ' ' LEU . 88.4 t -111.84 109.77 29.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.159 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 65.07 41.9 4.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 64.21 32.99 12.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.21 90.54 3.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.912 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.8 t -47.3 130.08 13.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.618 ' HA ' HD21 ' A' ' 80' ' ' LEU . 5.8 mt -83.31 8.34 13.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.965 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.5 OUTLIER -76.97 115.45 16.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.886 179.894 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.11 -32.52 5.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.468 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.618 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -88.04 167.12 13.96 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.918 0.389 . . . . 0.0 110.9 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.441 ' O ' ' N ' ' A' ' 84' ' ' GLU . 44.5 p -105.94 162.92 13.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.102 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.598 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.7 t-80 -34.82 -55.96 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.62 -41.12 49.23 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.442 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -73.16 -48.6 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.856 0.36 . . . . 0.0 110.868 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.4 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.3 -51.64 64.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.152 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.0 t -53.17 -62.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.125 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 15.9 mm-40 -49.51 -23.44 1.6 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -75.07 -33.47 61.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.773 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.2 -32.76 56.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 8.2 ptm180 -89.24 -3.36 58.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.1 m -91.41 33.52 0.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.84 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.3 p -112.88 145.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.115 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.25 -98.15 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -116.15 -6.96 11.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.923 0.392 . . . . 0.0 110.918 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.4 m -156.17 130.64 8.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.172 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.847 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.99 168.2 10.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.6 m -116.85 97.77 6.14 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.113 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 13' ' ' LEU . 3.3 m -95.43 129.32 45.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.152 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.3 tp -99.51 34.17 2.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.602 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.0 m -69.91 173.0 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.696 ' C ' HD23 ' A' ' 67' ' ' LEU . 7.9 p -165.15 168.34 17.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -52.51 114.32 1.34 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.317 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.494 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.443 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.496 -0.241 . . . . 0.0 112.496 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.707 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.79 38.99 0.73 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.924 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 53.8 mtp180 -109.68 144.95 37.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.438 ' OE2' HG21 ' A' ' 97' ' ' THR . 52.9 tt0 -55.52 110.09 0.65 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.5 mt -105.1 168.67 8.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.944 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.696 ' SG ' HG22 ' A' ' 95' ' ' THR . 7.2 t -150.35 144.22 25.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.931 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.814 ' O ' HG23 ' A' ' 95' ' ' THR . 15.6 mt -120.71 127.2 75.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -97.72 113.54 25.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -124.83 170.5 10.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.89 168.05 0.17 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.582 0.706 . . . . 0.0 111.1 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.813 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.81 2.37 3.62 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.344 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.05 39.43 0.17 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.6 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 26.1 tp10 -101.73 144.19 30.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.812 0.339 . . . . 0.0 110.926 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 25.5 mtt-85 -83.75 120.23 25.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.753 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -49.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.35 42.6 18.12 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.471 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.753 HG12 HD12 ' A' ' 23' ' ' LEU . 2.2 pt -122.74 161.5 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.803 0.335 . . . . 0.0 111.133 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.471 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -119.17 160.37 22.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.891 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 46' ' ' ILE . 17.7 pt -151.55 147.27 15.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.169 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.473 ' NH1' ' CB ' ' A' ' 49' ' ' SER . 6.1 ptt-85 -125.09 139.42 53.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 137.87 -149.93 20.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.514 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.542 -179.893 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.439 HG21 HD12 ' A' ' 27' ' ' ILE . 48.6 mt -123.62 118.69 55.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.844 0.354 . . . . 0.0 111.117 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.75 147.51 50.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.701 HD13 HD11 ' A' ' 63' ' ' LEU . 95.3 mt -55.88 135.66 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.149 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.473 ' CB ' ' NH1' ' A' ' 28' ' ' ARG . 70.0 p -113.87 -13.39 12.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.853 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.517 ' N ' HG13 ' A' ' 65' ' ' VAL . 17.9 ttmm -170.38 161.23 7.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.684 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.08 121.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -68.01 139.27 92.89 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 110.871 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -29.91 23.26 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.716 2.277 . . . . 0.0 112.367 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.3 p -92.7 4.49 53.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -85.45 161.45 35.46 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.447 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.459 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -51.39 -39.55 57.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.795 0.331 . . . . 0.0 111.116 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.65 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -70.55 -59.36 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -38.69 -42.43 1.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 24.9 ptt180 -82.95 -30.09 28.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.8 0.333 . . . . 0.0 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 57' ' ' ALA . 48.2 t0 -45.9 -56.97 4.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.876 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.4 -20.23 40.43 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.36 -20.52 18.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.845 0.355 . . . . 0.0 110.865 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.701 HD11 HD13 ' A' ' 48' ' ' ILE . 1.1 tm? -89.55 134.35 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.569 ' N ' HD13 ' A' ' 63' ' ' LEU . 14.2 mmm-85 -143.15 154.12 43.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.887 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 51' ' ' VAL . 18.3 t -70.49 87.21 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.99 -17.35 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.499 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.547 HD12 HD22 ' A' ' 63' ' ' LEU . 18.0 mt -67.82 124.64 23.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 36.2 ttt180 -71.84 119.74 16.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.766 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -67.04 111.43 3.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.887 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 70' ' ' LEU . 2.0 mm? -86.79 -54.24 4.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.92 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -156.58 133.6 10.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.782 HG13 HD12 ' A' ' 96' ' ' LEU . 93.1 t -106.76 110.92 33.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.505 ' ND2' HG22 ' A' ' 92' ' ' VAL . 15.0 m-20 64.91 41.06 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 37.4 mt-30 63.86 31.55 13.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -129.38 91.24 3.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -46.4 138.97 5.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 18.2 mt -91.52 5.17 50.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.4 117.97 17.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 117.28 -39.62 2.6 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.544 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.461 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -82.8 167.36 18.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.888 0.375 . . . . 0.0 110.894 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 72.5 p -103.84 162.06 13.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.672 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.83 -56.02 0.47 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.04 55.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.525 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.441 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.7 mm-40 -69.04 -49.02 61.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.829 0.347 . . . . 0.0 110.875 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.461 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.87 -45.34 74.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.734 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.7 t -57.2 -58.18 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.487 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 66.6 mm-40 -52.09 -22.48 4.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.4 tt -79.37 -28.24 41.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.906 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.734 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.7 OUTLIER -83.76 -25.86 30.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.896 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.487 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.8 ptm180 -96.04 0.91 52.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.834 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 32.6 t -93.68 28.04 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.684 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.1 t -92.81 148.91 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.76 -77.76 1.3 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.499 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -125.16 -17.72 5.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.916 0.388 . . . . 0.0 110.869 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.814 HG23 ' O ' ' A' ' 15' ' ' ILE . 5.0 m -158.38 137.28 11.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.782 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -122.69 160.65 25.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.912 179.986 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.438 HG21 ' OE2' ' A' ' 12' ' ' GLU . 3.4 m -113.24 96.62 6.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.103 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.563 HG23 HG22 ' A' ' 100' ' ' VAL . 3.0 m -91.96 130.01 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.1 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.7 tp -97.08 17.77 16.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.872 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.766 HG12 HD22 ' A' ' 69' ' ' LEU . 35.9 m -49.38 178.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.443 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 1.9 p -167.62 161.58 13.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -60.77 102.28 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.509 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.97 19.78 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -88.71 162.26 16.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.848 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.467 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -73.18 110.78 7.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.3 161.57 15.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.0 p -143.01 153.2 42.74 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.3 mt -121.85 120.94 62.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.111 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -93.12 110.59 22.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.575 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.1 179.75 4.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.764 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -59.18 166.4 2.84 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.566 0.698 . . . . 0.0 111.088 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.9 Cg_endo -69.71 -0.28 6.65 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.65 2.233 . . . . 0.0 112.369 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.59 29.34 0.22 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.688 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 52.2 tp10 -94.25 140.42 29.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.924 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 5.9 ptt-85 -82.95 120.57 25.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.715 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.99 -49.15 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.94 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.24 42.07 24.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 89' ' ' LEU . 1.5 pt -121.19 164.41 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.143 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.97 150.9 50.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.407 ' C ' ' HE2' ' A' ' 82' ' ' HIS . 30.2 pt -140.36 149.39 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.097 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 35.0 ptt180 -125.14 123.16 39.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.04 -141.87 8.49 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.475 -179.914 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.459 -0.257 . . . . 0.0 112.459 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.7 mt -128.76 119.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.911 0.386 . . . . 0.0 111.152 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.5 OUTLIER -132.14 -179.94 5.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.905 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.832 HD13 HD11 ' A' ' 63' ' ' LEU . 69.9 mt -88.01 121.4 38.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.5 t -97.32 -17.36 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.453 ' HA ' HG21 ' A' ' 65' ' ' VAL . 12.3 ttmt -166.23 160.09 15.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 84.0 t -149.31 115.08 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.136 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.6 t -60.3 134.37 90.95 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.694 0.759 . . . . 0.0 110.859 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -19.52 35.75 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.702 2.268 . . . . 0.0 112.351 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 19.4 p -102.24 3.47 38.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.16 172.89 49.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.73 -39.7 85.57 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.808 0.337 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.689 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -69.3 -61.5 1.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.83 -39.94 2.07 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 14.5 ptt180 -82.24 -25.06 34.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 0.0 110.852 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.472 ' N ' ' O ' ' A' ' 57' ' ' ALA . 30.3 t0 -53.27 -62.01 1.93 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 111.57 -16.24 26.56 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.1 -29.05 11.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.872 0.367 . . . . 0.0 110.866 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.1 tm? -87.4 134.16 33.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.966 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.924 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.72 150.2 24.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.463 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 44.2 t -56.63 104.48 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.33 -13.25 1.62 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.454 HD12 HD22 ' A' ' 63' ' ' LEU . 87.7 mt -83.49 123.75 30.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.547 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 36.7 ttt180 -72.55 125.39 27.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.65 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -74.35 107.56 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.835 HD12 ' O ' ' A' ' 99' ' ' LEU . 70.3 mt -86.58 -48.91 7.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.958 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.443 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 20.0 mt-10 -158.92 138.47 11.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.734 HG13 HD12 ' A' ' 96' ' ' LEU . 93.0 t -112.99 110.37 31.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.8 m-20 65.49 40.55 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 36.5 mt-30 64.4 32.13 12.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.929 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -127.23 89.58 2.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.0 t -44.26 132.23 5.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.458 ' HA ' HD21 ' A' ' 80' ' ' LEU . 19.8 mt -79.4 0.07 30.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.416 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.7 OUTLIER -72.99 119.94 17.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 179.885 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.416 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 116.31 -34.73 4.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.562 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -92.42 158.8 15.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.902 -179.91 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 49.5 p -92.04 178.94 5.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.407 ' HE2' ' C ' ' A' ' 27' ' ' ILE . 4.0 t-80 -50.06 -53.85 24.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.49 -48.69 63.89 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.484 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.468 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 22.4 mt-10 -61.04 -51.96 66.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.867 0.365 . . . . 0.0 110.887 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.562 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.19 -50.85 48.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.089 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.7 t -52.3 -58.84 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.479 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 59.9 mm-40 -53.11 -21.22 4.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.6 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.7 tt -78.03 -26.75 48.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.764 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -84.02 -28.47 27.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.479 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.3 ptm180 -93.72 1.19 56.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 46.3 t -96.24 33.1 1.81 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.841 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -111.28 136.53 47.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.163 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -57.46 -101.57 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.518 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -112.55 -3.71 14.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.868 0.366 . . . . 0.0 110.841 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 m -158.47 135.31 9.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.841 ' HB3' HG21 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -123.82 168.16 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.918 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.467 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -118.14 96.24 5.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.118 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -93.93 129.84 43.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.835 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.7 tp -99.18 25.19 7.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.934 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.65 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.7 m -62.43 166.84 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.119 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.9 p -158.37 152.84 24.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.446 ' HA ' HD23 ' A' ' 67' ' ' LEU . 3.8 m-20 -43.83 104.61 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.53 -179.959 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.693 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -94.98 28.07 2.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' HD12 ' A' ' 99' ' ' LEU . 1.0 OUTLIER -98.02 171.43 8.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.409 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 41.4 tt0 -74.39 108.45 7.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.23 158.02 21.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.923 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.9 p -137.83 148.68 45.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 57' ' ' ALA . 40.7 mt -114.18 96.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -69.2 112.95 6.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.437 ' HZ1' ' CD2' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.71 172.6 9.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -60.62 164.35 7.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.547 0.689 . . . . 0.0 111.091 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.717 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.77 2.41 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.329 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 24.74 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.774 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 9.1 tp10 -95.4 132.13 40.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.91 0.386 . . . . 0.0 110.892 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.441 ' O ' ' C ' ' A' ' 23' ' ' LEU . 67.2 mtt180 -82.35 118.49 23.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.872 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.783 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.19 -51.63 0.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.952 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.82 28.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.5 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.612 HG12 HD12 ' A' ' 23' ' ' LEU . 1.4 pt -119.42 170.36 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 111.143 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -132.61 166.86 21.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.44 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 19.7 pt -155.41 145.05 12.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ptt180 -124.02 124.76 43.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.76 -148.5 19.03 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.47 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.524 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.449 -0.26 . . . . 0.0 112.449 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.47 HG12 ' N ' ' A' ' 30' ' ' GLY . 39.5 mt -115.34 119.49 61.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.867 0.365 . . . . 0.0 111.131 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.608 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -133.09 -174.7 3.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.918 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.76 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -90.48 128.4 42.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.6 t -105.21 -12.95 15.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' O ' ' N ' ' A' ' 26' ' ' SER . 39.4 ttmt -175.79 139.7 0.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.76 HG21 HD12 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -146.14 118.38 2.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 18.2 t -48.01 134.08 11.75 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.675 0.75 . . . . 0.0 110.881 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -16.12 37.39 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.728 2.286 . . . . 0.0 112.319 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.67 -6.98 13.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.173 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -63.79 174.24 11.84 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.468 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.511 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -52.88 -37.13 60.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.783 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -80.8 -60.38 2.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.115 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -36.56 -47.25 1.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.478 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.478 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 21.1 ptt180 -69.72 -36.4 75.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.36 . . . . 0.0 110.897 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ALA . 28.7 t70 -39.91 -56.12 1.87 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.81 -22.78 15.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -95.29 -44.66 7.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.841 0.353 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.76 HD11 HD13 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -58.11 145.12 37.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 -179.956 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.724 ' N ' HD13 ' A' ' 63' ' ' LEU . 12.2 ptt-85 -175.23 146.61 0.85 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.483 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 57.4 t -57.89 105.49 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.106 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.72 -25.56 2.42 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.451 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.714 HD23 ' C ' ' A' ' 101' ' ' CYS . 11.4 mt -69.74 118.41 12.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.796 0.332 . . . . 0.0 110.933 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.551 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 25.4 ttt180 -68.85 123.25 20.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.576 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -74.24 110.03 8.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.933 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.434 ' HA ' HD13 ' A' ' 70' ' ' LEU . 2.1 mm? -85.61 -50.47 7.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -152.47 139.73 19.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.677 HG13 HD12 ' A' ' 96' ' ' LEU . 97.0 t -114.42 109.53 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.092 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.522 ' ND2' HG22 ' A' ' 92' ' ' VAL . 9.7 m-20 65.64 40.88 4.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 63.62 34.07 12.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 33.2 mt-30 -130.69 92.19 3.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 t -43.97 129.72 5.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.674 HD11 HG23 ' A' ' 72' ' ' VAL . 16.8 mt -89.65 10.14 24.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.884 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.576 HD13 ' N ' ' A' ' 79' ' ' GLY . 1.5 tm? -80.88 122.57 27.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.576 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.15 -33.51 5.68 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.541 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -85.82 164.2 17.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.93 -179.934 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.436 ' O ' ' C ' ' A' ' 82' ' ' HIS . 75.2 p -98.66 160.59 14.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.44 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.7 t-80 -33.67 -55.76 0.45 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -55.1 -46.99 76.17 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.466 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -62.86 -44.34 96.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 110.89 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.525 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -62.26 -51.77 66.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.56 ' HA ' HD23 ' A' ' 89' ' ' LEU . 38.2 t -49.45 -61.5 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.111 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.49 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 86.6 mm-40 -47.41 -24.08 0.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.556 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.4 tt -78.39 -33.03 49.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.897 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.597 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -78.9 -30.27 44.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 179.923 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.49 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.5 ptm180 -90.14 4.48 50.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.84 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.0 t -97.2 19.35 13.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 96' ' ' LEU . 26.1 t -82.14 150.54 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.64 -78.9 1.43 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -120.31 -22.35 6.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -160.23 131.94 6.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.134 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.677 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -113.09 171.5 7.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.409 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.0 m -121.19 97.65 5.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.3 m -95.54 130.13 44.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.7 tp -104.11 33.9 3.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.576 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.4 m -66.51 -179.27 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.714 ' C ' HD23 ' A' ' 67' ' ' LEU . 1.2 p -173.09 158.15 3.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.46 104.42 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.897 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 -179.921 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.53 16.12 1.83 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.812 0.339 . . . . 0.0 110.933 -179.935 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.5 mmt180 -85.63 160.92 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.918 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -70.44 113.82 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 19.6 mt -114.54 172.32 7.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.9 p -151.59 159.32 44.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.479 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 72.5 mt -129.12 112.43 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -80.33 127.44 32.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -139.92 173.62 11.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.851 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -61.4 169.18 2.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.593 0.711 . . . . 0.0 111.091 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.851 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.77 -3.07 11.29 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.333 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 34.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.623 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.8 tp10 -101.17 137.89 38.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.865 0.364 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.482 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.3 mtp180 -81.86 118.68 23.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.859 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.736 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.55 -43.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.937 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.92 40.89 42.8 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.727 HD11 HD13 ' A' ' 89' ' ' LEU . 1.2 pt -119.92 161.62 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -130.6 135.68 48.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.625 HD12 HG21 ' A' ' 46' ' ' ILE . 18.2 pt -129.56 156.41 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -132.73 132.93 42.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.36 -137.72 5.84 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.469 -179.931 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.625 HG21 HD12 ' A' ' 27' ' ' ILE . 26.4 mt -132.34 117.02 30.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 111.142 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.09 155.77 45.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.818 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.897 HD13 HD11 ' A' ' 63' ' ' LEU . 77.7 mt -64.57 126.32 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.156 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -105.37 -18.25 14.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.508 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.9 tttp -165.76 154.35 11.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 25' ' ' ILE . 98.1 t -145.27 124.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -68.05 133.15 91.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.67 0.748 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -8.35 23.37 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.645 2.23 . . . . 0.0 112.332 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 54.9 p -111.13 -9.58 14.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.68 168.53 51.32 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.55 -35.01 67.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.78 0.324 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.736 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.33 -65.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.103 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.79 -40.08 2.08 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -77.01 -28.45 55.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.796 0.331 . . . . 0.0 110.892 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 57' ' ' ALA . 9.9 t0 -54.28 -64.03 0.96 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.06 -24.23 6.36 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -92.46 -66.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.813 0.339 . . . . 0.0 110.833 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.897 HD11 HD13 ' A' ' 48' ' ' ILE . 1.4 tm? -48.34 118.02 2.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.579 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.2 ptp180 -142.69 154.85 44.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.508 HG21 ' HA ' ' A' ' 50' ' ' LYS . 63.1 t -61.31 106.06 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 147.68 -27.18 1.48 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.459 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.735 HD23 HG23 ' A' ' 100' ' ' VAL . 7.6 mp -74.79 140.62 44.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.773 0.32 . . . . 0.0 110.892 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 57.2 ttt180 -87.61 121.01 29.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.826 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.599 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.0 mm? -67.87 105.97 2.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.949 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.438 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 1.7 mm? -80.15 -50.43 10.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 24.2 mt-10 -159.17 142.92 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.908 HG13 HD12 ' A' ' 96' ' ' LEU . 95.6 t -114.75 109.6 29.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.131 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.1 m-20 65.38 41.77 4.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 28.4 mt-30 64.6 34.04 10.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.26 90.59 3.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.941 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.421 ' O ' HD21 ' A' ' 80' ' ' LEU . 38.5 t -46.1 129.19 9.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.879 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.456 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.0 mt -78.82 -0.49 30.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.06 116.7 17.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.59 -34.7 4.28 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.457 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.498 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -88.48 170.9 10.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.888 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' C ' ' A' ' 82' ' ' HIS . 42.0 p -107.8 160.92 15.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.095 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.486 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 t-80 -32.97 -53.5 0.36 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.87 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.28 -49.96 57.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.416 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 3.1 mm-40 -64.38 -45.41 87.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.844 0.354 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.498 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.67 -47.51 82.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 82' ' ' HIS . 78.6 t -59.25 -58.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 74.7 mm-40 -51.24 -26.06 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.1 tt -72.3 -29.24 63.67 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.962 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.727 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.5 -29.59 46.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.895 179.883 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 2.4 ptm85 -92.51 0.77 57.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 21.6 t -98.99 36.24 1.73 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.88 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.552 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.1 p -111.6 144.94 18.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.09 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.8 -105.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 19' ' ' PRO . 1.3 t70 -103.39 -3.33 25.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.912 0.386 . . . . 0.0 110.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.469 ' C ' HG21 ' A' ' 92' ' ' VAL . 49.8 m -166.14 143.08 5.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.908 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.8 168.41 11.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -120.33 98.18 5.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.16 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.469 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.2 m -98.65 130.37 47.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.104 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.4 tp -96.4 21.49 9.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.735 HG23 HD23 ' A' ' 67' ' ' LEU . 3.0 m -52.26 -175.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.106 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.5 p -175.96 157.58 1.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -52.65 100.82 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.465 -179.905 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.701 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.3 29.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.796 0.332 . . . . 0.0 110.914 -179.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 11' ' ' ARG . 23.1 mtm105 -96.32 142.36 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.442 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.5 tt0 -53.35 114.9 1.65 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.69 163.49 16.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.943 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.7 p -146.09 153.72 41.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.427 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 82.7 mt -120.95 110.34 27.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.083 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -85.11 102.45 13.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.464 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 3.4 ptpp? -112.33 171.56 7.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.854 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.842 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.72 168.79 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.619 0.723 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.842 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.85 0.95 4.97 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.321 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.61 41.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.507 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 48.9 tp10 -105.66 140.53 38.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.467 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.3 ptm180 -86.36 122.78 30.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.824 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.851 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.16 -46.9 0.17 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.32 44.76 51.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.911 HG22 HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -118.68 168.04 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.854 0.359 . . . . 0.0 111.111 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.8 m -133.75 147.16 51.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.52 HD12 HG21 ' A' ' 46' ' ' ILE . 28.7 pt -138.32 155.63 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.152 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.5 ptt180 -126.83 124.54 39.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.857 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.55 -147.15 15.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.52 HG21 HD12 ' A' ' 27' ' ' ILE . 26.8 mt -126.85 116.99 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.111 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.553 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -129.13 153.85 47.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.636 HD13 HD11 ' A' ' 63' ' ' LEU . 23.5 mt -62.78 138.26 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.1 t -118.18 -16.91 9.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.848 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.53 ' HA ' HG21 ' A' ' 65' ' ' VAL . 64.9 tttt -165.22 146.96 7.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.889 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 25' ' ' ILE . 32.4 t -142.11 133.62 26.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.168 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 7.8 t -74.7 141.79 76.31 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.681 0.753 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -31.21 20.96 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.663 2.242 . . . . 0.0 112.324 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 47.8 p -93.56 -6.66 46.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.151 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.9 150.63 46.37 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.72 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -40.88 -31.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.809 0.338 . . . . 0.0 111.098 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.8 -65.55 0.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.088 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -41.11 -34.44 0.88 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -90.82 -23.22 20.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.478 ' N ' ' O ' ' A' ' 57' ' ' ALA . 10.7 t0 -52.58 -52.24 56.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.34 -7.94 40.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.518 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -115.39 -48.61 2.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.869 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -67.39 130.84 44.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.598 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -161.52 157.41 24.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.849 179.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.53 HG21 ' HA ' ' A' ' 50' ' ' LYS . 80.5 t -59.67 105.89 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.31 -15.58 1.67 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.61 HD23 ' HA ' ' A' ' 102' ' ' ASP . 58.1 mt -85.45 134.27 34.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.553 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 72.3 ttt180 -84.1 121.79 27.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.69 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -70.28 116.14 10.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 99' ' ' LEU . 71.6 mt -96.87 -49.42 5.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.94 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -155.13 141.75 18.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.694 HG13 HD12 ' A' ' 96' ' ' LEU . 78.4 t -118.73 108.27 23.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.075 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 72' ' ' VAL . 15.0 m-20 65.7 40.91 4.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 64.01 35.21 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -131.07 91.1 2.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.4 t -42.4 128.79 3.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.548 ' HA ' HD11 ' A' ' 80' ' ' LEU . 9.9 mt -80.68 9.01 6.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.933 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.679 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -83.09 137.6 34.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.679 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 97.76 -33.22 6.05 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.489 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.548 HD11 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -88.08 166.96 14.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.887 0.375 . . . . 0.0 110.91 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.0 p -106.92 165.43 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.512 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.82 -60.54 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.53 -47.68 22.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.3 mt-10 -66.01 -53.01 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.853 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.401 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -49.4 -49.35 45.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.1 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.2 t -59.1 -57.06 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -53.04 -17.51 1.54 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.5 tt -83.98 -28.08 28.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.834 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -84.12 -27.4 28.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.9 ptm180 -97.03 5.74 49.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 m -102.27 32.43 3.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.885 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.5 p -111.11 140.04 32.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.117 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -56.56 -100.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.451 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -113.17 -10.56 13.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.906 0.384 . . . . 0.0 110.868 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.1 m -151.64 135.39 16.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.131 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.803 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -124.17 171.26 9.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.442 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.4 m -120.69 96.6 5.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.2 m -94.25 128.64 45.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.162 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.686 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.6 tp -97.11 29.07 3.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.69 HG12 HD22 ' A' ' 69' ' ' LEU . 14.0 m -58.48 172.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.115 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.8 p -162.27 148.47 13.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.61 ' HA ' HD23 ' A' ' 67' ' ' LEU . 4.9 m-20 -51.16 110.62 0.45 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.329 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.921 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 N-CA-C 112.531 -0.228 . . . . 0.0 112.531 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.706 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.21 33.94 0.51 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 110.939 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.822 ' O ' HD12 ' A' ' 13' ' ' LEU . 20.5 mtt-85 -99.28 165.03 11.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 42.1 tt0 -77.84 110.18 12.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.822 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -115.27 166.12 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.93 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.4 p -146.89 160.9 41.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.8 mt -124.1 115.17 44.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mp0 -85.21 113.11 21.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.6 ptpp? -126.89 165.41 19.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.65 169.12 0.13 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.78 -2.84 10.87 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.36 38.28 0.33 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.556 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.69 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 28.2 tp10 -103.53 140.64 37.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.815 0.34 . . . . 0.0 110.909 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.453 ' O ' ' C ' ' A' ' 23' ' ' LEU . 6.2 ptt85 -83.27 121.22 26.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.87 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -33.9 -54.12 0.47 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.37 40.51 9.98 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.439 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.928 HD11 HD13 ' A' ' 89' ' ' LEU . 4.1 pt -120.22 169.72 11.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.146 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.4 m -141.17 145.07 35.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.566 HD12 ' CG2' ' A' ' 46' ' ' ILE . 30.7 pt -134.85 158.96 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -131.4 133.29 45.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.73 -142.61 10.08 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.499 -179.929 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.566 ' CG2' HD12 ' A' ' 27' ' ' ILE . 40.2 mt -129.51 118.34 45.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.864 0.364 . . . . 0.0 111.151 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -132.17 -177.74 4.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.932 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -87.57 133.82 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.142 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -113.59 -14.55 12.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 24.6 tttm -172.51 145.21 1.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.944 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.596 HG12 HG23 ' A' ' 65' ' ' VAL . 0.6 OUTLIER -152.92 110.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.15 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.4 t -53.83 129.6 56.12 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.678 0.751 . . . . 0.0 110.85 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.403 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.5 Cg_endo -69.78 -6.36 18.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.712 2.274 . . . . 0.0 112.29 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 32.2 p -105.07 -18.43 14.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.173 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.24 179.81 14.15 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.49 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.441 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -57.69 -39.1 76.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.762 0.315 . . . . 0.0 111.08 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.87 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.99 -63.65 1.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.14 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.46 -48.56 1.69 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.441 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.441 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.5 ptt180 -70.63 -31.17 68.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 57' ' ' ALA . 31.2 t0 -44.55 -61.62 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.838 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.38 -20.34 10.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.477 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.6 mmp_? -99.61 -47.47 5.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.896 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.932 HD11 HD13 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -61.11 130.36 45.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.936 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.64 ' N ' HD13 ' A' ' 63' ' ' LEU . 16.8 ptt85 -162.01 146.0 12.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.596 HG23 HG12 ' A' ' 51' ' ' VAL . 82.7 t -53.87 106.58 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.156 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 143.09 -11.42 2.31 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.48 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.474 HD12 ' H ' ' A' ' 64' ' ' ARG . 34.6 mt -86.52 124.02 32.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.854 0.359 . . . . 0.0 110.922 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.533 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 57.5 ttt180 -75.23 117.49 17.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.733 HD22 HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -71.45 114.24 9.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.526 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.5 mt -90.43 -54.76 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.975 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -150.1 143.34 25.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 95.2 t -115.94 110.13 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.127 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 65.62 41.12 4.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.7 mt-30 64.43 30.46 13.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.956 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 22.8 mt-30 -124.64 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 t -44.04 133.87 4.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.811 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.756 ' HA ' HD21 ' A' ' 80' ' ' LEU . 13.3 mt -88.94 7.63 33.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.421 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.9 OUTLIER -77.31 116.16 17.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.76 -33.25 5.3 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.463 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.756 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -86.4 164.54 16.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.91 0.386 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' C ' ' A' ' 82' ' ' HIS . 81.9 p -104.1 165.51 11.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.167 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -34.7 -59.92 0.46 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.834 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.09 -49.85 23.3 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.9 mt-10 -63.02 -51.7 65.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.89 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.46 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -52.01 -51.75 55.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.117 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.549 ' HA ' HD23 ' A' ' 89' ' ' LEU . 69.2 t -53.15 -60.45 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 78.1 mm-40 -50.36 -26.17 4.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.3 tt -74.04 -29.95 62.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.923 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.928 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -79.84 -27.11 40.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 0.6 OUTLIER -96.96 -3.17 42.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.86 179.94 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.4 m -89.76 29.94 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.872 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.76 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -110.45 144.04 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.17 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.94 -101.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -111.39 -6.67 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.897 0.379 . . . . 0.0 110.854 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.7 m -155.24 136.47 13.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -126.49 167.2 15.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.983 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.41 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -116.54 94.52 4.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.175 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.5 m -91.05 127.15 43.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.162 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.526 ' O ' HD12 ' A' ' 70' ' ' LEU . 19.1 tp -95.97 33.03 1.77 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.878 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.733 HG12 HD22 ' A' ' 69' ' ' LEU . 5.9 m -60.98 174.62 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.146 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -167.78 155.12 8.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.83 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.417 ' HA ' HD23 ' A' ' 67' ' ' LEU . 5.6 p-10 -51.5 107.6 0.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.852 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.467 -179.948 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.263 0 N-CA-C 112.489 -0.245 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.733 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.43 30.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.328 . . . . 0.0 110.907 -179.916 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.411 ' O ' HD12 ' A' ' 99' ' ' LEU . 25.4 mtp180 -94.95 161.37 14.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -70.92 112.17 6.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.873 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.6 mt -116.88 159.52 22.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.581 ' SG ' HG23 ' A' ' 97' ' ' THR . 3.0 m -142.45 159.66 41.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 23' ' ' LEU . 40.5 mt -125.58 114.57 40.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.173 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -88.6 107.66 19.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.511 ' CB ' ' HB2' ' A' ' 56' ' ' ALA . 1.0 OUTLIER -116.18 166.14 12.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.836 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.25 168.72 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.578 0.704 . . . . 0.0 111.097 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.836 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.79 3.35 2.83 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.703 2.268 . . . . 0.0 112.334 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -169.79 36.24 0.18 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.462 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.614 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.7 tp10 -105.47 142.52 35.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.889 0.376 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' O ' ' C ' ' A' ' 23' ' ' LEU . 58.8 mtt180 -88.94 123.37 33.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.829 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.86 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.49 -49.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 77.41 32.48 47.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.487 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.697 HG23 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -108.87 160.0 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.817 0.342 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.495 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -123.6 150.61 43.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 27.5 pt -140.36 150.92 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -128.47 131.85 48.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.9 -144.85 13.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 26.8 mt -128.83 116.43 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.871 0.367 . . . . 0.0 111.133 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.554 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.6 m-85 -131.13 153.26 49.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.731 HD13 HD11 ' A' ' 63' ' ' LEU . 70.3 mt -62.67 128.22 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.4 t -107.13 -18.89 13.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.4 tttp -159.89 153.41 22.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 50' ' ' LYS . 78.7 t -143.28 127.52 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 29.1 t -66.24 140.29 96.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.726 0.774 . . . . 0.0 110.813 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -35.66 12.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.721 2.281 . . . . 0.0 112.328 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.02 -1.43 45.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.092 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -73.11 148.83 41.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.501 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.513 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -39.86 -35.18 0.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.82 0.343 . . . . 0.0 111.119 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.86 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.11 -59.66 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.082 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -47.89 -33.18 9.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.475 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.6 ptt-85 -84.97 -32.26 23.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 11.1 t0 -50.1 -61.57 2.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.839 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.22 -18.74 13.76 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.501 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -96.71 -42.81 7.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.828 0.347 . . . . 0.0 110.89 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.772 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.2 tm? -69.83 136.54 50.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.631 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -166.67 155.26 10.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 50' ' ' LYS . 85.2 t -61.25 105.55 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.45 -24.74 1.22 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.533 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.462 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.7 mt -74.85 135.88 41.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.554 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 45.8 ttt180 -85.69 117.59 24.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.873 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.782 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -68.11 116.07 8.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.8 mt -94.09 -52.29 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -152.13 145.71 24.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.873 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.874 HG13 HD12 ' A' ' 96' ' ' LEU . 75.9 t -119.5 108.38 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.118 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.5 m-20 65.12 41.54 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.9 mt-30 64.07 32.11 13.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -125.35 91.11 3.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 t -47.82 126.41 10.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD21 ' A' ' 80' ' ' LEU . 11.4 mt -78.04 -0.37 27.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.863 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.37 115.38 11.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.922 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.93 -34.4 4.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.479 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.552 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -90.99 164.01 14.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.841 0.353 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 82' ' ' HIS . 38.1 p -102.18 163.39 12.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -34.32 -58.33 0.47 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.837 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.33 -45.68 21.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.46 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 10.3 mm-40 -70.93 -53.46 14.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.853 0.359 . . . . 0.0 110.838 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.533 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.03 -49.01 21.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.049 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.565 ' HA ' HD23 ' A' ' 89' ' ' LEU . 70.0 t -57.34 -59.12 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.489 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 83.3 mm-40 -51.08 -22.79 2.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.917 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.557 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.62 -31.83 60.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.627 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.87 -27.93 49.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.962 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.489 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.9 ptm180 -94.41 1.5 55.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.866 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.9 t -94.62 30.92 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.583 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -113.17 146.48 17.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.13 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.62 -95.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -119.55 -2.08 10.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.912 0.387 . . . . 0.0 110.9 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 m -157.14 132.01 8.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.874 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -122.95 164.37 18.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.944 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.581 HG23 ' SG ' ' A' ' 14' ' ' CYS . 1.6 m -113.07 94.14 4.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.443 HG12 HD11 ' A' ' 96' ' ' LEU . 3.2 m -90.74 129.04 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.615 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.0 tp -98.51 29.81 3.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.956 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.782 HG12 HD22 ' A' ' 69' ' ' LEU . 15.7 m -54.42 179.19 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 3.3 p -171.52 148.75 2.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -41.19 113.61 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.849 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.467 -179.949 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.445 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.734 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.37 41.39 0.61 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.794 0.331 . . . . 0.0 110.889 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.7 mmm180 -111.34 152.37 27.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.484 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 19.0 tt0 -68.38 109.18 3.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.909 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.6 mt -106.52 168.72 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -151.4 147.85 27.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 95' ' ' THR . 71.1 mt -118.66 120.23 63.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -88.46 125.61 34.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.8 ptpp? -138.68 168.56 19.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.844 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -48.69 168.9 0.17 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.585 0.707 . . . . 0.0 111.122 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.844 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.7 2.02 3.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.672 2.248 . . . . 0.0 112.379 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.58 35.53 0.17 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.7 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 21.5 tp10 -99.02 149.74 22.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' C ' ' A' ' 23' ' ' LEU . 86.4 mtt180 -89.46 121.6 31.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -32.91 -46.55 0.15 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.5 42.55 17.7 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.766 HG22 HG13 ' A' ' 51' ' ' VAL . 2.6 pt -126.01 168.66 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.842 0.353 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -138.91 142.73 38.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.492 HD12 HG21 ' A' ' 46' ' ' ILE . 39.6 pt -128.82 163.08 34.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.488 ' CG ' ' HB3' ' A' ' 49' ' ' SER . 22.6 ptt180 -134.56 124.71 25.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 158.81 -143.17 8.99 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 -179.913 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.492 HG21 HD12 ' A' ' 27' ' ' ILE . 38.8 mt -133.86 117.75 27.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.821 0.343 . . . . 0.0 111.132 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.563 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.1 m-85 -131.25 154.07 48.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 63' ' ' LEU . 37.6 mt -58.99 138.14 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.488 ' HB3' ' CG ' ' A' ' 28' ' ' ARG . 60.7 p -117.48 -18.68 9.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.845 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 5.0 ttpm? -165.56 155.01 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.766 HG13 HG22 ' A' ' 25' ' ' ILE . 98.4 t -148.68 128.66 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 33.9 t -81.74 139.15 46.94 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.668 0.747 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.57 23.83 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.713 2.275 . . . . 0.0 112.356 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 59.7 p -80.83 -19.25 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.06 170.62 40.76 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.08 -33.65 72.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.326 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.615 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -71.2 -70.45 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.59 -40.95 0.76 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.471 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 10.7 ptt180 -75.68 -34.67 60.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.783 0.325 . . . . 0.0 110.829 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 57' ' ' ALA . 15.3 t0 -47.72 -64.7 0.72 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.36 -19.4 8.63 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.476 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 42.9 mtm180 -96.72 -61.55 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.888 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.586 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.8 tm? -46.4 133.4 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.553 ' H ' HD12 ' A' ' 67' ' ' LEU . 6.2 ptt180 -156.24 149.95 24.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.847 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.476 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 45.1 t -61.26 100.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.106 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 153.59 -19.89 0.7 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.445 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.553 HD12 ' H ' ' A' ' 64' ' ' ARG . 9.8 mt -77.81 140.74 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.783 0.325 . . . . 0.0 110.921 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 70.8 ttt180 -88.72 119.13 28.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.678 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -71.4 107.0 4.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.441 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 11.1 mp -83.45 -53.29 5.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.441 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -151.68 146.65 25.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.819 HG13 HD12 ' A' ' 96' ' ' LEU . 95.5 t -117.84 109.49 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.414 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 66.18 41.81 3.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.918 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.9 mt-30 64.64 29.96 12.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -122.9 89.04 3.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.1 t -40.49 129.03 2.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 83.9 mt -83.08 12.27 5.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.939 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -86.13 112.83 21.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.05 -38.97 2.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.57 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -84.15 168.53 15.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 23.0 p -108.62 166.1 11.04 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.168 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -33.13 -61.77 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.4 -48.55 21.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.481 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.465 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.6 mt-10 -65.05 -55.98 15.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.87 0.366 . . . . 0.0 110.863 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.5 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -45.76 -50.36 14.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.405 ' HA ' HD23 ' A' ' 89' ' ' LEU . 71.2 t -55.64 -59.61 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.486 ' NE2' ' HD3' ' A' ' 90' ' ' ARG . 51.8 mm-40 -50.12 -25.41 3.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.886 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.1 tt -74.85 -32.16 61.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.805 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.5 OUTLIER -77.96 -30.09 50.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.486 ' HD3' ' NE2' ' A' ' 87' ' ' GLN . 12.6 ptm180 -92.72 -7.13 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.874 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.5 m -87.84 30.01 0.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.709 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.9 p -106.69 143.73 16.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.51 -102.68 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.481 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -105.98 -13.41 15.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.886 0.374 . . . . 0.0 110.843 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 15' ' ' ILE . 3.3 m -153.89 141.29 19.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.177 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.819 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -124.01 169.52 11.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.484 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -122.02 99.35 6.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.9 m -96.14 130.99 44.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp -97.12 31.31 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.678 HG12 HD22 ' A' ' 69' ' ' LEU . 11.3 m -59.8 177.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.137 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.445 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 13.2 p -175.23 143.06 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -38.69 104.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.871 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.455 -179.954 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.514 -0.235 . . . . 0.0 112.514 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.739 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.17 39.87 0.6 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.915 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.8 mtp180 -111.76 148.13 34.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 33.7 tt0 -61.89 111.29 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.5 mt -113.08 161.83 16.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -140.66 155.25 46.55 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.434 HG22 ' HB1' ' A' ' 56' ' ' ALA . 88.7 mt -123.01 108.71 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -84.53 114.98 22.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 0.5 OUTLIER -125.65 171.02 10.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.85 168.2 0.11 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.583 0.706 . . . . 0.0 111.07 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.82 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 2.81 3.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.704 2.27 . . . . 0.0 112.379 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -173.61 41.04 0.14 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.481 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 32.7 tp10 -107.36 147.16 30.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.876 0.37 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.7 mmt-85 -83.95 122.95 29.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.658 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.53 -47.58 0.23 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.16 41.48 13.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.583 HG23 HD12 ' A' ' 23' ' ' LEU . 3.0 pt -121.54 166.89 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.845 0.355 . . . . 0.0 111.154 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.426 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -130.3 149.76 51.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.85 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 pt -140.57 149.25 21.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.102 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.432 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.3 ptm85 -130.81 144.37 51.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 125.51 -155.48 18.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.468 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.468 HG12 ' N ' ' A' ' 30' ' ' GLY . 52.5 mt -139.95 116.65 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.874 0.368 . . . . 0.0 111.114 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.558 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 0.7 OUTLIER -133.46 156.17 48.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.861 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.548 HD11 HD21 ' A' ' 63' ' ' LEU . 82.9 mt -58.98 129.95 21.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.145 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.2 p -103.89 -13.3 16.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.473 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 40.2 tttt -173.9 162.89 4.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.509 HG13 HG22 ' A' ' 25' ' ' ILE . 99.3 t -150.14 133.1 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -75.35 142.3 74.72 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.678 0.751 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -23.47 30.44 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.713 2.275 . . . . 0.0 112.343 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 80.0 p -103.52 -14.59 16.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.42 154.95 19.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -46.46 -33.75 4.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.821 0.343 . . . . 0.0 111.123 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.961 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -75.19 -60.52 2.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.35 -43.49 6.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -79.82 -21.88 43.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.77 0.319 . . . . 0.0 110.84 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 57' ' ' ALA . 12.9 t70 -55.02 -59.45 4.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.865 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.8 -4.19 14.56 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -118.48 -70.5 0.79 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 110.927 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.961 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -37.22 140.34 0.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.629 ' N ' HD13 ' A' ' 63' ' ' LEU . 9.0 ptm180 -167.04 161.4 14.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.47 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 18.7 t -70.27 102.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.125 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.68 -9.03 1.37 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 102' ' ' ASP . 17.5 mt -89.25 128.22 35.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.331 . . . . 0.0 110.88 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.558 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -78.59 121.54 24.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.604 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -70.24 111.79 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.668 HD12 ' O ' ' A' ' 99' ' ' LEU . 58.3 mt -89.24 -49.44 6.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -155.17 141.87 18.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.937 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.881 HG13 HD12 ' A' ' 96' ' ' LEU . 72.7 t -118.67 109.31 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 65.43 40.65 4.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.7 mt-30 63.75 34.62 11.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.881 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.832 ' HB2' HD21 ' A' ' 88' ' ' LEU . 59.1 mt-30 -129.2 90.31 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.7 t -42.89 131.47 4.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.691 HD23 HD13 ' A' ' 88' ' ' LEU . 23.5 mt -89.81 9.04 28.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.953 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -77.32 131.5 38.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.943 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.577 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 103.03 -43.98 1.57 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.657 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -79.18 155.89 28.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.884 0.373 . . . . 0.0 110.948 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 68.7 p -93.71 -174.54 3.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -49.52 -61.91 1.84 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -46.35 -57.48 6.42 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.459 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 27.2 mt-10 -56.08 -42.05 76.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.902 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -60.91 -48.54 81.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.11 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 67.8 t -52.52 -57.78 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.122 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.481 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 57.3 mm-40 -52.67 -20.35 3.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.899 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.842 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.7 tt -79.71 -26.85 40.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.944 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -82.27 -22.43 35.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.844 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.481 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.0 ptm180 -96.74 -0.15 48.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 p -83.21 16.69 2.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.814 HG21 ' HB3' ' A' ' 96' ' ' LEU . 4.5 p -106.8 141.05 22.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.99 -86.51 0.15 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.48 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.411 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 2.0 p30 -119.89 -12.54 9.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.2 m -149.3 132.65 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.175 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.881 HD12 HG13 ' A' ' 72' ' ' VAL . 0.8 OUTLIER -123.47 170.98 9.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.439 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -121.5 99.31 6.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.431 HG12 HD11 ' A' ' 96' ' ' LEU . 3.1 m -96.41 131.42 43.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.668 ' O ' HD12 ' A' ' 70' ' ' LEU . 18.4 tp -98.32 31.3 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.953 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 69' ' ' LEU . 5.8 m -62.59 176.88 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.112 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.1 p -171.67 145.23 1.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.597 ' HA ' HD23 ' A' ' 67' ' ' LEU . 2.2 p-10 -42.27 100.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.912 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.53 -179.956 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.339 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.67 16.06 1.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.888 -179.909 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -89.44 149.29 23.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.431 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 30.3 tt0 -59.7 115.31 3.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.1 mt -116.69 160.66 20.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.478 ' SG ' HG23 ' A' ' 97' ' ' THR . 2.7 m -139.93 157.39 45.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 57' ' ' ALA . 34.8 mt -125.42 107.04 17.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -80.53 107.76 13.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.403 ' HA ' ' NH2' ' A' ' 59' ' ' ARG . 0.9 OUTLIER -117.29 168.24 10.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.776 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.92 166.78 0.2 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.58 0.705 . . . . 0.0 111.103 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.776 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.4 Cg_endo -69.75 2.87 3.14 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.659 2.24 . . . . 0.0 112.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.24 38.18 0.19 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.482 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.679 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.5 tp10 -101.98 133.98 45.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.837 0.351 . . . . 0.0 110.869 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 23' ' ' LEU . 91.3 mtt180 -78.95 116.87 19.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.831 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -34.02 -51.84 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.939 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.27 42.62 34.57 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.474 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -116.26 177.59 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.881 0.372 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.501 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -141.91 157.53 44.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.414 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.3 pt -149.33 151.01 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -127.11 122.99 35.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.63 -156.91 28.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.486 -0.245 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 ' N ' ' A' ' 30' ' ' GLY . 62.9 mt -124.66 118.32 53.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.113 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CZ ' ' HD2' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.41 -175.6 3.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.696 HD13 ' CD1' ' A' ' 63' ' ' LEU . 96.4 mt -85.47 138.65 18.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.088 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 53.4 p -116.04 -16.44 11.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -171.83 150.94 2.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.517 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -160.95 110.24 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.092 179.836 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 40.1 t -58.12 137.75 84.23 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.742 . . . . 0.0 110.853 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.9 Cg_endo -69.76 -23.15 31.13 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.665 2.244 . . . . 0.0 112.353 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.5 p -89.24 -16.91 30.13 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.15 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.51 172.28 35.57 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.17 -38.84 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.78 0.324 . . . . 0.0 111.086 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.831 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -73.32 -59.33 2.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.072 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 53' ' ' PRO . . . -45.17 -39.38 6.84 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.51 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.403 ' NH2' ' HA ' ' A' ' 17' ' ' LYS . 23.5 ptt180 -80.73 -20.76 42.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.844 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.402 ' N ' ' O ' ' A' ' 57' ' ' ALA . 13.9 t70 -60.53 -58.99 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.28 -15.71 32.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.476 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? -108.37 8.92 27.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.858 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.696 ' CD1' HD13 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -123.3 119.38 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.493 ' O ' HD12 ' A' ' 48' ' ' ILE . 28.2 mtp180 -145.3 165.64 27.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.517 HG23 HG12 ' A' ' 51' ' ' VAL . 77.9 t -77.11 97.17 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.49 -23.21 0.5 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.478 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.432 ' N ' HD12 ' A' ' 67' ' ' LEU . 7.5 mp -71.75 159.93 33.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HD2' ' CZ ' ' A' ' 47' ' ' PHE . 29.8 ttt-85 -105.71 118.06 35.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.838 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -66.3 103.18 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.907 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.502 ' CD1' ' NH1' ' A' ' 68' ' ' ARG . 9.7 mp -82.42 -42.23 18.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 68.8 mt-10 -162.05 142.73 10.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.723 HG13 HD12 ' A' ' 96' ' ' LEU . 84.9 t -121.6 108.23 21.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.153 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.426 ' ND2' HG22 ' A' ' 92' ' ' VAL . 12.5 m-20 65.33 41.2 4.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 63.37 31.84 14.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.543 ' O ' HD23 ' A' ' 77' ' ' LEU . 27.7 mt-30 -126.16 92.61 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.8 t -46.4 124.09 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.577 ' HA ' HD21 ' A' ' 80' ' ' LEU . 9.6 mt -81.29 3.46 23.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.451 ' HA ' HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -78.66 122.67 26.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.87 -31.78 6.81 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -89.87 160.82 16.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.932 0.396 . . . . 0.0 110.901 -179.903 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 13.9 p -97.61 161.14 13.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.56 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.1 t-80 -33.91 -57.83 0.45 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.11 -44.05 56.71 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.495 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 23.5 mt-10 -67.17 -47.7 70.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.86 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.561 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.95 -55.71 31.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 82' ' ' HIS . 91.9 t -43.54 -64.46 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.08 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.493 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 70.4 mm-40 -46.86 -25.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.523 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.85 -34.35 60.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -76.67 -29.03 56.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.962 179.85 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.493 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.2 ptm180 -93.82 4.49 53.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.897 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.6 t -96.3 29.71 2.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.662 HG11 ' HB3' ' A' ' 96' ' ' LEU . 12.4 t -94.5 150.58 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -93.55 -75.15 1.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -121.27 -26.03 5.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 0.0 110.855 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 15' ' ' ILE . 32.1 m -155.81 138.74 15.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.138 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.723 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.01 165.25 14.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.478 HG23 ' SG ' ' A' ' 14' ' ' CYS . 2.8 m -116.41 96.47 5.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.136 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' A' ' 96' ' ' LEU . 3.4 m -98.38 129.42 48.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.413 ' CD1' ' HA ' ' A' ' 12' ' ' GLU . 22.6 tp -96.16 20.23 10.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.838 HG12 HD22 ' A' ' 69' ' ' LEU . 26.2 m -48.88 177.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.057 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -175.46 162.93 2.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.69 118.9 6.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.472 -179.933 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.715 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.88 36.86 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.791 0.329 . . . . 0.0 110.918 -179.919 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.689 ' O ' HD12 ' A' ' 13' ' ' LEU . 55.7 mtp180 -108.31 173.86 6.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.464 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.4 tt0 -81.92 112.71 19.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.906 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.689 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -117.26 168.92 9.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.899 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.5 p -148.29 157.02 43.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.422 ' O ' HG23 ' A' ' 95' ' ' THR . 86.8 mt -120.97 111.33 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -80.0 117.73 21.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.47 ' NZ ' HD23 ' A' ' 23' ' ' LEU . 1.7 ptpt -132.18 166.47 21.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.86 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.0 168.63 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.551 0.691 . . . . 0.0 111.115 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.828 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.1 Cg_endo -69.83 -2.26 9.93 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 0.0 112.3 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.82 35.69 0.25 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.669 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 24.7 tp10 -99.84 147.14 25.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.915 0.388 . . . . 0.0 110.85 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 11.2 mtt-85 -86.93 123.67 32.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.847 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.768 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -34.23 -52.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.68 41.3 9.01 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.768 HG12 HD12 ' A' ' 23' ' ' LEU . 3.5 pt -122.76 170.91 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.785 0.326 . . . . 0.0 111.16 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.425 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -130.36 160.79 32.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.829 -179.901 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.438 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 14.8 pt -151.2 145.62 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.169 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.466 ' CG ' ' HB2' ' A' ' 49' ' ' SER . 18.8 ptt85 -128.88 122.01 29.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 163.6 -149.41 16.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.408 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.26 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.278 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.408 HG12 ' N ' ' A' ' 30' ' ' GLY . 30.3 mt -132.84 117.9 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 111.097 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -131.63 154.86 48.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.93 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.679 HD11 HD21 ' A' ' 63' ' ' LEU . 38.7 mt -58.2 134.44 22.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.156 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.466 ' HB2' ' CG ' ' A' ' 28' ' ' ARG . 36.8 t -112.47 -10.49 13.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.884 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.469 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 19.8 ttmt -173.79 148.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.632 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -138.3 114.36 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.126 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.4 t -64.59 140.69 98.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.711 0.767 . . . . 0.0 110.846 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -30.15 22.75 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 30.1 p -89.99 -4.16 57.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.442 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -76.87 155.88 45.22 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.514 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.584 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -47.0 -39.11 11.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.764 0.316 . . . . 0.0 111.098 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.975 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.78 -58.76 3.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -39.3 -43.88 2.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 27.8 ptt180 -82.43 -26.15 32.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 110.855 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.444 ' N ' ' O ' ' A' ' 57' ' ' ALA . 24.5 t70 -53.58 -69.28 0.12 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.862 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.01 -13.73 12.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -101.5 -17.96 16.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.975 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.0 tm? -103.33 125.5 49.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.726 ' N ' HD13 ' A' ' 63' ' ' LEU . 15.1 mtm-85 -139.5 174.81 10.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 51' ' ' VAL . 8.0 t -82.64 90.01 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.69 -15.37 0.3 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.572 ' HB2' HD12 ' A' ' 48' ' ' ILE . 56.0 mt -74.35 132.7 42.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.56 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 55.4 ttt180 -81.7 119.58 24.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.624 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -72.19 108.27 5.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.945 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 11.1 mp -86.39 -52.46 5.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -151.41 141.81 22.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.867 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 66.9 t -115.77 110.0 30.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.493 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.65 40.56 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 64.03 30.08 14.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.7 mt-30 -125.26 90.86 3.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.938 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 35.9 t -40.2 130.29 2.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.854 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD11 ' A' ' 80' ' ' LEU . 24.9 mt -88.11 17.44 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.939 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.822 ' O ' HD23 ' A' ' 80' ' ' LEU . 1.1 tp -85.75 152.69 22.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.907 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.07 -31.77 2.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.498 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -88.19 163.24 16.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.862 0.363 . . . . 0.0 110.923 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 56.7 p -99.06 -174.68 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.126 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.519 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.0 t-80 -52.66 -55.07 25.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.14 -50.19 63.3 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -58.75 -45.47 89.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.905 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.475 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -63.01 -48.76 77.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 82' ' ' HIS . 54.0 t -53.96 -60.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.181 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.491 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 50.0 mm-40 -50.04 -23.42 2.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.957 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.571 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -76.8 -30.76 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.601 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -78.96 -30.55 44.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.925 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.491 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.2 ptp180 -89.96 1.74 55.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.4 t -93.26 29.51 1.9 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.666 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.6 t -97.39 149.12 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.109 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.57 -77.79 1.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -118.85 -23.88 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.889 0.376 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 15' ' ' ILE . 8.2 m -158.12 143.09 16.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.145 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -124.05 168.97 12.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.464 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.7 m -120.57 98.84 6.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.144 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.402 ' HB ' HG13 ' A' ' 100' ' ' VAL . 6.5 m -95.62 131.19 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.107 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 11' ' ' ARG . 17.6 tp -98.1 35.74 1.69 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.624 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.6 m -68.48 173.07 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.6 p -162.55 150.37 14.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -49.99 101.78 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.476 -179.898 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.281 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.721 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.07 39.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 -179.894 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.42 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 5.3 mmm180 -113.76 158.27 21.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.424 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -67.43 109.66 3.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.7 mt -114.98 155.5 26.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 96' ' ' LEU . 28.2 p -138.24 151.95 48.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.742 ' O ' HG23 ' A' ' 95' ' ' THR . 39.4 mt -115.06 116.44 52.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -87.95 120.52 29.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.91 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.89 164.27 24.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.31 169.13 0.1 OUTLIER Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.596 0.712 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.81 3.15 2.97 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.687 2.258 . . . . 0.0 112.308 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.35 34.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.546 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 11.1 tp10 -103.62 140.27 37.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.843 0.354 . . . . 0.0 110.908 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.0 mmp_? -85.83 123.93 31.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.751 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.05 -43.77 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.882 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 71.53 44.79 49.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.524 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.713 HG12 HD12 ' A' ' 23' ' ' LEU . 1.1 pt -125.76 177.58 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.809 0.338 . . . . 0.0 111.126 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -141.02 154.29 45.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.434 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.2 pt -138.72 149.37 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.419 ' HE ' ' CB ' ' A' ' 49' ' ' SER . 8.2 ptp180 -125.53 125.94 44.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.07 -150.79 22.6 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.492 -179.861 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 mt -123.38 118.13 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.896 0.379 . . . . 0.0 111.117 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -128.61 150.91 50.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.61 HD11 HD21 ' A' ' 63' ' ' LEU . 56.0 mt -56.37 146.36 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.104 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.419 ' CB ' ' HE ' ' A' ' 28' ' ' ARG . 82.1 p -120.85 -24.53 5.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.856 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 24.5 ttmt -154.97 156.05 35.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.491 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 76.8 t -147.95 113.83 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 42.5 t -57.6 137.14 82.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.688 0.756 . . . . 0.0 110.844 -179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -22.23 32.49 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.29 -9.22 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.77 155.86 53.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.494 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -44.15 -35.08 2.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 111.109 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.825 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.31 -56.47 5.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -51.5 -38.65 43.28 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.7 ptt-85 -76.73 -28.85 55.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.799 0.333 . . . . 0.0 110.86 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -55.27 -64.36 0.87 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.55 -6.02 16.6 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.468 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.432 ' O ' HD11 ' A' ' 67' ' ' LEU . 2.8 mmp_? -109.44 -50.36 3.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.836 0.35 . . . . 0.0 110.91 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.825 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.6 tm? -64.59 122.54 17.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.636 ' N ' HD13 ' A' ' 63' ' ' LEU . 30.9 mtt180 -152.81 141.53 20.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.727 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.1 OUTLIER -51.54 95.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 179.968 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.47 -12.82 0.5 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.492 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.457 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 50.5 mt -83.24 151.22 25.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.745 0.307 . . . . 0.0 110.95 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 74.6 ttt180 -95.68 114.79 26.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.698 HD22 HG12 ' A' ' 100' ' ' VAL . 3.3 mm? -72.71 108.11 5.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.429 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 10.1 mp -84.4 -45.73 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.429 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 39.2 mt-10 -158.64 146.64 18.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 72.3 t -119.37 108.17 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.165 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.51 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.68 41.38 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.0 mt-30 64.16 34.4 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . 0.405 ' HB3' HD11 ' A' ' 88' ' ' LEU . 26.6 mt-30 -128.49 91.24 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.6 t -47.76 123.88 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.67 ' HA ' HD21 ' A' ' 80' ' ' LEU . 10.9 mt -79.73 9.96 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.498 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -80.1 123.37 27.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.932 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.498 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 108.69 -35.97 4.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.478 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.67 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -81.66 166.29 20.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.895 0.378 . . . . 0.0 110.914 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.462 ' O ' ' C ' ' A' ' 82' ' ' HIS . 70.8 p -101.24 158.74 15.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.1 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.51 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -33.57 -52.82 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.8 -45.7 90.92 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.472 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.8 mm-40 -63.97 -46.55 84.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.931 0.396 . . . . 0.0 110.907 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.52 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.74 -47.87 83.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 82' ' ' HIS . 70.7 t -54.74 -63.16 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.128 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 7.1 mm-40 -47.5 -26.57 1.43 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.567 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -72.65 -33.82 66.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.964 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.612 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -74.78 -33.61 62.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.939 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.0 ptt85 -91.62 9.62 31.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 33.4 t -99.26 28.44 4.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.852 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.766 HG21 ' HB3' ' A' ' 96' ' ' LEU . 19.0 t -96.16 166.52 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.598 ' N ' HG12 ' A' ' 92' ' ' VAL . . . -103.04 -66.21 0.74 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.515 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.61 -24.92 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.899 0.381 . . . . 0.0 110.89 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.742 HG23 ' O ' ' A' ' 15' ' ' ILE . 24.9 m -159.8 140.48 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.182 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.48 167.64 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.929 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.424 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.0 m -118.91 96.36 5.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.17 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.8 m -95.9 128.45 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.1 tp -93.14 36.55 1.04 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.698 HG12 HD22 ' A' ' 69' ' ' LEU . 5.8 m -66.45 168.2 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.1 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.445 ' O ' ' C ' ' A' ' 102' ' ' ASP . 28.7 p -166.01 133.29 2.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.457 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 2.4 p30 -34.52 108.27 0.06 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 -179.91 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.616 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -86.4 26.54 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.744 ' O ' HD12 ' A' ' 13' ' ' LEU . 18.0 mmm180 -92.89 169.68 10.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 34.5 tt0 -80.06 110.44 15.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.744 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.3 mp -116.34 166.8 11.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.7 p -144.47 156.92 44.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.864 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.65 108.82 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.121 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -79.53 118.47 21.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.913 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.627 ' HZ2' ' C ' ' A' ' 94' ' ' ASP . 0.4 OUTLIER -128.87 171.05 12.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.808 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -49.58 168.07 0.21 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.632 0.729 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.808 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.74 2.9 3.11 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.313 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.62 34.82 0.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 49.5 tp10 -104.11 130.59 51.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.877 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 9.3 ptt-85 -80.3 117.46 21.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.651 HD23 HG12 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -33.36 -50.67 0.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.933 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.73 47.52 8.64 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.477 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.775 HD11 HD13 ' A' ' 89' ' ' LEU . 2.9 pt -112.39 158.1 12.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 111.168 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -125.08 134.9 52.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 46' ' ' ILE . 33.2 pt -126.86 163.51 29.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.4 ptt180 -136.23 125.75 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.61 -144.64 11.37 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.505 -179.915 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.454 -0.259 . . . . 0.0 112.454 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.447 HG21 HD12 ' A' ' 27' ' ' ILE . 33.1 mt -125.74 117.6 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.851 0.358 . . . . 0.0 111.087 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.565 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.86 154.26 46.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.893 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.807 HD13 HD11 ' A' ' 63' ' ' LEU . 85.2 mt -64.23 126.58 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.101 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . 0.419 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.9 t -103.97 -18.13 14.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.47 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 17.4 ttmt -165.56 160.75 17.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.927 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.706 HG13 HG22 ' A' ' 25' ' ' ILE . 95.6 t -157.07 127.98 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.105 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -67.94 141.99 94.99 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.658 0.742 . . . . 0.0 110.902 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -35.3 12.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.628 2.219 . . . . 0.0 112.403 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.2 p -91.25 3.65 54.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -78.49 161.5 48.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.437 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -51.12 -32.76 23.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.751 0.31 . . . . 0.0 111.104 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.711 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -80.54 -64.06 1.27 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.097 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.28 -33.4 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.475 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 60' ' ' ASP . 12.1 ptt180 -81.24 -47.09 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.868 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.451 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 17.2 t0 -40.95 -66.37 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.871 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 -13.52 13.85 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.466 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -97.76 -12.64 22.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.9 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.5 tm? -111.16 134.63 52.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.9 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -154.84 159.04 40.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.895 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 42.7 t -64.5 97.65 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.202 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.03 -20.91 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.518 HD12 HD22 ' A' ' 63' ' ' LEU . 66.3 mt -77.1 136.35 38.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.82 0.343 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.565 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 63.0 ttt180 -84.02 123.65 30.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.764 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -72.77 111.62 8.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 99' ' ' LEU . 49.1 mt -89.4 -49.36 6.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 13.5 mt-10 -158.28 140.86 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.849 HG13 HD12 ' A' ' 96' ' ' LEU . 84.0 t -112.09 111.2 35.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.0 m-20 65.23 40.96 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 40.4 mt-30 64.36 32.12 12.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -127.56 90.03 3.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 t -42.94 130.31 4.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.858 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.411 HD21 HG23 ' A' ' 72' ' ' VAL . 14.7 mt -81.31 6.93 12.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.95 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.546 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.3 OUTLIER -77.62 123.96 27.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.943 179.907 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.546 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.13 -37.19 3.78 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -84.99 168.88 14.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.933 -179.925 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' C ' ' A' ' 82' ' ' HIS . 77.8 p -106.69 161.27 14.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.471 ' C ' ' O ' ' A' ' 81' ' ' THR . 4.3 t-80 -32.81 -55.8 0.37 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.31 -47.32 56.3 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.464 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.434 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 11.1 mm-40 -66.51 -49.88 65.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.838 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.17 -50.15 49.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 68.9 t -56.16 -57.3 9.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.122 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.48 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 9.9 mm-40 -52.17 -23.33 5.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.912 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.562 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.5 tt -76.41 -27.15 56.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.775 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -82.84 -25.12 32.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.861 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.48 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.4 ptm180 -97.63 -3.57 39.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 31.2 t -89.6 28.82 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.902 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.3 p -109.26 147.66 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.23 -98.49 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.495 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.627 ' C ' ' HZ2' ' A' ' 17' ' ' LYS . 0.8 OUTLIER -112.4 -11.31 13.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.89 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.425 ' C ' HG21 ' A' ' 92' ' ' VAL . 6.4 m -153.03 137.22 16.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.104 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.849 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -121.65 169.42 10.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -117.28 95.58 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.412 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -91.98 128.87 43.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.148 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.523 HD12 ' O ' ' A' ' 11' ' ' ARG . 20.9 tp -96.9 21.13 10.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.764 HG12 HD22 ' A' ' 69' ' ' LEU . 22.6 m -49.8 177.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.8 p -169.26 147.62 3.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.517 ' HA ' HD23 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -43.07 113.4 0.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.508 -179.921 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.727 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.16 31.21 0.5 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.742 0.306 . . . . 0.0 110.854 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 13.6 mmm180 -104.91 162.48 13.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.865 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.48 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 50.2 tt0 -73.31 113.17 10.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 97' ' ' THR . 26.2 mt -105.46 -174.87 2.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.909 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.516 ' SG ' HG22 ' A' ' 95' ' ' THR . 1.7 t -164.47 153.28 13.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 95' ' ' THR . 19.5 mt -125.82 118.72 52.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -94.04 115.68 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -128.65 164.53 22.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.12 168.75 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.578 0.704 . . . . 0.0 111.092 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.83 1.19 4.71 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.679 2.253 . . . . 0.0 112.325 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.48 42.88 0.23 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.1 tp10 -107.77 141.24 39.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.903 0.383 . . . . 0.0 110.875 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.9 mtt180 -83.59 120.72 26.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.909 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -32.55 -56.97 0.35 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.56 41.1 7.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.545 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.819 HD11 HD13 ' A' ' 89' ' ' LEU . 2.7 pt -121.68 171.17 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.408 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.5 m -142.92 146.47 34.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 28.8 pt -136.41 161.32 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.153 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.431 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.4 ptm85 -132.14 140.42 48.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.11 -155.35 24.45 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.911 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.505 -0.238 . . . . 0.0 112.505 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 86.6 mt -127.81 117.95 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.837 0.351 . . . . 0.0 111.178 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.562 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.2 m-85 -131.49 -176.67 4.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.72 HD13 HD11 ' A' ' 63' ' ' LEU . 78.6 mt -84.74 139.92 16.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.136 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 24.4 p -119.07 -12.07 9.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.476 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 22.0 tttp -175.78 149.84 0.98 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.898 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.584 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -156.1 117.57 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.099 179.887 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.7 t -66.25 137.79 95.72 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.67 0.748 . . . . 0.0 110.846 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 54.0 Cg_endo -69.8 -26.45 27.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.354 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 67.5 p -82.33 -26.37 33.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.153 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.96 174.31 2.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.483 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.3 -32.3 73.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.845 0.355 . . . . 0.0 111.134 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.909 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -77.45 -69.33 0.54 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.19 -45.63 1.23 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.447 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.9 ptt180 -68.04 -35.27 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ALA . 32.0 t70 -45.29 -64.77 0.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.49 -19.35 6.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -98.34 -51.47 3.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.72 HD11 HD13 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -55.31 130.43 42.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.896 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.58 ' N ' HD13 ' A' ' 63' ' ' LEU . 5.2 ptp180 -162.69 151.23 14.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.584 HG23 HG12 ' A' ' 51' ' ' VAL . 64.7 t -59.92 104.89 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.67 -8.43 1.8 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.47 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.671 HD23 ' HA ' ' A' ' 102' ' ' ASP . 23.5 mt -89.95 129.29 36.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.562 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 62.2 ttt180 -79.31 124.24 28.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.886 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.78 HD22 HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -75.31 114.14 13.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 7.4 mp -91.16 -50.69 5.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -155.4 141.98 18.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.829 HG13 HD12 ' A' ' 96' ' ' LEU . 88.0 t -114.58 108.38 25.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 12.7 m-20 65.93 42.06 3.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 34.3 mt-30 64.43 29.86 13.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 -123.47 89.88 3.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.6 t -42.99 130.92 4.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.523 ' HA ' HD21 ' A' ' 80' ' ' LEU . 36.7 mt -85.25 7.68 21.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.522 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -77.41 126.66 31.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 105.41 -36.11 4.62 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.492 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.682 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -85.73 162.51 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.846 0.355 . . . . 0.0 110.928 -179.889 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' C ' ' A' ' 82' ' ' HIS . 43.0 p -105.68 167.38 9.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.54 -65.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -41.77 -48.1 5.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.477 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.6 mt-10 -66.86 -50.91 61.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.852 0.358 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.25 -55.27 22.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.537 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.4 t -51.37 -61.7 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.17 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.485 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.1 mm-40 -50.07 -24.78 2.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -74.6 -30.9 61.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.819 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -78.42 -28.9 46.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.485 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.9 ptp180 -93.61 1.16 56.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.1 t -95.05 31.3 1.92 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.8 p -112.89 142.93 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.08 -101.48 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.404 ' HB3' ' HA ' ' A' ' 19' ' ' PRO . 20.0 p-10 -114.81 0.24 13.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.516 HG22 ' SG ' ' A' ' 14' ' ' CYS . 19.3 m -159.02 135.72 9.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.128 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.829 HD12 HG13 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -132.13 157.21 44.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.894 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . 0.77 HG23 ' O ' ' A' ' 13' ' ' LEU . 9.6 m -107.99 103.53 12.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.128 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 98' ' ' VAL . 2.9 m -97.1 126.31 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 99' ' ' LEU . 20.0 tp -91.89 29.41 1.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.78 HG12 HD22 ' A' ' 69' ' ' LEU . 11.7 m -61.07 166.43 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.169 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 25.0 p -164.34 146.01 8.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.832 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.671 ' HA ' HD23 ' A' ' 67' ' ' LEU . 1.4 t70 -42.63 119.96 1.58 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.517 -179.951 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.652 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.94 23.53 1.46 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.791 0.329 . . . . 0.0 110.93 -179.935 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.422 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 4.7 mmm180 -93.1 157.65 16.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -65.71 106.84 1.59 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mt -109.25 170.73 7.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.936 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.9 p -150.59 155.35 39.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.438 ' O ' HG23 ' A' ' 95' ' ' THR . 34.4 mt -120.73 120.51 62.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.153 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -92.26 115.34 27.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.931 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.401 ' O ' ' O ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -128.17 164.62 22.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.895 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.832 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.33 168.65 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.562 0.696 . . . . 0.0 111.06 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.832 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.78 3.49 2.75 Favored 'Trans proline' 0 N--CA 1.466 -0.146 0 C-N-CA 122.698 2.265 . . . . 0.0 112.321 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.18 37.84 0.16 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.7 tp10 -100.29 138.41 37.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.463 ' O ' ' C ' ' A' ' 23' ' ' LEU . 30.1 mmt-85 -81.07 116.71 21.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.745 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -32.56 -46.79 0.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.81 42.82 52.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.838 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -119.56 166.54 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.338 . . . . 0.0 111.135 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.6 OUTLIER -130.51 150.37 51.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.416 HD11 HG22 ' A' ' 86' ' ' VAL . 30.7 pt -139.53 151.39 22.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.114 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -129.07 124.67 35.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.36 -150.83 22.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.485 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.361 0 N-CA-C 112.548 -0.221 . . . . 0.0 112.548 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 36.6 mt -135.72 115.95 17.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.592 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.59 149.97 51.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 26' ' ' SER . 18.1 mt -55.59 140.95 12.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.129 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 49.8 p -114.15 -26.55 8.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 37.5 tttm -158.61 157.05 31.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.553 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.79 116.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.114 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.5 t -62.91 140.48 97.48 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.679 0.752 . . . . 0.0 110.853 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -16.46 37.82 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.707 2.271 . . . . 0.0 112.353 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.9 p -105.62 -6.28 19.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.117 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' ALA . . . -76.72 145.9 31.94 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.503 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.495 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -37.51 -33.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 111.094 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -74.98 -62.71 1.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.02 -40.22 6.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.502 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.495 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 1.6 ptt-85 -73.91 -29.94 62.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.866 0.365 . . . . 0.0 110.893 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 6.5 t70 -55.16 -69.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.71 -22.01 4.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -96.28 -52.64 3.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.82 0.343 . . . . 0.0 110.905 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.883 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -61.9 110.85 1.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.944 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.411 ' HG3' ' CD1' ' A' ' 67' ' ' LEU . 5.1 ptp180 -152.8 136.3 15.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.836 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -39.59 99.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.123 179.944 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.66 -32.41 0.52 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.54 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.493 ' HB2' HD12 ' A' ' 48' ' ' ILE . 7.8 mp -73.73 151.82 40.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.845 0.355 . . . . 0.0 110.882 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 61.5 ttt180 -97.66 116.54 30.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.812 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -66.09 105.64 1.42 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.403 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 9.5 mp -80.5 -49.64 11.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.941 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.403 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 31.4 mt-10 -158.94 145.12 16.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.81 HG13 HD12 ' A' ' 96' ' ' LEU . 79.3 t -115.31 110.21 31.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.7 m-20 64.88 40.56 5.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 35.4 mt-30 64.61 29.85 12.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.955 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.8 mm100 -123.64 90.76 3.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.885 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.1 t -44.96 130.86 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.82 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.6 mt -79.85 0.26 31.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.527 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -74.7 118.4 17.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.881 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 119.6 -34.02 4.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.5 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.5 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -92.98 171.38 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.945 0.402 . . . . 0.0 110.903 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 33.7 p -109.85 162.5 14.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.162 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.543 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.6 t-80 -33.33 -55.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -49.83 -49.53 34.73 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.494 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -68.01 -51.75 43.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.878 0.37 . . . . 0.0 110.862 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.5 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.81 -48.62 30.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 82' ' ' HIS . 98.3 t -57.96 -54.24 34.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.135 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 61.6 mm-40 -56.79 -22.0 32.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.8 tt -76.42 -27.07 56.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.838 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -82.71 -29.1 30.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.964 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.7 ptm180 -92.49 0.81 57.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.871 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 44.4 t -94.25 28.06 2.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.834 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.825 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -108.77 140.28 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.164 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -59.59 -98.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.518 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -114.16 -11.87 12.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.883 0.373 . . . . 0.0 110.858 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 15' ' ' ILE . 2.0 m -150.29 137.11 19.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.116 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.825 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -125.95 167.94 14.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.936 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 m -115.98 97.54 6.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 98' ' ' VAL . 10.1 m -97.04 130.6 45.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.136 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.78 24.07 6.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.812 HG12 HD22 ' A' ' 69' ' ' LEU . 21.7 m -51.59 -176.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.111 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 5.3 p -175.45 153.93 1.58 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -55.68 105.38 0.18 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.749 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.46 18.47 1.47 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.928 -179.894 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.404 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.0 mmm180 -87.35 165.33 15.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.853 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -72.18 115.12 11.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -123.62 160.14 27.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 14.3 p -143.33 156.35 44.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.856 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HG23 ' A' ' 95' ' ' THR . 59.0 mt -117.74 102.66 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -77.31 117.85 19.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.511 ' NZ ' HD12 ' A' ' 23' ' ' LEU . 0.5 OUTLIER -134.03 165.4 25.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.837 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.841 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.38 168.43 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.633 0.73 . . . . 0.0 111.091 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.841 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.82 -0.15 6.54 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.626 2.217 . . . . 0.0 112.338 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -171.04 33.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.66 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.8 tp10 -92.1 126.05 37.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.866 0.365 . . . . 0.0 110.85 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.488 ' O ' ' C ' ' A' ' 23' ' ' LEU . 62.5 mtt180 -70.82 97.01 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.887 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.84 ' HG ' ' HB3' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -30.95 -48.85 0.12 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.6 47.64 7.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.47 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.543 HG22 HG13 ' A' ' 51' ' ' VAL . 4.8 pt -117.61 153.67 19.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.83 0.348 . . . . 0.0 111.161 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.57 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -122.04 151.77 40.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.888 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.0 pt -137.28 145.96 28.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.099 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.422 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 1.5 ptm85 -122.76 137.21 54.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.845 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.96 -145.57 17.54 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.491 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.367 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 -179.89 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 mt -126.22 119.53 54.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.886 0.374 . . . . 0.0 111.1 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.6 OUTLIER -132.04 150.68 52.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.858 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.571 HD13 HD11 ' A' ' 63' ' ' LEU . 44.1 mt -60.25 139.43 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.3 t -112.01 -24.53 9.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 23.9 tttp -155.1 154.87 33.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.543 HG13 HG22 ' A' ' 25' ' ' ILE . 80.4 t -148.71 120.59 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 42.9 t -58.79 138.02 86.86 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.652 0.739 . . . . 0.0 110.877 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -38.42 7.66 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.645 2.23 . . . . 0.0 112.36 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.9 p -92.95 -2.95 55.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.55 172.86 38.12 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.84 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -61.14 -34.04 74.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.75 0.31 . . . . 0.0 111.063 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.816 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -76.83 -60.97 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.41 -42.75 4.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.406 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.8 ptt180 -77.74 -27.96 50.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -53.55 -66.98 0.3 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.85 -5.7 22.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.509 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.425 ' HA ' ' NH1' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -115.22 -7.76 12.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.38 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.805 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.3 tm? -114.55 124.63 52.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.747 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.91 151.73 25.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 179.956 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.429 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -55.8 107.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.97 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.57 -25.54 1.67 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.675 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.5 mt -70.89 142.36 51.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.927 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.536 ' O ' HD22 ' A' ' 70' ' ' LEU . 75.5 ttt180 -88.91 112.89 23.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.705 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.9 mm? -64.94 103.06 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.924 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.536 HD22 ' O ' ' A' ' 68' ' ' ARG . 1.6 mm? -79.61 -52.37 8.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -155.72 136.98 13.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 97.3 t -107.44 110.35 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.15 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.5 m-20 64.79 41.72 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 29.6 mt-30 64.17 30.36 13.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -126.42 90.55 3.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.7 t -42.67 133.26 3.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.824 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.535 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.1 mt -87.62 13.19 10.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.941 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.634 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -80.74 133.18 35.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 179.88 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.634 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 101.18 -36.15 4.39 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.589 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -87.12 156.92 19.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.865 0.364 . . . . 0.0 110.925 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 30.7 p -92.06 -177.26 4.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . 0.435 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 3.2 t-80 -51.33 -56.12 14.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.868 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -53.29 -51.47 46.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.494 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 6.8 mm-40 -58.54 -45.92 87.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.881 0.372 . . . . 0.0 110.871 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.541 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.87 -49.62 76.07 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 55.4 t -53.08 -56.92 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.484 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.7 mm-40 -52.1 -22.84 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -78.92 -28.04 43.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.618 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -83.09 -26.36 31.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.864 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.484 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.5 ptp180 -95.05 0.89 54.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 24.9 t -96.36 33.28 1.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.0 p -112.0 145.57 17.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.63 -100.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.452 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -112.47 -1.69 14.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.884 0.373 . . . . 0.0 110.893 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.401 HG23 ' C ' ' A' ' 15' ' ' ILE . 26.8 m -162.96 136.6 5.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.143 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.39 166.83 12.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.6 m -115.68 96.08 5.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.131 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.454 ' HB ' HG13 ' A' ' 100' ' ' VAL . 5.6 m -93.49 133.0 36.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.404 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.8 tp -103.09 26.53 8.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.5 m -60.28 178.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.095 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.4 p -171.65 146.02 2.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -37.89 109.98 0.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.462 -179.918 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.738 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.33 32.43 0.5 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.799 0.333 . . . . 0.0 110.913 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -99.39 150.65 21.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.77 113.77 2.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.4 mt -117.37 167.35 11.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 23.0 p -146.42 158.9 43.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.423 ' C ' HG23 ' A' ' 95' ' ' THR . 22.6 mt -125.85 106.25 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.116 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -81.31 107.33 14.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.624 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -118.81 172.74 7.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.806 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -49.48 165.09 0.3 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.609 0.718 . . . . 0.0 111.099 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.83 1.87 4.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.337 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.55 32.1 0.18 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.466 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.806 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 33.5 tp10 -97.92 153.34 18.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.876 0.369 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.81 125.65 35.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . 0.698 HD12 HG23 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -37.58 -52.46 1.2 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.911 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.44 40.9 14.35 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.698 HG23 HD12 ' A' ' 23' ' ' LEU . 7.5 pt -121.26 157.43 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 111.096 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.506 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -122.16 144.1 49.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.1 pt -135.85 149.27 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.114 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.0 ptt180 -128.67 135.1 48.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 139.95 -140.93 11.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 N-CA-C 112.508 -0.237 . . . . 0.0 112.508 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.26 117.76 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.857 0.36 . . . . 0.0 111.132 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.555 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -131.04 149.61 52.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.806 HD11 HD21 ' A' ' 63' ' ' LEU . 65.1 mt -58.14 123.71 10.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.155 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.9 t -99.3 -10.8 21.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.855 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.523 ' N ' HG13 ' A' ' 65' ' ' VAL . 13.1 ttmt -175.06 160.35 2.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.915 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.688 HG23 HG22 ' A' ' 65' ' ' VAL . 58.8 t -144.42 114.09 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.6 t -61.54 138.28 94.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.681 0.753 . . . . 0.0 110.821 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -25.1 28.9 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.252 . . . . 0.0 112.329 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.3 p -94.99 1.22 55.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.78 158.94 34.07 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.484 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -50.25 -44.09 53.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -63.75 -58.76 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.089 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.11 -42.15 5.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.47 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 30.2 ptt180 -85.01 -24.22 28.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 110.914 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -54.42 -69.13 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.37 -13.54 15.9 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -101.38 -7.46 22.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.811 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 HD11 ' A' ' 48' ' ' ILE . 2.4 tm? -108.79 135.17 50.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.908 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.716 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.5 mmp_? -140.5 158.09 44.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 51' ' ' VAL . 5.4 t -73.82 88.95 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 155.8 -17.76 0.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.464 ' HB2' HD12 ' A' ' 48' ' ' ILE . 13.0 mt -65.72 130.35 42.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.803 0.335 . . . . 0.0 110.901 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.555 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 60.4 ttt180 -78.6 122.1 25.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.775 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -73.86 111.87 9.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.953 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 9.0 mp -87.48 -52.94 5.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.91 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -156.73 135.77 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.989 HG13 HD12 ' A' ' 96' ' ' LEU . 53.0 t -108.66 111.72 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.101 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 65.46 40.58 4.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 63.98 36.38 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.928 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -134.77 90.91 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.0 t -41.11 139.13 0.98 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.832 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.475 ' CD2' HD13 ' A' ' 88' ' ' LEU . 11.5 mt -86.11 9.78 16.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.958 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.8 tt -83.69 156.64 22.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 79.71 -19.51 6.1 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -110.38 155.06 22.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.381 . . . . 0.0 110.907 -179.91 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 65.5 p -91.75 179.03 5.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -48.62 -58.11 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.84 -49.87 27.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.0 mt-10 -61.72 -46.84 87.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.841 0.353 . . . . 0.0 110.923 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.43 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.63 -51.64 64.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.085 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 89' ' ' LEU . 65.0 t -48.22 -58.01 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.101 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLN . . . . . 0.743 ' N ' HE21 ' A' ' 87' ' ' GLN . 0.9 OUTLIER -51.49 -24.89 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.911 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.475 HD13 ' CD2' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -74.84 -32.19 61.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.914 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.574 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -75.83 -24.75 55.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.473 ' CZ ' ' OE1' ' A' ' 87' ' ' GLN . 4.2 ptt180 -96.55 -0.11 49.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 p -83.36 20.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -106.42 145.84 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.162 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -78.47 -80.66 0.71 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.501 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ASP . . . . . 0.446 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -121.13 -13.74 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.863 0.364 . . . . 0.0 110.852 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' C ' ' A' ' 15' ' ' ILE . 14.3 m -157.1 134.61 10.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.989 HD12 HG13 ' A' ' 72' ' ' VAL . 1.3 pt? -118.88 -179.24 3.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.926 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -126.61 95.92 4.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.4 m -96.92 129.31 47.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -94.96 21.6 7.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.775 HG12 HD22 ' A' ' 69' ' ' LEU . 20.8 m -49.65 169.29 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 8.6 p -161.6 154.08 20.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -48.8 111.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.853 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.964 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.512 -0.235 . . . . 0.0 112.512 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.1 t -82.58 135.23 35.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.829 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -147.44 138.94 23.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.862 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -117.28 -74.91 0.52 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.476 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.6 m -69.02 -64.55 0.85 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.88 0.372 . . . . 0.0 110.857 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.2 t 69.78 37.16 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.61 145.28 10.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.499 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 157.79 59.06 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.693 2.262 . . . . 0.0 112.326 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -141.4 -39.68 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.487 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.672 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -97.77 33.06 2.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.863 0.363 . . . . 0.0 110.939 -179.929 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.623 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.6 mmm180 -104.12 177.82 4.73 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.898 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.419 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.6 tt0 -78.0 112.22 14.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.907 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 16.2 mt -119.85 163.38 17.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.913 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' CB ' ' O ' ' A' ' 96' ' ' LEU . 18.9 p -144.3 159.47 42.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.87 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 86.6 mt -122.34 112.96 36.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 9.2 mp0 -84.47 115.39 22.54 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -127.41 166.77 17.26 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.889 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.06 168.27 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.543 0.687 . . . . 0.0 111.118 179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.8 -2.01 9.48 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.653 2.235 . . . . 0.0 112.333 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.49 37.89 0.27 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.514 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.537 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 40.8 tp10 -102.68 143.58 32.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.864 0.364 . . . . 0.0 110.893 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.6 ptt180 -84.13 121.5 27.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.849 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.751 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -33.63 -53.16 0.42 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.896 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 81.8 41.12 9.95 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.469 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.751 HG12 HD12 ' A' ' 23' ' ' LEU . 3.3 pt -121.35 162.57 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.332 . . . . 0.0 111.11 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.431 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.5 m -130.57 145.13 51.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.819 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.565 HD12 HG21 ' A' ' 46' ' ' ILE . 21.1 pt -136.2 156.2 36.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.107 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -132.48 132.9 43.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.873 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.07 -142.32 9.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.95 149.89 9.15 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.507 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.452 ' O ' ' CD ' ' A' ' 44' ' ' GLU . . . -57.86 -11.09 2.04 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.816 0.341 . . . . 0.0 111.105 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 33' ' ' GLY . 42.6 mtp180 -130.17 -44.76 1.14 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -35.39 150.5 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.47 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' C ' ' O ' ' A' ' 33' ' ' GLY . 7.9 p80 -35.67 129.23 0.6 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.86 0.362 . . . . 0.0 110.868 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -43.27 110.94 0.22 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.097 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -48.31 -40.11 22.02 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 54.4 t30 -88.35 118.96 70.07 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.569 0.7 . . . . 0.0 110.895 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -11.91 31.86 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.718 2.278 . . . . 0.0 112.342 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 15.8 tpt180 -81.17 -60.66 2.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.91 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -111.49 125.22 30.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.65 0.738 . . . . 0.0 110.874 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 -14.46 36.21 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.694 2.263 . . . . 0.0 112.342 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.3 p -87.43 33.64 0.69 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.161 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -124.91 115.79 21.17 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.824 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.452 ' CD ' ' O ' ' A' ' 31' ' ' ALA . 24.8 mt-10 -107.67 18.47 21.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.883 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -52.55 162.86 2.05 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.486 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.565 HG21 HD12 ' A' ' 27' ' ' ILE . 30.8 mt -126.88 119.2 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.907 0.385 . . . . 0.0 111.106 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.72 149.12 52.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.833 179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.541 HD13 HD11 ' A' ' 63' ' ' LEU . 94.7 mt -54.59 132.76 17.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.43 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.4 p -108.59 -13.41 14.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.857 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.412 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 28.4 tttm -175.5 156.47 1.96 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.853 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.56 HG13 HG22 ' A' ' 25' ' ' ILE . 93.4 t -143.63 123.24 8.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.109 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.5 t -69.22 143.15 93.49 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.684 0.754 . . . . 0.0 110.858 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -35.6 12.15 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.33 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 27.3 p -88.27 0.95 55.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.449 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -80.57 153.05 34.54 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.49 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.604 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -45.18 -38.9 5.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.769 0.319 . . . . 0.0 111.11 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -73.32 -64.0 1.07 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -35.44 -44.56 0.62 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.473 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.8 ptt180 -79.3 -37.24 38.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.425 ' N ' ' O ' ' A' ' 57' ' ' ALA . 22.1 t0 -40.66 -64.57 0.51 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.862 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.38 -9.75 22.23 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.457 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.24 -24.35 11.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.871 0.367 . . . . 0.0 110.877 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.0 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.29 126.25 37.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.929 -179.973 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -142.6 174.46 10.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.479 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 6.4 t -82.62 92.33 2.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.149 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.555 ' HA2' ' CE2' ' A' ' 104' ' ' PHE . . . 154.68 -13.66 0.5 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.47 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.611 HD12 HD22 ' A' ' 63' ' ' LEU . 52.7 mt -77.05 118.71 19.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.782 0.325 . . . . 0.0 110.921 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.559 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 46.5 ttt180 -69.12 122.69 19.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.855 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.688 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -72.95 108.96 6.15 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.434 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 4.4 mm? -84.31 -52.37 6.26 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.951 179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.434 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 11.3 mt-10 -157.85 134.99 10.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.837 HG13 HD12 ' A' ' 96' ' ' LEU . 88.8 t -106.58 110.4 31.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.075 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 18.6 m-20 64.73 41.66 5.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.0 mt-30 64.17 31.89 12.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.881 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 26.3 mt-30 -128.86 91.05 3.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.887 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 36.2 t -50.45 130.89 24.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.862 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.3 mt -80.29 5.14 15.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.896 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.402 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -73.04 114.95 11.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.932 179.918 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.4 -37.39 3.17 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.804 -0.713 . . . . 0.0 112.494 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.585 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -86.42 167.89 14.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.904 0.383 . . . . 0.0 110.917 -179.934 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 61.8 p -104.37 160.59 14.78 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 3.4 t-80 -33.1 -55.19 0.39 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.821 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.24 -46.11 51.77 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.505 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.437 ' N ' ' O ' ' A' ' 81' ' ' THR . 29.4 mm-40 -70.03 -47.87 60.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.863 0.364 . . . . 0.0 110.857 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -54.18 -48.76 70.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.097 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 82' ' ' HIS . 75.2 t -55.57 -55.22 18.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.144 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.9 mm-40 -54.27 -27.3 34.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -70.43 -29.59 66.22 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.958 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.67 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.41 -30.5 47.75 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.921 179.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.8 ptp180 -93.36 -1.14 56.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.83 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -90.64 30.0 1.23 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.867 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.636 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.6 p -112.1 144.66 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.154 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.73 -94.51 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.481 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -119.52 -8.78 9.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 12.6 m -152.92 134.68 14.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.174 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.837 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -122.8 171.87 8.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.901 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.419 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.4 m -120.8 98.64 6.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.158 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 m -95.46 131.91 40.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.623 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.1 tp -101.15 31.47 3.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.688 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.5 m -65.96 175.47 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.133 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.4 p -165.17 154.23 12.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.852 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -46.26 101.84 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -96.5 -51.73 1.66 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.478 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.555 ' CE2' ' HA2' ' A' ' 66' ' ' GLY . 6.0 p90 -168.34 121.87 0.88 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.795 0.331 . . . . 0.0 110.865 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -69.84 133.82 47.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.922 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 76.5 p -100.56 40.51 1.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.931 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 80.79 -176.53 54.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.522 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 155.98 64.6 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.701 2.267 . . . . 0.0 112.362 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 23.4 t -130.37 170.12 14.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 5.1 t -122.04 146.61 47.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.859 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.485 180.0 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 81.1 p -84.99 122.44 29.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.361 . . . . 0.0 110.874 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 31.4 m -112.09 -57.83 2.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.843 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.02 -151.52 20.02 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.465 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 97.5 p -85.25 -51.72 6.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.852 0.358 . . . . 0.0 110.859 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 99.0 p -68.49 117.14 9.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.837 -179.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -110.18 -78.56 1.0 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.513 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.82 158.54 56.53 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.688 2.259 . . . . 0.0 112.307 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -140.01 -36.5 0.12 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.485 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.748 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -83.31 20.19 1.36 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.892 -179.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.472 ' O ' HD12 ' A' ' 99' ' ' LEU . 15.3 mmt180 -90.24 168.01 12.26 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.897 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.458 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 31.9 tt0 -74.25 114.84 13.07 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.893 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 9.8 mt -118.58 160.06 22.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.954 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.6 p -139.5 155.77 47.33 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.426 ' O ' HG23 ' A' ' 95' ' ' THR . 31.0 mt -122.97 109.78 24.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.19 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.3 mt-30 -80.31 115.93 20.12 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.905 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.482 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -131.98 178.26 6.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.865 179.977 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -56.83 163.62 2.71 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.554 0.692 . . . . 0.0 111.093 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.2 Cg_endo -69.8 1.23 4.65 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.688 2.259 . . . . 0.0 112.328 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -162.59 26.14 0.23 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.488 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.783 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.1 tp10 -94.43 142.22 27.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.909 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.9 mpt_? -86.32 123.72 31.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.86 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.722 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -46.53 0.24 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.897 179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.58 41.18 30.29 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.527 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.722 HG12 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -121.41 162.97 19.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.827 0.346 . . . . 0.0 111.143 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.417 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -120.12 159.1 25.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.835 -179.894 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.437 HD11 ' CG2' ' A' ' 86' ' ' VAL . 14.4 pt -151.69 145.65 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.11 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 -129.26 132.14 47.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.929 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.67 -146.19 15.17 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.478 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 125.69 139.27 5.11 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.464 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -52.91 -14.74 0.61 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.784 0.326 . . . . 0.0 111.107 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.546 ' NE ' HG21 ' A' ' 81' ' ' THR . 12.1 ptp180 -123.53 -28.51 3.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.86 -179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.423 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -35.51 124.48 0.69 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.482 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' GLY . 91.9 m-70 -37.83 -34.56 0.11 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 110.844 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -174.96 173.87 2.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.09 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.25 32.83 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.467 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 24.9 t30 -155.2 117.29 2.39 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 0.0 110.911 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 2.19 3.73 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.73 2.287 . . . . 0.0 112.317 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.0 mtp180 -103.86 -47.67 4.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -140.41 116.88 7.87 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-O 121.605 0.717 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -29.21 24.25 Favored 'Trans proline' 0 C--O 1.232 0.207 0 C-N-CA 122.69 2.26 . . . . 0.0 112.357 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 18.6 p -82.39 44.57 0.89 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.139 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -143.71 115.55 8.26 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.852 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.485 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 14.2 mp0 -81.31 41.58 0.62 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -74.23 175.7 48.19 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.466 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 60.3 mt -139.18 115.86 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 111.135 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.4 OUTLIER -132.54 163.5 28.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.959 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.736 HD11 HD21 ' A' ' 63' ' ' LEU . 27.4 mt -67.72 125.49 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.139 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 82.7 p -96.85 -11.02 25.36 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.823 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 16.8 ttmm -175.86 167.25 3.08 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.914 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 64.5 t -150.06 114.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.139 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.5 t -67.27 140.01 95.17 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.61 0.719 . . . . 0.0 110.85 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.74 21.68 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.646 2.231 . . . . 0.0 112.361 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.5 p -86.57 -8.57 57.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.137 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -75.56 158.2 50.07 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.408 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -50.17 -39.39 43.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.766 0.317 . . . . 0.0 111.087 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.83 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -70.34 -60.26 2.38 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.079 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.63 -42.88 2.84 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.408 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 23.3 ptt180 -80.29 -31.53 38.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.83 0.348 . . . . 0.0 110.886 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -50.17 -72.29 0.05 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.822 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 119.72 -9.58 11.52 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.492 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -104.32 -10.93 17.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.876 0.37 . . . . 0.0 110.868 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.83 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.4 tm? -105.83 134.0 49.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.92 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.707 ' N ' HD13 ' A' ' 63' ' ' LEU . 19.7 mtp180 -144.28 178.97 7.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.86 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 51' ' ' VAL . 9.1 t -88.02 92.86 3.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.138 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 151.91 -13.16 0.74 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.465 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.557 ' HB2' HD12 ' A' ' 48' ' ' ILE . 32.6 mt -73.0 110.41 7.27 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.803 0.335 . . . . 0.0 110.879 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 16.6 ttm180 -62.34 122.8 16.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.858 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.67 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -71.24 107.03 4.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.495 ' O ' ' CG ' ' A' ' 71' ' ' GLU . 1.7 mm? -86.37 -42.14 13.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.908 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.495 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 40.3 mt-10 -161.82 139.55 8.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.885 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.745 HG13 HD12 ' A' ' 96' ' ' LEU . 66.7 t -117.6 108.0 23.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.089 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.476 ' ND2' HG22 ' A' ' 92' ' ' VAL . 11.5 m-20 65.44 41.35 4.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.5 mt-30 63.65 36.66 10.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 30.2 mt-30 -131.92 91.16 2.93 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 48.3 t -47.55 127.04 10.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.436 ' HA ' HD21 ' A' ' 80' ' ' LEU . 12.8 mt -78.01 1.06 22.07 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.884 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.442 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.4 OUTLIER -72.12 111.39 7.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.964 179.805 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 123.92 -37.28 2.73 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.524 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.501 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -87.16 167.03 14.51 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.953 0.406 . . . . 0.0 110.909 -179.974 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.546 HG21 ' NE ' ' A' ' 32' ' ' ARG . 81.0 p -102.66 -179.97 4.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.64 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -50.32 -51.48 44.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.85 -45.57 79.54 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.475 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.44 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.1 mt-10 -67.1 -58.36 5.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.819 0.342 . . . . 0.0 110.889 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -44.27 -46.79 9.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.123 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.746 ' HA ' HD23 ' A' ' 89' ' ' LEU . 74.5 t -57.05 -60.45 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.11 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.482 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.3 mm-40 -50.39 -26.27 4.79 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.902 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -74.73 -32.12 62.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.902 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.746 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.6 OUTLIER -79.08 -31.66 44.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.888 179.906 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.482 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.4 ptm180 -90.81 3.54 54.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.897 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 5.5 m -96.59 29.23 3.03 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.876 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.639 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.4 t -94.25 149.94 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.59 -76.7 1.29 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -123.28 -17.76 6.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.84 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.426 HG23 ' O ' ' A' ' 15' ' ' ILE . 56.2 m -163.16 137.04 5.97 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.093 -179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.745 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.0 169.08 10.2 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.458 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.1 m -119.71 100.15 7.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.146 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.428 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.0 m -96.72 130.66 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.115 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.472 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.7 tp -99.19 24.83 7.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.901 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.7 m -61.84 172.77 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.122 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.3 p -163.35 163.02 25.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.865 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -54.31 95.15 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.89 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -89.11 -47.44 4.13 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.485 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 7.9 p90 -171.51 117.49 0.43 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.817 0.342 . . . . 0.0 110.898 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -80.06 129.4 34.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 88.0 p -60.85 -44.73 96.61 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.835 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 176.17 142.6 4.34 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.46 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 154.69 67.54 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.707 2.271 . . . . 0.0 112.388 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 1.1 t -169.44 156.46 6.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.859 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 26.7 p -62.67 127.49 31.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.503 -179.969 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.3 m -100.28 117.65 34.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.901 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.5 m -53.16 -56.03 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.858 -179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.38 -121.22 6.25 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.534 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.3 t -121.41 87.94 2.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.827 0.346 . . . . 0.0 110.856 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 65.2 m -65.26 156.38 32.14 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 162.22 144.37 3.98 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.509 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 153.95 68.55 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.703 2.268 . . . . 0.0 112.381 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.401 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . 172.65 -43.34 0.17 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.497 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.31 28.81 0.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.813 0.339 . . . . 0.0 110.934 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 77.2 mtm180 -98.5 161.93 13.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 35.2 tt0 -68.21 107.37 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.869 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.47 ' O ' ' N ' ' A' ' 98' ' ' VAL . 18.9 mt -113.48 157.49 21.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.89 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 20.6 p -139.36 165.33 27.5 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.857 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.404 HG22 ' HB1' ' A' ' 56' ' ' ALA . 52.4 mt -128.99 105.62 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -80.68 117.55 21.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.932 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.4 ptpp? -126.91 168.6 14.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.823 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.51 168.34 0.12 Allowed Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.565 0.698 . . . . 0.0 111.103 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.823 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 1.61 4.27 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.727 2.285 . . . . 0.0 112.339 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.32 43.46 0.23 Allowed Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 38.8 tp10 -111.59 142.7 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.814 0.34 . . . . 0.0 110.86 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' C ' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -86.6 124.5 32.96 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.851 -179.926 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.777 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.46 -52.4 0.38 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.911 179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.51 41.04 13.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.505 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.685 HG23 HD12 ' A' ' 23' ' ' LEU . 3.1 pt -119.39 157.33 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.813 0.339 . . . . 0.0 111.141 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -123.5 140.06 53.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.628 HD12 HG21 ' A' ' 46' ' ' ILE . 21.5 pt -132.79 157.09 42.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.121 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.445 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 3.3 ptm85 -132.58 138.87 47.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.23 -144.75 13.2 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.503 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.79 162.87 12.97 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.474 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -91.16 -1.99 57.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.772 0.32 . . . . 0.0 111.077 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 28.9 mmt180 -130.72 -31.18 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.888 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.43 -156.17 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.47 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.493 ' O ' ' N ' ' A' ' 36' ' ' GLY . 9.8 m170 -81.26 43.24 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 110.845 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.714 ' HB1' ' O ' ' A' ' 43' ' ' ASP . . . 36.37 30.18 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.07 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 38.24 40.3 0.86 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -172.58 114.84 0.38 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.656 0.741 . . . . 0.0 110.926 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -8.63 24.09 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.691 2.26 . . . . 0.0 112.352 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 12.5 tpt180 -87.99 -57.44 2.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.866 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.429 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 5.8 m-20 -121.69 103.63 40.41 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.592 0.71 . . . . 0.0 110.868 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.652 ' HA ' ' HB3' ' A' ' 35' ' ' ALA . 53.8 Cg_endo -69.69 1.85 4.01 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.668 2.245 . . . . 0.0 112.378 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 73.0 p -89.2 -29.88 18.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.714 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 36.4 t70 -69.11 100.39 1.25 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.889 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 50.2 mp0 -80.62 13.9 2.33 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -59.95 150.4 39.71 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.491 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.628 HG21 HD12 ' A' ' 27' ' ' ILE . 39.6 mt -125.21 117.63 50.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.829 0.347 . . . . 0.0 111.136 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.06 156.53 43.7 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.619 HD13 HD11 ' A' ' 63' ' ' LEU . 65.3 mt -64.19 130.46 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.158 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 43.5 t -110.23 -14.57 14.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.837 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.474 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 11.2 tttm -167.02 161.21 14.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.904 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.659 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -152.78 129.28 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.144 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.1 t -72.52 137.65 80.72 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-O 121.611 0.719 . . . . 0.0 110.867 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -25.29 28.84 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.676 2.251 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.9 p -101.71 12.88 36.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.187 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -91.92 161.94 27.21 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.506 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.491 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -50.04 -35.51 25.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.768 0.318 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.811 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.17 -57.11 4.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.123 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.27 -43.85 4.79 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.497 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 19.3 ptt180 -80.83 -26.25 37.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.821 0.343 . . . . 0.0 110.889 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -48.58 -58.23 5.02 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.838 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 113.79 -25.12 11.19 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.468 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -94.73 -53.48 3.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.855 0.36 . . . . 0.0 110.883 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.811 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.4 OUTLIER -58.6 132.49 53.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.627 ' N ' HD13 ' A' ' 63' ' ' LEU . 3.6 ptp180 -165.33 147.57 7.76 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.474 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 62.0 t -49.79 106.97 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.153 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 144.13 -26.3 2.03 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.696 HD23 ' C ' ' A' ' 101' ' ' CYS . 20.3 mt -75.25 118.55 18.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.765 0.316 . . . . 0.0 110.942 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.56 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -69.61 131.66 45.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.873 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.602 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -80.29 111.75 16.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.913 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CG ' ' A' ' 71' ' ' GLU . 4.0 mm? -88.84 -49.78 6.61 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.957 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.416 ' CG ' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -158.39 140.41 13.96 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.923 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.847 HG13 HD12 ' A' ' 96' ' ' LEU . 88.4 t -111.84 109.77 29.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.159 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.6 m-20 65.07 41.9 4.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.894 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 30.4 mt-30 64.21 32.99 12.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.21 90.54 3.1 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.912 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.8 t -47.3 130.08 13.05 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.618 ' HA ' HD21 ' A' ' 80' ' ' LEU . 5.8 mt -83.31 8.34 13.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.965 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.5 OUTLIER -76.97 115.45 16.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.886 179.894 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 116.11 -32.52 5.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.468 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.618 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -88.04 167.12 13.96 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.918 0.389 . . . . 0.0 110.9 -179.918 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.441 ' O ' ' N ' ' A' ' 84' ' ' GLU . 44.5 p -105.94 162.92 13.16 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.102 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.598 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.7 t-80 -34.82 -55.96 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.88 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.62 -41.12 49.23 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.442 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -73.16 -48.6 33.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.856 0.36 . . . . 0.0 110.868 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.4 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.3 -51.64 64.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.152 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.0 t -53.17 -62.23 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.125 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 15.9 mm-40 -49.51 -23.44 1.6 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.533 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -75.07 -33.47 61.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.911 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.773 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.2 -32.76 56.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 8.2 ptm180 -89.24 -3.36 58.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.869 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.1 m -91.41 33.52 0.99 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.84 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.3 p -112.88 145.33 18.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.115 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.25 -98.15 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.519 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -116.15 -6.96 11.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.923 0.392 . . . . 0.0 110.918 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.4 m -156.17 130.64 8.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.172 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.847 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.99 168.2 10.45 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.881 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.6 m -116.85 97.77 6.14 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.113 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 13' ' ' LEU . 3.3 m -95.43 129.32 45.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.152 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.3 tp -99.51 34.17 2.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.602 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.0 m -69.91 173.0 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.143 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.696 ' C ' HD23 ' A' ' 67' ' ' LEU . 7.9 p -165.15 168.34 17.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -52.51 114.32 1.34 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.86 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.435 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -107.53 -36.73 2.38 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.494 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.435 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.6 OUTLIER -156.23 109.86 2.72 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.857 0.36 . . . . 0.0 110.892 -179.85 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 60.6 mt-10 -44.08 -45.24 7.97 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 80.3 p 43.73 34.91 0.93 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.819 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -71.75 -158.02 3.27 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.456 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 112.61 3.12 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.671 2.247 . . . . 0.0 112.366 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.9 t -84.64 113.91 21.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.895 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 12.2 t -144.74 111.47 5.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.882 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.475 -179.95 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 76.6 p -42.15 -44.43 3.68 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.877 0.37 . . . . 0.0 110.852 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 55.2 m -46.9 101.29 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.872 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.38 -136.85 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.445 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.7 m -110.56 124.87 52.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.896 0.379 . . . . 0.0 110.85 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 78.8 p -134.47 172.82 12.37 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.884 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.84 166.52 22.84 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.456 ' CB ' ' HD2' ' A' ' 11' ' ' ARG . 53.8 Cg_endo -69.81 158.22 57.62 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.681 2.254 . . . . 0.0 112.331 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.443 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . -145.13 -36.94 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.496 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.707 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.79 38.99 0.73 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.821 0.343 . . . . 0.0 110.9 -179.924 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.456 ' HD2' ' CB ' ' A' ' 8' ' ' PRO . 53.8 mtp180 -109.68 144.95 37.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.865 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.438 ' OE2' HG21 ' A' ' 97' ' ' THR . 52.9 tt0 -55.52 110.09 0.65 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.896 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 8.5 mt -105.1 168.67 8.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.944 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.696 ' SG ' HG22 ' A' ' 95' ' ' THR . 7.2 t -150.35 144.22 25.36 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.931 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.814 ' O ' HG23 ' A' ' 95' ' ' THR . 15.6 mt -120.71 127.2 75.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.136 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -97.72 113.54 25.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 1.2 ptpp? -124.83 170.5 10.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.928 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.813 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.89 168.05 0.17 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.582 0.706 . . . . 0.0 111.1 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.813 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.81 2.37 3.62 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.246 . . . . 0.0 112.344 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.05 39.43 0.17 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.471 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.6 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 26.1 tp10 -101.73 144.19 30.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.812 0.339 . . . . 0.0 110.926 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 25.5 mtt-85 -83.75 120.23 25.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.861 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.753 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -34.02 -49.66 0.35 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.877 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.35 42.6 18.12 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.471 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.753 HG12 HD12 ' A' ' 23' ' ' LEU . 2.2 pt -122.74 161.5 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.803 0.335 . . . . 0.0 111.133 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.471 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 1.0 OUTLIER -119.17 160.37 22.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.891 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.439 HD12 HG21 ' A' ' 46' ' ' ILE . 17.7 pt -151.55 147.27 15.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.169 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.473 ' NH1' ' CB ' ' A' ' 49' ' ' SER . 6.1 ptt-85 -125.09 139.42 53.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.855 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 137.87 -149.93 20.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.514 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 115.22 141.56 7.48 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.542 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.473 ' HA ' ' CG ' ' A' ' 44' ' ' GLU . . . -63.05 -7.98 6.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.719 0.295 . . . . 0.0 111.089 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.5 mtt180 -126.73 23.43 6.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.38 172.42 18.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.506 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' A' ' 35' ' ' ALA . 46.0 m170 -76.97 125.03 28.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.774 0.321 . . . . 0.0 110.871 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.432 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . -35.71 120.8 0.6 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' CA ' ' HD2' ' A' ' 28' ' ' ARG . . . -35.78 -52.11 1.13 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.514 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.441 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 21.1 t30 -88.79 134.23 34.2 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.576 0.703 . . . . 0.0 110.93 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -1.49 8.53 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.691 2.261 . . . . 0.0 112.32 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.441 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 9.5 tpp85 -66.17 -49.65 66.62 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.895 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.405 ' O ' ' CB ' ' A' ' 35' ' ' ALA . 26.3 m-20 -139.78 112.15 7.58 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.593 0.711 . . . . 0.0 110.827 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HA ' ' HB3' ' A' ' 35' ' ' ALA . 54.0 Cg_endo -69.75 -0.01 6.28 Favored 'Trans proline' 0 C--O 1.232 0.22 0 C-N-CA 122.664 2.243 . . . . 0.0 112.351 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 75.9 p -101.17 49.49 0.88 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.117 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 15.7 t0 -138.86 111.52 7.67 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.473 ' CG ' ' HA ' ' A' ' 31' ' ' ALA . 5.3 mp0 -84.75 3.19 38.61 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.912 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -53.98 153.43 9.06 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.503 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.439 HG21 HD12 ' A' ' 27' ' ' ILE . 48.6 mt -123.62 118.69 55.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.844 0.354 . . . . 0.0 111.117 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.75 147.51 50.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.701 HD13 HD11 ' A' ' 63' ' ' LEU . 95.3 mt -55.88 135.66 19.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.149 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.473 ' CB ' ' NH1' ' A' ' 28' ' ' ARG . 70.0 p -113.87 -13.39 12.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.853 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.517 ' N ' HG13 ' A' ' 65' ' ' VAL . 17.9 ttmm -170.38 161.23 7.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.684 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.08 121.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -68.01 139.27 92.89 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.636 0.731 . . . . 0.0 110.871 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -29.91 23.26 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.716 2.277 . . . . 0.0 112.367 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.3 p -92.7 4.49 53.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -85.45 161.45 35.46 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.447 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.459 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -51.39 -39.55 57.41 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.795 0.331 . . . . 0.0 111.116 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.65 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -70.55 -59.36 2.88 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -38.69 -42.43 1.43 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.49 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 24.9 ptt180 -82.95 -30.09 28.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.8 0.333 . . . . 0.0 110.84 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' O ' ' A' ' 57' ' ' ALA . 48.2 t0 -45.9 -56.97 4.75 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.876 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 104.4 -20.23 40.43 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.466 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.36 -20.52 18.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.845 0.355 . . . . 0.0 110.865 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.701 HD11 HD13 ' A' ' 48' ' ' ILE . 1.1 tm? -89.55 134.35 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.948 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.569 ' N ' HD13 ' A' ' 63' ' ' LEU . 14.2 mmm-85 -143.15 154.12 43.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.887 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 51' ' ' VAL . 18.3 t -70.49 87.21 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.101 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.99 -17.35 0.32 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.499 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.547 HD12 HD22 ' A' ' 63' ' ' LEU . 18.0 mt -67.82 124.64 23.89 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.794 0.33 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 36.2 ttt180 -71.84 119.74 16.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.766 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -67.04 111.43 3.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.887 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.431 HD13 ' HA ' ' A' ' 70' ' ' LEU . 2.0 mm? -86.79 -54.24 4.48 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.92 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -156.58 133.6 10.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.866 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.782 HG13 HD12 ' A' ' 96' ' ' LEU . 93.1 t -106.76 110.92 33.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.124 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.505 ' ND2' HG22 ' A' ' 92' ' ' VAL . 15.0 m-20 64.91 41.06 5.02 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.884 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 37.4 mt-30 63.86 31.55 13.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.896 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -129.38 91.24 3.14 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.4 t -46.4 138.97 5.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.854 -179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 18.2 mt -91.52 5.17 50.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.93 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -75.4 117.97 17.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 117.28 -39.62 2.6 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.544 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.461 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -82.8 167.36 18.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.888 0.375 . . . . 0.0 110.894 -179.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.449 HG22 ' HB3' ' A' ' 31' ' ' ALA . 72.5 p -103.84 162.06 13.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.154 179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.672 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.83 -56.02 0.47 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.865 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -51.81 -45.04 55.65 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.525 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.441 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 14.7 mm-40 -69.04 -49.02 61.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.829 0.347 . . . . 0.0 110.875 -179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.461 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.87 -45.34 74.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.095 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.734 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.7 t -57.2 -58.18 7.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.487 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 66.6 mm-40 -52.09 -22.48 4.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 -179.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.545 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.4 tt -79.37 -28.24 41.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.906 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.734 HD23 ' HA ' ' A' ' 86' ' ' VAL . 0.7 OUTLIER -83.76 -25.86 30.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.896 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.487 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.8 ptm180 -96.04 0.91 52.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.834 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 32.6 t -93.68 28.04 2.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.684 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.1 t -92.81 148.91 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.76 -77.76 1.3 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.499 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -125.16 -17.72 5.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.916 0.388 . . . . 0.0 110.869 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.814 HG23 ' O ' ' A' ' 15' ' ' ILE . 5.0 m -158.38 137.28 11.34 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.142 -179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.782 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -122.69 160.65 25.41 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.912 179.986 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.438 HG21 ' OE2' ' A' ' 12' ' ' GLU . 3.4 m -113.24 96.62 6.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.103 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.563 HG23 HG22 ' A' ' 100' ' ' VAL . 3.0 m -91.96 130.01 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.1 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.7 tp -97.08 17.77 16.32 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.872 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.766 HG12 HD22 ' A' ' 69' ' ' LEU . 35.9 m -49.38 178.37 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.443 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 1.9 p -167.62 161.58 13.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.866 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -60.77 102.28 0.18 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.887 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -92.56 -60.29 1.23 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.509 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -164.39 113.39 1.15 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.862 0.363 . . . . 0.0 110.883 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -54.79 -55.61 28.28 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.4 m 58.59 51.4 7.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.884 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -138.65 -126.89 2.44 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.483 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -7.24 20.57 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.708 2.272 . . . . 0.0 112.343 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 96.0 p -53.0 -28.98 26.61 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.87 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 10.7 m -50.03 -52.59 32.94 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.842 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.481 -179.988 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.0 t -47.22 -58.68 3.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.868 0.366 . . . . 0.0 110.869 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 68.5 p -75.98 75.09 2.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -103.95 -71.45 0.85 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.514 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 74.3 m -98.29 142.75 29.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.876 0.37 . . . . 0.0 110.866 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 m -97.18 56.17 1.35 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.872 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -132.86 145.81 17.74 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.481 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.79 176.59 6.59 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.669 2.246 . . . . 0.0 112.315 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 169.26 -55.21 0.21 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.48 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.97 19.78 1.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.954 -179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 52.4 mtp180 -88.71 162.26 16.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.848 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.467 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -73.18 110.78 7.72 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.922 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.3 161.57 15.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.0 p -143.01 153.2 42.74 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.892 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.3 mt -121.85 120.94 62.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.111 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.1 mp0 -93.12 110.59 22.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.575 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.1 179.75 4.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.89 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.764 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -59.18 166.4 2.84 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.566 0.698 . . . . 0.0 111.088 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.9 Cg_endo -69.71 -0.28 6.65 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.65 2.233 . . . . 0.0 112.369 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.59 29.34 0.22 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.48 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.688 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 52.2 tp10 -94.25 140.42 29.79 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.924 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 5.9 ptt-85 -82.95 120.57 25.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.715 HD12 HG12 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -33.99 -49.15 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.94 179.98 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 76.24 42.07 24.59 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 89' ' ' LEU . 1.5 pt -121.19 164.41 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.864 0.364 . . . . 0.0 111.143 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.97 150.9 50.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.809 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.407 ' C ' ' HE2' ' A' ' 82' ' ' HIS . 30.2 pt -140.36 149.39 21.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.097 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 35.0 ptt180 -125.14 123.16 39.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.904 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.04 -141.87 8.49 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.495 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 119.34 133.62 4.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.475 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.443 ' O ' HG22 ' A' ' 81' ' ' THR . . . -70.82 112.1 6.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.741 0.305 . . . . 0.0 111.124 179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 61.8 mtp180 70.11 27.83 4.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.896 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -99.26 -101.35 2.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.426 ' O ' ' C ' ' A' ' 35' ' ' ALA . 9.7 p80 -128.52 116.37 19.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.826 0.346 . . . . 0.0 110.873 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.426 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -35.97 125.68 0.73 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.056 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.37 -52.57 0.87 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.517 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.0 m-20 -88.9 127.76 54.68 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.656 0.741 . . . . 0.0 110.877 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.8 Cg_endo -69.75 -43.57 2.58 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.729 2.286 . . . . 0.0 112.323 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.441 ' C ' ' O ' ' A' ' 38' ' ' PRO . 16.0 mmm180 -34.21 -70.2 0.08 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.846 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -119.06 119.89 31.69 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.632 0.729 . . . . 0.0 110.848 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -24.42 29.7 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.356 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 59.9 p -89.04 41.73 1.05 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.153 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -136.85 111.3 8.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.853 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.507 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 7.2 mp0 -101.3 71.36 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.912 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -94.88 162.5 24.12 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.459 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.7 mt -128.76 119.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.911 0.386 . . . . 0.0 111.152 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.5 OUTLIER -132.14 -179.94 5.72 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.905 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.832 HD13 HD11 ' A' ' 63' ' ' LEU . 69.9 mt -88.01 121.4 38.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.5 t -97.32 -17.36 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.453 ' HA ' HG21 ' A' ' 65' ' ' VAL . 12.3 ttmt -166.23 160.09 15.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.921 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.512 HG13 HG22 ' A' ' 25' ' ' ILE . 84.0 t -149.31 115.08 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.136 179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.6 t -60.3 134.37 90.95 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.694 0.759 . . . . 0.0 110.859 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -19.52 35.75 Favored 'Trans proline' 0 C--O 1.232 0.206 0 C-N-CA 122.702 2.268 . . . . 0.0 112.351 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 19.4 p -102.24 3.47 38.27 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.16 172.89 49.82 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.73 -39.7 85.57 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.808 0.337 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.689 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -69.3 -61.5 1.77 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.077 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.83 -39.94 2.07 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.514 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 14.5 ptt180 -82.24 -25.06 34.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.846 0.355 . . . . 0.0 110.852 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.472 ' N ' ' O ' ' A' ' 57' ' ' ALA . 30.3 t0 -53.27 -62.01 1.93 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.853 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 111.57 -16.24 26.56 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.1 -29.05 11.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.872 0.367 . . . . 0.0 110.866 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.1 tm? -87.4 134.16 33.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.966 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.924 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.72 150.2 24.42 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.873 179.981 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.463 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 44.2 t -56.63 104.48 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.136 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.33 -13.25 1.62 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.522 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.454 HD12 HD22 ' A' ' 63' ' ' LEU . 87.7 mt -83.49 123.75 30.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.823 0.344 . . . . 0.0 110.931 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.547 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 36.7 ttt180 -72.55 125.39 27.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.9 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.65 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -74.35 107.56 6.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.922 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.835 HD12 ' O ' ' A' ' 99' ' ' LEU . 70.3 mt -86.58 -48.91 7.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.958 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.443 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 20.0 mt-10 -158.92 138.47 11.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.898 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.734 HG13 HD12 ' A' ' 96' ' ' LEU . 93.0 t -112.99 110.37 31.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.097 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.8 m-20 65.49 40.55 4.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.893 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 36.5 mt-30 64.4 32.13 12.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.929 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -127.23 89.58 2.99 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 33.0 t -44.26 132.23 5.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.888 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.458 ' HA ' HD21 ' A' ' 80' ' ' LEU . 19.8 mt -79.4 0.07 30.73 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.416 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.7 OUTLIER -72.99 119.94 17.94 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.879 179.885 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.416 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 116.31 -34.73 4.56 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.499 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.562 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -92.42 158.8 15.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.902 -179.91 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.443 HG22 ' O ' ' A' ' 31' ' ' ALA . 49.5 p -92.04 178.94 5.73 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.407 ' HE2' ' C ' ' A' ' 27' ' ' ILE . 4.0 t-80 -50.06 -53.85 24.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.49 -48.69 63.89 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.484 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.468 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 22.4 mt-10 -61.04 -51.96 66.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.867 0.365 . . . . 0.0 110.887 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.562 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.19 -50.85 48.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.089 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 54.7 t -52.3 -58.84 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.479 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 59.9 mm-40 -53.11 -21.22 4.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.901 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.6 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.7 tt -78.03 -26.75 48.57 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.88 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.764 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -84.02 -28.47 27.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.946 179.887 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.479 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.3 ptm180 -93.72 1.19 56.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.879 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 46.3 t -96.24 33.1 1.81 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.841 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -111.28 136.53 47.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.163 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -57.46 -101.57 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.518 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -112.55 -3.71 14.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.868 0.366 . . . . 0.0 110.841 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.9 m -158.47 135.31 9.71 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.137 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.841 ' HB3' HG21 ' A' ' 92' ' ' VAL . 0.9 OUTLIER -123.82 168.16 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.918 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.467 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -118.14 96.24 5.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.118 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -93.93 129.84 43.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.835 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.7 tp -99.18 25.19 7.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.934 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.65 HG12 ' HA ' ' A' ' 69' ' ' LEU . 3.7 m -62.43 166.84 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.119 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.9 p -158.37 152.84 24.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.871 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.446 ' HA ' HD23 ' A' ' 67' ' ' LEU . 3.8 m-20 -43.83 104.61 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.859 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.81 -41.81 5.24 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.53 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -144.96 106.75 4.27 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.86 0.362 . . . . 0.0 110.84 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -39.05 -39.02 0.51 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.864 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 1.4 t 44.76 41.83 5.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.856 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 64.81 121.02 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.71 -50.61 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.257 . . . . 0.0 112.343 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 49.0 m -73.61 146.12 44.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 69.9 p -50.4 126.18 14.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 -179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.469 -179.997 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.3 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.6 t -61.1 88.69 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.893 0.378 . . . . 0.0 110.859 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 t -71.33 142.71 50.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.845 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.04 147.71 49.62 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.9 m -92.0 166.03 12.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.89 0.376 . . . . 0.0 110.843 -179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 30.4 t -105.27 -73.36 0.68 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.909 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.59 87.36 1.14 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.5 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 176.79 6.3 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.68 2.253 . . . . 0.0 112.365 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 163.06 -27.78 0.24 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.457 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.693 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -94.98 28.07 2.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.81 0.338 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' HD12 ' A' ' 99' ' ' LEU . 1.0 OUTLIER -98.02 171.43 8.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.877 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.409 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 41.4 tt0 -74.39 108.45 7.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 61.6 mt -113.23 158.02 21.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.923 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.9 p -137.83 148.68 45.67 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.872 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 57' ' ' ALA . 40.7 mt -114.18 96.64 4.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -69.2 112.95 6.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.904 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.437 ' HZ1' ' CD2' ' A' ' 23' ' ' LEU . 0.0 OUTLIER -124.71 172.6 9.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.912 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.774 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -60.62 164.35 7.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.547 0.689 . . . . 0.0 111.091 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.717 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.77 2.41 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.661 2.241 . . . . 0.0 112.329 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 24.74 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.467 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.774 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 9.1 tp10 -95.4 132.13 40.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.91 0.386 . . . . 0.0 110.892 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.441 ' O ' ' C ' ' A' ' 23' ' ' LEU . 67.2 mtt180 -82.35 118.49 23.21 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.872 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.783 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.19 -51.63 0.44 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.952 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.82 28.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.5 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.612 HG12 HD12 ' A' ' 23' ' ' LEU . 1.4 pt -119.42 170.36 9.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.819 0.342 . . . . 0.0 111.143 -180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.501 ' N ' ' O ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -132.61 166.86 21.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.922 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.44 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 19.7 pt -155.41 145.05 12.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.113 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.7 ptt180 -124.02 124.76 43.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.857 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.76 -148.5 19.03 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.509 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.47 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 121.68 140.51 5.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.524 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.931 ' O ' HG22 ' A' ' 81' ' ' THR . . . -88.38 117.98 27.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.82 0.343 . . . . 0.0 111.125 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 58.3 mtp180 63.08 39.34 10.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.76 -88.57 0.48 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.514 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 19.4 m170 -116.21 119.67 36.52 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.812 0.339 . . . . 0.0 110.887 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -48.0 124.56 7.72 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.096 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.38 -49.98 7.79 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.477 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 45.4 m-20 -118.31 140.76 28.53 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.587 0.708 . . . . 0.0 110.907 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.4 Cg_endo -69.77 -50.55 0.45 Allowed 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.713 2.275 . . . . 0.0 112.328 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.44 ' C ' ' O ' ' A' ' 38' ' ' PRO . 23.4 tpt180 -34.25 -72.39 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 48.0 m-20 -121.14 119.72 29.53 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.655 0.74 . . . . 0.0 110.854 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -1.41 8.42 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.69 2.26 . . . . 0.0 112.331 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 66.3 p -85.56 26.93 0.88 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.162 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -124.31 114.21 19.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.883 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 6.0 mp0 -113.66 28.43 8.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.851 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.61 144.04 43.21 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.449 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.47 HG12 ' N ' ' A' ' 30' ' ' GLY . 39.5 mt -115.34 119.49 61.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.867 0.365 . . . . 0.0 111.131 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.608 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -133.09 -174.7 3.56 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.918 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.76 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -90.48 128.4 42.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.156 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.6 t -105.21 -12.95 15.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.907 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' O ' ' N ' ' A' ' 26' ' ' SER . 39.4 ttmt -175.79 139.7 0.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.76 HG21 HD12 ' A' ' 63' ' ' LEU . 0.2 OUTLIER -146.14 118.38 2.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 18.2 t -48.01 134.08 11.75 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.675 0.75 . . . . 0.0 110.881 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -16.12 37.39 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.728 2.286 . . . . 0.0 112.319 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -113.67 -6.98 13.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.173 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -63.79 174.24 11.84 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.468 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.511 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -52.88 -37.13 60.1 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 0.0 111.122 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.783 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -80.8 -60.38 2.33 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.115 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -36.56 -47.25 1.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.478 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.478 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 21.1 ptt180 -69.72 -36.4 75.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.857 0.36 . . . . 0.0 110.897 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.476 ' N ' ' O ' ' A' ' 57' ' ' ALA . 28.7 t70 -39.91 -56.12 1.87 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.881 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 112.81 -22.78 15.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 4.2 mmp_? -95.29 -44.66 7.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.841 0.353 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.76 HD11 HD13 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -58.11 145.12 37.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.903 -179.956 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.724 ' N ' HD13 ' A' ' 63' ' ' LEU . 12.2 ptt-85 -175.23 146.61 0.85 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.483 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 57.4 t -57.89 105.49 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.106 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 141.72 -25.56 2.42 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.451 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.714 HD23 ' C ' ' A' ' 101' ' ' CYS . 11.4 mt -69.74 118.41 12.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.796 0.332 . . . . 0.0 110.933 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.551 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 25.4 ttt180 -68.85 123.25 20.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.845 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.576 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -74.24 110.03 8.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.933 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.434 ' HA ' HD13 ' A' ' 70' ' ' LEU . 2.1 mm? -85.61 -50.47 7.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.924 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -152.47 139.73 19.41 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.677 HG13 HD12 ' A' ' 96' ' ' LEU . 97.0 t -114.42 109.53 28.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.092 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.522 ' ND2' HG22 ' A' ' 92' ' ' VAL . 9.7 m-20 65.64 40.88 4.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 63.62 34.07 12.71 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.906 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 33.2 mt-30 -130.69 92.19 3.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 t -43.97 129.72 5.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.885 -179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.674 HD11 HG23 ' A' ' 72' ' ' VAL . 16.8 mt -89.65 10.14 24.32 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.884 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.576 HD13 ' N ' ' A' ' 79' ' ' GLY . 1.5 tm? -80.88 122.57 27.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.576 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.15 -33.51 5.68 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.477 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.541 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -85.82 164.2 17.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.882 0.372 . . . . 0.0 110.93 -179.934 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.931 HG22 ' O ' ' A' ' 31' ' ' ALA . 75.2 p -98.66 160.59 14.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.44 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 2.7 t-80 -33.67 -55.76 0.45 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.842 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -55.1 -46.99 76.17 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.466 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -62.86 -44.34 96.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.808 0.337 . . . . 0.0 110.89 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.525 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -62.26 -51.77 66.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.097 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.56 ' HA ' HD23 ' A' ' 89' ' ' LEU . 38.2 t -49.45 -61.5 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.111 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.49 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 86.6 mm-40 -47.41 -24.08 0.73 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.556 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.4 tt -78.39 -33.03 49.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.897 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.597 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -78.9 -30.27 44.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 179.923 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.49 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.5 ptm180 -90.14 4.48 50.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.84 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.0 t -97.2 19.35 13.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.546 HG11 ' HB3' ' A' ' 96' ' ' LEU . 26.1 t -82.14 150.54 4.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -94.64 -78.9 1.43 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.481 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -120.31 -22.35 6.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.89 0.376 . . . . 0.0 110.862 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 21.1 m -160.23 131.94 6.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.134 -179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.677 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -113.09 171.5 7.51 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.409 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 2.0 m -121.19 97.65 5.61 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.149 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.3 m -95.54 130.13 44.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.105 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 11' ' ' ARG . 23.7 tp -104.11 33.9 3.28 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.873 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.576 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.4 m -66.51 -179.27 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.108 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.714 ' C ' HD23 ' A' ' 67' ' ' LEU . 1.2 p -173.09 158.15 3.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.889 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -51.46 104.42 0.08 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.897 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -91.82 -48.87 3.05 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.479 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -163.95 119.52 1.59 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.776 0.322 . . . . 0.0 110.891 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -63.62 131.77 49.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.888 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 38.3 p -43.65 -49.93 7.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.914 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.61 -166.22 42.21 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.509 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 108.74 2.14 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.734 2.289 . . . . 0.0 112.339 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.8 t -54.77 -46.47 74.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.828 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 59.1 m -69.59 167.94 15.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.814 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.986 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.6 t -113.21 117.28 31.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.894 0.378 . . . . 0.0 110.859 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.5 m -86.53 148.85 25.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.837 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.81 -157.96 13.82 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.472 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.5 t -92.51 82.23 4.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.85 0.357 . . . . 0.0 110.833 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.9 m -121.73 43.77 2.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.839 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.23 79.72 0.05 OUTLIER Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.474 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 156.15 64.17 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.707 2.272 . . . . 0.0 112.346 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -144.04 -37.01 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.444 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.696 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.53 16.12 1.83 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.812 0.339 . . . . 0.0 110.933 -179.935 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 17.5 mmt180 -85.63 160.92 19.48 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.918 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -70.44 113.82 7.95 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.913 -179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 19.6 mt -114.54 172.32 7.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.905 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 4.9 p -151.59 159.32 44.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.479 ' HB ' ' CD2' ' A' ' 96' ' ' LEU . 72.5 mt -129.12 112.43 25.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -80.33 127.44 32.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.908 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.7 ptpp? -139.92 173.62 11.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.851 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -61.4 169.18 2.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.593 0.711 . . . . 0.0 111.091 179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.851 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.77 -3.07 11.29 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.699 2.266 . . . . 0.0 112.333 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -160.1 34.11 0.43 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.443 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.623 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.8 tp10 -101.17 137.89 38.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.865 0.364 . . . . 0.0 110.9 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.482 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.3 mtp180 -81.86 118.68 23.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.859 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.736 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.55 -43.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.937 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 73.92 40.89 42.8 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.473 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.727 HD11 HD13 ' A' ' 89' ' ' LEU . 1.2 pt -119.92 161.62 19.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.83 0.348 . . . . 0.0 111.123 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -130.6 135.68 48.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.869 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.625 HD12 HG21 ' A' ' 46' ' ' ILE . 18.2 pt -129.56 156.41 41.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.176 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -132.73 132.93 42.84 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.36 -137.72 5.84 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.482 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 116.68 155.43 10.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.469 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.509 ' HB3' HG22 ' A' ' 81' ' ' THR . . . -63.74 -6.24 5.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.805 0.336 . . . . 0.0 111.083 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.429 ' O ' ' C ' ' A' ' 33' ' ' GLY . 9.6 mmt85 -134.26 -33.59 1.0 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.909 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -34.02 109.37 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.504 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' C ' ' A' ' 35' ' ' ALA . 36.0 m170 -36.1 129.01 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.751 0.31 . . . . 0.0 110.885 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 36' ' ' GLY . . . 35.06 41.6 0.07 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.073 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 35' ' ' ALA . . . -35.04 -49.18 0.79 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.468 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -79.52 126.53 80.66 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.656 0.741 . . . . 0.0 110.871 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 0.59 5.42 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.702 2.268 . . . . 0.0 112.328 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.9 mtp180 -115.94 -49.19 2.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.433 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 0.7 OUTLIER -116.05 107.5 47.75 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.588 0.708 . . . . 0.0 110.9 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 53.5 Cg_endo -69.78 -13.85 35.2 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.714 2.276 . . . . 0.0 112.347 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.8 t -102.41 5.98 39.97 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.117 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -122.46 110.84 16.11 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.899 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.429 ' H ' ' CD ' ' A' ' 44' ' ' GLU . 4.7 mp0 -63.56 83.55 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -107.76 164.13 12.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.509 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.625 HG21 HD12 ' A' ' 27' ' ' ILE . 26.4 mt -132.34 117.02 30.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.827 0.346 . . . . 0.0 111.142 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -130.09 155.77 45.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.818 179.997 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.897 HD13 HD11 ' A' ' 63' ' ' LEU . 77.7 mt -64.57 126.32 23.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.156 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -105.37 -18.25 14.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.865 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.508 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.9 tttp -165.76 154.35 11.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.897 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.577 HG13 HG22 ' A' ' 25' ' ' ILE . 98.1 t -145.27 124.08 5.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.107 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.2 t -68.05 133.15 91.85 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.67 0.748 . . . . 0.0 110.864 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -8.35 23.37 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.645 2.23 . . . . 0.0 112.332 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 54.9 p -111.13 -9.58 14.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.123 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.68 168.53 51.32 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.496 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.55 -35.01 67.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.78 0.324 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.736 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.33 -65.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.103 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -40.79 -40.08 2.08 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.478 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -77.01 -28.45 55.01 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.796 0.331 . . . . 0.0 110.892 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.479 ' N ' ' O ' ' A' ' 57' ' ' ALA . 9.9 t0 -54.28 -64.03 0.96 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 124.06 -24.23 6.36 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.2 mmp_? -92.46 -66.58 0.91 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.813 0.339 . . . . 0.0 110.833 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.897 HD11 HD13 ' A' ' 48' ' ' ILE . 1.4 tm? -48.34 118.02 2.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.945 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.579 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.2 ptp180 -142.69 154.85 44.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.848 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.508 HG21 ' HA ' ' A' ' 50' ' ' LYS . 63.1 t -61.31 106.06 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 147.68 -27.18 1.48 Allowed Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.459 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.735 HD23 HG23 ' A' ' 100' ' ' VAL . 7.6 mp -74.79 140.62 44.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.773 0.32 . . . . 0.0 110.892 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.579 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 57.2 ttt180 -87.61 121.01 29.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.826 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.599 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.0 mm? -67.87 105.97 2.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.949 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.438 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 1.7 mm? -80.15 -50.43 10.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.899 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.438 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 24.2 mt-10 -159.17 142.92 14.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.908 HG13 HD12 ' A' ' 96' ' ' LEU . 95.6 t -114.75 109.6 29.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.131 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.41 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.1 m-20 65.38 41.77 4.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.888 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 28.4 mt-30 64.6 34.04 10.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -128.26 90.59 3.1 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.941 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.421 ' O ' HD21 ' A' ' 80' ' ' LEU . 38.5 t -46.1 129.19 9.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.879 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.456 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.0 mt -78.82 -0.49 30.75 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.879 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -76.06 116.7 17.02 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.875 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 118.59 -34.7 4.28 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.457 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.498 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.2 OUTLIER -88.48 170.9 10.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.913 0.387 . . . . 0.0 110.888 -179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.509 HG22 ' HB3' ' A' ' 31' ' ' ALA . 42.0 p -107.8 160.92 15.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.095 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.486 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.8 t-80 -32.97 -53.5 0.36 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.87 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -54.28 -49.96 57.98 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.5 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.416 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 3.1 mm-40 -64.38 -45.41 87.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.844 0.354 . . . . 0.0 110.895 -179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.498 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.67 -47.51 82.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 82' ' ' HIS . 78.6 t -59.25 -58.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 74.7 mm-40 -51.24 -26.06 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.855 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.1 tt -72.3 -29.24 63.67 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.962 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.727 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -78.5 -29.59 46.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.895 179.883 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 2.4 ptm85 -92.51 0.77 57.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.874 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 21.6 t -98.99 36.24 1.73 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.88 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.552 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.1 p -111.6 144.94 18.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.09 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.8 -105.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.527 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 19' ' ' PRO . 1.3 t70 -103.39 -3.33 25.63 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.912 0.386 . . . . 0.0 110.876 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.469 ' C ' HG21 ' A' ' 92' ' ' VAL . 49.8 m -166.14 143.08 5.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.167 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.908 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.8 168.41 11.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.87 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.0 m -120.33 98.18 5.93 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.16 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.469 ' HB ' HG13 ' A' ' 100' ' ' VAL . 3.2 m -98.65 130.37 47.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.104 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 22.4 tp -96.4 21.49 9.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.89 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.735 HG23 HD23 ' A' ' 67' ' ' LEU . 3.0 m -52.26 -175.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.106 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.5 p -175.96 157.58 1.92 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -52.65 100.82 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.893 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.32 -56.47 1.79 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.465 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -166.08 110.61 0.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 0.0 110.847 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -67.16 114.37 5.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.904 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.7 t -57.42 -44.02 84.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.897 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 141.61 146.02 4.64 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.486 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 173.84 10.34 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.708 2.272 . . . . 0.0 112.4 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 22.8 t -167.66 147.33 5.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.829 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 31.0 m -133.8 165.44 24.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.5 -179.964 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.1 t -84.99 112.05 20.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.869 0.366 . . . . 0.0 110.881 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.7 m -87.29 118.82 26.97 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.863 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.73 -158.61 28.41 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.466 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 8.4 t -45.19 106.97 0.08 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.858 0.361 . . . . 0.0 110.85 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 79.1 p -42.24 -57.08 2.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.867 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 138.18 149.8 5.56 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.444 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.77 134.96 29.23 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.642 2.228 . . . . 0.0 112.322 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 176.49 -28.48 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.521 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.701 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.3 29.25 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.796 0.332 . . . . 0.0 110.914 -179.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 11' ' ' ARG . 23.1 mtm105 -96.32 142.36 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.442 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.5 tt0 -53.35 114.9 1.65 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.896 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.69 163.49 16.4 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.943 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.7 p -146.09 153.72 41.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.427 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 82.7 mt -120.95 110.34 27.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.083 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -85.11 102.45 13.26 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.464 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 3.4 ptpp? -112.33 171.56 7.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.854 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.842 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.72 168.79 0.06 OUTLIER Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.619 0.723 . . . . 0.0 111.087 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.842 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.5 Cg_endo -69.85 0.95 4.97 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.674 2.249 . . . . 0.0 112.321 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.61 41.25 0.19 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.507 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.567 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 48.9 tp10 -105.66 140.53 38.58 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.851 0.358 . . . . 0.0 110.889 -179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.467 ' O ' ' C ' ' A' ' 23' ' ' LEU . 4.3 ptm180 -86.36 122.78 30.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.824 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.851 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.16 -46.9 0.17 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.99 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.32 44.76 51.27 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.484 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.911 HG22 HG22 ' A' ' 51' ' ' VAL . 0.9 OUTLIER -118.68 168.04 11.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.854 0.359 . . . . 0.0 111.111 -179.971 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.8 m -133.75 147.16 51.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.52 HD12 HG21 ' A' ' 46' ' ' ILE . 28.7 pt -138.32 155.63 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.152 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 21.5 ptt180 -126.83 124.54 39.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.857 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 155.55 -147.15 15.6 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.509 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.04 152.39 10.69 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.473 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -74.16 4.65 5.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.757 0.313 . . . . 0.0 111.08 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.452 ' HD3' HG21 ' A' ' 81' ' ' THR . 28.9 ptt85 -131.05 16.53 5.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.28 164.67 14.43 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.5 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.45 ' O ' ' C ' ' A' ' 35' ' ' ALA . 54.7 p-80 -70.89 127.07 31.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.844 0.355 . . . . 0.0 110.852 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -34.24 123.9 0.5 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -55.3 -25.57 41.0 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.484 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -111.23 135.91 20.92 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.608 0.718 . . . . 0.0 110.919 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.7 -1.17 7.96 Favored 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.713 2.275 . . . . 0.0 112.322 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 10.1 tpp180 -65.71 -69.79 0.28 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.86 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.72 120.98 31.11 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.641 0.734 . . . . 0.0 110.859 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.71 29.24 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.7 2.267 . . . . 0.0 112.302 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 77.9 p -105.17 55.71 0.69 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.139 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -137.79 112.25 8.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.858 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 7.0 mp0 -89.25 34.16 0.8 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.865 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.16 149.26 49.92 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.497 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.52 HG21 HD12 ' A' ' 27' ' ' ILE . 26.8 mt -126.85 116.99 46.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.864 0.364 . . . . 0.0 111.111 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.553 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -129.13 153.85 47.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.636 HD13 HD11 ' A' ' 63' ' ' LEU . 23.5 mt -62.78 138.26 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.141 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.1 t -118.18 -16.91 9.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.848 -179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.53 ' HA ' HG21 ' A' ' 65' ' ' VAL . 64.9 tttt -165.22 146.96 7.66 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.889 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.911 HG22 HG22 ' A' ' 25' ' ' ILE . 32.4 t -142.11 133.62 26.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.168 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 7.8 t -74.7 141.79 76.31 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.681 0.753 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.76 -31.21 20.96 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.663 2.242 . . . . 0.0 112.324 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 47.8 p -93.56 -6.66 46.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.151 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -71.9 150.63 46.37 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.72 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -40.88 -31.81 0.19 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.809 0.338 . . . . 0.0 111.098 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.869 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -77.8 -65.55 0.95 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.088 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -41.11 -34.44 0.88 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.476 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -90.82 -23.22 20.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.799 0.333 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.478 ' N ' ' O ' ' A' ' 57' ' ' ALA . 10.7 t0 -52.58 -52.24 56.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 106.34 -7.94 40.65 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.518 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -115.39 -48.61 2.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.831 0.348 . . . . 0.0 110.875 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.869 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -67.39 130.84 44.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.916 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.598 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.4 OUTLIER -161.52 157.41 24.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.849 179.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.53 HG21 ' HA ' ' A' ' 50' ' ' LYS . 80.5 t -59.67 105.89 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.185 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.31 -15.58 1.67 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.61 HD23 ' HA ' ' A' ' 102' ' ' ASP . 58.1 mt -85.45 134.27 34.07 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.348 . . . . 0.0 110.887 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.553 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 72.3 ttt180 -84.1 121.79 27.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.69 HD22 HG12 ' A' ' 100' ' ' VAL . 1.6 mm? -70.28 116.14 10.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.916 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 99' ' ' LEU . 71.6 mt -96.87 -49.42 5.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.94 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -155.13 141.75 18.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.694 HG13 HD12 ' A' ' 96' ' ' LEU . 78.4 t -118.73 108.27 23.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.075 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' HB2' ' O ' ' A' ' 72' ' ' VAL . 15.0 m-20 65.7 40.91 4.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 64.01 35.21 10.78 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -131.07 91.1 2.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.91 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.4 t -42.4 128.79 3.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.86 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.548 ' HA ' HD11 ' A' ' 80' ' ' LEU . 9.9 mt -80.68 9.01 6.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.933 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.679 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -83.09 137.6 34.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.679 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 97.76 -33.22 6.05 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.489 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.548 HD11 ' HA ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -88.08 166.96 14.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.887 0.375 . . . . 0.0 110.91 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.452 HG21 ' HD3' ' A' ' 32' ' ' ARG . 33.0 p -106.92 165.43 11.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.132 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.512 ' O ' HG23 ' A' ' 86' ' ' VAL . 1.8 t-80 -33.82 -60.54 0.37 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.53 -47.68 22.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.507 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.3 mt-10 -66.01 -53.01 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.901 0.381 . . . . 0.0 110.853 -179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.401 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -49.4 -49.35 45.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.1 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 82' ' ' HIS . 61.2 t -59.1 -57.06 13.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.17 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 80.6 mm-40 -53.04 -17.51 1.54 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.573 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.5 tt -83.98 -28.08 28.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.928 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.834 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -84.12 -27.4 28.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.901 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.9 ptm180 -97.03 5.74 49.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 m -102.27 32.43 3.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.885 -179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.5 p -111.11 140.04 32.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.117 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -56.56 -100.55 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.487 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.451 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -113.17 -10.56 13.38 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.906 0.384 . . . . 0.0 110.868 -179.95 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.1 m -151.64 135.39 16.35 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.131 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.803 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -124.17 171.26 9.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.442 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.4 m -120.69 96.6 5.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.2 m -94.25 128.64 45.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.162 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.686 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.6 tp -97.11 29.07 3.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.938 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.69 HG12 HD22 ' A' ' 69' ' ' LEU . 14.0 m -58.48 172.57 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.115 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.8 p -162.27 148.47 13.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.61 ' HA ' HD23 ' A' ' 67' ' ' LEU . 4.9 m-20 -51.16 110.62 0.45 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.869 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -100.25 -54.7 1.01 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.488 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -165.31 116.09 1.1 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.866 0.365 . . . . 0.0 110.861 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 31.1 mt-10 -62.98 -49.55 74.27 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.891 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 25.1 p 41.06 32.14 0.16 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.83 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.402 ' HA3' ' HD2' ' A' ' 108' ' ' PRO . . . -126.59 -150.6 7.6 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.526 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.402 ' HD2' ' HA3' ' A' ' 107' ' ' GLY . 53.6 Cg_endo -69.8 121.43 8.12 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.709 2.273 . . . . 0.0 112.312 -179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 7.2 m -116.42 113.29 22.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.881 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.4 t -79.88 -47.26 15.38 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.884 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.467 179.972 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.3 m -130.62 129.98 43.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.847 0.356 . . . . 0.0 110.879 -179.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 97.1 p -81.57 13.79 2.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.96 105.49 0.18 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.492 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.5 t -116.66 88.96 3.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.849 0.356 . . . . 0.0 110.858 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.1 t -59.84 103.11 0.19 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 -179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.59 162.36 27.34 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.469 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.75 172.35 12.78 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.714 2.276 . . . . 0.0 112.326 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 175.29 -52.44 0.13 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.531 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.706 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.21 33.94 0.51 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.841 0.353 . . . . 0.0 110.939 -179.96 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.822 ' O ' HD12 ' A' ' 13' ' ' LEU . 20.5 mtt-85 -99.28 165.03 11.88 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.883 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 42.1 tt0 -77.84 110.18 12.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.908 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.822 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -115.27 166.12 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.93 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.4 p -146.89 160.9 41.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.868 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.8 mt -124.1 115.17 44.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.166 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mp0 -85.21 113.11 21.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.922 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.6 ptpp? -126.89 165.41 19.41 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.65 169.12 0.13 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.595 0.712 . . . . 0.0 111.096 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.78 -2.84 10.87 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.696 2.264 . . . . 0.0 112.309 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -163.36 38.28 0.33 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.556 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.69 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 28.2 tp10 -103.53 140.64 37.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.815 0.34 . . . . 0.0 110.909 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.453 ' O ' ' C ' ' A' ' 23' ' ' LEU . 6.2 ptt85 -83.27 121.22 26.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.849 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.87 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -33.9 -54.12 0.47 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.878 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.37 40.51 9.98 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.439 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.928 HD11 HD13 ' A' ' 89' ' ' LEU . 4.1 pt -120.22 169.72 11.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.803 0.335 . . . . 0.0 111.146 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.466 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.4 m -141.17 145.07 35.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.853 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.566 HD12 ' CG2' ' A' ' 46' ' ' ILE . 30.7 pt -134.85 158.96 41.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -131.4 133.29 45.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 148.73 -142.61 10.08 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.486 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 119.69 142.79 6.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.499 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.428 ' HB3' HG22 ' A' ' 81' ' ' THR . . . -51.12 -16.73 0.51 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 111.139 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 12.9 mmm180 -127.44 -38.8 1.91 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -41.88 152.61 0.17 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.469 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -44.35 123.32 3.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.825 0.345 . . . . 0.0 110.841 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -44.85 123.59 3.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.101 179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -43.98 -42.38 6.48 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.462 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -91.89 120.11 68.08 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.618 0.723 . . . . 0.0 110.889 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 1.37 4.46 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.722 2.281 . . . . 0.0 112.405 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 6.1 ttm-85 -84.8 -64.2 1.2 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -111.48 124.57 32.28 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.595 0.712 . . . . 0.0 110.866 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -10.9 29.67 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.659 2.239 . . . . 0.0 112.353 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 68.2 p -89.11 41.08 1.01 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.096 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -134.92 89.49 2.53 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.875 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.439 ' CD ' ' N ' ' A' ' 44' ' ' GLU . 5.9 mp0 -90.13 30.08 1.14 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.885 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.08 162.38 31.88 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.476 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.566 ' CG2' HD12 ' A' ' 27' ' ' ILE . 40.2 mt -129.51 118.34 45.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.864 0.364 . . . . 0.0 111.151 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.7 OUTLIER -132.17 -177.74 4.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.932 HD13 HD11 ' A' ' 63' ' ' LEU . 54.8 mt -87.57 133.82 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.142 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.5 t -113.59 -14.55 12.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 24.6 tttm -172.51 145.21 1.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.944 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.596 HG12 HG23 ' A' ' 65' ' ' VAL . 0.6 OUTLIER -152.92 110.26 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.15 179.88 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 2.4 t -53.83 129.6 56.12 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.678 0.751 . . . . 0.0 110.85 -179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.403 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.5 Cg_endo -69.78 -6.36 18.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.712 2.274 . . . . 0.0 112.29 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 32.2 p -105.07 -18.43 14.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.173 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -67.24 179.81 14.15 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.49 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.441 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -57.69 -39.1 76.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.762 0.315 . . . . 0.0 111.08 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.87 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.99 -63.65 1.22 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.14 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.46 -48.56 1.69 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.441 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.441 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.5 ptt180 -70.63 -31.17 68.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 57' ' ' ALA . 31.2 t0 -44.55 -61.62 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.838 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.38 -20.34 10.4 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.477 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.6 mmp_? -99.61 -47.47 5.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.81 0.338 . . . . 0.0 110.896 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.932 HD11 HD13 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -61.11 130.36 45.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.936 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.64 ' N ' HD13 ' A' ' 63' ' ' LEU . 16.8 ptt85 -162.01 146.0 12.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.846 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.596 HG23 HG12 ' A' ' 51' ' ' VAL . 82.7 t -53.87 106.58 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.156 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 143.09 -11.42 2.31 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.48 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.474 HD12 ' H ' ' A' ' 64' ' ' ARG . 34.6 mt -86.52 124.02 32.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.854 0.359 . . . . 0.0 110.922 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.533 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 57.5 ttt180 -75.23 117.49 17.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.87 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.733 HD22 HG12 ' A' ' 100' ' ' VAL . 2.6 mm? -71.45 114.24 9.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.954 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.526 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.5 mt -90.43 -54.76 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.975 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -150.1 143.34 25.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.919 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 95.2 t -115.94 110.13 30.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.127 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 65.62 41.12 4.18 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.87 179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.405 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.7 mt-30 64.43 30.46 13.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.956 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 22.8 mt-30 -124.64 90.09 3.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.875 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 t -44.04 133.87 4.93 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.811 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.756 ' HA ' HD21 ' A' ' 80' ' ' LEU . 13.3 mt -88.94 7.63 33.57 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.891 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.421 HD22 ' HA ' ' A' ' 78' ' ' LEU . 0.9 OUTLIER -77.31 116.16 17.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.9 179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 115.76 -33.25 5.3 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.463 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.756 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -86.4 164.54 16.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.91 0.386 . . . . 0.0 110.901 -179.928 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.428 HG22 ' HB3' ' A' ' 31' ' ' ALA . 81.9 p -104.1 165.51 11.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.167 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.427 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.8 t-80 -34.7 -59.92 0.46 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.834 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.09 -49.85 23.3 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.9 mt-10 -63.02 -51.7 65.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.835 0.35 . . . . 0.0 110.89 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.46 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -52.01 -51.75 55.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.117 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.549 ' HA ' HD23 ' A' ' 89' ' ' LEU . 69.2 t -53.15 -60.45 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.483 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 78.1 mm-40 -50.36 -26.17 4.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.925 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.3 tt -74.04 -29.95 62.17 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.923 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.928 HD13 HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -79.84 -27.11 40.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.904 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.483 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 0.6 OUTLIER -96.96 -3.17 42.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.86 179.94 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.4 m -89.76 29.94 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.872 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.76 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -110.45 144.04 19.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.17 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -61.94 -101.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.506 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -111.39 -6.67 14.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.897 0.379 . . . . 0.0 110.854 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.7 m -155.24 136.47 13.95 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.156 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -126.49 167.2 15.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.898 179.983 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.41 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -116.54 94.52 4.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.175 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.5 m -91.05 127.15 43.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.162 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.526 ' O ' HD12 ' A' ' 70' ' ' LEU . 19.1 tp -95.97 33.03 1.77 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.878 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.733 HG12 HD22 ' A' ' 69' ' ' LEU . 5.9 m -60.98 174.62 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.146 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -167.78 155.12 8.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.83 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.417 ' HA ' HD23 ' A' ' 67' ' ' LEU . 5.6 p-10 -51.5 107.6 0.2 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.852 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -97.72 -54.98 1.18 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.467 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.413 ' O ' ' C ' ' A' ' 105' ' ' GLU . 2.5 p90 -166.41 110.06 0.76 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.824 0.345 . . . . 0.0 110.851 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 104' ' ' PHE . 3.3 mp0 -37.61 -57.03 0.99 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.919 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 80.1 p 49.91 41.76 23.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 91.4 120.53 2.47 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 132.1 22.59 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.68 2.254 . . . . 0.0 112.343 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.1 m -59.84 122.79 15.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.863 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 2.5 m -162.95 146.06 10.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.832 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.486 -179.974 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 t -94.75 -40.25 9.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.821 0.343 . . . . 0.0 110.836 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 m -117.35 72.48 0.84 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.824 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 67.62 -100.39 0.61 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.481 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 72.7 m -63.6 175.28 1.11 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.889 0.376 . . . . 0.0 110.866 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 54.4 m -85.03 173.0 10.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.889 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.73 166.49 22.69 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.48 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 158.47 56.88 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.258 . . . . 0.0 112.388 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -156.79 -46.88 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.489 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.733 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.43 30.82 0.6 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.788 0.328 . . . . 0.0 110.907 -179.916 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.411 ' O ' HD12 ' A' ' 99' ' ' LEU . 25.4 mtp180 -94.95 161.37 14.17 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -70.92 112.17 6.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.873 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.6 mt -116.88 159.52 22.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.888 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.581 ' SG ' HG23 ' A' ' 97' ' ' THR . 3.0 m -142.45 159.66 41.79 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.875 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.517 HD12 HD21 ' A' ' 23' ' ' LEU . 40.5 mt -125.58 114.57 40.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.173 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.7 mt-30 -88.6 107.66 19.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.511 ' CB ' ' HB2' ' A' ' 56' ' ' ALA . 1.0 OUTLIER -116.18 166.14 12.37 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.925 179.927 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.836 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.25 168.72 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.578 0.704 . . . . 0.0 111.097 179.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.836 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.79 3.35 2.83 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.703 2.268 . . . . 0.0 112.334 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -169.79 36.24 0.18 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.462 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.614 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.7 tp10 -105.47 142.52 35.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.889 0.376 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' O ' ' C ' ' A' ' 23' ' ' LEU . 58.8 mtt180 -88.94 123.37 33.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.829 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.86 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -31.49 -49.94 0.17 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.926 -179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 77.41 32.48 47.2 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.487 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.697 HG23 HD12 ' A' ' 23' ' ' LEU . 1.5 pt -108.87 160.0 7.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.817 0.342 . . . . 0.0 111.145 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.495 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -123.6 150.61 43.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 -179.909 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.419 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 27.5 pt -140.36 150.92 21.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.11 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 10.8 ptm180 -128.47 131.85 48.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.9 -144.85 13.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 133.74 140.67 4.38 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.508 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.481 ' CB ' ' O ' ' A' ' 80' ' ' LEU . . . -59.84 -6.21 1.19 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.787 0.327 . . . . 0.0 111.13 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.458 ' O ' ' C ' ' A' ' 33' ' ' GLY . 22.9 mmm-85 -130.96 -31.74 1.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.869 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' O ' ' N ' ' A' ' 35' ' ' ALA . . . -33.88 124.14 0.41 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.462 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 12.1 m170 -37.55 -29.5 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.777 0.323 . . . . 0.0 110.806 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.475 ' N ' ' O ' ' A' ' 33' ' ' GLY . . . -168.67 158.59 9.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.081 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -145.63 -39.35 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.532 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.432 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 32.4 t30 -110.87 132.14 21.78 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.581 0.705 . . . . 0.0 110.921 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -10.47 28.65 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.708 2.272 . . . . 0.0 112.358 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.432 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 23.5 mmm180 -91.73 -49.76 6.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.859 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -119.57 92.66 46.44 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.629 0.728 . . . . 0.0 110.841 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.7 -17.44 37.85 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.728 2.286 . . . . 0.0 112.348 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.3 t -97.94 11.62 36.86 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.153 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 45' ' ' GLY . 5.2 t0 -126.39 109.92 12.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.866 179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.414 ' HB3' ' O ' ' A' ' 30' ' ' GLY . 19.5 mm-40 -57.14 84.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 43' ' ' ASP . . . -105.48 153.46 17.21 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.453 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 26.8 mt -128.83 116.43 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.871 0.367 . . . . 0.0 111.133 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.554 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.6 m-85 -131.13 153.26 49.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.934 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.731 HD13 HD11 ' A' ' 63' ' ' LEU . 70.3 mt -62.67 128.22 24.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.108 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.4 t -107.13 -18.89 13.77 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.478 ' HA ' HG21 ' A' ' 65' ' ' VAL . 8.4 tttp -159.89 153.41 22.47 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.908 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.456 ' N ' ' HG3' ' A' ' 50' ' ' LYS . 78.7 t -143.28 127.52 14.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.135 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 29.1 t -66.24 140.29 96.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.726 0.774 . . . . 0.0 110.813 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -35.66 12.28 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.721 2.281 . . . . 0.0 112.328 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.02 -1.43 45.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.092 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -73.11 148.83 41.69 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.501 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.513 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -39.86 -35.18 0.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.82 0.343 . . . . 0.0 111.119 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.86 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -74.11 -59.66 2.62 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.082 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -47.89 -33.18 9.47 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.467 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.475 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.6 ptt-85 -84.97 -32.26 23.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.824 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.466 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 11.1 t0 -50.1 -61.57 2.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.839 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.22 -18.74 13.76 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.501 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 65.1 mtm180 -96.71 -42.81 7.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.828 0.347 . . . . 0.0 110.89 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.772 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.2 tm? -69.83 136.54 50.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.941 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.631 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.3 OUTLIER -166.67 155.26 10.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.859 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.478 HG21 ' HA ' ' A' ' 50' ' ' LYS . 85.2 t -61.25 105.55 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.117 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 149.45 -24.74 1.22 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.533 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.462 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.7 mt -74.85 135.88 41.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.554 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 45.8 ttt180 -85.69 117.59 24.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.873 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.782 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -68.11 116.07 8.31 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.919 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.615 HD12 ' O ' ' A' ' 99' ' ' LEU . 75.8 mt -94.09 -52.29 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.922 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -152.13 145.71 24.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.873 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.874 HG13 HD12 ' A' ' 96' ' ' LEU . 75.9 t -119.5 108.38 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.118 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.5 m-20 65.12 41.54 4.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.884 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 32.9 mt-30 64.07 32.11 13.03 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -125.35 91.11 3.35 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.7 t -47.82 126.41 10.32 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.812 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD21 ' A' ' 80' ' ' LEU . 11.4 mt -78.04 -0.37 27.71 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.863 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.37 115.38 11.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.922 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 119.93 -34.4 4.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.479 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.552 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -90.99 164.01 14.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.841 0.353 . . . . 0.0 110.897 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 82' ' ' HIS . 38.1 p -102.18 163.39 12.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.196 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -34.32 -58.33 0.47 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.837 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.33 -45.68 21.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.46 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 10.3 mm-40 -70.93 -53.46 14.89 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.853 0.359 . . . . 0.0 110.838 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.533 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.03 -49.01 21.96 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.049 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.565 ' HA ' HD23 ' A' ' 89' ' ' LEU . 70.0 t -57.34 -59.12 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.126 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.489 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 83.3 mm-40 -51.08 -22.79 2.62 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.917 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.557 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.62 -31.83 60.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.966 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.627 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -77.87 -27.93 49.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.962 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.489 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 6.9 ptm180 -94.41 1.5 55.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.866 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.9 t -94.62 30.92 1.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.872 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.583 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -113.17 146.48 17.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.13 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -63.62 -95.88 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.492 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -119.55 -2.08 10.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.912 0.387 . . . . 0.0 110.9 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 9.0 m -157.14 132.01 8.82 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.165 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.874 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -122.95 164.37 18.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.944 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.581 HG23 ' SG ' ' A' ' 14' ' ' CYS . 1.6 m -113.07 94.14 4.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.148 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.443 HG12 HD11 ' A' ' 96' ' ' LEU . 3.2 m -90.74 129.04 42.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.124 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.615 ' O ' HD12 ' A' ' 70' ' ' LEU . 21.0 tp -98.51 29.81 3.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.956 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.782 HG12 HD22 ' A' ' 69' ' ' LEU . 15.7 m -54.42 179.19 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.134 179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 3.3 p -171.52 148.75 2.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.864 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -41.19 113.61 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.849 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.19 -47.31 2.87 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.467 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.427 ' O ' ' C ' ' A' ' 105' ' ' GLU . 1.3 m-85 -144.99 116.66 8.15 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.821 0.343 . . . . 0.0 110.915 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.427 ' C ' ' O ' ' A' ' 104' ' ' PHE . 6.4 mp0 -36.28 -47.95 0.61 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.885 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.5 m 48.43 47.87 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.85 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -95.04 -167.12 35.87 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.477 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -32.19 19.04 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.728 2.285 . . . . 0.0 112.347 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 110' ' ' SER . 77.3 p -59.57 151.01 25.5 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.846 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.408 ' C ' ' O ' ' A' ' 109' ' ' SER . 77.5 p -37.29 -44.97 0.63 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.857 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.506 -179.961 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.354 0 N-CA-C 112.478 -0.249 . . . . 0.0 112.478 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.8 m -107.33 -45.01 4.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.85 0.357 . . . . 0.0 110.848 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 33.7 m -86.21 128.3 34.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.877 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 169.47 -89.71 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 p -72.88 -4.84 34.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.909 0.385 . . . . 0.0 110.86 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.0 m -122.48 94.84 4.41 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.858 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.15 87.11 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.505 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 155.42 65.81 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.677 2.251 . . . . 0.0 112.352 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.445 ' C ' ' HB2' ' A' ' 101' ' ' CYS . . . -140.75 -36.79 0.1 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.448 -179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.734 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.37 41.39 0.61 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.794 0.331 . . . . 0.0 110.889 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 15.7 mmm180 -111.34 152.37 27.33 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.484 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 19.0 tt0 -68.38 109.18 3.54 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.909 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.6 mt -106.52 168.72 8.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -151.4 147.85 27.4 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 95' ' ' THR . 71.1 mt -118.66 120.23 63.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.159 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -88.46 125.61 34.83 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.8 ptpp? -138.68 168.56 19.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.884 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.844 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -48.69 168.9 0.17 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.585 0.707 . . . . 0.0 111.122 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.844 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.1 Cg_endo -69.7 2.02 3.87 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.672 2.248 . . . . 0.0 112.379 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.58 35.53 0.17 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.5 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.7 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 21.5 tp10 -99.02 149.74 22.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' C ' ' A' ' 23' ' ' LEU . 86.4 mtt180 -89.46 121.6 31.85 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.865 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -32.91 -46.55 0.15 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.916 -179.948 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.5 42.55 17.7 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.466 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.766 HG22 HG13 ' A' ' 51' ' ' VAL . 2.6 pt -126.01 168.66 18.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.842 0.353 . . . . 0.0 111.099 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -138.91 142.73 38.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.864 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.492 HD12 HG21 ' A' ' 46' ' ' ILE . 39.6 pt -128.82 163.08 34.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.115 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.488 ' CG ' ' HB3' ' A' ' 49' ' ' SER . 22.6 ptt180 -134.56 124.71 25.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 158.81 -143.17 8.99 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.498 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 126.01 147.23 6.84 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.496 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -71.49 2.83 4.46 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.77 0.319 . . . . 0.0 111.132 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 79.7 mtt180 -135.01 14.62 3.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.61 154.71 21.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.503 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.457 ' O ' ' C ' ' A' ' 35' ' ' ALA . 13.5 m170 -72.15 125.77 28.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.779 0.323 . . . . 0.0 110.877 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 37' ' ' ASN . . . -32.38 108.01 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.147 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' A' ' 35' ' ' ALA . . . -34.32 -32.57 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.471 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.494 ' N ' ' O ' ' A' ' 35' ' ' ALA . 7.8 p-10 -89.0 146.89 37.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.636 0.731 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.77 9.01 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.717 2.278 . . . . 0.0 112.368 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 19.0 ttt180 -51.08 -72.18 0.05 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -143.4 107.06 5.15 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.588 0.708 . . . . 0.0 110.932 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -30.83 21.77 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.663 2.242 . . . . 0.0 112.371 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 7.0 t -64.25 -24.42 67.66 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.114 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -92.77 115.91 28.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.88 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.43 ' H ' ' CD ' ' A' ' 44' ' ' GLU . 24.6 mp0 -75.36 49.57 0.48 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.53 168.85 54.59 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.492 HG21 HD12 ' A' ' 27' ' ' ILE . 38.8 mt -133.86 117.75 27.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.821 0.343 . . . . 0.0 111.132 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.563 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.1 m-85 -131.25 154.07 48.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.54 HD11 HD21 ' A' ' 63' ' ' LEU . 37.6 mt -58.99 138.14 20.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.488 ' HB3' ' CG ' ' A' ' 28' ' ' ARG . 60.7 p -117.48 -18.68 9.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.845 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 5.0 ttpm? -165.56 155.01 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.919 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.766 HG13 HG22 ' A' ' 25' ' ' ILE . 98.4 t -148.68 128.66 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.122 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 33.9 t -81.74 139.15 46.94 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.668 0.747 . . . . 0.0 110.853 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -29.57 23.83 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.713 2.275 . . . . 0.0 112.356 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 59.7 p -80.83 -19.25 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.06 170.62 40.76 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.473 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.08 -33.65 72.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.326 . . . . 0.0 111.133 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.615 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -71.2 -70.45 0.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.59 -40.95 0.76 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.471 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 10.7 ptt180 -75.68 -34.67 60.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.783 0.325 . . . . 0.0 110.829 -179.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.488 ' N ' ' O ' ' A' ' 57' ' ' ALA . 15.3 t0 -47.72 -64.7 0.72 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.844 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 121.36 -19.4 8.63 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.476 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 42.9 mtm180 -96.72 -61.55 1.4 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.8 0.333 . . . . 0.0 110.888 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.586 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.8 tm? -46.4 133.4 9.83 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.553 ' H ' HD12 ' A' ' 67' ' ' LEU . 6.2 ptt180 -156.24 149.95 24.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.847 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.476 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 45.1 t -61.26 100.63 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.106 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 153.59 -19.89 0.7 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.445 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.553 HD12 ' H ' ' A' ' 64' ' ' ARG . 9.8 mt -77.81 140.74 39.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.783 0.325 . . . . 0.0 110.921 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.563 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 70.8 ttt180 -88.72 119.13 28.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.678 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -71.4 107.0 4.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.877 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.441 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 11.1 mp -83.45 -53.29 5.82 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.905 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.441 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 9.2 mt-10 -151.68 146.65 25.94 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.819 HG13 HD12 ' A' ' 96' ' ' LEU . 95.5 t -117.84 109.49 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.113 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.414 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 14.2 m-20 66.18 41.81 3.37 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.918 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.414 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.9 mt-30 64.64 29.96 12.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -122.9 89.04 3.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.917 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 32.1 t -40.49 129.03 2.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 83.9 mt -83.08 12.27 5.29 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.939 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -86.13 112.83 21.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.907 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.05 -38.97 2.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.57 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.1 OUTLIER -84.15 168.53 15.71 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.905 0.383 . . . . 0.0 110.904 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.464 ' O ' ' C ' ' A' ' 82' ' ' HIS . 23.0 p -108.62 166.1 11.04 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.168 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.464 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.7 t-80 -33.13 -61.77 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -47.4 -48.55 21.46 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.481 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.465 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 16.6 mt-10 -65.05 -55.98 15.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.87 0.366 . . . . 0.0 110.863 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.5 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -45.76 -50.36 14.0 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.405 ' HA ' HD23 ' A' ' 89' ' ' LEU . 71.2 t -55.64 -59.61 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.128 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.486 ' NE2' ' HD3' ' A' ' 90' ' ' ARG . 51.8 mm-40 -50.12 -25.41 3.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.886 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.1 tt -74.85 -32.16 61.84 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.881 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.805 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.5 OUTLIER -77.96 -30.09 50.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.874 179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.486 ' HD3' ' NE2' ' A' ' 87' ' ' GLN . 12.6 ptm180 -92.72 -7.13 47.56 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.874 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.5 m -87.84 30.01 0.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.893 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.709 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.9 p -106.69 143.73 16.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -62.51 -102.68 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.481 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -105.98 -13.41 15.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.886 0.374 . . . . 0.0 110.843 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 15' ' ' ILE . 3.3 m -153.89 141.29 19.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.177 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.819 HD12 HG13 ' A' ' 72' ' ' VAL . 0.9 OUTLIER -124.01 169.52 11.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.908 179.985 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.484 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -122.02 99.35 6.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.184 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 5.9 m -96.14 130.99 44.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.133 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp -97.12 31.31 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.953 179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.678 HG12 HD22 ' A' ' 69' ' ' LEU . 11.3 m -59.8 177.62 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.137 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.445 ' HB2' ' C ' ' A' ' 9' ' ' GLY . 13.2 p -175.23 143.06 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.924 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -38.69 104.47 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.871 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.05 -48.6 2.62 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.455 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.406 ' CE2' ' CD2' ' A' ' 47' ' ' PHE . 1.6 p90 -171.59 115.01 0.38 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.833 0.349 . . . . 0.0 110.896 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -69.97 -52.48 23.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.856 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.4 m 56.28 40.89 29.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.877 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -76.63 -173.26 36.95 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.458 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 171.5 14.3 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.706 2.271 . . . . 0.0 112.37 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 93.8 p -105.98 107.36 18.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.822 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.2 t 70.95 42.35 0.76 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.829 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.497 -179.963 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.366 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 p -110.01 102.51 11.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.865 0.364 . . . . 0.0 110.867 -179.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 39.4 p -50.19 121.32 5.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.829 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.44 47.47 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.497 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.5 m -66.75 123.99 21.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.915 0.388 . . . . 0.0 110.859 -179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.4 m -119.15 78.04 1.25 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.849 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 103.58 153.5 23.64 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 160.38 49.93 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.712 2.275 . . . . 0.0 112.312 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -164.08 -46.16 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.514 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.739 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.17 39.87 0.6 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.771 0.319 . . . . 0.0 110.882 -179.915 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.8 mtp180 -111.76 148.13 34.16 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.439 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 33.7 tt0 -61.89 111.29 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 29.5 mt -113.08 161.83 16.63 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.8 m -140.66 155.25 46.55 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.434 HG22 ' HB1' ' A' ' 56' ' ' ALA . 88.7 mt -123.01 108.71 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.159 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -84.53 114.98 22.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.933 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.432 ' HB3' ' CB ' ' A' ' 56' ' ' ALA . 0.5 OUTLIER -125.65 171.02 10.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.82 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.85 168.2 0.11 Allowed Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.583 0.706 . . . . 0.0 111.07 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.82 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.74 2.81 3.18 Favored 'Trans proline' 0 C--N 1.341 0.138 0 C-N-CA 122.704 2.27 . . . . 0.0 112.379 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -173.61 41.04 0.14 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.481 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 32.7 tp10 -107.36 147.16 30.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.876 0.37 . . . . 0.0 110.899 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.7 mmt-85 -83.95 122.95 29.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.658 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -33.53 -47.58 0.23 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.916 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.16 41.48 13.82 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.484 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.583 HG23 HD12 ' A' ' 23' ' ' LEU . 3.0 pt -121.54 166.89 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.845 0.355 . . . . 0.0 111.154 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.426 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.5 OUTLIER -130.3 149.76 51.84 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.85 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 pt -140.57 149.25 21.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.102 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.432 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.3 ptm85 -130.81 144.37 51.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 125.51 -155.48 18.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.496 -179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.468 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 165.56 -155.65 27.11 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.488 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.63 ' HB2' ' O ' ' A' ' 80' ' ' LEU . . . -129.16 -6.52 4.87 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.8 0.333 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 19.5 mmt180 -133.48 -40.12 0.89 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.858 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.97 -108.0 3.26 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.461 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 61.3 m80 -41.1 129.67 2.79 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.798 0.332 . . . . 0.0 110.845 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.412 ' HB1' ' O ' ' A' ' 43' ' ' ASP . . . -98.57 -18.75 17.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.088 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 97.78 -39.14 2.85 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.463 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -112.61 127.85 26.32 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.655 0.74 . . . . 0.0 110.858 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 0.66 5.34 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.681 2.254 . . . . 0.0 112.317 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -76.33 -67.72 0.66 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.909 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -128.62 111.86 19.14 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.58 0.705 . . . . 0.0 110.903 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 1.87 4.06 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.7 2.267 . . . . 0.0 112.339 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.417 ' OG1' ' N ' ' A' ' 43' ' ' ASP . 37.8 p -66.84 -68.61 0.36 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.127 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.417 ' N ' ' OG1' ' A' ' 42' ' ' THR . 14.0 t0 -63.8 112.87 3.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.455 ' CB ' ' HA ' ' A' ' 31' ' ' ALA . 35.7 mm-40 -81.43 75.91 8.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -93.47 169.87 30.65 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.497 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.468 HG12 ' N ' ' A' ' 30' ' ' GLY . 52.5 mt -139.95 116.65 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.874 0.368 . . . . 0.0 111.114 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.558 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 0.7 OUTLIER -133.46 156.17 48.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.861 179.972 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.548 HD11 HD21 ' A' ' 63' ' ' LEU . 82.9 mt -58.98 129.95 21.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.145 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.2 p -103.89 -13.3 16.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.868 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.473 ' CG ' ' N ' ' A' ' 51' ' ' VAL . 40.2 tttt -173.9 162.89 4.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.899 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.509 HG13 HG22 ' A' ' 25' ' ' ILE . 99.3 t -150.14 133.1 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.13 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 8.2 t -75.35 142.3 74.72 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.678 0.751 . . . . 0.0 110.878 -179.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -23.47 30.44 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.713 2.275 . . . . 0.0 112.343 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 80.0 p -103.52 -14.59 16.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.42 154.95 19.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.49 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB1' HG22 ' A' ' 15' ' ' ILE . . . -46.46 -33.75 4.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.821 0.343 . . . . 0.0 111.123 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.961 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -75.19 -60.52 2.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.096 179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.35 -43.49 6.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.482 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.7 ptm180 -79.82 -21.88 43.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.77 0.319 . . . . 0.0 110.84 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 57' ' ' ALA . 12.9 t70 -55.02 -59.45 4.73 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.865 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.8 -4.19 14.56 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -118.48 -70.5 0.79 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.848 0.356 . . . . 0.0 110.927 -179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.961 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -37.22 140.34 0.19 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.938 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.629 ' N ' HD13 ' A' ' 63' ' ' LEU . 9.0 ptm180 -167.04 161.4 14.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.873 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.47 ' HA ' ' CG2' ' A' ' 48' ' ' ILE . 18.7 t -70.27 102.1 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.125 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.68 -9.03 1.37 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.47 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 102' ' ' ASP . 17.5 mt -89.25 128.22 35.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.794 0.331 . . . . 0.0 110.88 -179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.558 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 55.5 ttt180 -78.59 121.54 24.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.604 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -70.24 111.79 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.668 HD12 ' O ' ' A' ' 99' ' ' LEU . 58.3 mt -89.24 -49.44 6.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.928 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -155.17 141.87 18.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.937 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.881 HG13 HD12 ' A' ' 96' ' ' LEU . 72.7 t -118.67 109.31 26.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.101 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.0 m-20 65.43 40.65 4.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 31.7 mt-30 63.75 34.62 11.9 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.881 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.832 ' HB2' HD21 ' A' ' 88' ' ' LEU . 59.1 mt-30 -129.2 90.31 3.0 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.7 t -42.89 131.47 4.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.871 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.691 HD23 HD13 ' A' ' 88' ' ' LEU . 23.5 mt -89.81 9.04 28.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.953 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.577 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -77.32 131.5 38.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.943 179.88 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.577 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 103.03 -43.98 1.57 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.49 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.657 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -79.18 155.89 28.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.884 0.373 . . . . 0.0 110.948 -179.937 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 68.7 p -93.71 -174.54 3.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -49.52 -61.91 1.84 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -46.35 -57.48 6.42 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.445 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.459 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 27.2 mt-10 -56.08 -42.05 76.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.904 0.383 . . . . 0.0 110.902 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.438 ' HA ' HD12 ' A' ' 80' ' ' LEU . . . -60.91 -48.54 81.34 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.11 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 67.8 t -52.52 -57.78 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.122 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.481 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 57.3 mm-40 -52.67 -20.35 3.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.899 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.842 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.7 tt -79.71 -26.85 40.74 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.944 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -82.27 -22.43 35.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.959 179.844 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.481 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.0 ptm180 -96.74 -0.15 48.61 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.894 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 p -83.21 16.69 2.32 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.814 HG21 ' HB3' ' A' ' 96' ' ' LEU . 4.5 p -106.8 141.05 22.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.139 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -70.99 -86.51 0.15 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.48 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.411 ' C ' ' NZ ' ' A' ' 17' ' ' LYS . 2.0 p30 -119.89 -12.54 9.17 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.837 0.351 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.2 m -149.3 132.65 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.175 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.881 HD12 HG13 ' A' ' 72' ' ' VAL . 0.8 OUTLIER -123.47 170.98 9.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.907 179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.439 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.3 m -121.5 99.31 6.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.431 HG12 HD11 ' A' ' 96' ' ' LEU . 3.1 m -96.41 131.42 43.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.668 ' O ' HD12 ' A' ' 70' ' ' LEU . 18.4 tp -98.32 31.3 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.953 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.604 HG12 ' HA ' ' A' ' 69' ' ' LEU . 5.8 m -62.59 176.88 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.112 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 11.1 p -171.67 145.23 1.96 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.843 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.597 ' HA ' HD23 ' A' ' 67' ' ' LEU . 2.2 p-10 -42.27 100.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.912 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -86.29 -44.24 5.98 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.53 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -166.37 109.6 0.76 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.807 0.337 . . . . 0.0 110.919 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -65.89 129.28 39.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.859 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 71.7 m -100.52 -44.13 5.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.893 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 147.88 120.33 1.14 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.487 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 111.75 2.91 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.651 2.234 . . . . 0.0 112.382 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.4 m -130.11 113.84 15.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.913 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 1.8 t -38.84 -43.43 0.94 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.825 -179.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.477 -179.995 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.291 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.4 m -125.94 43.41 3.08 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.87 0.367 . . . . 0.0 110.864 -179.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 t -76.31 85.01 3.09 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.857 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.69 -123.43 0.99 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.504 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.7 m -83.36 100.98 11.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.958 0.409 . . . . 0.0 110.831 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.0 m -161.73 115.47 1.89 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.864 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -175.42 129.68 1.59 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.511 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 -169.79 0.35 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.737 2.291 . . . . 0.0 112.345 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' A' ' 100' ' ' VAL . . . 167.54 -46.1 0.25 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.493 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.713 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -81.67 16.06 1.91 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.888 -179.909 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.9 mtt85 -89.44 149.29 23.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.431 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 30.3 tt0 -59.7 115.31 3.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.862 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.1 mt -116.69 160.66 20.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.958 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.478 ' SG ' HG23 ' A' ' 97' ' ' THR . 2.7 m -139.93 157.39 45.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.899 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.566 HD13 ' HA ' ' A' ' 57' ' ' ALA . 34.8 mt -125.42 107.04 17.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.147 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -80.53 107.76 13.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.906 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.403 ' HA ' ' NH2' ' A' ' 59' ' ' ARG . 0.9 OUTLIER -117.29 168.24 10.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.907 179.979 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.776 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -47.92 166.78 0.2 Allowed Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.58 0.705 . . . . 0.0 111.103 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.776 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.4 Cg_endo -69.75 2.87 3.14 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.659 2.24 . . . . 0.0 112.339 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.24 38.18 0.19 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.482 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.679 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.5 tp10 -101.98 133.98 45.93 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.837 0.351 . . . . 0.0 110.869 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' C ' ' A' ' 23' ' ' LEU . 91.3 mtt180 -78.95 116.87 19.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.858 -179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.831 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -34.02 -51.84 0.43 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.939 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.27 42.62 34.57 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.474 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -116.26 177.59 2.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.881 0.372 . . . . 0.0 111.117 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.501 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -141.91 157.53 44.87 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.894 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.414 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.3 pt -149.33 151.01 13.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.139 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 29.1 ptt180 -127.11 122.99 35.81 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.838 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.63 -156.91 28.3 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.445 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.407 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 131.09 166.98 11.85 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.515 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -92.6 1.62 57.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.815 0.34 . . . . 0.0 111.062 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 63.9 mtt180 -116.48 31.91 6.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.86 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 112.6 -138.92 15.33 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.502 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 60.34 36.72 20.49 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.861 0.362 . . . . 0.0 110.899 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -42.24 104.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.083 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -57.13 -58.73 13.08 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.507 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -97.09 139.7 21.66 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.613 0.72 . . . . 0.0 110.892 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . 0.42 ' O ' ' C ' ' A' ' 39' ' ' ARG . 53.9 Cg_endo -69.75 -28.98 24.67 Favored 'Trans proline' 0 C--O 1.231 0.175 0 C-N-CA 122.699 2.266 . . . . 0.0 112.355 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -36.21 -54.32 0.81 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.863 -179.959 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -136.74 116.84 10.82 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.642 0.734 . . . . 0.0 110.849 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -14.78 36.61 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.661 2.24 . . . . 0.0 112.329 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 80.8 p -97.61 51.36 1.07 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.147 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -133.0 114.43 13.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.853 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -84.99 27.36 0.77 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.926 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -66.44 148.02 50.36 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.407 HG12 ' N ' ' A' ' 30' ' ' GLY . 62.9 mt -124.66 118.32 53.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.894 0.378 . . . . 0.0 111.113 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.567 ' CZ ' ' HD2' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.41 -175.6 3.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.696 HD13 ' CD1' ' A' ' 63' ' ' LEU . 96.4 mt -85.47 138.65 18.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.088 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 53.4 p -116.04 -16.44 11.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.867 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CB ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -171.83 150.94 2.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.517 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -160.95 110.24 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.092 179.836 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 40.1 t -58.12 137.75 84.23 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.742 . . . . 0.0 110.853 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.427 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 53.9 Cg_endo -69.76 -23.15 31.13 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.665 2.244 . . . . 0.0 112.353 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 12.5 p -89.24 -16.91 30.13 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.15 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.51 172.28 35.57 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.17 -38.84 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.78 0.324 . . . . 0.0 111.086 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.831 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -73.32 -59.33 2.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.072 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 53' ' ' PRO . . . -45.17 -39.38 6.84 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.51 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.403 ' NH2' ' HA ' ' A' ' 17' ' ' LYS . 23.5 ptt180 -80.73 -20.76 42.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.834 0.35 . . . . 0.0 110.844 -179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.402 ' N ' ' O ' ' A' ' 57' ' ' ALA . 13.9 t70 -60.53 -58.99 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.9 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 109.28 -15.71 32.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.476 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.1 mmp_? -108.37 8.92 27.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.892 0.377 . . . . 0.0 110.858 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.696 ' CD1' HD13 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -123.3 119.38 29.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.927 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.493 ' O ' HD12 ' A' ' 48' ' ' ILE . 28.2 mtp180 -145.3 165.64 27.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.858 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.517 HG23 HG12 ' A' ' 51' ' ' VAL . 77.9 t -77.11 97.17 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.119 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.49 -23.21 0.5 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.478 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.432 ' N ' HD12 ' A' ' 67' ' ' LEU . 7.5 mp -71.75 159.93 33.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.847 0.356 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.567 ' HD2' ' CZ ' ' A' ' 47' ' ' PHE . 29.8 ttt-85 -105.71 118.06 35.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.838 HD22 HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -66.3 103.18 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.907 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.502 ' CD1' ' NH1' ' A' ' 68' ' ' ARG . 9.7 mp -82.42 -42.23 18.86 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 70' ' ' LEU . 68.8 mt-10 -162.05 142.73 10.44 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.723 HG13 HD12 ' A' ' 96' ' ' LEU . 84.9 t -121.6 108.23 21.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.153 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.426 ' ND2' HG22 ' A' ' 92' ' ' VAL . 12.5 m-20 65.33 41.2 4.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 63.37 31.84 14.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.883 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.543 ' O ' HD23 ' A' ' 77' ' ' LEU . 27.7 mt-30 -126.16 92.61 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.8 t -46.4 124.09 5.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.895 -179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.577 ' HA ' HD21 ' A' ' 80' ' ' LEU . 9.6 mt -81.29 3.46 23.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.451 ' HA ' HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -78.66 122.67 26.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.912 179.904 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.87 -31.78 6.81 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.489 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -89.87 160.82 16.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.932 0.396 . . . . 0.0 110.901 -179.903 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.437 ' O ' ' C ' ' A' ' 82' ' ' HIS . 13.9 p -97.61 161.14 13.91 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.139 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.56 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.1 t-80 -33.91 -57.83 0.45 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.878 179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.11 -44.05 56.71 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.495 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.462 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 23.5 mt-10 -67.17 -47.7 70.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.86 -179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.561 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.95 -55.71 31.66 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.081 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.56 HG23 ' O ' ' A' ' 82' ' ' HIS . 91.9 t -43.54 -64.46 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.08 -179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.493 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 70.4 mm-40 -46.86 -25.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.523 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -75.85 -34.35 60.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.886 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -76.67 -29.03 56.18 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.962 179.85 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.493 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 12.2 ptm180 -93.82 4.49 53.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.897 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.6 t -96.3 29.71 2.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.842 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.662 HG11 ' HB3' ' A' ' 96' ' ' LEU . 12.4 t -94.5 150.58 4.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -93.55 -75.15 1.29 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.514 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -121.27 -26.03 5.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.878 0.37 . . . . 0.0 110.855 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.417 HG23 ' C ' ' A' ' 15' ' ' ILE . 32.1 m -155.81 138.74 15.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.138 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.723 HD12 HG13 ' A' ' 72' ' ' VAL . 1.0 OUTLIER -120.01 165.25 14.94 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.941 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.478 HG23 ' SG ' ' A' ' 14' ' ' CYS . 2.8 m -116.41 96.47 5.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.136 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.471 ' CG1' HD11 ' A' ' 96' ' ' LEU . 3.4 m -98.38 129.42 48.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.413 ' CD1' ' HA ' ' A' ' 12' ' ' GLU . 22.6 tp -96.16 20.23 10.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.911 179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.838 HG12 HD22 ' A' ' 69' ' ' LEU . 26.2 m -48.88 177.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.057 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.7 p -175.46 162.93 2.91 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.69 118.9 6.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.827 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -106.84 -38.58 2.16 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.472 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 2.2 p90 -170.8 111.42 0.37 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.828 0.347 . . . . 0.0 110.908 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -59.09 127.72 33.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.875 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 67.0 m -53.3 -53.49 50.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.864 -179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 161.21 -165.79 35.52 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.511 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 0.14 6.08 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.653 2.235 . . . . 0.0 112.339 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 51.4 p -45.53 -41.97 10.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.868 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.5 t -140.06 108.78 5.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.873 -179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.378 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.949 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.2 t 56.97 42.86 25.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 0.0 110.836 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.3 t -46.13 -55.19 7.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.875 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -48.52 -48.62 28.04 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.517 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.8 m -109.66 91.51 3.68 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.901 0.382 . . . . 0.0 110.848 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -165.39 117.48 1.14 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.869 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 102' ' ' ASP . . . 123.18 75.1 0.3 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.467 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 158.22 57.65 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.661 2.241 . . . . 0.0 112.317 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.21 24.4 0.22 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.489 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.715 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.88 36.86 0.68 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.791 0.329 . . . . 0.0 110.918 -179.919 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.689 ' O ' HD12 ' A' ' 13' ' ' LEU . 55.7 mtp180 -108.31 173.86 6.13 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.883 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.464 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 26.4 tt0 -81.92 112.71 19.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.906 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.689 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.2 mp -117.26 168.92 9.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.899 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.5 p -148.29 157.02 43.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.854 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.422 ' O ' HG23 ' A' ' 95' ' ' THR . 86.8 mt -120.97 111.33 31.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.148 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -80.0 117.73 21.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.891 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.47 ' NZ ' HD23 ' A' ' 23' ' ' LEU . 1.7 ptpt -132.18 166.47 21.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.86 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.828 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.0 168.63 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.551 0.691 . . . . 0.0 111.115 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.828 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.1 Cg_endo -69.83 -2.26 9.93 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.677 2.251 . . . . 0.0 112.3 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -165.82 35.69 0.25 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.491 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.669 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 24.7 tp10 -99.84 147.14 25.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.915 0.388 . . . . 0.0 110.85 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' C ' ' A' ' 23' ' ' LEU . 11.2 mtt-85 -86.93 123.67 32.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.847 -179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.768 HD12 HG12 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -34.23 -52.95 0.48 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.922 179.99 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 82.68 41.3 9.01 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.768 HG12 HD12 ' A' ' 23' ' ' LEU . 3.5 pt -122.76 170.91 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.785 0.326 . . . . 0.0 111.16 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.425 ' CB ' ' HB3' ' A' ' 50' ' ' LYS . 0.9 OUTLIER -130.36 160.79 32.92 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.829 -179.901 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.438 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 14.8 pt -151.2 145.62 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.169 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.466 ' CG ' ' HB2' ' A' ' 49' ' ' SER . 18.8 ptt85 -128.88 122.01 29.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 163.6 -149.41 16.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.47 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.408 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 129.51 156.19 8.73 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.471 -179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -60.83 -9.1 3.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.792 0.329 . . . . 0.0 111.044 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.407 ' O ' ' C ' ' A' ' 33' ' ' GLY . 3.2 mpt_? -131.9 -39.93 1.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.917 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.407 ' C ' ' O ' ' A' ' 32' ' ' ARG . . . -37.3 154.32 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.508 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.447 ' O ' ' C ' ' A' ' 35' ' ' ALA . 3.3 t-160 -63.01 124.78 21.98 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.804 0.335 . . . . 0.0 110.865 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.447 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -34.01 125.58 0.46 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.079 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -39.17 -36.18 0.52 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.489 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 46.2 m-20 -109.76 137.99 20.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.602 0.715 . . . . 0.0 110.897 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.69 -0.97 7.62 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.705 2.27 . . . . 0.0 112.354 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 16.0 tpp180 -66.4 -71.92 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.874 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.401 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 0.5 OUTLIER -113.62 113.97 47.54 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.637 0.732 . . . . 0.0 110.884 179.965 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 54.1 Cg_endo -69.77 -7.77 21.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.706 2.271 . . . . 0.0 112.326 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 75.0 p -95.51 41.96 1.09 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -134.22 94.17 3.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.896 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -80.81 44.45 0.74 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.928 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -82.48 167.76 47.19 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.465 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.408 HG12 ' N ' ' A' ' 30' ' ' GLY . 30.3 mt -132.84 117.9 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 111.097 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.56 ' CD2' ' HB2' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -131.63 154.86 48.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.856 179.93 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.679 HD11 HD21 ' A' ' 63' ' ' LEU . 38.7 mt -58.2 134.44 22.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.156 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.466 ' HB2' ' CG ' ' A' ' 28' ' ' ARG . 36.8 t -112.47 -10.49 13.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.884 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.469 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 19.8 ttmt -173.79 148.0 1.41 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.86 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.632 HG13 HG22 ' A' ' 25' ' ' ILE . 86.7 t -138.3 114.36 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.126 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 4.4 t -64.59 140.69 98.08 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.711 0.767 . . . . 0.0 110.846 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -30.15 22.75 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 30.1 p -89.99 -4.16 57.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.142 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.442 ' CA ' ' O ' ' A' ' 23' ' ' LEU . . . -76.87 155.88 45.22 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.514 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.584 ' HB3' HD22 ' A' ' 23' ' ' LEU . . . -47.0 -39.11 11.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.764 0.316 . . . . 0.0 111.098 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.975 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.78 -58.76 3.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.131 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -39.3 -43.88 2.1 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.48 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 27.8 ptt180 -82.43 -26.15 32.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 110.855 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.444 ' N ' ' O ' ' A' ' 57' ' ' ALA . 24.5 t70 -53.58 -69.28 0.12 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.862 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 118.01 -13.73 12.7 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.471 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.5 mmp_? -101.5 -17.96 16.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.874 0.369 . . . . 0.0 110.874 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.975 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 2.0 tm? -103.33 125.5 49.99 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.866 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.726 ' N ' HD13 ' A' ' 63' ' ' LEU . 15.1 mtm-85 -139.5 174.81 10.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.527 HG22 HG23 ' A' ' 51' ' ' VAL . 8.0 t -82.64 90.01 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.15 179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.69 -15.37 0.3 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.516 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.572 ' HB2' HD12 ' A' ' 48' ' ' ILE . 56.0 mt -74.35 132.7 42.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.802 0.334 . . . . 0.0 110.915 -179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.56 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . 55.4 ttt180 -81.7 119.58 24.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.859 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.624 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.3 mm? -72.19 108.27 5.27 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.945 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 11.1 mp -86.39 -52.46 5.59 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.928 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -151.41 141.81 22.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.867 179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.801 HG13 HD12 ' A' ' 96' ' ' LEU . 66.9 t -115.77 110.0 30.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.13 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.493 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.65 40.56 4.39 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 64.03 30.08 14.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.877 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 36.7 mt-30 -125.26 90.86 3.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.938 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 35.9 t -40.2 130.29 2.2 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.854 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.549 ' HA ' HD11 ' A' ' 80' ' ' LEU . 24.9 mt -88.11 17.44 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.939 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.822 ' O ' HD23 ' A' ' 80' ' ' LEU . 1.1 tp -85.75 152.69 22.85 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.907 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.07 -31.77 2.81 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.498 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.822 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -88.19 163.24 16.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.862 0.363 . . . . 0.0 110.923 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 56.7 p -99.06 -174.68 2.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.126 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.519 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.0 t-80 -52.66 -55.07 25.16 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.881 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.14 -50.19 63.3 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.494 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.438 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 5.7 mm-40 -58.75 -45.47 89.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.905 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.475 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -63.01 -48.76 77.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.115 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 82' ' ' HIS . 54.0 t -53.96 -60.24 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.181 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.491 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 50.0 mm-40 -50.04 -23.42 2.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.957 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.571 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.9 tt -76.8 -30.76 56.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.601 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -78.96 -30.55 44.57 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.925 179.866 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.491 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 13.2 ptp180 -89.96 1.74 55.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.89 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.4 t -93.26 29.51 1.9 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.857 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.666 HG11 ' HB3' ' A' ' 96' ' ' LEU . 17.6 t -97.39 149.12 5.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.109 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -88.57 -77.79 1.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -118.85 -23.88 6.81 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.889 0.376 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 15' ' ' ILE . 8.2 m -158.12 143.09 16.5 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.145 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.801 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -124.05 168.97 12.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.464 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.7 m -120.57 98.84 6.22 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.144 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.402 ' HB ' HG13 ' A' ' 100' ' ' VAL . 6.5 m -95.62 131.19 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.107 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 11' ' ' ARG . 17.6 tp -98.1 35.74 1.69 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.899 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.624 HG12 ' HA ' ' A' ' 69' ' ' LEU . 4.6 m -68.48 173.07 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.6 p -162.55 150.37 14.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.866 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.431 ' CG ' ' O ' ' A' ' 7' ' ' GLY . 0.3 OUTLIER -49.99 101.78 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -87.12 -63.24 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.476 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 104' ' ' PHE . 0.0 OUTLIER -169.25 108.14 0.43 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.902 -179.902 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -84.12 115.99 22.67 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.841 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 5.0 t -97.44 26.04 5.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.87 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.16 -109.64 1.37 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.489 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 152.42 69.0 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.65 2.233 . . . . 0.0 112.339 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 49.3 m -120.38 137.05 54.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.0 p -99.11 151.23 21.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.863 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.533 179.985 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.311 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 m -129.46 161.63 29.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.371 . . . . 0.0 110.843 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.2 p 39.74 42.21 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.842 -179.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 48.91 -159.02 0.88 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.518 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 90.6 p -117.16 156.97 26.75 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.833 0.349 . . . . 0.0 110.887 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.1 m -54.69 94.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.859 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.4 111.25 2.51 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.519 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 157.3 60.79 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.681 2.254 . . . . 0.0 112.346 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -128.9 -33.86 0.54 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.493 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.721 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.07 39.2 0.56 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.786 0.327 . . . . 0.0 110.888 -179.894 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.42 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 5.3 mmm180 -113.76 158.27 21.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.877 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.424 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 28.9 tt0 -67.43 109.66 3.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.846 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 14.7 mt -114.98 155.5 26.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 96' ' ' LEU . 28.2 p -138.24 151.95 48.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.742 ' O ' HG23 ' A' ' 95' ' ' THR . 39.4 mt -115.06 116.44 52.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -87.95 120.52 29.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.91 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.89 164.27 24.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.934 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.849 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -46.31 169.13 0.1 OUTLIER Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.596 0.712 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.849 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.3 Cg_endo -69.81 3.15 2.97 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.687 2.258 . . . . 0.0 112.308 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.35 34.6 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.443 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.546 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 11.1 tp10 -103.62 140.27 37.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.843 0.354 . . . . 0.0 110.908 -179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' O ' ' C ' ' A' ' 23' ' ' LEU . 2.0 mmp_? -85.83 123.93 31.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.908 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.751 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -34.05 -43.77 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.882 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' A' ' 52' ' ' SER . . . 71.53 44.79 49.17 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.524 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.713 HG12 HD12 ' A' ' 23' ' ' LEU . 1.1 pt -125.76 177.58 4.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.809 0.338 . . . . 0.0 111.126 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.548 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.7 OUTLIER -141.02 154.29 45.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.848 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.434 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 28.2 pt -138.72 149.37 23.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.124 179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.419 ' HE ' ' CB ' ' A' ' 49' ' ' SER . 8.2 ptp180 -125.53 125.94 44.05 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.87 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 153.07 -150.79 22.6 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 122.74 152.74 8.64 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.492 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -61.83 -7.78 4.08 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.81 0.338 . . . . 0.0 111.104 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 10.6 mmm180 -131.11 -40.47 1.15 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.815 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.445 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . -52.09 155.08 4.7 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.453 ' O ' ' N ' ' A' ' 36' ' ' GLY . 2.9 p80 -34.37 123.46 0.51 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 0.0 110.818 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -41.46 -23.73 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.142 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 34' ' ' HIS . . . 100.5 -49.67 1.1 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.76 -0.734 . . . . 0.0 112.476 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 22.8 m-20 -108.49 137.26 19.92 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.653 0.74 . . . . 0.0 110.846 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -37.96 8.46 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.685 2.257 . . . . 0.0 112.385 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 13.5 ttp85 -54.83 -56.67 16.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.899 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -110.13 85.4 4.28 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.622 0.725 . . . . 0.0 110.906 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -1.28 8.2 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.631 2.221 . . . . 0.0 112.35 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.3 p -106.73 28.59 7.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.131 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.436 ' O ' ' CG ' ' A' ' 43' ' ' ASP . 0.2 OUTLIER -117.56 117.57 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.854 179.917 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 14.6 mp0 -90.17 24.33 2.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.869 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.86 150.69 35.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.469 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 31.8 mt -123.38 118.13 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.896 0.379 . . . . 0.0 111.117 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.561 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.1 m-85 -128.61 150.91 50.01 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.889 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.61 HD11 HD21 ' A' ' 63' ' ' LEU . 56.0 mt -56.37 146.36 5.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.104 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.419 ' CB ' ' HE ' ' A' ' 28' ' ' ARG . 82.1 p -120.85 -24.53 5.63 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.856 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.485 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 24.5 ttmt -154.97 156.05 35.32 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.935 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.491 ' CG2' ' CD1' ' A' ' 63' ' ' LEU . 76.8 t -147.95 113.83 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.1 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.495 ' CB ' ' O ' ' A' ' 24' ' ' GLY . 42.5 t -57.6 137.14 82.38 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.688 0.756 . . . . 0.0 110.844 -179.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.73 -22.23 32.49 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.683 2.255 . . . . 0.0 112.338 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.29 -9.22 16.12 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.119 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -68.77 155.86 53.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.437 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.494 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -44.15 -35.08 2.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.766 0.317 . . . . 0.0 111.109 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.825 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -72.31 -56.47 5.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.143 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -51.5 -38.65 43.28 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.464 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 2.7 ptt-85 -76.73 -28.85 55.96 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.799 0.333 . . . . 0.0 110.86 -179.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -55.27 -64.36 0.87 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.55 -6.02 16.6 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.468 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.432 ' O ' HD11 ' A' ' 67' ' ' LEU . 2.8 mmp_? -109.44 -50.36 3.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.836 0.35 . . . . 0.0 110.91 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.825 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.6 tm? -64.59 122.54 17.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.636 ' N ' HD13 ' A' ' 63' ' ' LEU . 30.9 mtt180 -152.81 141.53 20.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.876 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.727 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.1 OUTLIER -51.54 95.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 179.968 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 154.47 -12.82 0.5 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.492 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.457 ' CD2' ' HA ' ' A' ' 102' ' ' ASP . 50.5 mt -83.24 151.22 25.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.745 0.307 . . . . 0.0 110.95 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.561 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 74.6 ttt180 -95.68 114.79 26.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.698 HD22 HG12 ' A' ' 100' ' ' VAL . 3.3 mm? -72.71 108.11 5.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.429 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 10.1 mp -84.4 -45.73 12.42 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.429 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 39.2 mt-10 -158.64 146.64 18.18 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.899 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 72.3 t -119.37 108.17 23.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.165 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.51 ' ND2' HG22 ' A' ' 92' ' ' VAL . 13.3 m-20 65.68 41.38 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.891 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 31.0 mt-30 64.16 34.4 11.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.857 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . 0.405 ' HB3' HD11 ' A' ' 88' ' ' LEU . 26.6 mt-30 -128.49 91.24 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 5.6 t -47.76 123.88 6.55 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.843 -179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.67 ' HA ' HD21 ' A' ' 80' ' ' LEU . 10.9 mt -79.73 9.96 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.96 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.498 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -80.1 123.37 27.82 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.932 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.498 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 108.69 -35.97 4.63 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.478 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.67 HD21 ' HA ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -81.66 166.29 20.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.895 0.378 . . . . 0.0 110.914 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.462 ' O ' ' C ' ' A' ' 82' ' ' HIS . 70.8 p -101.24 158.74 15.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.1 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.51 ' O ' HG23 ' A' ' 86' ' ' VAL . 3.4 t-80 -33.57 -52.82 0.41 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.805 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -56.8 -45.7 90.92 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.472 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.456 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.8 mm-40 -63.97 -46.55 84.11 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.931 0.396 . . . . 0.0 110.907 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.52 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -58.74 -47.87 83.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.105 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 82' ' ' HIS . 70.7 t -54.74 -63.16 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.128 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . . . . . . . . . 7.1 mm-40 -47.5 -26.57 1.43 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.567 HD23 ' O ' ' A' ' 88' ' ' LEU . 2.6 tt -72.65 -33.82 66.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.964 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.612 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -74.78 -33.61 62.3 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.939 179.862 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.0 ptt85 -91.62 9.62 31.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 33.4 t -99.26 28.44 4.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.852 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.766 HG21 ' HB3' ' A' ' 96' ' ' LEU . 19.0 t -96.16 166.52 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.598 ' N ' HG12 ' A' ' 92' ' ' VAL . . . -103.04 -66.21 0.74 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.515 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -126.61 -24.92 3.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.899 0.381 . . . . 0.0 110.89 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.742 HG23 ' O ' ' A' ' 15' ' ' ILE . 24.9 m -159.8 140.48 12.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.182 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -116.48 167.64 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.929 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.424 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 3.0 m -118.91 96.36 5.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.17 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.8 m -95.9 128.45 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.125 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.1 tp -93.14 36.55 1.04 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.887 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.698 HG12 HD22 ' A' ' 69' ' ' LEU . 5.8 m -66.45 168.2 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.1 179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.445 ' O ' ' C ' ' A' ' 102' ' ' ASP . 28.7 p -166.01 133.29 2.76 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.9 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.457 ' HA ' ' CD2' ' A' ' 67' ' ' LEU . 2.4 p30 -34.52 108.27 0.06 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.864 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -101.26 -52.99 1.03 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.439 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.43 ' CZ ' ' CD2' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -172.77 135.7 0.67 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.775 0.321 . . . . 0.0 110.933 -179.828 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -97.92 127.94 44.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.902 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 9.2 m -86.88 35.12 0.68 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 109.59 169.45 20.25 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 151.89 69.51 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.679 2.252 . . . . 0.0 112.356 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.3 t -127.26 104.9 8.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.857 -179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 111' ' ' GLY . 89.0 p -162.01 156.25 21.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.845 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 110' ' ' SER . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.521 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.28 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.6 p -68.11 129.52 40.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.946 0.403 . . . . 0.0 110.835 -179.735 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 75.4 m -101.84 42.0 1.17 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.833 -179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -92.71 101.03 2.73 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.469 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.3 p -162.3 140.91 9.03 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.818 -179.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.3 t -105.36 155.64 18.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.874 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.77 89.99 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.49 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 148.58 65.49 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.73 2.287 . . . . 0.0 112.298 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 159.89 -40.53 0.46 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.616 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -86.4 26.54 1.05 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.938 -179.924 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.744 ' O ' HD12 ' A' ' 13' ' ' LEU . 18.0 mmm180 -92.89 169.68 10.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.441 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 34.5 tt0 -80.06 110.44 15.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.902 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.744 HD12 ' O ' ' A' ' 11' ' ' ARG . 5.3 mp -116.34 166.8 11.64 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 7.7 p -144.47 156.92 44.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.864 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 96.6 mt -121.65 108.82 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.121 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -79.53 118.47 21.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.913 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.627 ' HZ2' ' C ' ' A' ' 94' ' ' ASP . 0.4 OUTLIER -128.87 171.05 12.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.882 179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.808 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -49.58 168.07 0.21 Allowed Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.632 0.729 . . . . 0.0 111.086 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.808 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 54.0 Cg_endo -69.74 2.9 3.11 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 0.0 112.313 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -170.62 34.82 0.17 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.47 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.634 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 49.5 tp10 -104.11 130.59 51.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.877 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.448 ' O ' ' C ' ' A' ' 23' ' ' LEU . 9.3 ptt-85 -80.3 117.46 21.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.871 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.651 HD23 HG12 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -33.36 -50.67 0.32 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.933 179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 77.73 47.52 8.64 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.477 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.775 HD11 HD13 ' A' ' 89' ' ' LEU . 2.9 pt -112.39 158.1 12.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 111.168 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.9 m -125.08 134.9 52.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.856 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.447 HD12 HG21 ' A' ' 46' ' ' ILE . 33.2 pt -126.86 163.51 29.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.123 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 19.4 ptt180 -136.23 125.75 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.851 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 154.61 -144.64 11.37 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.462 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.57 157.08 12.28 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.505 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.438 ' HA ' ' CG ' ' A' ' 44' ' ' GLU . . . -68.74 -6.09 24.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.725 0.297 . . . . 0.0 111.034 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 6.6 mmm180 -133.05 -38.66 0.96 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.855 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . -47.28 134.83 12.95 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.47 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.441 ' C ' ' O ' ' A' ' 33' ' ' GLY . 23.3 m80 -34.67 114.34 0.22 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.879 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.425 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -35.96 112.59 0.18 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -45.38 -48.86 11.22 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.524 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.423 ' ND2' ' HB2' ' A' ' 39' ' ' ARG . 32.7 t30 -89.27 126.07 59.83 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.86 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -30.68 21.77 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.671 2.247 . . . . 0.0 112.325 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.423 ' HB2' ' ND2' ' A' ' 37' ' ' ASN . 81.2 mtt180 -44.11 -69.66 0.13 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.865 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -115.07 119.34 39.0 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.614 0.721 . . . . 0.0 110.841 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -18.07 37.21 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.687 2.258 . . . . 0.0 112.363 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 37.5 p -88.75 42.37 1.07 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -129.85 104.97 7.69 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.841 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.438 ' CG ' ' HA ' ' A' ' 31' ' ' ALA . 9.8 mp0 -88.68 27.23 1.33 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.887 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.44 150.88 46.87 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.454 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.447 HG21 HD12 ' A' ' 27' ' ' ILE . 33.1 mt -125.74 117.6 49.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.851 0.358 . . . . 0.0 111.087 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.565 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -128.86 154.26 46.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.893 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.807 HD13 HD11 ' A' ' 63' ' ' LEU . 85.2 mt -64.23 126.58 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.101 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.419 ' C ' HG13 ' A' ' 65' ' ' VAL . 4.9 t -103.97 -18.13 14.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.47 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 17.4 ttmt -165.56 160.75 17.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.927 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.706 HG13 HG22 ' A' ' 25' ' ' ILE . 95.6 t -157.07 127.98 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.105 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.4 t -67.94 141.99 94.99 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.658 0.742 . . . . 0.0 110.902 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 -35.3 12.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.628 2.219 . . . . 0.0 112.403 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 16.2 p -91.25 3.65 54.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -78.49 161.5 48.44 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.437 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.434 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -51.12 -32.76 23.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.751 0.31 . . . . 0.0 111.104 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.711 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -80.54 -64.06 1.27 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.097 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.28 -33.4 1.98 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.475 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.451 ' HG3' ' N ' ' A' ' 60' ' ' ASP . 12.1 ptt180 -81.24 -47.09 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.868 -179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.451 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 17.2 t0 -40.95 -66.37 0.33 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.871 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 117.24 -13.52 13.85 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.466 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -97.76 -12.64 22.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.841 0.353 . . . . 0.0 110.879 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.9 HD13 ' N ' ' A' ' 64' ' ' ARG . 1.5 tm? -111.16 134.63 52.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.898 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.9 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -154.84 159.04 40.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.895 179.917 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 50' ' ' LYS . 42.7 t -64.5 97.65 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.202 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 156.03 -20.91 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.486 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.518 HD12 HD22 ' A' ' 63' ' ' LEU . 66.3 mt -77.1 136.35 38.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.82 0.343 . . . . 0.0 110.895 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.565 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 63.0 ttt180 -84.02 123.65 30.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.764 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -72.77 111.62 8.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.492 HD12 ' O ' ' A' ' 99' ' ' LEU . 49.1 mt -89.4 -49.36 6.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.902 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 13.5 mt-10 -158.28 140.86 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.849 HG13 HD12 ' A' ' 96' ' ' LEU . 84.0 t -112.09 111.2 35.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.163 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 17.0 m-20 65.23 40.96 4.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 40.4 mt-30 64.36 32.12 12.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.6 mt-30 -127.56 90.03 3.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.909 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 t -42.94 130.31 4.32 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.858 -179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.411 HD21 HG23 ' A' ' 72' ' ' VAL . 14.7 mt -81.31 6.93 12.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.95 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.546 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.3 OUTLIER -77.62 123.96 27.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.943 179.907 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.546 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 112.13 -37.19 3.78 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.462 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.587 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -84.99 168.88 14.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.872 0.368 . . . . 0.0 110.933 -179.925 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' C ' ' A' ' 82' ' ' HIS . 77.8 p -106.69 161.27 14.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.152 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.471 ' C ' ' O ' ' A' ' 81' ' ' THR . 4.3 t-80 -32.81 -55.8 0.37 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.844 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -52.31 -47.32 56.3 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.464 -179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.434 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 11.1 mm-40 -66.51 -49.88 65.08 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.825 0.345 . . . . 0.0 110.838 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.501 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -50.17 -50.15 49.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.121 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 68.9 t -56.16 -57.3 9.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.122 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.48 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 9.9 mm-40 -52.17 -23.33 5.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.912 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.562 HD22 ' HB ' ' A' ' 72' ' ' VAL . 1.5 tt -76.41 -27.15 56.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.775 HD13 HD11 ' A' ' 25' ' ' ILE . 0.5 OUTLIER -82.84 -25.12 32.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.921 179.861 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.48 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 9.4 ptm180 -97.63 -3.57 39.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 31.2 t -89.6 28.82 1.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.902 -179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.3 p -109.26 147.66 13.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.132 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.23 -98.49 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.495 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.627 ' C ' ' HZ2' ' A' ' 17' ' ' LYS . 0.8 OUTLIER -112.4 -11.31 13.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.895 0.378 . . . . 0.0 110.89 -179.97 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.425 ' C ' HG21 ' A' ' 92' ' ' VAL . 6.4 m -153.03 137.22 16.48 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.104 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.849 HD12 HG13 ' A' ' 72' ' ' VAL . 1.1 pt? -121.65 169.42 10.72 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.9 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.441 ' CG2' ' HG2' ' A' ' 12' ' ' GLU . 1.3 m -117.28 95.58 5.04 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.144 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.412 ' O ' HG23 ' A' ' 98' ' ' VAL . 3.4 m -91.98 128.87 43.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.148 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.523 HD12 ' O ' ' A' ' 11' ' ' ARG . 20.9 tp -96.9 21.13 10.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.764 HG12 HD22 ' A' ' 69' ' ' LEU . 22.6 m -49.8 177.38 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.101 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 1.8 p -169.26 147.62 3.77 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.517 ' HA ' HD23 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -43.07 113.4 0.48 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.464 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -95.66 -43.55 3.36 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.508 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.464 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.2 OUTLIER -157.31 124.43 5.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.832 0.349 . . . . 0.0 110.903 -179.904 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -37.96 -47.62 1.09 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.929 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 2.5 m 49.86 42.16 23.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.862 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -100.49 147.44 18.0 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.484 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 176.43 6.78 Favored 'Trans proline' 0 C--O 1.231 0.138 0 C-N-CA 122.696 2.264 . . . . 0.0 112.34 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.7 t -125.72 138.38 53.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.84 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.8 p -50.6 147.36 4.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.822 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.331 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.482 179.967 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.461 -0.256 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.7 m -141.75 144.13 33.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.915 0.388 . . . . 0.0 110.854 -179.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.4 m -120.54 131.72 54.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.815 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.29 105.49 0.54 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.47 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.4 p -139.81 141.54 36.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.916 0.388 . . . . 0.0 110.898 -179.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 45.8 m -117.26 85.66 2.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.855 -179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 65.78 150.22 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.51 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.421 ' HB2' ' CG ' ' A' ' 11' ' ' ARG . 54.1 Cg_endo -69.75 147.31 62.63 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.708 2.272 . . . . 0.0 112.349 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -115.85 -25.49 3.61 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.469 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.727 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.16 31.21 0.5 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.742 0.306 . . . . 0.0 110.854 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.421 ' CG ' ' HB2' ' A' ' 8' ' ' PRO . 13.6 mmm180 -104.91 162.48 13.3 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.865 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.48 ' HG2' ' CG2' ' A' ' 97' ' ' THR . 50.2 tt0 -73.31 113.17 10.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.77 ' O ' HG23 ' A' ' 97' ' ' THR . 26.2 mt -105.46 -174.87 2.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.909 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.516 ' SG ' HG22 ' A' ' 95' ' ' THR . 1.7 t -164.47 153.28 13.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.887 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 95' ' ' THR . 19.5 mt -125.82 118.72 52.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.083 -179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 5.5 mt-30 -94.04 115.68 28.03 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.886 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 ptpp? -128.65 164.53 22.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.92 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.833 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -45.12 168.75 0.08 OUTLIER Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.578 0.704 . . . . 0.0 111.092 179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.833 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.83 1.19 4.71 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.679 2.253 . . . . 0.0 112.325 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.48 42.88 0.23 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.472 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.592 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 17.1 tp10 -107.77 141.24 39.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.903 0.383 . . . . 0.0 110.875 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' C ' ' A' ' 23' ' ' LEU . 49.9 mtt180 -83.59 120.72 26.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.862 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.909 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.1 OUTLIER -32.55 -56.97 0.35 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.911 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 84.56 41.1 7.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.545 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.819 HD11 HD13 ' A' ' 89' ' ' LEU . 2.7 pt -121.68 171.17 10.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.863 0.363 . . . . 0.0 111.133 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.408 ' N ' ' O ' ' A' ' 50' ' ' LYS . 1.5 m -142.92 146.47 34.04 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 28.8 pt -136.41 161.32 37.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.153 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.431 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 4.4 ptm85 -132.14 140.42 48.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.856 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.421 ' HA2' ' C ' ' A' ' 34' ' ' HIS . . . 140.11 -155.35 24.45 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 139.22 172.48 12.64 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.51 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.736 ' HB3' HG22 ' A' ' 81' ' ' THR . . . -97.28 15.22 23.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.728 0.299 . . . . 0.0 111.068 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -127.37 40.66 3.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.869 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.458 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . 111.2 -77.32 0.23 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.434 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.458 ' C ' ' O ' ' A' ' 33' ' ' GLY . 24.7 m170 -33.19 125.81 0.36 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.77 0.319 . . . . 0.0 110.856 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -147.27 148.89 31.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.079 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.546 ' HA3' ' CD1' ' A' ' 47' ' ' PHE . . . -44.08 -74.31 0.21 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.462 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -83.07 122.0 77.47 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.588 0.709 . . . . 0.0 110.908 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.83 -7.71 21.76 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.674 2.249 . . . . 0.0 112.355 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 63.6 ttp85 -49.19 -51.55 32.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.851 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -138.98 111.26 7.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 0.0 110.89 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -18.72 36.85 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.722 2.281 . . . . 0.0 112.342 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 72.3 p -56.04 -37.91 69.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -83.56 110.22 18.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.859 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 17.9 mp0 -75.56 65.19 1.74 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -87.15 148.59 21.53 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 86.6 mt -127.81 117.95 47.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.837 0.351 . . . . 0.0 111.178 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.562 ' CE2' ' HG3' ' A' ' 68' ' ' ARG . 1.2 m-85 -131.49 -176.67 4.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.838 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.72 HD13 HD11 ' A' ' 63' ' ' LEU . 78.6 mt -84.74 139.92 16.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.136 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 24.4 p -119.07 -12.07 9.55 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.86 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.476 ' HA ' ' CG2' ' A' ' 65' ' ' VAL . 22.0 tttp -175.78 149.84 0.98 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.898 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.584 HG12 HG23 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -156.1 117.57 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.099 179.887 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 14.7 t -66.25 137.79 95.72 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.67 0.748 . . . . 0.0 110.846 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HA ' ' HA3' ' A' ' 58' ' ' GLY . 54.0 Cg_endo -69.8 -26.45 27.38 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.659 2.239 . . . . 0.0 112.354 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 67.5 p -82.33 -26.37 33.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.153 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -57.96 174.31 2.51 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.483 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.3 -32.3 73.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.845 0.355 . . . . 0.0 111.134 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.909 ' HB2' HD11 ' A' ' 23' ' ' LEU . . . -77.45 -69.33 0.54 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.076 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 57' ' ' ALA . . . -37.19 -45.63 1.23 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.447 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.9 ptt180 -68.04 -35.27 77.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.812 0.339 . . . . 0.0 110.865 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.499 ' N ' ' O ' ' A' ' 57' ' ' ALA . 32.0 t70 -45.29 -64.77 0.65 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.873 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 125.49 -19.35 6.7 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.519 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 2.8 mmp_? -98.34 -51.47 3.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.913 0.387 . . . . 0.0 110.869 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.72 HD11 HD13 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -55.31 130.43 42.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.896 -179.952 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.58 ' N ' HD13 ' A' ' 63' ' ' LEU . 5.2 ptp180 -162.69 151.23 14.51 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.584 HG23 HG12 ' A' ' 51' ' ' VAL . 64.7 t -59.92 104.89 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.554 ' HA2' ' CE1' ' A' ' 104' ' ' PHE . . . 144.67 -8.43 1.8 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.47 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.671 HD23 ' HA ' ' A' ' 102' ' ' ASP . 23.5 mt -89.95 129.29 36.31 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.777 0.322 . . . . 0.0 110.921 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.562 ' HG3' ' CE2' ' A' ' 47' ' ' PHE . 62.2 ttt180 -79.31 124.24 28.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.886 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.78 HD22 HG12 ' A' ' 100' ' ' VAL . 2.4 mm? -75.31 114.14 13.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 7.4 mp -91.16 -50.69 5.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.917 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -155.4 141.98 18.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.878 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.829 HG13 HD12 ' A' ' 96' ' ' LEU . 88.0 t -114.58 108.38 25.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.14 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 12.7 m-20 65.93 42.06 3.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.925 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.406 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 34.3 mt-30 64.43 29.86 13.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.883 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 -123.47 89.88 3.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.877 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 41.6 t -42.99 130.92 4.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.523 ' HA ' HD21 ' A' ' 80' ' ' LEU . 36.7 mt -85.25 7.68 21.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.933 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.522 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.2 OUTLIER -77.41 126.66 31.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 105.41 -36.11 4.62 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.492 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.682 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -85.73 162.51 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.846 0.355 . . . . 0.0 110.928 -179.889 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.736 HG22 ' HB3' ' A' ' 31' ' ' ALA . 43.0 p -105.68 167.38 9.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.445 ' C ' ' O ' ' A' ' 81' ' ' THR . 2.6 t-80 -33.54 -65.47 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.845 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -41.77 -48.1 5.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.477 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 8.6 mt-10 -66.86 -50.91 61.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.852 0.358 . . . . 0.0 110.867 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -52.25 -55.27 22.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.1 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.537 ' HA ' HD23 ' A' ' 89' ' ' LEU . 88.4 t -51.37 -61.7 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.17 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.485 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 51.1 mm-40 -50.07 -24.78 2.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.9 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -74.6 -30.9 61.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.819 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -78.42 -28.9 46.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.926 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.485 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 11.9 ptp180 -93.61 1.16 56.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 23.1 t -95.05 31.3 1.92 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.902 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.821 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.8 p -112.89 142.93 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.125 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -60.08 -101.48 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.452 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.404 ' HB3' ' HA ' ' A' ' 19' ' ' PRO . 20.0 p-10 -114.81 0.24 13.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 0.0 110.876 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.516 HG22 ' SG ' ' A' ' 14' ' ' CYS . 19.3 m -159.02 135.72 9.43 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.128 -179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.829 HD12 HG13 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -132.13 157.21 44.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.894 179.969 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . 0.77 HG23 ' O ' ' A' ' 13' ' ' LEU . 9.6 m -107.99 103.53 12.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.128 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.462 HG23 ' O ' ' A' ' 98' ' ' VAL . 2.9 m -97.1 126.31 49.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.093 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 99' ' ' LEU . 20.0 tp -91.89 29.41 1.58 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.78 HG12 HD22 ' A' ' 69' ' ' LEU . 11.7 m -61.07 166.43 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.169 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 25.0 p -164.34 146.01 8.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.832 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.671 ' HA ' HD23 ' A' ' 67' ' ' LEU . 1.4 t70 -42.63 119.96 1.58 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.885 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -112.75 -36.47 1.54 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.517 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.554 ' CE1' ' HA2' ' A' ' 66' ' ' GLY . 3.2 p90 -173.72 118.47 0.27 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.816 0.341 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -73.93 122.79 23.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.881 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.4 t -75.84 -45.89 33.4 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.893 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 120.9 145.85 7.37 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.491 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 117.32 5.01 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.367 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.1 t 62.06 44.51 7.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.827 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 3.6 m 57.38 49.67 12.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.831 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.509 179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 6.4 t -123.66 90.89 3.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.897 0.379 . . . . 0.0 110.88 -179.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 24.6 p -130.07 84.83 2.24 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.908 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -42.6 160.24 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.507 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 p -90.2 118.0 29.39 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 0.0 110.822 -179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.6 m -146.23 122.58 10.95 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.861 -179.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 79.81 89.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.481 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.75 143.77 51.94 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.657 2.238 . . . . 0.0 112.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 166.96 -42.16 0.25 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.47 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.652 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -85.94 23.53 1.46 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.791 0.329 . . . . 0.0 110.93 -179.935 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.422 ' HB3' ' NH1' ' A' ' 11' ' ' ARG . 4.7 mmm180 -93.1 157.65 16.18 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.873 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -65.71 106.84 1.59 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.898 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 4.5 mt -109.25 170.73 7.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.936 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 25.9 p -150.59 155.35 39.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.438 ' O ' HG23 ' A' ' 95' ' ' THR . 34.4 mt -120.73 120.51 62.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.153 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 11.7 mp0 -92.26 115.34 27.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.931 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.401 ' O ' ' O ' ' A' ' 18' ' ' ALA . 0.6 OUTLIER -128.17 164.62 22.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.895 -179.985 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.832 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.33 168.65 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.562 0.696 . . . . 0.0 111.06 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.832 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.4 Cg_endo -69.78 3.49 2.75 Favored 'Trans proline' 0 N--CA 1.466 -0.146 0 C-N-CA 122.698 2.265 . . . . 0.0 112.321 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -172.18 37.84 0.16 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.47 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 31.7 tp10 -100.29 138.41 37.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.837 0.351 . . . . 0.0 110.891 -179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.463 ' O ' ' C ' ' A' ' 23' ' ' LEU . 30.1 mmt-85 -81.07 116.71 21.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.901 -179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.745 HD11 ' HB2' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -32.56 -46.79 0.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.898 -179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 71.81 42.82 52.48 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.838 HD11 HD13 ' A' ' 89' ' ' LEU . 1.3 pt -119.56 166.54 13.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.811 0.338 . . . . 0.0 111.135 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.508 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.6 OUTLIER -130.51 150.37 51.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.416 HD11 HG22 ' A' ' 86' ' ' VAL . 30.7 pt -139.53 151.39 22.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.114 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 6.6 ptp180 -129.07 124.67 35.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . 155.36 -150.83 22.39 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.485 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.46 ' N ' HG12 ' A' ' 46' ' ' ILE . . . 139.41 144.01 4.49 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.496 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.451 ' CB ' ' O ' ' A' ' 80' ' ' LEU . . . -73.17 5.62 3.36 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.748 0.309 . . . . 0.0 111.075 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.478 ' HD2' HG21 ' A' ' 81' ' ' THR . 3.2 ptm85 -115.06 47.87 1.23 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.846 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.432 ' O ' ' C ' ' A' ' 34' ' ' HIS . . . 100.14 -72.25 0.46 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.524 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.448 ' O ' ' C ' ' A' ' 29' ' ' GLY . 56.7 m-70 -35.6 101.14 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.771 0.32 . . . . 0.0 110.853 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -93.52 -18.87 21.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 75.16 -47.36 1.95 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.504 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.675 ' ND2' ' CE1' ' A' ' 104' ' ' PHE . 20.7 t-20 -95.18 131.57 29.72 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.622 0.725 . . . . 0.0 110.912 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -6.93 19.76 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.453 ' HA ' ' NE ' ' A' ' 39' ' ' ARG . 8.4 mmp_? -55.42 -70.7 0.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.826 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.41 ' HA ' ' HD2' ' A' ' 41' ' ' PRO . 79.8 m-20 -121.8 99.47 44.45 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.586 0.708 . . . . 0.0 110.917 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 40' ' ' ASP . 53.3 Cg_endo -69.77 -22.67 31.69 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.316 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 9.0 t -83.37 -9.59 58.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.167 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -107.29 110.63 22.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.914 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.432 ' H ' ' CD ' ' A' ' 44' ' ' GLU . 4.4 mp0 -62.69 84.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.3 163.86 13.63 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.548 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.46 HG12 ' N ' ' A' ' 30' ' ' GLY . 36.6 mt -135.72 115.95 17.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.592 ' CE2' ' CG ' ' A' ' 68' ' ' ARG . 1.1 m-85 -129.59 149.97 51.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.508 HG23 ' O ' ' A' ' 26' ' ' SER . 18.1 mt -55.59 140.95 12.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.129 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 49.8 p -114.15 -26.55 8.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.445 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 37.5 tttm -158.61 157.05 31.18 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.553 HG13 HG22 ' A' ' 25' ' ' ILE . 85.8 t -150.79 116.09 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.114 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 5.5 t -62.91 140.48 97.48 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.679 0.752 . . . . 0.0 110.853 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 -16.46 37.82 Favored 'Trans proline' 0 C--O 1.232 0.21 0 C-N-CA 122.707 2.271 . . . . 0.0 112.353 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 43.9 p -105.62 -6.28 19.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.117 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . 0.402 ' O ' ' C ' ' A' ' 56' ' ' ALA . . . -76.72 145.9 31.94 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.503 -179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.495 ' HA ' ' NE ' ' A' ' 59' ' ' ARG . . . -37.51 -33.45 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.784 0.326 . . . . 0.0 111.094 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.883 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -74.98 -62.71 1.45 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.116 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -45.02 -40.22 6.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.502 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.495 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 1.6 ptt-85 -73.91 -29.94 62.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.866 0.365 . . . . 0.0 110.893 -179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . 0.429 ' N ' ' HG3' ' A' ' 59' ' ' ARG . 6.5 t70 -55.16 -69.74 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 129.71 -22.01 4.96 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.504 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -96.28 -52.64 3.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.82 0.343 . . . . 0.0 110.905 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.883 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -61.9 110.85 1.67 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.944 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.411 ' HG3' ' CD1' ' A' ' 67' ' ' LEU . 5.1 ptp180 -152.8 136.3 15.95 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.836 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -39.59 99.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.123 179.944 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 157.66 -32.41 0.52 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.54 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.493 ' HB2' HD12 ' A' ' 48' ' ' ILE . 7.8 mp -73.73 151.82 40.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.845 0.355 . . . . 0.0 110.882 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.592 ' CG ' ' CE2' ' A' ' 47' ' ' PHE . 61.5 ttt180 -97.66 116.54 30.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.882 179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.812 HD22 HG12 ' A' ' 100' ' ' VAL . 2.1 mm? -66.09 105.64 1.42 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.902 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.403 ' C ' ' HG3' ' A' ' 71' ' ' GLU . 9.5 mp -80.5 -49.64 11.11 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.941 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.403 ' HG3' ' C ' ' A' ' 70' ' ' LEU . 31.4 mt-10 -158.94 145.12 16.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.869 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.81 HG13 HD12 ' A' ' 96' ' ' LEU . 79.3 t -115.31 110.21 31.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.11 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.4 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.7 m-20 64.88 40.56 5.34 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.899 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.4 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 35.4 mt-30 64.61 29.85 12.9 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.955 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 6.8 mm100 -123.64 90.76 3.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.885 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 38.1 t -44.96 130.86 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.82 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.6 mt -79.85 0.26 31.78 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.901 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.527 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -74.7 118.4 17.62 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.925 179.881 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.527 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 119.6 -34.02 4.41 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.5 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.5 HD12 ' CA ' ' A' ' 85' ' ' ALA . 0.1 OUTLIER -92.98 171.38 8.99 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.945 0.402 . . . . 0.0 110.903 -179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.478 HG21 ' HD2' ' A' ' 32' ' ' ARG . 33.7 p -109.85 162.5 14.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.162 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.543 ' O ' HG23 ' A' ' 86' ' ' VAL . 2.6 t-80 -33.33 -55.55 0.42 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.857 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -49.83 -49.53 34.73 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.494 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 19.7 mm-40 -68.01 -51.75 43.46 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.878 0.37 . . . . 0.0 110.862 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.5 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -47.81 -48.62 30.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 82' ' ' HIS . 98.3 t -57.96 -54.24 34.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.135 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.488 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 61.6 mm-40 -56.79 -22.0 32.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.8 tt -76.42 -27.07 56.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.93 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.838 HD13 HD11 ' A' ' 25' ' ' ILE . 0.7 OUTLIER -82.71 -29.1 30.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.964 179.863 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.488 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.7 ptm180 -92.49 0.81 57.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.871 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 44.4 t -94.25 28.06 2.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.834 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.825 HG21 ' HB3' ' A' ' 96' ' ' LEU . 3.0 p -108.77 140.28 28.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.164 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -59.59 -98.05 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.518 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -114.16 -11.87 12.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.883 0.373 . . . . 0.0 110.858 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.438 HG23 ' O ' ' A' ' 15' ' ' ILE . 2.0 m -150.29 137.11 19.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.116 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.825 ' HB3' HG21 ' A' ' 92' ' ' VAL . 1.1 pt? -125.95 167.94 14.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.936 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.1 m -115.98 97.54 6.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.115 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 98' ' ' VAL . 10.1 m -97.04 130.6 45.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.136 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 20.9 tp -96.78 24.07 6.45 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.812 HG12 HD22 ' A' ' 69' ' ' LEU . 21.7 m -51.59 -176.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.111 179.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 5.3 p -175.45 153.93 1.58 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.909 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -55.68 105.38 0.18 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.888 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -96.75 -55.78 1.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.675 ' CE1' ' ND2' ' A' ' 37' ' ' ASN . 2.4 p90 -164.44 110.01 1.0 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.846 0.355 . . . . 0.0 110.863 -179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 25.5 mp0 -84.75 124.01 31.06 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.876 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 21.5 t -48.99 -52.17 26.44 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.862 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 160.54 172.42 27.79 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.448 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -2.47 10.21 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.667 2.245 . . . . 0.0 112.372 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 15.6 m -39.62 -47.91 2.02 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 -179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 29.0 t -57.26 134.06 55.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.822 -179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.498 179.991 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 60.6 m -65.92 155.38 36.64 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.877 0.37 . . . . 0.0 110.858 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.5 m -59.27 157.13 11.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.83 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.63 83.24 0.22 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 58.8 m 51.23 47.24 25.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.883 0.373 . . . . 0.0 110.887 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 85.5 p -98.74 -53.91 3.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.851 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.21 146.43 9.49 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.486 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -168.02 0.25 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.724 2.283 . . . . 0.0 112.344 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 166.98 -45.23 0.26 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.463 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.749 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -82.46 18.47 1.47 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.822 0.344 . . . . 0.0 110.928 -179.894 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.404 ' O ' HD12 ' A' ' 99' ' ' LEU . 13.0 mmm180 -87.35 165.33 15.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.853 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -72.18 115.12 11.04 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.874 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -123.62 160.14 27.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.862 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 14.3 p -143.33 156.35 44.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.856 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HG23 ' A' ' 95' ' ' THR . 59.0 mt -117.74 102.66 13.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.149 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 6.0 mt-30 -77.31 117.85 19.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.913 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.511 ' NZ ' HD12 ' A' ' 23' ' ' LEU . 0.5 OUTLIER -134.03 165.4 25.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.837 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.841 ' HB1' ' HD2' ' A' ' 19' ' ' PRO . . . -43.38 168.43 0.06 OUTLIER Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.633 0.73 . . . . 0.0 111.091 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.841 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.8 Cg_endo -69.82 -0.15 6.54 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.626 2.217 . . . . 0.0 112.338 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -171.04 33.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.66 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 22.8 tp10 -92.1 126.05 37.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.866 0.365 . . . . 0.0 110.85 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.488 ' O ' ' C ' ' A' ' 23' ' ' LEU . 62.5 mtt180 -70.82 97.01 1.32 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.887 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.84 ' HG ' ' HB3' ' A' ' 56' ' ' ALA . 0.2 OUTLIER -30.95 -48.85 0.12 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.6 47.64 7.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.47 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.543 HG22 HG13 ' A' ' 51' ' ' VAL . 4.8 pt -117.61 153.67 19.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.83 0.348 . . . . 0.0 111.161 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.57 ' O ' HG23 ' A' ' 48' ' ' ILE . 0.9 OUTLIER -122.04 151.77 40.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.866 -179.888 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.435 ' O ' ' NE2' ' A' ' 82' ' ' HIS . 23.0 pt -137.28 145.96 28.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.099 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.422 ' NH1' ' HB2' ' A' ' 28' ' ' ARG . 1.5 ptm85 -122.76 137.21 54.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.845 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 135.96 -145.57 17.54 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.491 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 114.58 132.71 5.4 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.519 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.659 ' O ' HG22 ' A' ' 81' ' ' THR . . . -63.28 115.14 4.27 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.784 0.325 . . . . 0.0 111.078 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . 0.417 ' HD3' ' C ' ' A' ' 31' ' ' ALA . 1.6 mpp_? 64.01 39.98 7.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.895 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -163.28 105.62 0.26 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.508 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.438 ' O ' ' C ' ' A' ' 35' ' ' ALA . 46.1 m-70 65.63 54.09 1.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.764 0.316 . . . . 0.0 110.891 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.438 ' C ' ' O ' ' A' ' 34' ' ' HIS . . . -33.71 113.07 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.06 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -51.54 -78.09 0.11 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -83.05 128.49 65.04 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.611 0.719 . . . . 0.0 110.883 -179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 -9.8 27.0 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.647 2.231 . . . . 0.0 112.351 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.0 mtt85 -59.33 -72.97 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.885 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -128.26 116.32 20.1 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.615 0.722 . . . . 0.0 110.837 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.81 -2.86 10.92 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.689 2.259 . . . . 0.0 112.348 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 67.1 p -70.16 -53.84 15.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -81.07 94.24 6.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -88.12 94.86 9.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.891 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -102.49 161.9 16.87 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.463 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 15.5 mt -126.22 119.53 54.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.886 0.374 . . . . 0.0 111.1 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.559 ' CD1' ' N ' ' A' ' 47' ' ' PHE . 0.6 OUTLIER -132.04 150.68 52.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.858 179.946 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.571 HD13 HD11 ' A' ' 63' ' ' LEU . 44.1 mt -60.25 139.43 19.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.3 t -112.01 -24.53 9.87 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.84 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' N ' ' A' ' 51' ' ' VAL . 23.9 tttp -155.1 154.87 33.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.896 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.543 HG13 HG22 ' A' ' 25' ' ' ILE . 80.4 t -148.71 120.59 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.13 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 42.9 t -58.79 138.02 86.86 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.652 0.739 . . . . 0.0 110.877 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.83 -38.42 7.66 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.645 2.23 . . . . 0.0 112.36 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 22.9 p -92.95 -2.95 55.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -69.55 172.86 38.12 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.497 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.84 ' HB3' ' HG ' ' A' ' 23' ' ' LEU . . . -61.14 -34.04 74.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.75 0.31 . . . . 0.0 111.063 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.816 ' HB2' HD21 ' A' ' 23' ' ' LEU . . . -76.83 -60.97 2.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -42.41 -42.75 4.58 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.486 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.406 ' NE ' ' HA ' ' A' ' 56' ' ' ALA . 20.8 ptt180 -77.74 -27.96 50.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 110.844 -179.83 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -53.55 -66.98 0.3 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.862 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 114.85 -5.7 22.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.509 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.425 ' HA ' ' NH1' ' A' ' 64' ' ' ARG . 1.0 OUTLIER -115.22 -7.76 12.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.897 0.38 . . . . 0.0 110.931 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.805 ' HB3' ' HB1' ' A' ' 57' ' ' ALA . 1.3 tm? -114.55 124.63 52.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.747 ' N ' HD13 ' A' ' 63' ' ' LEU . 0.0 OUTLIER -156.91 151.73 25.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.875 179.956 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.429 ' O ' HG22 ' A' ' 65' ' ' VAL . 0.2 OUTLIER -55.8 107.17 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.09 179.97 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 146.57 -25.54 1.67 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.675 HD12 ' H ' ' A' ' 64' ' ' ARG . 12.5 mt -70.89 142.36 51.16 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.774 0.321 . . . . 0.0 110.927 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.536 ' O ' HD22 ' A' ' 70' ' ' LEU . 75.5 ttt180 -88.91 112.89 23.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.856 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.705 ' HA ' HG12 ' A' ' 100' ' ' VAL . 2.9 mm? -64.94 103.06 0.67 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.924 -179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.536 HD22 ' O ' ' A' ' 68' ' ' ARG . 1.6 mm? -79.61 -52.37 8.08 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.885 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -155.72 136.98 13.88 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.836 HG13 HD12 ' A' ' 96' ' ' LEU . 97.3 t -107.44 110.35 31.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.15 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.401 ' O ' ' HB2' ' A' ' 74' ' ' GLN . 18.5 m-20 64.79 41.72 4.91 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.914 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 73' ' ' ASN . 29.6 mt-30 64.17 30.36 13.71 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.885 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 24.7 mt-30 -126.42 90.55 3.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.927 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 46.7 t -42.67 133.26 3.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.824 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.535 ' HA ' HD21 ' A' ' 80' ' ' LEU . 20.1 mt -87.62 13.19 10.8 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.941 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.634 HD13 ' N ' ' A' ' 79' ' ' GLY . 0.4 OUTLIER -80.74 133.18 35.63 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.944 179.88 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.634 ' N ' HD13 ' A' ' 78' ' ' LEU . . . 101.18 -36.15 4.39 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.464 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.589 HD23 ' H ' ' A' ' 80' ' ' LEU . 0.2 OUTLIER -87.12 156.92 19.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.865 0.364 . . . . 0.0 110.925 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.659 HG22 ' O ' ' A' ' 31' ' ' ALA . 30.7 p -92.06 -177.26 4.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.14 179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . 0.435 ' NE2' ' O ' ' A' ' 27' ' ' ILE . 3.2 t-80 -51.33 -56.12 14.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.868 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -53.29 -51.47 46.99 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.494 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.457 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 6.8 mm-40 -58.54 -45.92 87.89 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.881 0.372 . . . . 0.0 110.871 -179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.541 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -57.87 -49.62 76.07 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 55.4 t -53.08 -56.92 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.14 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.484 ' HA ' ' CG ' ' A' ' 90' ' ' ARG . 46.7 mm-40 -52.1 -22.84 4.53 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.884 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.596 HD23 ' O ' ' A' ' 88' ' ' LEU . 1.6 tt -78.92 -28.04 43.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.929 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.618 ' C ' HD12 ' A' ' 89' ' ' LEU . 0.5 OUTLIER -83.09 -26.36 31.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.901 179.864 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.484 ' CG ' ' HA ' ' A' ' 87' ' ' GLN . 10.5 ptp180 -95.05 0.89 54.89 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 24.9 t -96.36 33.28 1.81 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.851 -179.778 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.0 p -112.0 145.57 17.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -64.63 -100.28 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.452 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . . . . . . . . . 21.3 p-10 -112.47 -1.69 14.9 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.884 0.373 . . . . 0.0 110.893 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.401 HG23 ' C ' ' A' ' 15' ' ' ILE . 26.8 m -162.96 136.6 5.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.143 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.836 HD12 HG13 ' A' ' 72' ' ' VAL . 1.2 pt? -119.39 166.83 12.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 2.6 m -115.68 96.08 5.45 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.131 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.454 ' HB ' HG13 ' A' ' 100' ' ' VAL . 5.6 m -93.49 133.0 36.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.119 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.404 HD12 ' O ' ' A' ' 11' ' ' ARG . 21.8 tp -103.09 26.53 8.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.929 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 69' ' ' LEU . 2.5 m -60.28 178.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.095 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 2.4 p -171.65 146.02 2.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.878 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -37.89 109.98 0.11 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -104.01 -50.05 1.03 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.462 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -168.46 117.13 0.72 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.81 0.338 . . . . 0.0 110.907 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -53.67 -62.08 1.89 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.931 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 6.7 t 55.23 41.66 31.2 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.873 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -89.48 127.99 8.97 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.487 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 169.15 19.52 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.655 2.237 . . . . 0.0 112.339 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 42.5 t -105.51 118.0 35.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.88 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 48.6 p -109.08 138.61 45.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.856 -179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.466 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.485 -0.246 . . . . 0.0 112.485 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.3 m -90.3 -57.09 2.96 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.855 0.36 . . . . 0.0 110.858 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -52.12 132.87 33.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.837 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 39.94 43.81 2.57 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.497 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 40.9 t -68.17 147.25 52.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.903 0.383 . . . . 0.0 110.829 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.2 m -103.18 110.93 23.07 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.866 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 155.17 175.48 26.27 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.508 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 142.5 47.85 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.661 2.241 . . . . 0.0 112.304 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 160.84 -47.61 0.38 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.551 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.738 HD13 ' H ' ' A' ' 10' ' ' LEU . 0.0 OUTLIER -84.33 32.43 0.5 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.799 0.333 . . . . 0.0 110.913 -179.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 43.8 mtt180 -99.39 150.65 21.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 25.2 tt0 -60.77 113.77 2.67 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 11.4 mt -117.37 167.35 11.33 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.902 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 23.0 p -146.42 158.9 43.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.895 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.423 ' C ' HG23 ' A' ' 95' ' ' THR . 22.6 mt -125.85 106.25 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.116 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 7.2 mt-30 -81.31 107.33 14.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.914 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.624 ' HZ2' HD22 ' A' ' 23' ' ' LEU . 0.0 OUTLIER -118.81 172.74 7.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.89 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.806 ' HB3' ' HB2' ' A' ' 21' ' ' GLU . . . -49.48 165.09 0.3 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.609 0.718 . . . . 0.0 111.099 179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 18' ' ' ALA . 53.6 Cg_endo -69.83 1.87 4.09 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.687 2.258 . . . . 0.0 112.337 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -168.55 32.1 0.18 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.466 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.806 ' HB2' ' HB3' ' A' ' 18' ' ' ALA . 33.5 tp10 -97.92 153.34 18.41 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.876 0.369 . . . . 0.0 110.886 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.81 125.65 35.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.906 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . 0.698 HD12 HG23 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -37.58 -52.46 1.2 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.911 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 79.44 40.9 14.35 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.467 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.698 HG23 HD12 ' A' ' 23' ' ' LEU . 7.5 pt -121.26 157.43 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.862 0.363 . . . . 0.0 111.096 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.506 ' O ' HG23 ' A' ' 48' ' ' ILE . 1.6 m -122.16 144.1 49.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.853 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.1 pt -135.85 149.27 27.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.114 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 17.0 ptt180 -128.67 135.1 48.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 139.95 -140.93 11.1 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 113.82 135.43 6.13 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.942 ' O ' HG22 ' A' ' 81' ' ' THR . . . -61.68 114.29 3.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.736 0.303 . . . . 0.0 111.13 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ARG . . . . . . . . . . . . . 15.9 mmm180 64.24 25.84 13.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.88 -179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.56 -91.26 2.16 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.503 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 15.1 m80 -108.15 109.68 21.14 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.813 0.339 . . . . 0.0 110.819 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -55.31 102.42 0.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.067 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -79.24 -58.01 3.04 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.475 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 56.4 t30 -90.38 118.93 69.15 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.621 0.724 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 -30.93 21.16 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.637 2.225 . . . . 0.0 112.344 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 53.5 mtt85 -42.59 -63.26 0.8 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.911 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -123.19 117.14 28.3 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.604 0.716 . . . . 0.0 110.86 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 2.76 3.25 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 0.0 112.348 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 17.2 p -102.17 -26.76 13.23 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.156 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.38 108.0 9.03 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.894 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 10.4 mm-40 -102.41 104.18 14.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.928 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -119.28 165.23 13.19 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.508 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 21.6 mt -132.26 117.76 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.857 0.36 . . . . 0.0 111.132 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.555 ' CE2' ' HB2' ' A' ' 68' ' ' ARG . 1.0 OUTLIER -131.04 149.61 52.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 179.948 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.806 HD11 HD21 ' A' ' 63' ' ' LEU . 65.1 mt -58.14 123.71 10.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.155 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 3.9 t -99.3 -10.8 21.89 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.855 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.523 ' N ' HG13 ' A' ' 65' ' ' VAL . 13.1 ttmt -175.06 160.35 2.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.915 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.688 HG23 HG22 ' A' ' 65' ' ' VAL . 58.8 t -144.42 114.09 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.116 179.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 3.6 t -61.54 138.28 94.98 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.681 0.753 . . . . 0.0 110.821 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -25.1 28.9 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.679 2.252 . . . . 0.0 112.329 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.3 p -94.99 1.22 55.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.106 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -84.78 158.94 34.07 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.484 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' LEU . . . -50.25 -44.09 53.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.81 0.338 . . . . 0.0 111.118 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' HB1' ' HB3' ' A' ' 63' ' ' LEU . . . -63.75 -58.76 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.089 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -43.11 -42.15 5.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.47 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 30.2 ptt180 -85.01 -24.22 28.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.836 0.351 . . . . 0.0 110.914 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASP . . . . . . . . . . . . . 32.0 t0 -54.42 -69.13 0.13 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 116.37 -13.54 15.9 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -101.38 -7.46 22.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 110.811 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 HD11 ' A' ' 48' ' ' ILE . 2.4 tm? -108.79 135.17 50.45 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.908 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.716 ' N ' HD13 ' A' ' 63' ' ' LEU . 2.5 mmp_? -140.5 158.09 44.52 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 51' ' ' VAL . 5.4 t -73.82 88.95 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.153 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 155.8 -17.76 0.48 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.484 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.464 ' HB2' HD12 ' A' ' 48' ' ' ILE . 13.0 mt -65.72 130.35 42.97 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.803 0.335 . . . . 0.0 110.901 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.555 ' HB2' ' CE2' ' A' ' 47' ' ' PHE . 60.4 ttt180 -78.6 122.1 25.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.775 HD22 HG12 ' A' ' 100' ' ' VAL . 2.2 mm? -73.86 111.87 9.42 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.953 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 9.0 mp -87.48 -52.94 5.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.91 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -156.73 135.77 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.989 HG13 HD12 ' A' ' 96' ' ' LEU . 53.0 t -108.66 111.72 37.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.101 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.4 m-20 65.46 40.58 4.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.905 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 34.1 mt-30 63.98 36.38 10.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.928 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLN . . . . . . . . . . . . . 20.8 mt-30 -134.77 90.91 2.7 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.913 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.0 t -41.11 139.13 0.98 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.832 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.475 ' CD2' HD13 ' A' ' 88' ' ' LEU . 11.5 mt -86.11 9.78 16.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.958 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.882 ' O ' HD23 ' A' ' 80' ' ' LEU . 6.8 tt -83.69 156.64 22.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 79.71 -19.51 6.1 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.478 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' LEU . . . . . 0.882 HD23 ' O ' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -110.38 155.06 22.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.899 0.381 . . . . 0.0 110.907 -179.91 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.942 HG22 ' O ' ' A' ' 31' ' ' ALA . 65.5 p -91.75 179.03 5.74 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 -48.62 -58.11 5.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.866 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -48.84 -49.87 27.69 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.502 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.47 ' CB ' ' HB2' ' A' ' 80' ' ' LEU . 21.0 mt-10 -61.72 -46.84 87.91 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.841 0.353 . . . . 0.0 110.923 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.43 ' CA ' HD12 ' A' ' 80' ' ' LEU . . . -54.63 -51.64 64.76 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.085 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 89' ' ' LEU . 65.0 t -48.22 -58.01 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.101 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLN . . . . . 0.743 ' N ' HE21 ' A' ' 87' ' ' GLN . 0.9 OUTLIER -51.49 -24.89 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.911 179.996 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.475 HD13 ' CD2' ' A' ' 77' ' ' LEU . 0.9 OUTLIER -74.84 -32.19 61.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.914 -179.973 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.574 ' HA ' HG11 ' A' ' 72' ' ' VAL . 0.6 OUTLIER -75.83 -24.75 55.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.877 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.473 ' CZ ' ' OE1' ' A' ' 87' ' ' GLN . 4.2 ptt180 -96.55 -0.11 49.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.905 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.2 p -83.36 20.29 1.36 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' A' ' 96' ' ' LEU . 2.4 p -106.42 145.84 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.162 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -78.47 -80.66 0.71 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.501 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ASP . . . . . 0.446 ' CG ' ' HA ' ' A' ' 19' ' ' PRO . 0.6 OUTLIER -121.13 -13.74 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.863 0.364 . . . . 0.0 110.852 -179.98 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' C ' ' A' ' 15' ' ' ILE . 14.3 m -157.1 134.61 10.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.989 HD12 HG13 ' A' ' 72' ' ' VAL . 1.3 pt? -118.88 -179.24 3.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.926 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 1.6 m -126.61 95.92 4.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.415 HG23 ' O ' ' A' ' 98' ' ' VAL . 3.4 m -96.92 129.31 47.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.124 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 21.8 tp -94.96 21.6 7.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.775 HG12 HD22 ' A' ' 69' ' ' LEU . 20.8 m -49.65 169.29 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.115 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 8.6 p -161.6 154.08 20.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -48.8 111.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.853 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . 0.437 ' C ' ' CG ' ' A' ' 104' ' ' PHE . . . -102.56 -46.33 1.54 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.511 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.437 ' CG ' ' C ' ' A' ' 103' ' ' GLY . 0.5 OUTLIER -155.19 115.29 3.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 110.875 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLU . . . . . 0.453 ' O ' ' C ' ' A' ' 106' ' ' SER . 18.7 mt-10 -83.91 34.28 0.5 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.913 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.453 ' C ' ' O ' ' A' ' 105' ' ' GLU . 25.6 t -34.49 -39.44 0.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.873 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 123.2 153.14 8.67 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.514 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 140.55 43.16 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.662 2.241 . . . . 0.0 112.356 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 88.5 p -64.81 134.56 54.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.838 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 60.7 p -51.09 152.86 2.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.839 -179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.538 -179.983 . . . . . . . . 0 0 . 1 stop_ save_